Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:substituted aniline
go back to main search page
Accession:CHEBI:48975 term browser browse the term
Synonyms:related_synonym: substituted anilines


show annotations for term's descendants           Sort by:
2,4-diaminotoluene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aadat aminoadipate aminotransferase increases expression ISO 2,4-diaminotoluene results in increased expression of AADAT mRNA CTD PMID:22016648 NCBI chr16:34,520,236...34,566,388
Ensembl chr16:34,520,238...34,566,540 		JBrowse link
G Abcb1b ATP-binding cassette, sub-family B member 1B increases expression EXP 2,4-diaminotoluene results in increased expression of ABCB1B mRNA CTD PMID:17070881 NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567 		JBrowse link
G Acmsd aminocarboxymuconate semialdehyde decarboxylase decreases expression EXP 2,4-diaminotoluene results in decreased expression of ACMSD mRNA CTD PMID:17070881 NCBI chr13:41,752,894...41,798,427
Ensembl chr13:41,752,875...41,798,427 		JBrowse link
G Acsl3 acyl-CoA synthetase long-chain family member 3 increases expression EXP 2,4-diaminotoluene results in increased expression of ACSL3 mRNA CTD PMID:17070881 NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097 		JBrowse link
G Adam8 ADAM metallopeptidase domain 8 increases expression ISO 2,4-diaminotoluene results in increased expression of ADAM8 mRNA CTD PMID:20713471 NCBI chr 1:204,206,206...204,218,988
Ensembl chr 1:204,206,199...204,218,485 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 decreases expression ISO 2,4-diaminotoluene results in decreased expression of ADAMTS1 mRNA CTD PMID:20713471 NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390 		JBrowse link
G Adamts4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 increases expression ISO 2,4-diaminotoluene results in increased expression of ADAMTS4 mRNA CTD PMID:20713471 NCBI chr13:86,203,011...86,212,500
Ensembl chr13:86,202,642...86,212,514 		JBrowse link
G Adgrl2 adhesion G protein-coupled receptor L2 decreases expression ISO 2,4-diaminotoluene results in decreased expression of ADGRL2 mRNA CTD PMID:20713471 NCBI chr 2:240,356,176...240,987,246
Ensembl chr 2:240,356,177...240,855,933 		JBrowse link
G Aen apoptosis enhancing nuclease increases expression EXP 2,4-diaminotoluene results in increased expression of AEN mRNA CTD PMID:17070881 NCBI chr 1:142,224,499...142,233,902
Ensembl chr 1:142,224,493...142,233,898 		JBrowse link
G Afp alpha-fetoprotein increases expression ISO 2,4-diaminotoluene results in increased expression of AFP mRNA CTD PMID:20713471 NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649 		JBrowse link
G Ahr aryl hydrocarbon receptor affects binding
multiple interactions 		EXP 2,4-diaminotoluene binds to AHR protein
2,4-diaminotoluene inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] 		CTD PMID:8685904 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 increases expression EXP 2,4-diaminotoluene results in increased expression of AKR7A3 mRNA CTD PMID:17070881 NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153 		JBrowse link
G Alcam activated leukocyte cell adhesion molecule increases expression ISO 2,4-diaminotoluene results in increased expression of ALCAM mRNA CTD PMID:20713471 NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 increases expression EXP 2,4-diaminotoluene results in increased expression of ALDH1A1 mRNA CTD PMID:17070881 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 increases expression ISO 2,4-diaminotoluene results in increased expression of ALDH3A1 mRNA CTD PMID:20713471 NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151 		JBrowse link
G Ankh ANKH inorganic pyrophosphate transport regulator increases expression ISO 2,4-diaminotoluene results in increased expression of ANK mRNA CTD PMID:20713471 NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699 		JBrowse link
G Ankrd37 ankyrin repeat domain 37 decreases expression ISO 2,4-diaminotoluene results in decreased expression of ANKRD37 mRNA CTD PMID:20713471 NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545 		JBrowse link
G Anln anillin, actin binding protein increases expression ISO 2,4-diaminotoluene results in increased expression of ANLN mRNA CTD PMID:20713471 NCBI chr 8:29,134,222...29,197,513
Ensembl chr 8:29,134,222...29,197,513 		JBrowse link
G Anxa8 annexin A8 increases expression ISO 2,4-diaminotoluene results in increased expression of ANXA8 mRNA CTD PMID:20713471 NCBI chr16:9,403,267...9,418,317
Ensembl chr16:9,403,353...9,418,310 		JBrowse link
G Apcdd1 APC down-regulated 1 increases expression ISO 2,4-diaminotoluene results in increased expression of APCDD1 mRNA CTD PMID:20713471 NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356 		JBrowse link
G Apoa2 apolipoprotein A2 decreases expression EXP 2,4-diaminotoluene results in decreased expression of APOA2 mRNA CTD PMID:17070881 NCBI chr13:86,176,767...86,178,819
Ensembl chr13:86,174,741...86,179,410 		JBrowse link
G Apoa4 apolipoprotein A4 decreases expression EXP 2,4-diaminotoluene results in decreased expression of APOA4 mRNA CTD PMID:17070881 NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164 		JBrowse link
G Apoc3 apolipoprotein C3 decreases expression EXP 2,4-diaminotoluene results in decreased expression of APOC3 mRNA CTD PMID:17070881 NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:55,428,024...55,458,679 		JBrowse link
G Arhgap11a Rho GTPase activating protein 11A increases expression ISO 2,4-diaminotoluene results in increased expression of ARHGAP11A mRNA CTD PMID:20713471 NCBI chr 3:121,045,187...121,071,985
Ensembl chr 3:121,045,187...121,061,468 		JBrowse link
G Arhgap22 Rho GTPase activating protein 22 increases expression ISO 2,4-diaminotoluene results in increased expression of ARHGAP22 mRNA CTD PMID:20713471 NCBI chr16:8,480,222...8,637,823
Ensembl chr16:8,479,956...8,637,822 		JBrowse link
G Arrdc3 arrestin domain containing 3 increases expression ISO 2,4-diaminotoluene results in increased expression of ARRDC3 mRNA CTD PMID:20713471 NCBI chr 2:12,873,202...12,885,716
Ensembl chr 2:12,873,202...12,885,875 		JBrowse link
G Asf1b anti-silencing function 1B histone chaperone increases expression ISO 2,4-diaminotoluene results in increased expression of ASF1B mRNA CTD PMID:20713471 NCBI chr19:41,085,786...41,100,352
Ensembl chr19:41,086,114...41,100,352 		JBrowse link
G Aspn asporin decreases expression ISO 2,4-diaminotoluene results in decreased expression of ASPN mRNA CTD PMID:20713471 NCBI chr17:15,286,338...15,310,567
Ensembl chr17:15,287,065...15,310,632 		JBrowse link
G Atp6v1d ATPase H+ transporting V1 subunit D increases expression EXP 2,4-diaminotoluene results in increased expression of ATP6V1D mRNA CTD PMID:17070881 NCBI chr 6:103,389,778...103,405,346
Ensembl chr 6:103,389,783...103,405,346 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP 2,4-diaminotoluene results in increased expression of BAX mRNA CTD PMID:17070881 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression ISO 2,4-diaminotoluene results in increased expression of BIRC5 mRNA CTD PMID:20713471 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression ISO
EXP 		2,4-diaminotoluene results in increased expression of BTG2 mRNA CTD PMID:17070881 PMID:20713471 NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690 		JBrowse link
G C1s complement C1s increases expression ISO 2,4-diaminotoluene results in increased expression of C1S mRNA CTD PMID:20713471 NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736 		JBrowse link
G C7 complement C7 increases expression EXP 2,4-diaminotoluene results in increased expression of C7 mRNA CTD PMID:17070881 NCBI chr 2:55,815,687...55,892,605
Ensembl chr 2:55,816,807...55,892,672 		JBrowse link
G Calr3 calreticulin 3 increases expression ISO 2,4-diaminotoluene results in increased expression of CALR3 mRNA CTD PMID:20713471 NCBI chr16:17,430,105...17,456,777
Ensembl chr16:17,430,153...17,457,198 		JBrowse link
G Casp3 caspase 3 increases expression ISO 2,4-diaminotoluene results in increased expression of CASP3 mRNA CTD PMID:20713471 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cblc Cbl proto-oncogene C increases expression EXP 2,4-diaminotoluene results in increased expression of CBLC mRNA CTD PMID:17070881 NCBI chr 1:88,567,930...88,584,709
Ensembl chr 1:88,567,932...88,584,709 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases expression ISO 2,4-diaminotoluene results in increased expression of CCL2 mRNA CTD PMID:20713471 NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Ccn1 cellular communication network factor 1 decreases expression ISO 2,4-diaminotoluene results in decreased expression of CCN1 mRNA CTD PMID:20713471 NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883 		JBrowse link
G Ccna2 cyclin A2 increases expression ISO 2,4-diaminotoluene results in increased expression of CCNA2 mRNA CTD PMID:20713471 NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701 		JBrowse link
G Ccnb2 cyclin B2 increases expression ISO 2,4-diaminotoluene results in increased expression of CCNB2 mRNA CTD PMID:20713471 NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682 		JBrowse link
G Ccng1 cyclin G1 increases expression EXP 2,4-diaminotoluene results in increased expression of CCNG1 mRNA CTD PMID:17070881 NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766 		JBrowse link
G Cd276 Cd276 molecule increases expression EXP 2,4-diaminotoluene results in increased expression of CD276 mRNA CTD PMID:17070881 NCBI chr 8:67,833,587...67,863,918
Ensembl chr 8:67,829,048...67,864,505 		JBrowse link
G Cd300lb CD300 molecule-like family member b increases expression ISO 2,4-diaminotoluene results in increased expression of CD300LB mRNA CTD PMID:20713471 NCBI chr10:100,463,815...100,473,804
Ensembl chr10:100,463,815...100,473,804 		JBrowse link
G Cd48 Cd48 molecule increases expression ISO 2,4-diaminotoluene results in increased expression of CD48 mRNA CTD PMID:20713471 NCBI chr13:86,717,960...86,741,540
Ensembl chr13:86,717,961...86,742,942 		JBrowse link
G Cda cytidine deaminase increases expression ISO 2,4-diaminotoluene results in increased expression of CDA mRNA CTD PMID:20713471 NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541 		JBrowse link
G Cdc45 cell division cycle 45 increases expression ISO 2,4-diaminotoluene results in increased expression of CDC45 mRNA CTD PMID:20713471 NCBI chr11:95,689,702...95,714,980
Ensembl chr11:95,689,919...95,714,981 		JBrowse link
G Cdc6 cell division cycle 6 increases expression ISO 2,4-diaminotoluene results in increased expression of CDC6 mRNA CTD PMID:20713471 NCBI chr10:84,360,361...84,374,239
Ensembl chr10:84,360,381...84,374,241 		JBrowse link
G Cdca8 cell division cycle associated 8 increases expression ISO 2,4-diaminotoluene results in increased expression of CDCA8 mRNA CTD PMID:20713471 NCBI chr 5:142,461,082...142,483,336
Ensembl chr 5:142,461,084...142,483,283 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO
EXP 		2,4-diaminotoluene results in increased expression of CDKN1A mRNA CTD PMID:17070881 PMID:20713471 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 increases expression ISO 2,4-diaminotoluene results in increased expression of CDT1 mRNA CTD PMID:20713471 NCBI chr19:67,529,249...67,534,195
Ensembl chr19:67,529,201...67,534,194 		JBrowse link
G Cenpu centromere protein U increases expression ISO 2,4-diaminotoluene results in increased expression of CENPU mRNA CTD PMID:20713471 NCBI chr16:52,448,446...52,471,662
Ensembl chr16:52,425,096...52,471,662 		JBrowse link
G Cep43 centrosomal protein 43 increases expression ISO 2,4-diaminotoluene results in increased expression of CEP43 mRNA CTD PMID:20713471 NCBI chr 1:55,080,983...55,111,509
Ensembl chr 1:55,082,712...55,111,509 		JBrowse link
G Ces3a carboxylesterase 3a increases expression ISO 2,4-diaminotoluene results in increased expression of CES3 mRNA CTD PMID:20713471 NCBI chr19:49,902,312...49,910,484 JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO 2,4-diaminotoluene results in increased expression of CHAC1 mRNA CTD PMID:20713471 NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361 		JBrowse link
G Ckap2 cytoskeleton associated protein 2 increases expression ISO 2,4-diaminotoluene results in increased expression of CKAP2 mRNA CTD PMID:20713471 NCBI chr16:76,542,114...76,567,297
Ensembl chr16:76,542,104...76,567,352 		JBrowse link
G Cntn1 contactin 1 increases expression ISO 2,4-diaminotoluene results in increased expression of CNTN1 mRNA CTD PMID:20713471 NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391 		JBrowse link
G Col5a2 collagen type V alpha 2 chain decreases expression ISO 2,4-diaminotoluene results in decreased expression of COL5A2 mRNA CTD PMID:20713471 NCBI chr 9:54,940,768...55,090,151
Ensembl chr 9:54,940,764...55,090,150 		JBrowse link
G Cpox coproporphyrinogen oxidase increases expression ISO 2,4-diaminotoluene results in increased expression of CPOX mRNA CTD PMID:20713471 NCBI chr11:55,405,778...55,415,761
Ensembl chr11:55,405,784...55,415,761 		JBrowse link
G Cpq carboxypeptidase Q decreases expression EXP 2,4-diaminotoluene results in decreased expression of CPQ mRNA CTD PMID:17070881 NCBI chr 7:66,148,973...66,719,189
Ensembl chr 7:66,149,377...66,716,137 		JBrowse link
G Crebl2 cAMP responsive element binding protein-like 2 increases expression ISO 2,4-diaminotoluene results in increased expression of CREBL2 mRNA CTD PMID:20713471 NCBI chr 4:169,404,630...169,430,618
Ensembl chr 4:169,376,495...169,430,611 		JBrowse link
G Cryab crystallin, alpha B increases expression EXP 2,4-diaminotoluene results in increased expression of CRYAB mRNA CTD PMID:17070881 NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 increases expression ISO 2,4-diaminotoluene results in increased expression of CX3CL1 mRNA CTD PMID:20713471 NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression EXP
ISO 		2,4-diaminotoluene results in increased expression of CYP1A1 protein
2,4-diaminotoluene results in increased expression of CYP1A1 mRNA 		CTD PMID:8685904 PMID:20713471 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases expression EXP 2,4-diaminotoluene results in increased expression of CYP1A2 protein CTD PMID:8685904 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO 2,4-diaminotoluene results in increased expression of CYP1B1 mRNA CTD PMID:20713471 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp2c13 cytochrome P450, family 2, subfamily c, polypeptide 13 increases expression EXP 2,4-diaminotoluene results in increased expression of CYP2C13 mRNA CTD PMID:17070881 NCBI chr 1:248,706,787...248,787,239
Ensembl chr 1:248,706,788...248,787,210 		JBrowse link
G Cyp4f5 cytochrome P450, family 4, subfamily f, polypeptide 5 increases expression EXP 2,4-diaminotoluene results in increased expression of CYP4F5 mRNA CTD PMID:17070881 NCBI chr 7:12,194,567...12,209,495
Ensembl chr 7:12,195,022...12,209,965 		JBrowse link
G Ddah1 dimethylarginine dimethylaminohydrolase 1 increases expression EXP 2,4-diaminotoluene results in increased expression of DDAH1 mRNA CTD PMID:17070881 NCBI chr 2:237,327,812...237,460,624
Ensembl chr 2:237,327,766...237,460,626 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO 2,4-diaminotoluene results in increased expression of DDIT3 mRNA CTD PMID:22016648 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509 		JBrowse link
G Depdc1b DEP domain containing 1B increases expression ISO 2,4-diaminotoluene results in increased expression of DEPDC1B mRNA CTD PMID:20713471 NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:41,624,922...41,697,202 		JBrowse link
G Dmp1 dentin matrix acidic phosphoprotein 1 increases expression ISO 2,4-diaminotoluene results in increased expression of DMP1 mRNA CTD PMID:20713471 NCBI chr14:5,833,111...5,867,154
Ensembl chr14:5,833,111...5,843,993 		JBrowse link
G Dnaja2 DnaJ heat shock protein family (Hsp40) member A2 decreases expression ISO 2,4-diaminotoluene results in decreased expression of DNAJA2 mRNA CTD PMID:22016648 NCBI chr19:37,671,019...37,689,163
Ensembl chr19:37,670,945...37,690,120 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 increases expression ISO 2,4-diaminotoluene results in increased expression of DNAJB9 mRNA CTD PMID:20713471 NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344 		JBrowse link
G Dusp1 dual specificity phosphatase 1 increases expression ISO 2,4-diaminotoluene results in increased expression of DUSP1 mRNA CTD PMID:20713471 NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644 		JBrowse link
G Dusp4 dual specificity phosphatase 4 increases expression ISO 2,4-diaminotoluene results in increased expression of DUSP4 mRNA CTD PMID:20713471 NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700 		JBrowse link
G Dusp6 dual specificity phosphatase 6 increases expression ISO 2,4-diaminotoluene results in increased expression of DUSP6 mRNA CTD PMID:20713471 NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833 		JBrowse link
G Dyrk2 dual specificity tyrosine phosphorylation regulated kinase 2 decreases expression ISO 2,4-diaminotoluene results in decreased expression of DYRK2 mRNA CTD PMID:20713471 NCBI chr 7:56,235,276...56,265,741
Ensembl chr 7:56,235,276...56,265,942 		JBrowse link
G E2f7 E2F transcription factor 7 increases expression ISO 2,4-diaminotoluene results in increased expression of E2F7 mRNA CTD PMID:20713471 NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055 		JBrowse link
G E2f8 E2F transcription factor 8 increases expression ISO 2,4-diaminotoluene results in increased expression of E2F8 mRNA CTD PMID:20713471 NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009 		JBrowse link
G Eda2r ectodysplasin A2 receptor increases expression ISO 2,4-diaminotoluene results in increased expression of EDA2R mRNA CTD PMID:20713471 NCBI chr  X:66,225,557...66,280,674
Ensembl chr  X:66,236,111...66,280,663 		JBrowse link
G Eif1a eukaryotic translation initiation factor 1A decreases expression ISO 2,4-diaminotoluene results in decreased expression of EIF1A mRNA CTD PMID:20713471 NCBI chr18:41,512,298...41,524,645
Ensembl chr18:41,503,180...41,549,696 		JBrowse link
G Emp1 epithelial membrane protein 1 increases expression ISO 2,4-diaminotoluene results in increased expression of EMP1 mRNA CTD PMID:20713471 NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365 		JBrowse link
G Epcam epithelial cell adhesion molecule increases expression EXP 2,4-diaminotoluene results in increased expression of EPCAM mRNA CTD PMID:17070881 NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702 		JBrowse link
G Ephx1 epoxide hydrolase 1 increases expression EXP 2,4-diaminotoluene results in increased expression of EPHX1 mRNA CTD PMID:17070881 NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981 		JBrowse link
G Ereg epiregulin increases expression ISO 2,4-diaminotoluene results in increased expression of EREG mRNA CTD PMID:20713471 NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260 		JBrowse link
G Espl1 extra spindle pole bodies like 1, separase increases expression ISO 2,4-diaminotoluene results in increased expression of ESPL1 mRNA CTD PMID:20713471 NCBI chr 7:135,302,460...135,329,570
Ensembl chr 7:135,302,716...135,329,570 		JBrowse link
G Etv1 ETS variant transcription factor 1 increases expression ISO 2,4-diaminotoluene results in increased expression of ETV1 mRNA CTD PMID:20713471 NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:61,317,429...61,408,959 		JBrowse link
G Etv5 ETS variant transcription factor 5 increases expression ISO 2,4-diaminotoluene results in increased expression of ETV5 mRNA CTD PMID:20713471 NCBI chr11:92,113,171...92,170,758
Ensembl chr11:92,113,224...92,170,767 		JBrowse link
G Exo1 exonuclease 1 increases expression ISO 2,4-diaminotoluene results in increased expression of EXO1 mRNA CTD PMID:20713471 NCBI chr13:90,341,947...90,366,861
Ensembl chr13:90,342,018...90,366,861 		JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression ISO 2,4-diaminotoluene results in decreased expression of FABP4 mRNA CTD PMID:22016648 NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972 		JBrowse link
G Fas Fas cell surface death receptor increases expression EXP 2,4-diaminotoluene results in increased expression of FAS mRNA CTD PMID:17070881 NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104 		JBrowse link
G Fdps farnesyl diphosphate synthase decreases expression ISO 2,4-diaminotoluene results in decreased expression of FDPS mRNA CTD PMID:20713471 NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:176,795,192...176,807,136 		JBrowse link
G Fhit fragile histidine triad diadenosine triphosphatase decreases expression EXP 2,4-diaminotoluene results in decreased expression of FHIT mRNA CTD PMID:17070881 NCBI chr15:16,365,401...17,872,901
Ensembl chr15:16,747,338...17,872,621 		JBrowse link
G Fignl1 fidgetin-like 1 increases expression ISO 2,4-diaminotoluene results in increased expression of FIGNL1 mRNA CTD PMID:20713471 NCBI chr14:90,573,090...90,595,342
Ensembl chr14:90,581,771...90,592,316 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression ISO 2,4-diaminotoluene results in increased expression of FOSL1 mRNA CTD PMID:20713471 NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391 		JBrowse link
G Ftl1 ferritin light chain 1 increases expression ISO 2,4-diaminotoluene results in increased expression of FTL1 mRNA CTD PMID:22016648 NCBI chr 1:105,072,858...105,074,705
Ensembl chr  X:45,399,355...45,399,915
Ensembl chr 2:45,399,355...45,399,915
Ensembl chr 1:45,399,355...45,399,915 		JBrowse link
G Fut8 fucosyltransferase 8 increases expression ISO 2,4-diaminotoluene results in increased expression of FUT8 mRNA CTD PMID:20713471 NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:101,683,007...101,909,775 		JBrowse link
G Fxyd5 FXYD domain-containing ion transport regulator 5 increases expression ISO 2,4-diaminotoluene results in increased expression of FXYD5 mRNA CTD PMID:20713471 NCBI chr 1:95,395,327...95,404,722
Ensembl chr 1:95,395,146...95,405,364 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO 2,4-diaminotoluene results in increased expression of GADD45A mRNA CTD PMID:20713471 NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807 		JBrowse link
G Gas2l3 growth arrest-specific 2 like 3 increases expression ISO 2,4-diaminotoluene results in increased expression of GAS2L3 mRNA CTD PMID:20713471 NCBI chr 7:25,690,929...25,726,806
Ensembl chr 7:25,693,660...25,716,942 		JBrowse link
G Gcat glycine C-acetyltransferase increases expression ISO 2,4-diaminotoluene results in increased expression of GCAT mRNA CTD PMID:20713471 NCBI chr 7:112,475,572...112,481,920
Ensembl chr 7:112,475,496...112,482,664 		JBrowse link
G Gch1 GTP cyclohydrolase 1 increases expression ISO 2,4-diaminotoluene results in increased expression of GCH1 mRNA CTD PMID:20713471 NCBI chr15:22,884,006...22,917,412
Ensembl chr15:22,884,006...22,917,412 		JBrowse link
G Gchfr GTP cyclohydrolase I feedback regulator increases expression ISO 2,4-diaminotoluene results in increased expression of GCHFR mRNA CTD PMID:20713471 NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926 		JBrowse link
G Gins4 GINS complex subunit 4 increases expression ISO 2,4-diaminotoluene results in increased expression of GINS4 mRNA CTD PMID:20713471 NCBI chr16:75,489,990...75,502,455
Ensembl chr16:75,490,126...75,505,000 		JBrowse link
G Gja1 gap junction protein, alpha 1 increases expression ISO 2,4-diaminotoluene results in increased expression of GJA1 mRNA CTD PMID:20713471 NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689 		JBrowse link
G Gnb4 G protein subunit beta 4 increases expression ISO 2,4-diaminotoluene results in increased expression of GNB4 mRNA CTD PMID:20713471 NCBI chr 2:117,289,112...117,329,050
Ensembl chr 2:117,293,284...117,328,945 		JBrowse link
G Gpc1 glypican 1 increases expression ISO 2,4-diaminotoluene results in increased expression of GPC1 mRNA CTD PMID:20713471 NCBI chr 9:100,843,645...100,871,458
Ensembl chr 9:100,843,645...100,879,933 		JBrowse link
G Gpnmb glycoprotein nmb increases expression ISO 2,4-diaminotoluene results in increased expression of GPNMB mRNA CTD PMID:20713471 NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240 		JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 increases expression EXP 2,4-diaminotoluene results in increased expression of GRIA3 mRNA CTD PMID:17070881 NCBI chr  X:125,103,975...125,369,690
Ensembl chr  X:125,103,782...125,369,679 		JBrowse link
G Gsdme gasdermin E increases expression ISO 2,4-diaminotoluene results in increased expression of GSDME mRNA CTD PMID:20713471 NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 increases expression EXP 2,4-diaminotoluene results in increased expression of GSTM1 mRNA CTD PMID:17070881 NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569 		JBrowse link
G Gtdc1 glycosyltransferase-like domain containing 1 decreases expression ISO 2,4-diaminotoluene results in decreased expression of GTDC1 mRNA CTD PMID:20713471 NCBI chr 3:49,176,110...49,571,594
Ensembl chr 3:49,176,110...49,571,843 		JBrowse link
G Gtse1 G-2 and S-phase expressed 1 increases expression ISO 2,4-diaminotoluene results in increased expression of GTSE1 mRNA CTD PMID:20713471 NCBI chr 7:118,829,793...118,846,662
Ensembl chr 7:118,829,903...118,846,661 		JBrowse link
G H1f0 H1.0 linker histone decreases expression ISO 2,4-diaminotoluene results in decreased expression of H1F0 mRNA CTD PMID:20713471 NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006 		JBrowse link
G H2ax H2A.X variant histone decreases expression
increases phosphorylation 		ISO 2,4-diaminotoluene results in decreased expression of H2AX mRNA
2,4-diaminotoluene results in increased phosphorylation of H2AX protein 		CTD PMID:20713471 PMID:34510228 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G H3f3b H3.3 histone B decreases expression ISO 2,4-diaminotoluene results in decreased expression of H3F3B mRNA CTD PMID:20713471 NCBI chr10:101,755,404...101,764,616
Ensembl chr10:101,755,404...101,757,636 		JBrowse link
G H4c8 H4 clustered histone 8 decreases expression ISO 2,4-diaminotoluene results in decreased expression of H4C9 mRNA CTD PMID:20713471 NCBI chr17:47,176,246...47,180,690
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr 4:41,797,152...41,806,539 		JBrowse link
G Hacd2 3-hydroxyacyl-CoA dehydratase 2 decreases expression ISO 2,4-diaminotoluene results in decreased expression of HACD2 mRNA CTD PMID:20713471 NCBI chr11:79,175,470...79,268,975
Ensembl chr11:79,175,482...79,268,126 		JBrowse link
G Hba-a1 hemoglobin alpha, adult chain 1 increases expression ISO 2,4-diaminotoluene results in increased expression of HBA-A1 mRNA CTD PMID:20713471 NCBI chr10:15,841,724...15,842,580
Ensembl chr10:15,841,763...15,842,603 		JBrowse link
G Higd1a HIG1 hypoxia inducible domain family, member 1A increases expression ISO 2,4-diaminotoluene results in increased expression of HIGD1A mRNA CTD PMID:20713471 NCBI chr 8:130,391,658...130,400,888
Ensembl chr 8:130,391,661...130,400,888 		JBrowse link
G Hmga1 high mobility group AT-hook 1 increases expression ISO 2,4-diaminotoluene results in increased expression of HMGA1 mRNA CTD PMID:20713471 NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,613,471...5,620,593 		JBrowse link
G Hmga2 high mobility group AT-hook 2 increases expression ISO 2,4-diaminotoluene results in increased expression of HMGA2 mRNA CTD PMID:20713471 NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 decreases expression ISO 2,4-diaminotoluene results in decreased expression of HMGCS1 mRNA CTD PMID:20713471 NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802 		JBrowse link
G Hmmr hyaluronan-mediated motility receptor increases expression ISO 2,4-diaminotoluene results in increased expression of HMMR mRNA CTD PMID:20713471 NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,635,915...25,665,390 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 increases expression ISO 2,4-diaminotoluene results in increased expression of HSD17B4 mRNA CTD PMID:22016648 NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 decreases expression EXP 2,4-diaminotoluene results in decreased expression of HSD17B6 mRNA CTD PMID:17070881 NCBI chr 7:831,407...850,950
Ensembl chr 7:831,421...850,873 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 decreases expression ISO 2,4-diaminotoluene results in decreased expression of HSP90AB1 mRNA CTD PMID:22016648 NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926 		JBrowse link
G Ier3 immediate early response 3 increases expression ISO 2,4-diaminotoluene results in increased expression of IER3 mRNA CTD PMID:20713471 NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377 		JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase increases expression ISO 2,4-diaminotoluene results in increased expression of IFI30 mRNA CTD PMID:20713471 NCBI chr16:18,709,570...18,713,635
Ensembl chr16:18,709,563...18,715,711 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [2,4-diaminotoluene co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Il12rb1 interleukin 12 receptor subunit beta 1 increases expression ISO 2,4-diaminotoluene results in increased expression of IL12RB1 mRNA CTD PMID:20713471 NCBI chr16:18,654,207...18,668,887
Ensembl chr16:18,654,207...18,666,824 		JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 increases expression ISO 2,4-diaminotoluene results in increased expression of IL1RL1 mRNA CTD PMID:20713471 NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:50,204,551...50,222,891 		JBrowse link
G Il2ra interleukin 2 receptor subunit alpha increases expression EXP 2,4-diaminotoluene results in increased expression of IL2RA mRNA CTD PMID:17070881 NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507 		JBrowse link
G Iqgap3 IQ motif containing GTPase activating protein 3 increases expression ISO 2,4-diaminotoluene results in increased expression of IQGAP3 mRNA CTD PMID:20713471 NCBI chr 2:175,840,001...175,881,799
Ensembl chr 2:175,839,949...175,881,797 		JBrowse link
G Jarid2 jumonji and AT-rich interaction domain containing 2 decreases expression ISO 2,4-diaminotoluene results in decreased expression of JARID2 mRNA CTD PMID:20713471 NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,983,217...20,161,970 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO 2,4-diaminotoluene results in increased expression of JUN mRNA CTD PMID:20713471 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Kcnk2 potassium two pore domain channel subfamily K member 2 increases expression ISO 2,4-diaminotoluene results in increased expression of KCNK2 mRNA CTD PMID:20713471 NCBI chr13:103,297,387...103,494,686
Ensembl chr13:103,297,393...103,494,686 		JBrowse link
G Kcnn4 potassium calcium-activated channel subfamily N member 4 increases expression ISO 2,4-diaminotoluene results in increased expression of KCNN4 mRNA CTD PMID:20713471 NCBI chr 1:89,084,306...89,102,279
Ensembl chr 1:89,086,814...89,102,275 		JBrowse link
G Kif2c kinesin family member 2C increases expression ISO 2,4-diaminotoluene results in increased expression of KIF2C mRNA CTD PMID:20713471 NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212 		JBrowse link
G Kitlg KIT ligand increases expression ISO 2,4-diaminotoluene results in increased expression of KITL mRNA CTD PMID:20713471 NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793 		JBrowse link
G Klhdc8a kelch domain containing 8A increases expression ISO 2,4-diaminotoluene results in increased expression of KLHDC8A mRNA CTD PMID:20713471 NCBI chr13:46,287,011...46,296,429
Ensembl chr13:46,288,344...46,296,429 		JBrowse link
G Krt7 keratin 7 increases expression ISO 2,4-diaminotoluene results in increased expression of KRT7 mRNA CTD PMID:20713471 NCBI chr 7:134,407,626...134,423,787
Ensembl chr 7:134,407,584...134,423,786 		JBrowse link
G L3mbtl3 L3MBTL histone methyl-lysine binding protein 3 decreases expression ISO 2,4-diaminotoluene results in decreased expression of L3MBTL3 mRNA CTD PMID:20713471 NCBI chr 1:20,807,679...20,908,609
Ensembl chr 1:20,808,973...20,908,608 		JBrowse link
G Lgals2 galectin 2 increases expression ISO 2,4-diaminotoluene results in increased expression of LGALS2 mRNA CTD PMID:20713471 NCBI chr 7:112,283,630...112,290,228
Ensembl chr 7:112,282,822...112,285,392 		JBrowse link
G Lif LIF, interleukin 6 family cytokine increases expression ISO 2,4-diaminotoluene results in increased expression of LIF mRNA CTD PMID:20713471 NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053 		JBrowse link
G Lmnb1 lamin B1 increases expression ISO 2,4-diaminotoluene results in increased expression of LMNB1 mRNA CTD PMID:20713471 NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283 		JBrowse link
G Lrr1 leucine rich repeat protein 1 increases expression ISO 2,4-diaminotoluene results in increased expression of LRR1 mRNA CTD PMID:20713471 NCBI chr 6:93,379,159...93,387,950
Ensembl chr 6:93,379,169...93,387,950 		JBrowse link
G Lrrc8d leucine rich repeat containing 8 VRAC subunit D increases expression ISO 2,4-diaminotoluene results in increased expression of LRRC8D mRNA CTD PMID:20713471 NCBI chr14:4,335,114...4,411,549
Ensembl chr14:4,332,130...4,445,639 		JBrowse link
G Ly6a lymphocyte antigen 6 family member A increases expression ISO 2,4-diaminotoluene results in increased expression of LY6A mRNA CTD PMID:20713471 NCBI chr 7:109,064,222...109,067,757 JBrowse link
G Ly6e lymphocyte antigen 6 family member E increases expression ISO 2,4-diaminotoluene results in increased expression of LY6E mRNA CTD PMID:20713471 NCBI chr 7:108,815,970...108,820,444
Ensembl chr 7:108,816,887...108,820,443 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 increases expression ISO 2,4-diaminotoluene results in increased expression of MCM3 mRNA CTD PMID:20713471 NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746 		JBrowse link
G Mcm5 minichromosome maintenance complex component 5 increases expression ISO 2,4-diaminotoluene results in increased expression of MCM5 mRNA CTD PMID:20713471 NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758 		JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase increases expression
affects expression 		EXP 2,4-diaminotoluene results in increased expression of MGMT mRNA
2,4-diaminotoluene affects the expression of MGMT mRNA 		CTD PMID:17070881 PMID:22084566 NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482 		JBrowse link
G Mmp13 matrix metallopeptidase 13 increases expression ISO 2,4-diaminotoluene results in increased expression of MMP13 mRNA CTD PMID:20713471 NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105 		JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression ISO 2,4-diaminotoluene results in increased expression of MMP3 mRNA CTD PMID:20713471 NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826 		JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression ISO 2,4-diaminotoluene results in increased expression of MMP9 mRNA CTD PMID:20713471 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Msln mesothelin increases expression ISO 2,4-diaminotoluene results in increased expression of MSLN mRNA CTD PMID:20713471 NCBI chr10:15,276,489...15,285,921
Ensembl chr10:15,275,659...15,282,153 		JBrowse link
G Mvd mevalonate diphosphate decarboxylase decreases expression ISO 2,4-diaminotoluene results in decreased expression of MVD mRNA CTD PMID:20713471 NCBI chr19:67,404,911...67,414,974
Ensembl chr19:67,404,911...67,422,366 		JBrowse link
G Myo1c myosin 1C increases expression ISO 2,4-diaminotoluene results in increased expression of MYO1C mRNA CTD PMID:20713471 NCBI chr10:60,996,642...61,019,022
Ensembl chr10:60,996,638...61,019,022 		JBrowse link
G Ncapg2 non-SMC condensin II complex, subunit G2 increases expression ISO 2,4-diaminotoluene results in increased expression of NCAPG2 mRNA CTD PMID:20713471 NCBI chr 6:143,484,651...143,561,850
Ensembl chr 6:143,485,944...143,560,249 		JBrowse link
G Ncf4 neutrophil cytosolic factor 4 increases expression ISO 2,4-diaminotoluene results in increased expression of NCF4 mRNA CTD PMID:20713471 NCBI chr 7:111,705,926...111,723,893
Ensembl chr 7:111,706,520...111,723,898 		JBrowse link
G Ndc80 NDC80 kinetochore complex component increases expression ISO 2,4-diaminotoluene results in increased expression of NDC80 mRNA CTD PMID:20713471 NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:118,853,806...118,887,568 		JBrowse link
G Neil3 nei-like DNA glycosylase 3 increases expression ISO 2,4-diaminotoluene results in increased expression of NEIL3 mRNA CTD PMID:20713471 NCBI chr16:45,091,401...45,151,419
Ensembl chr16:45,092,200...45,151,205 		JBrowse link
G Niban1 niban apoptosis regulator 1 increases expression ISO 2,4-diaminotoluene results in increased expression of NIBAN1 mRNA CTD PMID:20713471 NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724 		JBrowse link
G Nolc1 nucleolar and coiled-body phosphoprotein 1 increases expression ISO 2,4-diaminotoluene results in increased expression of NOLC1 mRNA CTD PMID:20713471 NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:254,870,319...254,881,069 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO 2,4-diaminotoluene results in increased expression of NQO1 mRNA CTD PMID:20713471 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nrep neuronal regeneration related protein decreases expression ISO 2,4-diaminotoluene results in decreased expression of NREP mRNA CTD PMID:20713471 NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742 		JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator decreases expression
increases expression 		EXP
ISO 		2,4-diaminotoluene results in decreased expression of NUPR1 mRNA
2,4-diaminotoluene results in increased expression of NUPR1 mRNA 		CTD PMID:17070881 PMID:20713471 NCBI chr 1:190,643,866...190,645,901
Ensembl chr 1:190,643,867...190,645,901 		JBrowse link
G Oat ornithine aminotransferase decreases expression ISO 2,4-diaminotoluene results in decreased expression of OAT mRNA CTD PMID:22016648 NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754 		JBrowse link
G Ogn osteoglycin decreases expression ISO 2,4-diaminotoluene results in decreased expression of OGN mRNA CTD PMID:20713471 NCBI chr17:15,238,500...15,259,167
Ensembl chr17:15,238,500...15,259,252 		JBrowse link
G Or2at1 olfactory receptor family 2 subfamily AT member 1 decreases expression EXP 2,4-diaminotoluene results in decreased expression of OR2AT1 mRNA CTD PMID:17070881 NCBI chr 1:163,501,335...163,502,300
Ensembl chr 1:163,501,335...163,502,300 		JBrowse link
G Ormdl3 ORMDL sphingolipid biosynthesis regulator 3 increases expression ISO 2,4-diaminotoluene results in increased expression of ORMDL3 mRNA CTD PMID:20713471 NCBI chr10:84,086,317...84,092,673
Ensembl chr10:84,086,317...84,093,548 		JBrowse link
G P2rx7 purinergic receptor P2X 7 decreases expression ISO 2,4-diaminotoluene results in decreased expression of P2RX7 mRNA CTD PMID:20713471 NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193 		JBrowse link
G Pard3 par-3 family cell polarity regulator decreases expression ISO 2,4-diaminotoluene results in decreased expression of PARD3 mRNA CTD PMID:20713471 NCBI chr19:71,977,420...72,527,273
Ensembl chr19:71,977,470...72,526,941 		JBrowse link
G Pbk PDZ binding kinase increases expression ISO 2,4-diaminotoluene results in increased expression of PBK mRNA CTD PMID:20713471 NCBI chr15:44,198,506...44,209,572
Ensembl chr15:44,198,544...44,209,570 		JBrowse link
G Pbsn probasin increases expression EXP 2,4-diaminotoluene results in increased expression of PBSN mRNA CTD PMID:17070881 NCBI chr  X:45,792,738...45,807,983
Ensembl chr  X:45,792,738...45,807,983 		JBrowse link
G Pcdh18 protocadherin 18 decreases expression ISO 2,4-diaminotoluene results in decreased expression of PCDH18 mRNA CTD PMID:20713471 NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:135,983,144...135,996,826 		JBrowse link
G Pcdh7 protocadherin 7 decreases expression ISO 2,4-diaminotoluene results in decreased expression of PCDH7 mRNA CTD PMID:20713471 NCBI chr14:56,684,817...57,114,976
Ensembl chr14:56,687,725...57,112,665 		JBrowse link
G Pcdhb22 protocadherin beta 22 decreases expression ISO 2,4-diaminotoluene results in decreased expression of PCDHB22 mRNA CTD PMID:20713471 NCBI chr18:29,497,038...29,503,142
Ensembl chr18:29,495,389...29,503,336 		JBrowse link
G Pdrg1 p53 and DNA damage regulated 1 increases expression ISO 2,4-diaminotoluene results in increased expression of PDRG1 mRNA CTD PMID:20713471 NCBI chr 3:161,937,812...161,943,981
Ensembl chr 3:161,937,815...161,948,995 		JBrowse link
G Pgam2 phosphoglycerate mutase 2 increases expression ISO 2,4-diaminotoluene results in increased expression of PGAM2 mRNA CTD PMID:22016648 NCBI chr14:84,895,763...84,897,874
Ensembl chr14:84,895,744...84,897,894 		JBrowse link
G Phex phosphate regulating endopeptidase X-linked increases expression ISO 2,4-diaminotoluene results in increased expression of PHEX mRNA CTD PMID:20713471 NCBI chr  X:41,422,561...41,671,226
Ensembl chr  X:41,426,101...41,671,226 		JBrowse link
G Phf11 PHD finger protein 11 increases expression ISO 2,4-diaminotoluene results in increased expression of PHF11D mRNA CTD PMID:20713471 NCBI chr15:37,568,090...37,592,490
Ensembl chr15:37,568,090...37,591,016 		JBrowse link
G Phlda3 pleckstrin homology-like domain, family A, member 3 increases expression EXP 2,4-diaminotoluene results in increased expression of PHLDA3 mRNA CTD PMID:17070881 NCBI chr13:49,745,003...49,748,088
Ensembl chr13:49,742,591...49,749,621 		JBrowse link
G Pola1 DNA polymerase alpha 1, catalytic subunit increases expression ISO 2,4-diaminotoluene results in increased expression of POLA1 mRNA CTD PMID:20713471 NCBI chr  X:62,028,475...62,342,455
Ensembl chr  X:62,028,476...62,342,355 		JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO 2,4-diaminotoluene results in increased expression of PPP1R15A mRNA CTD PMID:20713471 NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774 		JBrowse link
G Prdx1 peroxiredoxin 1 increases expression ISO 2,4-diaminotoluene results in increased expression of PRDX1 mRNA CTD PMID:22016648 NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:135,383,906...135,399,504 		JBrowse link
G Prdx3 peroxiredoxin 3 decreases expression ISO 2,4-diaminotoluene results in decreased expression of PRDX3 mRNA CTD PMID:22016648 NCBI chr 1:269,987,691...270,000,111
Ensembl chr 1:269,987,685...270,000,300 		JBrowse link
G Psrc1 proline and serine rich coiled-coil 1 increases expression ISO 2,4-diaminotoluene results in increased expression of PSRC1 mRNA CTD PMID:20713471 NCBI chr 2:198,710,427...198,715,001
Ensembl chr 2:198,705,839...198,714,997 		JBrowse link
G Ptgfr prostaglandin F receptor decreases expression ISO 2,4-diaminotoluene results in decreased expression of PTGFR mRNA CTD PMID:20713471 NCBI chr 2:243,390,820...243,426,647
Ensembl chr 2:243,393,350...243,425,623 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO 2,4-diaminotoluene results in increased expression of PTGS2 mRNA CTD PMID:20713471 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Ptpn6 protein tyrosine phosphatase, non-receptor type 6 increases expression ISO 2,4-diaminotoluene results in increased expression of PTPN6 mRNA CTD PMID:20713471 NCBI chr 4:159,212,320...159,237,069
Ensembl chr 4:159,212,320...159,237,069 		JBrowse link
G Ptx3 pentraxin 3 decreases expression ISO 2,4-diaminotoluene results in decreased expression of PTX3 mRNA CTD PMID:20713471 NCBI chr 2:152,797,563...152,803,372
Ensembl chr 2:152,781,955...152,803,372 		JBrowse link
G Pvr PVR cell adhesion molecule increases expression ISO 2,4-diaminotoluene results in increased expression of PVR mRNA CTD PMID:20713471 NCBI chr 1:88,689,235...88,704,641
Ensembl chr 1:88,688,981...88,704,630 		JBrowse link
G Rad51 RAD51 recombinase increases expression ISO 2,4-diaminotoluene results in increased expression of RAD51 mRNA CTD PMID:20713471 NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469 		JBrowse link
G Rad51ap1 RAD51 associated protein 1 increases expression ISO 2,4-diaminotoluene results in increased expression of RAD51AP1 mRNA CTD PMID:20713471 NCBI chr 4:161,445,610...161,458,661
Ensembl chr 4:161,445,512...161,458,680 		JBrowse link
G Rad54l RAD54 like increases expression ISO 2,4-diaminotoluene results in increased expression of RAD54L mRNA CTD PMID:20713471 NCBI chr 5:134,812,158...134,841,821
Ensembl chr 5:134,811,532...134,841,425 		JBrowse link
G Rassf1 Ras association domain family member 1 increases expression ISO 2,4-diaminotoluene results in increased expression of RASSF1 mRNA CTD PMID:20713471 NCBI chr 8:117,103,665...117,114,805
Ensembl chr 8:117,103,362...117,114,805 		JBrowse link
G Rbm3 RNA binding motif protein 3 increases expression ISO 2,4-diaminotoluene results in increased expression of RBM3 mRNA CTD PMID:20713471 NCBI chr  X:17,020,863...17,024,341
Ensembl chr  X:17,020,864...17,024,841 		JBrowse link
G Rbmx RNA binding motif protein, X-linked decreases expression ISO 2,4-diaminotoluene results in decreased expression of RBMX mRNA CTD PMID:20713471 NCBI chr  X:140,342,544...140,352,121
Ensembl chr  X:140,345,571...140,352,035 		JBrowse link
G Rbpj recombination signal binding protein for immunoglobulin kappa J region increases expression ISO 2,4-diaminotoluene results in increased expression of RBPJ mRNA CTD PMID:20713471 NCBI chr14:61,551,366...61,736,220
Ensembl chr14:61,551,366...61,736,307 		JBrowse link
G Rfc3 replication factor C subunit 3 increases expression ISO 2,4-diaminotoluene results in increased expression of RFC3 mRNA CTD PMID:20713471 NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340 		JBrowse link
G Rfc4 replication factor C subunit 4 increases expression ISO 2,4-diaminotoluene results in increased expression of RFC4 mRNA CTD PMID:20713471 NCBI chr11:91,254,273...91,268,727
Ensembl chr11:91,254,243...91,268,730 		JBrowse link
G Rhobtb2 Rho-related BTB domain containing 2 increases expression EXP 2,4-diaminotoluene results in increased expression of RHOBTB2 mRNA CTD PMID:17070881 NCBI chr15:51,278,024...51,298,209
Ensembl chr15:51,280,149...51,298,209 		JBrowse link
G Rngtt RNA guanylyltransferase and 5'-phosphatase decreases expression ISO 2,4-diaminotoluene results in decreased expression of RNGTT mRNA CTD PMID:20713471 NCBI chr 5:52,503,335...52,709,604
Ensembl chr 5:52,503,313...52,709,597 		JBrowse link
G Rrm2 ribonucleotide reductase regulatory subunit M2 increases expression ISO 2,4-diaminotoluene results in increased expression of RRM2 mRNA CTD PMID:20713471 NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370 		JBrowse link
G Rrm2b ribonucleotide reductase regulatory TP53 inducible subunit M2B increases expression ISO 2,4-diaminotoluene results in increased expression of RRM2B mRNA CTD PMID:21704725 NCBI chr 7:70,962,008...70,993,726
Ensembl chr 7:70,965,590...70,993,670 		JBrowse link
G Rsad2 radical S-adenosyl methionine domain containing 2 increases expression ISO 2,4-diaminotoluene results in increased expression of RSAD2 mRNA CTD PMID:20713471 NCBI chr 6:48,774,985...48,788,245
Ensembl chr 6:48,774,985...48,788,320 		JBrowse link
G Rtp4 receptor (chemosensory) transporter protein 4 increases expression ISO 2,4-diaminotoluene results in increased expression of RTP4 mRNA CTD PMID:20713471 NCBI chr11:90,741,992...90,840,061
Ensembl chr11:90,741,992...90,753,851 		JBrowse link
G Sema3c semaphorin 3C decreases expression ISO 2,4-diaminotoluene results in decreased expression of SEMA3C mRNA CTD PMID:20713471 NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:18,538,454...18,701,740 		JBrowse link
G Sema5a semaphorin 5A increases expression ISO 2,4-diaminotoluene results in increased expression of SEMA5A mRNA CTD PMID:20713471 NCBI chr 2:85,020,724...85,451,938
Ensembl chr 2:85,020,724...85,451,938 		JBrowse link
G Sema6d semaphorin 6D increases expression ISO 2,4-diaminotoluene results in increased expression of SEMA6D mRNA CTD PMID:20713471 NCBI chr 3:131,801,680...132,394,578
Ensembl chr 3:132,337,343...132,394,584 		JBrowse link
G Sema7a semaphorin 7A (John Milton Hagen blood group) increases expression ISO 2,4-diaminotoluene results in increased expression of SEMA7A mRNA CTD PMID:20713471 NCBI chr 8:67,244,318...67,267,060
Ensembl chr 8:67,243,824...67,267,058 		JBrowse link
G Serpina7 serpin family A member 7 increases expression EXP 2,4-diaminotoluene results in increased expression of SERPINA7 mRNA CTD PMID:17070881 NCBI chr  X:107,452,044...107,510,958
Ensembl chr  X:107,452,044...107,457,681 		JBrowse link
G Serpine1 serpin family E member 1 increases expression ISO 2,4-diaminotoluene results in increased expression of SERPINE1 mRNA CTD PMID:22016648 NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357 		JBrowse link
G Shbg sex hormone binding globulin increases expression EXP 2,4-diaminotoluene results in increased expression of SHBG protein CTD PMID:3199457 NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760 		JBrowse link
G Shcbp1 SHC binding and spindle associated 1 increases expression ISO 2,4-diaminotoluene results in increased expression of SHCBP1 mRNA CTD PMID:20713471 NCBI chr16:91,373,843...91,405,409
Ensembl chr16:91,373,871...91,405,409 		JBrowse link
G Skic8 SKI8 subunit of superkiller complex increases expression ISO 2,4-diaminotoluene results in increased expression of SKIC8 mRNA CTD PMID:20713471 NCBI chr 8:63,999,669...64,016,959
Ensembl chr 8:63,999,671...64,016,846 		JBrowse link
G Slc16a10 solute carrier family 16 member 10 decreases expression EXP 2,4-diaminotoluene results in decreased expression of SLC16A10 mRNA CTD PMID:17070881 NCBI chr20:45,014,229...45,122,392
Ensembl chr20:45,014,235...45,122,358 		JBrowse link
G Slc16a6 solute carrier family 16, member 6 increases expression ISO 2,4-diaminotoluene results in increased expression of SLC16A6 mRNA CTD PMID:20713471 NCBI chr10:94,923,888...94,946,990
Ensembl chr10:94,923,888...94,947,965 		JBrowse link
G Slfn2 schlafen family member 2 increases expression ISO 2,4-diaminotoluene results in increased expression of SLFN2 mRNA CTD PMID:20713471 NCBI chr10:68,450,861...68,457,198
Ensembl chr10:68,455,363...68,457,329 		JBrowse link
G Slfn9 schlafen family member 9 increases expression ISO 2,4-diaminotoluene results in increased expression of SLFN9 mRNA CTD PMID:20713471 NCBI chr10:68,406,641...68,420,062
Ensembl chr10:68,406,642...68,421,134 		JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO 2,4-diaminotoluene results in increased expression of SLPI mRNA CTD PMID:20713471 NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822 		JBrowse link
G Sod1 superoxide dismutase 1 decreases expression ISO 2,4-diaminotoluene results in decreased expression of SOD1 mRNA CTD PMID:22016648 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399 		JBrowse link
G Spag5 sperm associated antigen 5 increases expression ISO 2,4-diaminotoluene results in increased expression of SPAG5 mRNA CTD PMID:20713471 NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,696,466...63,714,811 		JBrowse link
G Spc25 SPC25 component of NDC80 kinetochore complex increases expression ISO 2,4-diaminotoluene results in increased expression of SPC25 mRNA CTD PMID:20713471 NCBI chr 3:74,337,872...74,396,825
Ensembl chr 3:74,383,548...74,396,718 		JBrowse link
G Spink1 serine peptidase inhibitor, Kazal type 1 decreases expression EXP 2,4-diaminotoluene results in decreased expression of SPINK1 mRNA CTD PMID:17070881 NCBI chr18:36,121,626...36,133,596
Ensembl chr18:36,076,399...36,133,545 		JBrowse link
G Sqle squalene epoxidase decreases expression ISO 2,4-diaminotoluene results in decreased expression of SQLE mRNA CTD PMID:20713471 NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:92,757,409...92,773,050 		JBrowse link
G Stag1 STAG1 cohesin complex component decreases expression ISO 2,4-diaminotoluene results in decreased expression of STAG1 mRNA CTD PMID:20713471 NCBI chr 8:110,057,981...110,443,666
Ensembl chr 8:110,058,056...110,443,665 		JBrowse link
G Sugct succinylCoA:glutarate-CoA transferase decreases expression EXP 2,4-diaminotoluene results in decreased expression of SUGCT mRNA CTD PMID:17070881 NCBI chr17:52,072,012...52,929,852
Ensembl chr17:52,072,052...52,930,281 		JBrowse link
G Sulf2 sulfatase 2 increases expression EXP 2,4-diaminotoluene results in increased expression of SULF2 mRNA CTD PMID:17070881 NCBI chr 3:175,241,322...175,323,808
Ensembl chr 3:175,241,322...175,323,651 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 decreases expression EXP 2,4-diaminotoluene results in decreased expression of SULT2A1 mRNA CTD PMID:17070881 NCBI chr 1:84,582,011...84,639,001 JBrowse link
G Tapbpl TAP binding protein-like increases expression ISO 2,4-diaminotoluene results in increased expression of TAPBPL mRNA CTD PMID:20713471 NCBI chr 4:159,707,686...159,715,137
Ensembl chr 4:159,708,511...159,715,137 		JBrowse link
G Tbx18 T-box transcription factor 18 decreases expression ISO 2,4-diaminotoluene results in decreased expression of TBX18 mRNA CTD PMID:20713471 NCBI chr 8:97,531,960...97,559,988
Ensembl chr 8:97,531,960...97,559,965 		JBrowse link
G Tcp11l2 t-complex 11 like 2 decreases expression ISO 2,4-diaminotoluene results in decreased expression of TCP11L2 mRNA CTD PMID:20713471 NCBI chr 7:21,037,955...21,072,857
Ensembl chr 7:21,037,958...21,064,681 		JBrowse link
G Tecrl trans-2,3-enoyl-CoA reductase-like decreases expression ISO 2,4-diaminotoluene results in decreased expression of TECRL mRNA CTD PMID:20713471 NCBI chr14:25,086,930...25,159,957
Ensembl chr14:25,086,930...25,159,957 		JBrowse link
G Tenm4 teneurin transmembrane protein 4 increases expression ISO 2,4-diaminotoluene results in increased expression of TENM4 mRNA CTD PMID:20713471 NCBI chr 1:157,699,611...160,674,549
Ensembl chr 1:159,974,017...160,674,549 		JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 decreases expression ISO 2,4-diaminotoluene results in decreased expression of TIMP2 mRNA CTD PMID:22016648 NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214 		JBrowse link
G Tiparp TCDD-inducible poly(ADP-ribose) polymerase increases expression ISO 2,4-diaminotoluene results in increased expression of TIPARP mRNA CTD PMID:20713471 NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:152,063,751...152,090,406 		JBrowse link
G Tk1 thymidine kinase 1 increases expression
increases mutagenesis 		ISO 2,4-diaminotoluene results in increased expression of TK1 mRNA
2,4-diaminotoluene results in increased mutagenesis of TK1 gene 		CTD PMID:6694660 PMID:20713471 NCBI chr10:103,533,449...103,544,818
Ensembl chr10:103,533,449...103,556,228 		JBrowse link
G Tm4sf1 transmembrane 4 L six family member 1 increases expression ISO 2,4-diaminotoluene results in increased expression of TM4SF1 mRNA CTD PMID:20713471 NCBI chr 2:143,606,980...143,616,176
Ensembl chr 2:143,603,271...143,616,176 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 increases expression ISO 2,4-diaminotoluene results in increased expression of TNFRSF9 mRNA CTD PMID:20713471 NCBI chr 5:166,664,494...166,690,834
Ensembl chr 5:166,664,494...166,690,831 		JBrowse link
G Tnnt2 troponin T2, cardiac type increases expression ISO 2,4-diaminotoluene results in increased expression of TNNT2 mRNA CTD PMID:20713471 NCBI chr13:49,819,123...49,837,125
Ensembl chr13:49,822,304...49,837,125 		JBrowse link
G Top2a DNA topoisomerase II alpha increases expression ISO 2,4-diaminotoluene results in increased expression of TOP2A mRNA CTD PMID:20713471 NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366 		JBrowse link
G Tp63 tumor protein p63 decreases expression ISO 2,4-diaminotoluene results in decreased expression of TRP63 mRNA CTD PMID:20713471 NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177 		JBrowse link
G Tpd52 tumor protein D52 increases expression ISO 2,4-diaminotoluene results in increased expression of TPD52 mRNA CTD PMID:20713471 NCBI chr 2:94,642,514...94,723,442
Ensembl chr 2:94,642,585...94,724,241 		JBrowse link
G Trib2 tribbles pseudokinase 2 increases expression ISO 2,4-diaminotoluene results in increased expression of TRIB2 mRNA CTD PMID:20713471 NCBI chr 6:44,274,762...44,299,139
Ensembl chr 6:44,274,762...44,299,094 		JBrowse link
G Tspan8 tetraspanin 8 increases expression ISO 2,4-diaminotoluene results in increased expression of TSPAN8 mRNA CTD PMID:20713471 NCBI chr 7:53,331,019...53,365,402
Ensembl chr 7:53,330,963...53,365,401 		JBrowse link
G Ube2c ubiquitin-conjugating enzyme E2C increases expression ISO 2,4-diaminotoluene results in increased expression of UBE2C mRNA CTD PMID:20713471 NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678 		JBrowse link
G Upp1 uridine phosphorylase 1 increases expression ISO 2,4-diaminotoluene results in increased expression of UPP1 mRNA CTD PMID:20713471 NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034 		JBrowse link
G Usp17la ubiquitin specific peptidase 17-like A decreases expression ISO 2,4-diaminotoluene results in decreased expression of USP17LA mRNA CTD PMID:20713471 NCBI chr 1:168,577,824...168,581,601 JBrowse link
G Xdh xanthine dehydrogenase increases expression ISO 2,4-diaminotoluene results in increased expression of XDH mRNA CTD PMID:20713471 NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350 		JBrowse link
G Zbp1 Z-DNA binding protein 1 increases expression ISO 2,4-diaminotoluene results in increased expression of ZBP1 mRNA CTD PMID:20713471 NCBI chr 3:182,411,665...182,427,604
Ensembl chr 3:182,411,665...182,422,839 		JBrowse link
G Zfand2a zinc finger AN1-type containing 2A increases expression ISO 2,4-diaminotoluene results in increased expression of ZFAND2A mRNA CTD PMID:20713471 NCBI chr12:20,275,435...20,286,513
Ensembl chr12:20,275,450...20,286,513 		JBrowse link
G Zmat3 zinc finger, matrin type 3 increases expression EXP 2,4-diaminotoluene results in increased expression of ZMAT3 mRNA CTD PMID:17070881 NCBI chr 2:117,034,517...117,066,141
Ensembl chr 2:117,034,517...117,065,294 		JBrowse link
2,4-dichloroaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
2,4-dimethylaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
2,5-dimethylaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nat2 N-acetyltransferase 2 increases metabolic processing ISO NAT2 protein results in increased metabolism of 2,5-xylidene CTD PMID:33136180 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
2,6-dimethylaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 affects metabolic processing
multiple interactions 		ISO CYP2E1 protein affects the metabolism of 2,6-xylidine metabolite
fomepizole inhibits the reaction [CYP2E1 protein affects the metabolism of 2,6-xylidine metabolite] 		CTD PMID:11409937 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
2-amino-4,6-dinitrotoluene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc3 ATP binding cassette subfamily C member 3 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ABCC3 mRNA CTD PMID:21346803 NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of AKR7A3 mRNA CTD PMID:21346803 NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ALDH1A1 mRNA CTD PMID:21346803 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ALDH1B1 mRNA CTD PMID:21346803 NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365 		JBrowse link
G Alms1 ALMS1, centrosome and basal body associated protein affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ALMS1 mRNA CTD PMID:21346803 NCBI chr 4:119,683,085...119,783,471
Ensembl chr 4:119,683,076...119,783,471 		JBrowse link
G Atad1 ATPase family, AAA domain containing 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ATAD1 mRNA CTD PMID:21346803 NCBI chr 1:239,957,329...240,023,792
Ensembl chr 1:239,957,882...240,009,822 		JBrowse link
G Bspry B-box and SPRY domain containing affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of BSPRY mRNA CTD PMID:21346803 NCBI chr 5:80,942,974...80,965,157
Ensembl chr 5:80,942,979...80,988,154 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of CDKN1A mRNA CTD PMID:21346803 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Chchd6 coiled-coil-helix-coiled-coil-helix domain containing 6 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of CHCHD6 mRNA CTD PMID:21346803 NCBI chr 4:123,360,729...123,581,429
Ensembl chr 4:123,349,187...123,581,421 		JBrowse link
G Cryl1 crystallin, lambda 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of CRYL1 mRNA CTD PMID:21346803 NCBI chr15:35,542,628...35,661,563
Ensembl chr15:35,542,628...35,661,563 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of CYP1A1 mRNA CTD PMID:21346803 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of CYP1A2 mRNA CTD PMID:21346803 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Dusp13b dual specificity phosphatase 13B affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of DUSP13B mRNA CTD PMID:21346803 NCBI chr15:2,616,761...2,624,434
Ensembl chr15:2,609,049...2,624,887 		JBrowse link
G Entpd5 ectonucleoside triphosphate diphosphohydrolase 5 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ENTPD5 mRNA CTD PMID:21346803 NCBI chr 6:109,750,210...109,786,376
Ensembl chr 6:109,753,204...109,786,495 		JBrowse link
G Evl Enah/Vasp-like affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of EVL mRNA CTD PMID:21346803 NCBI chr 6:133,238,547...133,358,730
Ensembl chr 6:133,238,547...133,358,729 		JBrowse link
G Glul glutamate-ammonia ligase affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of GLUL mRNA CTD PMID:21346803 NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520 		JBrowse link
G Gpr68 G protein-coupled receptor 68 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of GPR68 mRNA CTD PMID:21346803 NCBI chr 6:125,865,205...125,895,674
Ensembl chr 6:125,864,942...125,895,674 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of GSTM1 mRNA CTD PMID:21346803 NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of GSTP1 mRNA; 2-amino-4,6-dinitrotoluene affects the expression of GSTP2 mRNA CTD PMID:21346803 NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705 		JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of HSD17B2 mRNA CTD PMID:21346803 NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of HSP90AA1 mRNA CTD PMID:21346803 NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of HSP90AB1 mRNA CTD PMID:21346803 NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of HSPB1 mRNA CTD PMID:21346803 NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Mt1a metallothionein 1A affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of MT1A mRNA CTD PMID:21346803 NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr  X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200 		JBrowse link
G Nectin1 nectin cell adhesion molecule 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of NECTIN1 mRNA CTD PMID:21346803 NCBI chr 8:52,998,662...53,061,745
Ensembl chr 8:52,998,662...53,086,664 		JBrowse link
G Nedd9 neural precursor cell expressed, developmentally down-regulated 9 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of NEDD9 mRNA CTD PMID:21346803 NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of NQO1 mRNA CTD PMID:21346803 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr1d1 nuclear receptor subfamily 1, group D, member 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of NR1D1 mRNA CTD PMID:21346803 NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812 		JBrowse link
G Oat ornithine aminotransferase affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of OAT mRNA CTD PMID:21346803 NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754 		JBrowse link
G Panx2 pannexin 2 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of PANX2 mRNA CTD PMID:21346803 NCBI chr 7:122,018,937...122,032,009
Ensembl chr 7:122,018,937...122,032,004 		JBrowse link
G Pir pirin affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of PIR mRNA CTD PMID:21346803 NCBI chr  X:33,740,428...33,851,049
Ensembl chr  X:33,740,429...33,851,049 		JBrowse link
G Ropn1 rhophilin associated tail protein 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ROPN1 mRNA CTD PMID:21346803 NCBI chr11:79,603,053...79,632,344
Ensembl chr11:79,603,055...79,632,344 		JBrowse link
G Serpina6 serpin family A member 6 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of SERPINA6 mRNA CTD PMID:21346803 NCBI chr 6:128,544,828...128,555,064
Ensembl chr 6:128,544,831...128,555,139 		JBrowse link
G Sgk2 serum/glucocorticoid regulated kinase 2 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of SGK2 mRNA CTD PMID:21346803 NCBI chr 3:172,063,625...172,089,000
Ensembl chr 3:172,063,776...172,089,011 		JBrowse link
G Slc35b4 solute carrier family 35 member B4 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of SLC35B4 mRNA CTD PMID:21346803 NCBI chr 4:63,744,188...63,766,200
Ensembl chr 4:63,744,188...63,766,196 		JBrowse link
G Sord sorbitol dehydrogenase affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of SORD mRNA CTD PMID:21346803 NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100 		JBrowse link
G Styxl1 serine/threonine/tyrosine interacting-like 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of STYXL1 mRNA CTD PMID:21346803 NCBI chr12:26,544,059...26,576,365
Ensembl chr12:26,544,067...26,576,366 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of SULT1A1 mRNA CTD PMID:21346803 NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131 		JBrowse link
G Tnr tenascin R affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of TNR mRNA CTD PMID:21346803 NCBI chr13:74,285,141...74,706,174
Ensembl chr13:74,507,366...74,701,115 		JBrowse link
G Tp53 tumor protein p53 increases expression
increases activity 		ISO 2-amino-4,6-dinitrotoluene results in increased expression of TP53 protein
2-amino-4,6-dinitrotoluene results in increased activity of TP53 protein 		CTD PMID:14577614 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Trib1 tribbles pseudokinase 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of TRIB1 mRNA CTD PMID:21346803 NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:93,095,973...93,117,480 		JBrowse link
G Trim2 tripartite motif-containing 2 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of TRIM2 mRNA CTD PMID:21346803 NCBI chr 2:171,798,654...171,950,193
Ensembl chr 2:171,798,660...171,913,468 		JBrowse link
G Tubb2b tubulin, beta 2B class IIb affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of TUBB2B mRNA CTD PMID:21346803 NCBI chr17:30,953,086...30,956,133
Ensembl chr17:30,952,923...30,955,990 		JBrowse link
G Tubb6 tubulin, beta 6 class V affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of TUBB6 mRNA CTD PMID:21346803 NCBI chr18:63,213,287...63,222,926
Ensembl chr18:63,213,279...63,224,303 		JBrowse link
G Tymp thymidine phosphorylase affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of TYMP mRNA CTD PMID:21346803 NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of UGT1A2 mRNA CTD PMID:21346803 NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt1a6a UDP glucuronosyltransferase family 1 member A6a affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of UGT1A6 mRNA CTD PMID:21346803 NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Wfdc3 WAP four-disulfide core domain 3 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of WFDC3 mRNA CTD PMID:21346803 NCBI chr 3:173,884,206...173,898,294
Ensembl chr 3:173,884,206...173,898,294 		JBrowse link
G Zap70 zeta chain of T cell receptor associated protein kinase 70 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ZAP70 mRNA CTD PMID:21346803 NCBI chr 9:46,485,605...46,507,552
Ensembl chr 9:46,485,598...46,509,062 		JBrowse link
G Zcwpw1 zinc finger CW-type and PWWP domain containing 1 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ZCWPW1 mRNA CTD PMID:21346803 NCBI chr12:24,517,428...24,547,942
Ensembl chr12:24,516,574...24,548,630 		JBrowse link
G Zdhhc6 zinc finger DHHC-type palmitoyltransferase 6 affects expression EXP 2-amino-4,6-dinitrotoluene affects the expression of ZDHHC6 mRNA CTD PMID:21346803 NCBI chr 1:264,340,883...264,361,435
Ensembl chr 1:264,317,494...264,361,435 		JBrowse link
2-amino-4-methylphenol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc7a11 solute carrier family 7 member 11 affects response to substance ISO SLC7A11 gene SNP affects the susceptibility to 2-amino-4-methylphenol CTD PMID:25622337 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
2-aminobiphenyl term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO 2-aminodiphenyl inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:18324785 NCBI chr  X:67,135,317...67,304,476
Ensembl chr  X:67,135,317...67,304,467 		JBrowse link
G Atf2 activating transcription factor 2 increases phosphorylation
multiple interactions 		ISO 2-aminodiphenyl results in increased phosphorylation of ATF2 protein
2-aminodiphenyl results in increased expression of and results in increased phosphorylation of ATF2 protein; acetovanillone inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of ATF2 protein]; Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of ATF2 protein]; U 0126 inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of ATF2 protein]; U 0126 inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of ATF2 protein] 		CTD PMID:22288910 PMID:23836369 NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity 		ISO Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased activity of CASP3 protein] CTD PMID:23836369 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
increases expression 		ISO CYBA mutant form inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]
2-aminodiphenyl results in increased expression of CYBA protein 		CTD PMID:22288910 NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO 2-aminodiphenyl results in increased expression of and results in increased phosphorylation of JUN protein; 2-aminodiphenyl results in increased phosphorylation of and results in increased expression of JUN protein; [U 0126 co-treated with pyrazolanthrone] inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of and results in increased expression of JUN protein]; acetovanillone inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of and results in increased expression of JUN protein]; Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of and results in increased expression of JUN protein]; JUN mutant form inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of JUN protein]; U 0126 inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of JUN protein] CTD PMID:22288910 PMID:23836369 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO MAP2K1 protein promotes the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein] CTD PMID:22288910 NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions 		ISO 2-aminodiphenyl results in increased phosphorylation of MAPK1 protein
acetovanillone inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK1 protein] 		CTD PMID:22288910 PMID:23836369 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions 		ISO 2-aminodiphenyl results in increased phosphorylation of MAPK3 protein
acetovanillone inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK3 protein] 		CTD PMID:22288910 PMID:23836369 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions 		ISO 2-aminodiphenyl results in increased phosphorylation of MAPK8 protein
Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK8 protein] 		CTD PMID:23836369 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
increases phosphorylation 		ISO Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of MAPK9 protein] CTD PMID:23836369 NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228 		JBrowse link
G Ogg1 8-oxoguanine DNA glycosylase decreases expression ISO 2-aminodiphenyl results in decreased expression of OGG1 mRNA; 2-aminodiphenyl results in decreased expression of OGG1 protein CTD PMID:16112689 NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions 		ISO 2-aminodiphenyl results in increased expression of PTGS2 mRNA; 2-aminodiphenyl results in increased expression of PTGS2 protein
acetovanillone inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; Acetylcysteine inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; CYBA mutant form inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; diphenyleneiodonium inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; JUN mutant form inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; MAP2K1 protein promotes the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; pyrazolanthrone promotes the reaction [U 0126 inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]]; tanshinone inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]; U 0126 inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein] 		CTD PMID:22288910 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
2-aminophenol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1c2 aldo-keto reductase family 1, member C2 increases expression ISO 2-aminophenol results in increased expression of AKR1C2 mRNA CTD PMID:20491607 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression ISO 2-aminophenol results in increased expression of CYP1A1 mRNA CTD PMID:20491607 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO 2-aminophenol results in increased expression of HMOX1 mRNA CTD PMID:20491607 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
affects response to substance 		ISO 2-aminophenol results in increased expression of NQO1 mRNA
NQO1 gene SNP affects the susceptibility to 2-aminophenol 		CTD PMID:20491607 PMID:25622337 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 affects response to substance ISO NR3C1 gene SNP affects the susceptibility to 2-aminophenol CTD PMID:25622337 NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843 		JBrowse link
G Rnf115 ring finger protein 115 affects response to substance ISO RNF115 gene SNP affects the susceptibility to 2-aminophenol CTD PMID:25622337 NCBI chr 2:186,950,959...187,018,673
Ensembl chr 2:186,950,760...187,019,561 		JBrowse link
2-aminothiophenol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G C1s complement C1s multiple interactions ISO 2-aminothiophenol inhibits the reaction [C4A protein binds to C1S protein]; 2-aminothiophenol inhibits the reaction [C4B protein binds to C1S protein] CTD PMID:8435078 NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736 		JBrowse link
G C4a complement C4A (Rodgers blood group) multiple interactions ISO 2-aminothiophenol inhibits the reaction [C4A protein binds to C1S protein] CTD PMID:8435078 NCBI chr20:4,010,306...4,024,707 JBrowse link
G C4b complement C4B multiple interactions ISO 2-aminothiophenol inhibits the reaction [C4B protein binds to C1S protein] CTD PMID:8435078 NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,201,961...4,216,289 		JBrowse link
3,4-dichloroaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acss2 acyl-CoA synthetase short-chain family member 2 decreases expression EXP 3,4-dichloroaniline results in decreased expression of ACSS2 mRNA CTD PMID:24172598 NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830 		JBrowse link
G Acvr1c activin A receptor type 1C increases expression ISO 3,4-dichloroaniline results in increased expression of ACVR1C mRNA CTD PMID:24172598 NCBI chr 3:63,224,322...63,301,252
Ensembl chr 3:63,227,559...63,301,205 		JBrowse link
G Adamts9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 increases expression ISO 3,4-dichloroaniline results in increased expression of ADAMTS9 mRNA CTD PMID:24172598 NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876 		JBrowse link
G Ajuba ajuba LIM protein decreases expression ISO 3,4-dichloroaniline results in decreased expression of AJUBA mRNA CTD PMID:24172598 NCBI chr15:31,989,796...32,000,042
Ensembl chr15:31,989,799...32,000,042 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases expression ISO 3,4-dichloroaniline results in increased expression of AKR1C1 mRNA CTD PMID:24172598 NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 increases expression ISO 3,4-dichloroaniline results in increased expression of AKR1C2 mRNA CTD PMID:24172598 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO 3,4-dichloroaniline results in increased expression of AKR1C3 mRNA CTD PMID:24172598 NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438 		JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression EXP 3,4-dichloroaniline results in increased expression of ALDH1A3 mRNA CTD PMID:24172598 NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777 		JBrowse link
G Anln anillin, actin binding protein decreases expression ISO 3,4-dichloroaniline results in decreased expression of ANLN mRNA CTD PMID:24172598 NCBI chr 8:29,134,222...29,197,513
Ensembl chr 8:29,134,222...29,197,513 		JBrowse link
G Anp32e acidic nuclear phosphoprotein 32 family member E decreases expression ISO 3,4-dichloroaniline results in decreased expression of ANP32E mRNA CTD PMID:24172598 NCBI chr 2:186,161,520...186,177,984
Ensembl chr 2:186,161,532...186,177,986 		JBrowse link
G Antxr2 ANTXR cell adhesion molecule 2 increases expression ISO 3,4-dichloroaniline results in increased expression of ANTXR2 mRNA CTD PMID:24172598 NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168 		JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of AOX1 mRNA CTD PMID:24172598 NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980 		JBrowse link
G Ass1 argininosuccinate synthase 1 increases expression EXP 3,4-dichloroaniline results in increased expression of ASS1 mRNA CTD PMID:24172598 NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627 		JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO 3,4-dichloroaniline results in increased expression of ATF3 mRNA CTD PMID:24172598 NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 increases expression ISO 3,4-dichloroaniline results in increased expression of ATP6V0D2 mRNA CTD PMID:24172598 NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:38,133,158...38,182,245 		JBrowse link
G Axl Axl receptor tyrosine kinase decreases expression ISO 3,4-dichloroaniline results in decreased expression of AXL mRNA CTD PMID:24172598 NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009 		JBrowse link
G Bmp6 bone morphogenetic protein 6 increases expression ISO 3,4-dichloroaniline results in increased expression of BMP6 mRNA CTD PMID:24172598 NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261 		JBrowse link
G C3 complement C3 increases expression ISO
EXP 		3,4-dichloroaniline results in increased expression of C3 mRNA CTD PMID:24172598 NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339 		JBrowse link
G C5h1orf210 similar to human chromosome 1 open reading frame 210 increases expression ISO 3,4-dichloroaniline results in increased expression of C1ORF210 mRNA CTD PMID:24172598 NCBI chr 5:137,334,142...137,337,300
Ensembl chr 5:137,334,142...137,337,300 		JBrowse link
G Ccn1 cellular communication network factor 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of CCN1 mRNA CTD PMID:24172598 NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883 		JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression ISO 3,4-dichloroaniline results in decreased expression of CCN2 mRNA CTD PMID:24172598 NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976 		JBrowse link
G Cdcp1 CUB domain containing protein 1 increases expression ISO 3,4-dichloroaniline results in increased expression of CDCP1 mRNA CTD PMID:24172598 NCBI chr 8:131,706,140...131,742,799
Ensembl chr 8:131,706,140...131,742,877 		JBrowse link
G Ceacam1 CEA cell adhesion molecule 1 increases expression ISO 3,4-dichloroaniline results in increased expression of CEACAM1 mRNA CTD PMID:24172598 NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798 		JBrowse link
G Cep126 centrosomal protein 126 decreases expression ISO 3,4-dichloroaniline results in decreased expression of CEP126 mRNA CTD PMID:24172598 NCBI chr 8:13,485,211...13,552,711
Ensembl chr 8:13,490,685...13,552,221 		JBrowse link
G Cfap20dc CFAP20 domain containing increases expression ISO 3,4-dichloroaniline results in increased expression of CFAP20DC mRNA CTD PMID:24172598 NCBI chr15:18,661,562...18,907,226
Ensembl chr15:18,661,508...18,907,225 		JBrowse link
G Cfap263 cilia and flagella associated protein 263 decreases expression ISO 3,4-dichloroaniline results in decreased expression of CFAP263 mRNA CTD PMID:24172598 NCBI chr19:9,503,062...9,522,957
Ensembl chr19:9,503,066...9,522,957 		JBrowse link
G Cfap300 cilia and flagella associated protein 300 decreases expression ISO 3,4-dichloroaniline results in decreased expression of CFAP300 mRNA CTD PMID:24172598 NCBI chr 8:13,465,016...13,483,679
Ensembl chr 8:13,464,984...13,483,839 		JBrowse link
G Cldn11 claudin 11 decreases expression ISO 3,4-dichloroaniline results in decreased expression of CLDN11 mRNA CTD PMID:24172598 NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539 		JBrowse link
G Clgn calmegin increases expression ISO 3,4-dichloroaniline results in increased expression of CLGN mRNA CTD PMID:24172598 NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325 		JBrowse link
G Cndp1 carnosine dipeptidase 1 increases expression EXP 3,4-dichloroaniline results in increased expression of CNDP1 mRNA CTD PMID:24172598 NCBI chr18:80,254,499...80,305,845
Ensembl chr18:80,255,784...80,282,643 		JBrowse link
G Col8a1 collagen type VIII alpha 1 chain decreases expression ISO 3,4-dichloroaniline results in decreased expression of COL8A1 mRNA CTD PMID:24172598 NCBI chr11:56,245,998...56,378,586
Ensembl chr11:56,369,868...56,376,229 		JBrowse link
G Cstb cystatin B increases expression ISO 3,4-dichloroaniline results in increased expression of CSTB mRNA CTD PMID:24172598 NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,158...10,247,199 		JBrowse link
G Ctse cathepsin E increases expression EXP 3,4-dichloroaniline results in increased expression of CTSE mRNA CTD PMID:24172598 NCBI chr13:45,644,168...45,666,722
Ensembl chr13:45,644,147...45,666,722 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 increases expression EXP 3,4-dichloroaniline results in increased expression of CX3CL1 mRNA CTD PMID:24172598 NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of CYP17A1 mRNA CTD PMID:31100596 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 increases expression ISO 3,4-dichloroaniline results in increased expression of CYP19A1 mRNA CTD PMID:31100596 NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression ISO 3,4-dichloroaniline results in increased expression of CYP1A1 mRNA; 3,4-dichloroaniline results in increased expression of CYP1A1 protein CTD PMID:21784029 PMID:24172598 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases expression ISO 3,4-dichloroaniline results in increased expression of CYP1A2 mRNA; 3,4-dichloroaniline results in increased expression of CYP1A2 protein CTD PMID:21784029 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO 3,4-dichloroaniline results in increased expression of CYP1B1 mRNA CTD PMID:24172598 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 increases expression ISO 3,4-dichloroaniline results in increased expression of CYP4F3 mRNA CTD PMID:24172598 NCBI chr16:17,797,558...17,838,958
Ensembl chr16:17,740,001...17,838,958 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 increases expression ISO 3,4-dichloroaniline results in increased expression of DNAJB9 mRNA CTD PMID:24172598 NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344 		JBrowse link
G Dner delta/notch-like EGF repeat containing increases expression ISO 3,4-dichloroaniline results in increased expression of DNER mRNA CTD PMID:24172598 NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568 		JBrowse link
G Dpp4 dipeptidylpeptidase 4 increases expression ISO 3,4-dichloroaniline results in increased expression of DPP4 mRNA CTD PMID:24172598 NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422 		JBrowse link
G Dst dystonin decreases expression ISO 3,4-dichloroaniline results in decreased expression of DST mRNA CTD PMID:24172598 NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533 		JBrowse link
G Efemp1 EGF containing fibulin extracellular matrix protein 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of EFEMP1 mRNA CTD PMID:24172598 NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808 		JBrowse link
G Egr1 early growth response 1 decreases expression EXP 3,4-dichloroaniline results in decreased expression of EGR1 mRNA CTD PMID:24172598 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Elovl6 ELOVL fatty acid elongase 6 decreases expression EXP 3,4-dichloroaniline results in decreased expression of ELOVL6 mRNA CTD PMID:24172598 NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:220,738,064...220,845,549 		JBrowse link
G Eno2 enolase 2 increases expression ISO 3,4-dichloroaniline results in increased expression of ENO2 mRNA CTD PMID:24172598 NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220 		JBrowse link
G Entpd3 ectonucleoside triphosphate diphosphohydrolase 3 increases expression ISO 3,4-dichloroaniline results in increased expression of ENTPD3 mRNA CTD PMID:24172598 NCBI chr 8:129,124,540...129,155,528
Ensembl chr 8:129,124,709...129,156,252 		JBrowse link
G Erp27 endoplasmic reticulum protein 27 decreases expression ISO 3,4-dichloroaniline results in decreased expression of ERP27 mRNA CTD PMID:24172598 NCBI chr 4:171,535,845...171,552,848
Ensembl chr 4:171,535,847...171,553,072 		JBrowse link
G Fgfbp1 fibroblast growth factor binding protein 1 decreases expression EXP 3,4-dichloroaniline results in decreased expression of FGFBP1 mRNA CTD PMID:24172598 NCBI chr14:71,316,171...71,319,965
Ensembl chr14:71,317,065...71,320,309 		JBrowse link
G Fkbp1b FKBP prolyl isomerase 1B decreases expression ISO 3,4-dichloroaniline results in decreased expression of FKBP1B mRNA CTD PMID:24172598 NCBI chr 6:33,551,583...33,570,055
Ensembl chr 6:33,558,517...33,568,129 		JBrowse link
G Fstl1 follistatin-like 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of FSTL1 mRNA CTD PMID:24172598 NCBI chr11:76,400,870...76,454,053
Ensembl chr11:76,391,315...76,455,126 		JBrowse link
G Fyb1 FYN binding protein 1 increases expression ISO 3,4-dichloroaniline results in increased expression of FYB1 mRNA CTD PMID:24172598 NCBI chr 2:57,360,084...57,508,609
Ensembl chr 2:57,360,096...57,508,608 		JBrowse link
G Gask1b golgi associated kinase 1B decreases expression ISO 3,4-dichloroaniline results in decreased expression of GASK1B mRNA CTD PMID:24172598 NCBI chr 2:167,345,738...167,410,606
Ensembl chr 2:167,345,809...167,410,603 		JBrowse link
G Gdf15 growth differentiation factor 15 increases expression EXP 3,4-dichloroaniline results in increased expression of GDF15 mRNA CTD PMID:24172598 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Gjb6 gap junction protein, beta 6 decreases expression ISO 3,4-dichloroaniline results in decreased expression of GJB6 mRNA CTD PMID:24172598 NCBI chr15:35,400,147...35,410,649
Ensembl chr15:35,398,770...35,410,849 		JBrowse link
G H2ac6 H2A clustered histone 6 increases expression ISO 3,4-dichloroaniline results in increased expression of H2AC6 mRNA CTD PMID:24172598 NCBI chr17:47,403,701...47,404,167 JBrowse link
G Has2 hyaluronan synthase 2 increases expression ISO 3,4-dichloroaniline results in increased expression of HAS2 mRNA CTD PMID:24172598 NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression ISO 3,4-dichloroaniline results in increased expression of HPGD mRNA CTD PMID:24172598 NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831 		JBrowse link
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 increases expression ISO 3,4-dichloroaniline results in increased expression of HSD17B2 mRNA CTD PMID:24172598 NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 decreases expression EXP 3,4-dichloroaniline results in decreased expression of HSD17B7 mRNA CTD PMID:24172598 NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754 		JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 increases expression ISO 3,4-dichloroaniline results in increased expression of HSPA6 mRNA CTD PMID:24172598 NCBI chr13:85,805,911...85,807,052 JBrowse link
G Id3 inhibitor of DNA binding 3 decreases expression ISO 3,4-dichloroaniline results in decreased expression of ID3 mRNA CTD PMID:24172598 NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856 		JBrowse link
G Idi1 isopentenyl-diphosphate delta isomerase 1 decreases expression EXP 3,4-dichloroaniline results in decreased expression of IDI1 mRNA CTD PMID:24172598 NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524 		JBrowse link
G Ifitm3 interferon induced transmembrane protein 3 increases expression EXP 3,4-dichloroaniline results in increased expression of IFITM3 mRNA CTD PMID:24172598 NCBI chr 1:205,540,649...205,541,758
Ensembl chr 1:205,481,168...205,547,920 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 increases expression ISO 3,4-dichloroaniline results in increased expression of IGFBP3 mRNA CTD PMID:24172598 NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944 		JBrowse link
G Igfbp6 insulin-like growth factor binding protein 6 decreases expression EXP 3,4-dichloroaniline results in decreased expression of IGFBP6 mRNA CTD PMID:24172598 NCBI chr 7:135,154,919...135,159,550
Ensembl chr 7:135,154,685...135,159,795 		JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 increases expression ISO 3,4-dichloroaniline results in increased expression of IL1RL1 mRNA CTD PMID:24172598 NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:50,204,551...50,222,891 		JBrowse link
G Il1rn interleukin 1 receptor antagonist increases expression ISO 3,4-dichloroaniline results in increased expression of IL1RN mRNA CTD PMID:24172598 NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732 		JBrowse link
G Itga1 integrin subunit alpha 1 increases expression EXP 3,4-dichloroaniline results in increased expression of ITGA1 mRNA CTD PMID:24172598 NCBI chr 2:48,379,181...48,545,336
Ensembl chr 2:48,386,249...48,545,284 		JBrowse link
G Kcnj2 potassium inwardly-rectifying channel, subfamily J, member 2 decreases expression ISO 3,4-dichloroaniline results in decreased expression of KCNJ2 mRNA CTD PMID:24172598 NCBI chr10:96,560,225...96,570,788
Ensembl chr10:96,565,600...96,570,901 		JBrowse link
G Kif20a kinesin family member 20A decreases expression ISO 3,4-dichloroaniline results in decreased expression of KIF20A mRNA CTD PMID:24172598 NCBI chr18:26,504,422...26,512,908
Ensembl chr18:26,504,072...26,512,909 		JBrowse link
G Klhl13 kelch-like family member 13 decreases expression ISO 3,4-dichloroaniline results in decreased expression of KLHL13 mRNA CTD PMID:24172598 NCBI chr  X:118,747,298...118,912,279
Ensembl chr  X:118,747,298...118,855,035 		JBrowse link
G Klhl24 kelch-like family member 24 increases expression EXP 3,4-dichloroaniline results in increased expression of KLHL24 mRNA CTD PMID:24172598 NCBI chr11:94,348,024...94,382,085
Ensembl chr11:94,351,157...94,382,050 		JBrowse link
G Klrc3 killer cell lectin like receptor C3 decreases expression ISO 3,4-dichloroaniline results in decreased expression of KLRC3 mRNA CTD PMID:24172598 NCBI chr 4:164,791,102...164,798,758
Ensembl chr 4:164,791,128...164,798,758 		JBrowse link
G Klrg2 killer cell lectin like receptor G2 decreases expression ISO 3,4-dichloroaniline results in decreased expression of KLRG2 mRNA CTD PMID:24172598 NCBI chr 4:68,314,347...68,341,759
Ensembl chr 4:68,330,660...68,341,043 		JBrowse link
G Knl1 kinetochore scaffold 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of KNL1 mRNA CTD PMID:24172598 NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:126,483,544...126,545,774 		JBrowse link
G Krt34 keratin 34 increases expression ISO 3,4-dichloroaniline results in increased expression of KRT34 mRNA CTD PMID:24172598 NCBI chr10:85,470,391...85,474,501
Ensembl chr10:85,470,391...85,474,501 		JBrowse link
G Lamb3 laminin subunit beta 3 increases expression ISO 3,4-dichloroaniline results in increased expression of LAMB3 mRNA CTD PMID:24172598 NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081 		JBrowse link
G Lcn2 lipocalin 2 increases expression ISO
EXP 		3,4-dichloroaniline results in increased expression of LCN2 mRNA CTD PMID:24172598 NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842 		JBrowse link
G Maf MAF bZIP transcription factor increases expression ISO 3,4-dichloroaniline results in increased expression of MAF mRNA CTD PMID:24172598 NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378 		JBrowse link
G Matn3 matrilin 3 decreases expression ISO 3,4-dichloroaniline results in decreased expression of MATN3 mRNA CTD PMID:24172598 NCBI chr 6:37,467,729...37,487,776
Ensembl chr 6:37,467,729...37,487,776 		JBrowse link
G Mctp1 multiple C2 and transmembrane domain containing 1 increases expression ISO 3,4-dichloroaniline results in increased expression of MCTP1 mRNA CTD PMID:24172598 NCBI chr 2:7,798,968...8,493,596
Ensembl chr 2:7,803,382...8,493,596 		JBrowse link
G Mex3b mex-3 RNA binding family member B increases expression EXP 3,4-dichloroaniline results in increased expression of MEX3B mRNA CTD PMID:24172598 NCBI chr 1:146,264,319...146,268,554
Ensembl chr 1:146,264,318...146,268,543 		JBrowse link
G Mical2 microtubule associated monooxygenase, calponin and LIM domain containing 2 increases expression ISO 3,4-dichloroaniline results in increased expression of MICAL2 mRNA CTD PMID:24172598 NCBI chr 1:175,780,441...175,965,157
Ensembl chr 1:175,825,596...175,905,155 		JBrowse link
G Mmp1 matrix metallopeptidase 1 increases expression ISO 3,4-dichloroaniline results in increased expression of MMP1 mRNA CTD PMID:24172598 NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964 		JBrowse link
G Mmp10 matrix metallopeptidase 10 increases expression ISO 3,4-dichloroaniline results in increased expression of MMP10 mRNA CTD PMID:24172598 NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:12,974,707...12,982,613 		JBrowse link
G Mmp13 matrix metallopeptidase 13 increases expression EXP 3,4-dichloroaniline results in increased expression of MMP13 mRNA CTD PMID:24172598 NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105 		JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression EXP 3,4-dichloroaniline results in increased expression of MMP3 mRNA CTD PMID:24172598 NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Msrb3 methionine sulfoxide reductase B3 decreases expression ISO 3,4-dichloroaniline results in decreased expression of MSRB3 mRNA CTD PMID:24172598 NCBI chr 7:58,188,827...58,311,459
Ensembl chr 7:57,968,124...58,311,116 		JBrowse link
G Muc1 mucin 1, cell surface associated increases expression ISO 3,4-dichloroaniline results in increased expression of MUC1 mRNA CTD PMID:24172598 NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:176,933,047...176,938,491 		JBrowse link
G Muc16 mucin 16, cell surface associated increases expression ISO 3,4-dichloroaniline results in increased expression of MUC16 mRNA CTD PMID:24172598 NCBI chr 8:24,440,840...24,644,494 JBrowse link
G Myo10 myosin X increases expression ISO 3,4-dichloroaniline results in increased expression of MYO10 mRNA CTD PMID:24172598 NCBI chr 2:77,831,532...78,036,137
Ensembl chr 2:77,831,532...78,036,137 		JBrowse link
G Nat2 N-acetyltransferase 2 increases acetylation ISO NAT2 protein results in increased acetylation of 3,4-dichloroaniline CTD PMID:15627487 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression ISO 3,4-dichloroaniline results in increased expression of NDRG1 mRNA CTD PMID:24172598 NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913 		JBrowse link
G Nedd9 neural precursor cell expressed, developmentally down-regulated 9 decreases expression
increases expression 		ISO
EXP 		3,4-dichloroaniline results in decreased expression of NEDD9 mRNA
3,4-dichloroaniline results in increased expression of NEDD9 mRNA 		CTD PMID:24172598 NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668 		JBrowse link
G Nt5e 5' nucleotidase, ecto increases expression ISO 3,4-dichloroaniline results in increased expression of NT5E mRNA CTD PMID:24172598 NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645 		JBrowse link
G Nusap1 nucleolar and spindle associated protein 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of NUSAP1 mRNA CTD PMID:24172598 NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:127,057,265...127,087,237 		JBrowse link
G Ostm1 osteoclastogenesis associated transmembrane protein 1 increases expression ISO 3,4-dichloroaniline results in increased expression of OSTM1 mRNA CTD PMID:24172598 NCBI chr20:47,653,696...47,769,248
Ensembl chr20:47,653,670...47,769,237 		JBrowse link
G Pappa pappalysin 1 increases expression ISO 3,4-dichloroaniline results in increased expression of PAPPA mRNA CTD PMID:24172598 NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:83,513,358...83,751,361 		JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 increases expression ISO 3,4-dichloroaniline results in increased expression of PDK4 mRNA CTD PMID:24172598 NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381 		JBrowse link
G Pgbd5 piggyBac transposable element derived 5 increases expression ISO 3,4-dichloroaniline results in increased expression of PGBD5 mRNA CTD PMID:24172598 NCBI chr19:69,234,171...69,299,315
Ensembl chr19:69,234,171...69,299,560 		JBrowse link
G Plaur plasminogen activator, urokinase receptor increases expression ISO 3,4-dichloroaniline results in increased expression of PLAUR mRNA CTD PMID:24172598 NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130 		JBrowse link
G Pld5 phospholipase D family, member 5 increases expression ISO 3,4-dichloroaniline results in increased expression of PLD5 mRNA CTD PMID:24172598 NCBI chr13:90,426,689...90,765,072
Ensembl chr13:90,428,490...90,783,066 		JBrowse link
G Plk2 polo-like kinase 2 decreases expression ISO 3,4-dichloroaniline results in decreased expression of PLK2 mRNA CTD PMID:24172598 NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296 		JBrowse link
G Prdm1 PR/SET domain 1 increases expression ISO 3,4-dichloroaniline results in increased expression of PRDM1 mRNA CTD PMID:24172598 NCBI chr20:49,542,465...49,564,088
Ensembl chr20:49,542,465...49,564,088 		JBrowse link
G Prnp prion protein decreases expression ISO 3,4-dichloroaniline results in decreased expression of PRNP mRNA CTD PMID:24172598 NCBI chr 3:139,639,076...139,654,420
Ensembl chr 3:139,630,144...139,658,436 		JBrowse link
G Prss23 serine protease 23 increases expression EXP 3,4-dichloroaniline results in increased expression of PRSS23 mRNA CTD PMID:24172598 NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:152,813,670...152,947,871 		JBrowse link
G Ptger4 prostaglandin E receptor 4 decreases expression ISO 3,4-dichloroaniline results in decreased expression of PTGER4 mRNA CTD PMID:24172598 NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:56,062,890...56,074,135 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO 3,4-dichloroaniline results in increased expression of PTGS2 mRNA CTD PMID:24172598 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Ptprz1 protein tyrosine phosphatase, receptor type Z1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of PTPRZ1 mRNA CTD PMID:24172598 NCBI chr 4:52,363,006...52,560,905
Ensembl chr 4:52,363,295...52,560,903 		JBrowse link
G Ralbp1 ralA binding protein 1 increases expression ISO 3,4-dichloroaniline results in increased expression of RALBP1 mRNA CTD PMID:24172598 NCBI chr 9:112,903,289...112,940,093
Ensembl chr 9:112,903,302...112,939,659 		JBrowse link
G Rarres1 retinoic acid receptor responder 1 increases expression ISO 3,4-dichloroaniline results in increased expression of RARRES1 mRNA CTD PMID:24172598 NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:154,059,761...154,094,024 		JBrowse link
G Rbck1 RANBP2-type and C3HC4-type zinc finger containing 1 increases expression ISO 3,4-dichloroaniline results in increased expression of RBCK1 mRNA CTD PMID:24172598 NCBI chr 3:161,249,389...161,266,321
Ensembl chr 3:161,249,390...161,266,032 		JBrowse link
G Rnf128 ring finger protein 128 increases expression EXP 3,4-dichloroaniline results in increased expression of RNF128 mRNA CTD PMID:24172598 NCBI chr  X:107,968,973...108,087,037
Ensembl chr  X:107,972,348...108,087,288 		JBrowse link
G Rora RAR-related orphan receptor A increases expression ISO 3,4-dichloroaniline results in increased expression of RORA mRNA CTD PMID:24172598 NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:78,182,620...78,915,730 		JBrowse link
G Scd stearoyl-CoA desaturase increases expression ISO 3,4-dichloroaniline results in increased expression of SCD mRNA CTD PMID:24172598 NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785 		JBrowse link
G Scg5 secretogranin V increases expression ISO 3,4-dichloroaniline results in increased expression of SCG5 mRNA CTD PMID:24172598 NCBI chr 3:120,998,420...121,042,881
Ensembl chr 3:120,998,420...121,042,795 		JBrowse link
G Scrn1 secernin 1 decreases expression EXP 3,4-dichloroaniline results in decreased expression of SCRN1 mRNA CTD PMID:24172598 NCBI chr 4:84,962,450...85,024,577
Ensembl chr 4:84,965,751...85,031,205 		JBrowse link
G Serpinb2 serpin family B member 2 increases expression
decreases expression 		ISO
EXP 		3,4-dichloroaniline results in increased expression of SERPINB2 mRNA
3,4-dichloroaniline results in decreased expression of SERPINB2 mRNA 		CTD PMID:24172598 NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031 		JBrowse link
G Slc16a6 solute carrier family 16, member 6 increases expression ISO 3,4-dichloroaniline results in increased expression of SLC16A6 mRNA CTD PMID:24172598 NCBI chr10:94,923,888...94,946,990
Ensembl chr10:94,923,888...94,947,965 		JBrowse link
G Slc1a6 solute carrier family 1 member 6 decreases expression ISO 3,4-dichloroaniline results in decreased expression of SLC1A6 mRNA CTD PMID:24172598 NCBI chr 7:11,492,422...11,521,007
Ensembl chr 7:11,492,422...11,553,997 		JBrowse link
G Slco4a1 solute carrier organic anion transporter family, member 4a1 increases expression ISO 3,4-dichloroaniline results in increased expression of SLCO4A1 mRNA CTD PMID:24172598 NCBI chr 3:187,936,735...187,955,873
Ensembl chr 3:187,936,820...187,955,871 		JBrowse link
G Smpd3 sphingomyelin phosphodiesterase 3 increases expression EXP 3,4-dichloroaniline results in increased expression of SMPD3 mRNA CTD PMID:24172598 NCBI chr19:51,072,209...51,155,639
Ensembl chr19:51,072,209...51,085,936 		JBrowse link
G Sohlh2 spermatogenesis and oogenesis specific basic helix-loop-helix 2 decreases expression ISO 3,4-dichloroaniline results in decreased expression of SOHLH2 mRNA CTD PMID:24172598 NCBI chr 2:141,512,410...141,534,864
Ensembl chr 2:141,512,293...141,534,863 		JBrowse link
G Sowaha sosondowah ankyrin repeat domain family member A decreases expression ISO 3,4-dichloroaniline results in decreased expression of SOWAHA mRNA CTD PMID:24172598 NCBI chr10:38,142,633...38,146,199
Ensembl chr10:38,144,782...38,147,171 		JBrowse link
G Spc24 SPC24 component of NDC80 kinetochore complex decreases expression ISO 3,4-dichloroaniline results in decreased expression of SPC24 mRNA CTD PMID:24172598 NCBI chr 8:28,576,409...28,581,481
Ensembl chr 8:28,576,409...28,581,299 		JBrowse link
G St6gal1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 increases expression EXP 3,4-dichloroaniline results in increased expression of ST6GAL1 mRNA CTD PMID:24172598 NCBI chr11:91,031,481...91,158,111
Ensembl chr11:91,032,450...91,040,415 		JBrowse link
G Star steroidogenic acute regulatory protein decreases expression ISO 3,4-dichloroaniline results in decreased expression of STAR mRNA CTD PMID:31100596 NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Sult1b1 sulfotransferase family 1B member 1 increases expression EXP 3,4-dichloroaniline results in increased expression of SULT1B1 mRNA CTD PMID:24172598 NCBI chr14:20,771,917...20,784,665
Ensembl chr14:20,771,868...20,785,549 		JBrowse link
G Sun3 Sad1 and UNC84 domain containing 3 increases expression ISO 3,4-dichloroaniline results in increased expression of SUN3 mRNA CTD PMID:24172598 NCBI chr14:87,923,891...87,962,699
Ensembl chr14:87,923,074...87,962,867 		JBrowse link
G Taf9b TATA-box binding protein associated factor 9b decreases expression ISO 3,4-dichloroaniline results in decreased expression of TAF9B mRNA CTD PMID:24172598 NCBI chr  X:75,354,823...75,366,166
Ensembl chr  X:75,354,825...75,366,414 		JBrowse link
G Tent5b terminal nucleotidyltransferase 5B decreases expression ISO 3,4-dichloroaniline results in decreased expression of TENT5B mRNA CTD PMID:24172598 NCBI chr 5:150,979,238...150,986,548
Ensembl chr11:27,212,316...27,214,238
Ensembl chr 5:27,212,316...27,214,238 		JBrowse link
G Tgfbi transforming growth factor, beta induced decreases expression EXP 3,4-dichloroaniline results in decreased expression of TGFBI mRNA CTD PMID:24172598 NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 increases expression ISO 3,4-dichloroaniline results in increased expression of TIMP1 mRNA CTD PMID:24172598 NCBI chr  X:3,766,509...3,772,578
Ensembl chr  X:3,766,510...3,771,135 		JBrowse link
G Tmcc3 transmembrane and coiled-coil domain family 3 increases expression ISO 3,4-dichloroaniline results in increased expression of TMCC3 mRNA CTD PMID:24172598 NCBI chr 7:30,781,452...31,058,888
Ensembl chr 7:30,897,991...31,058,889 		JBrowse link
G Tmem117 transmembrane protein 117 increases expression ISO 3,4-dichloroaniline results in increased expression of TMEM117 mRNA CTD PMID:24172598 NCBI chr 7:127,636,862...128,098,944
Ensembl chr 7:127,636,825...128,098,941 		JBrowse link
G Tmem154 transmembrane protein 154 increases expression ISO 3,4-dichloroaniline results in increased expression of TMEM154 mRNA CTD PMID:24172598 NCBI chr 2:172,313,290...172,352,939
Ensembl chr 2:172,313,240...172,361,723 		JBrowse link
G Tmem40 transmembrane protein 40 decreases expression ISO 3,4-dichloroaniline results in decreased expression of TMEM40 mRNA CTD PMID:24172598 NCBI chr 4:150,464,123...150,491,895
Ensembl chr 4:150,464,128...150,492,183 		JBrowse link
G Tnfaip8l1 TNF alpha induced protein 8 like 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of TNFAIP8L1 mRNA CTD PMID:24172598 NCBI chr 9:1,075,724...1,088,256
Ensembl chr 9:1,055,801...1,092,803 		JBrowse link
G Tnfsf13b TNF superfamily member 13b increases expression ISO 3,4-dichloroaniline results in increased expression of TNFSF13B mRNA CTD PMID:24172598 NCBI chr16:86,164,377...86,195,072
Ensembl chr16:86,164,377...86,194,499 		JBrowse link
G Tp63 tumor protein p63 decreases expression EXP 3,4-dichloroaniline results in decreased expression of TP63 mRNA CTD PMID:24172598 NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177 		JBrowse link
G Tprg1 tumor protein p63 regulated 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of TPRG1 mRNA CTD PMID:24172598 NCBI chr11:88,827,231...88,954,668
Ensembl chr11:88,827,231...88,954,668 		JBrowse link
G Trib3 tribbles pseudokinase 3 decreases expression EXP 3,4-dichloroaniline results in decreased expression of TRIB3 mRNA CTD PMID:24172598 NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802 		JBrowse link
G Trim59 tripartite motif-containing 59 decreases expression ISO 3,4-dichloroaniline results in decreased expression of TRIM59 mRNA CTD PMID:24172598 NCBI chr 2:155,579,183...155,593,450
Ensembl chr 2:155,567,115...155,598,645 		JBrowse link
G Trim6 tripartite motif containing 6 decreases expression ISO 3,4-dichloroaniline results in decreased expression of TRIM6 mRNA CTD PMID:24172598 NCBI chr 1:168,095,619...168,108,809
Ensembl chr 1:168,095,564...168,109,719 		JBrowse link
G Ubd ubiquitin D increases expression EXP 3,4-dichloroaniline results in increased expression of UBD mRNA CTD PMID:24172598 NCBI chr20:1,390,734...1,392,685
Ensembl chr20:1,390,600...1,413,965 		JBrowse link
G Vgll1 vestigial-like family member 1 decreases expression ISO 3,4-dichloroaniline results in decreased expression of VGLL1 mRNA CTD PMID:24172598 NCBI chr  X:140,016,938...140,036,348 JBrowse link
G Zbtb1 zinc finger and BTB domain containing 1 increases expression ISO 3,4-dichloroaniline results in increased expression of ZBTB1 mRNA CTD PMID:24172598 NCBI chr 6:100,832,506...100,864,019
Ensembl chr 6:100,838,714...100,852,643 		JBrowse link
G Zc3h13 zinc finger CCCH type containing 13 decreases expression EXP 3,4-dichloroaniline results in decreased expression of ZC3H13 mRNA CTD PMID:24172598 NCBI chr15:57,016,686...57,081,201
Ensembl chr15:57,016,781...57,081,201 		JBrowse link
G Zfp866 zinc finger protein 866 increases expression EXP 3,4-dichloroaniline results in increased expression of CXCL5 mRNA CTD PMID:24172598 NCBI chr16:19,687,869...19,710,407
Ensembl chr16:19,702,297...19,709,330 		JBrowse link
3,4-dimethylaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Nat1 N-acetyltransferase 1 increases metabolic processing ISO NAT1 protein results in increased metabolism of 3,4-xylidine CTD PMID:33136180 NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527 		JBrowse link
3-aminobenzamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]
3-aminobenzamide promotes the reaction [Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]]; 3-aminobenzamide promotes the reaction [Alitretinoin results in increased expression of ABCA1 mRNA]; 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA] 		CTD PMID:27026705 NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases expression EXP
ISO 		3-aminobenzamide results in increased expression of ADIPOQ mRNA CTD PMID:18815186 NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169 		JBrowse link
G Adipor1 adiponectin receptor 1 increases expression ISO
EXP 		3-aminobenzamide results in increased expression of ADIPOR1 mRNA CTD PMID:18815186 NCBI chr13:48,411,438...48,431,251
Ensembl chr13:48,411,826...48,431,255 		JBrowse link
G Adipor2 adiponectin receptor 2 increases expression EXP
ISO 		3-aminobenzamide results in increased expression of ADIPOR2 mRNA CTD PMID:18815186 NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:154,172,567...154,231,666 		JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein] CTD PMID:22226932 NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases expression ISO 3-aminobenzamide results in increased expression of BGLAP mRNA CTD PMID:15670817 NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318 		JBrowse link
G Casp3 caspase 3 multiple interactions EXP
ISO 		3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]
3-aminobenzamide inhibits the reaction [[oxyhyponitrite results in increased abundance of nitroxyl] which results in increased activity of CASP3 protein] 		CTD PMID:11744336 PMID:16505238 PMID:30377735 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp9 caspase 9 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein] CTD PMID:16505238 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO 3-aminobenzamide results in decreased expression of CCND1 mRNA CTD PMID:15670817 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Cd36 CD36 molecule increases expression EXP 3-aminobenzamide results in increased expression of CD36 mRNA CTD PMID:18815186 NCBI chr 4:18,209,088...18,302,142 JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO 3-aminobenzamide results in increased expression of CDKN1A mRNA CTD PMID:15670817 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Ctnnb1 catenin beta 1 decreases expression ISO 3-aminobenzamide results in decreased expression of CTNNB1 mRNA CTD PMID:15670817 NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein] CTD PMID:26600069 NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255 		JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein] CTD PMID:15670817 NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563 		JBrowse link
G Ep300 E1A binding protein p300 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of EP300 mRNA] CTD PMID:22228707 NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression 		ISO
EXP 		3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]
3-aminobenzamide results in decreased expression of ERCC1 mRNA; 3-aminobenzamide results in decreased expression of ERCC1 protein 		CTD PMID:22228707 NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120 		JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit multiple interactions
decreases expression 		ISO
EXP 		3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA]
3-aminobenzamide results in decreased expression of ERCC4 mRNA; 3-aminobenzamide results in decreased expression of ERCC4 protein 		CTD PMID:22228707 NCBI chr10:2,926,085...2,958,176
Ensembl chr10:2,920,455...2,955,539 		JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
affects response to substance 		ISO 3-aminobenzamide inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to 3-aminobenzamide 		CTD PMID:25440059 NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895 		JBrowse link
G Fn1 fibronectin 1 multiple interactions
decreases expression 		ISO
EXP 		3-aminobenzamide inhibits the reaction [Glucose results in increased expression of FN1 mRNA]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]
3-aminobenzamide results in decreased expression of FN1 protein 		CTD PMID:22228707 NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of HRAS protein] CTD PMID:26047893 NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590 		JBrowse link
G Id2 inhibitor of DNA binding 2 decreases expression ISO 3-aminobenzamide results in decreased expression of ID2 mRNA CTD PMID:15670817 NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:47,457,554...47,472,961 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] CTD PMID:19962977 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression ISO 3-aminobenzamide results in decreased expression of JUN mRNA CTD PMID:15670817 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285 		JBrowse link
G Lep leptin increases expression EXP 3-aminobenzamide results in increased expression of LEP mRNA CTD PMID:18815186 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661 		JBrowse link
G Lpl lipoprotein lipase increases expression EXP 3-aminobenzamide results in increased expression of LPL mRNA CTD PMID:18815186 NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107 		JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO
EXP 		3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]
3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA protein] 		CTD PMID:16505238 NCBI chr 7:109,313,021...109,315,813
Ensembl chr 7:109,313,121...109,315,760 		JBrowse link
G Mir126a microRNA 126a decreases expression
multiple interactions 		ISO 3-aminobenzamide results in decreased expression of MIR126 mRNA
3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]; [Decitabine co-treated with 3-aminobenzamide] inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA] 		CTD PMID:32006662 NCBI chr 3:29,813,150...29,813,267 JBrowse link
G Mpo myeloperoxidase multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MPO protein] CTD PMID:19962977 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO 3-aminobenzamide results in decreased expression of MYC mRNA CTD PMID:15670817 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFKBIA mRNA] CTD PMID:19962977 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 decreases ADP-ribosylation ISO 3-aminobenzamide results in decreased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity 		ISO
EXP 		3-aminobenzamide inhibits the reaction [Asbestos, Amosite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Benzoyl Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased ADP-ribosylation of PARP1 protein modified form]; 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Lithocholic Acid analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [mezerein results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to [Potassium Dichromate co-treated with nickel sulfate]]; 3-aminobenzamide inhibits the reaction [Smoke analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased cleavage of and results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased expression of PARP1 protein]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [3-aminobenzamide results in decreased activity of PARP1 protein] which results in increased susceptibility to Cisplatin
3-aminobenzamide inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased cleavage of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein]
3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to Acetaminophen] 		CTD PMID:2120135 PMID:2126186 PMID:11217149 PMID:15075382 PMID:15601672 More... NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 affects binding ISO PARP2 protein binds to 3-aminobenzamide CTD PMID:20092359 NCBI chr15:26,494,722...26,517,893
Ensembl chr15:26,494,731...26,517,891 		JBrowse link
G Pcna proliferating cell nuclear antigen increases expression EXP 3-aminobenzamide results in increased expression of PCNA protein CTD PMID:11049868 NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901 		JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Palmitic Acid results in decreased expression of PDX1 protein] CTD PMID:19513971 NCBI chr12:12,793,957...12,799,156
Ensembl chr12:12,793,957...12,799,156 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases activity
multiple interactions
decreases ADP-ribosylation 		EXP 3-aminobenzamide results in increased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein]
3-aminobenzamide results in decreased ADP-ribosylation of PPARG protein 		CTD PMID:18815186 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104 		JBrowse link
G Prkdc protein kinase, DNA-activated, catalytic subunit multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of PRKDC protein] CTD PMID:22226932 NCBI chr11:98,544,952...98,762,499
Ensembl chr11:98,544,954...98,762,108 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein]; 3-aminobenzamide results in decreased phosphorylation of and results in increased activity of RB1 protein CTD PMID:15670817 NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP 3-aminobenzamide inhibits the reaction [Methylnitrosourea results in decreased expression of RELA protein modified form] CTD PMID:17137578 NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Sfrp1 secreted frizzled-related protein 1 multiple interactions EXP 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] CTD PMID:30377735 NCBI chr16:75,278,325...75,316,736
Ensembl chr16:75,278,325...75,316,736 		JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression ISO 3-aminobenzamide results in increased expression of SPP1 mRNA CTD PMID:15670817 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO 3-aminobenzamide inhibits the reaction [resveratrol results in increased phosphorylation of STK11 protein] CTD PMID:19620254 NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965 		JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO 3-aminobenzamide inhibits the reaction [TERT protein mutant form results in decreased susceptibility to temozolomide] CTD PMID:12488552 NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased expression of TP53 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] CTD PMID:22226932 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
3-Chloroaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
3-hydroxykynurenine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kmo kynurenine 3-monooxygenase multiple interactions EXP [KMO protein results in increased hydroxylation of Kynurenine] which results in increased chemical synthesis of 3-hydroxykynurenine CTD PMID:32243540 NCBI chr13:90,089,340...90,121,108
Ensembl chr13:90,089,463...90,125,151 		JBrowse link
4,4'-methylene-bis-(2-chloroaniline) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Methylenebis(chloroaniline) results in increased expression of AKR1B10 mRNA CTD PMID:26198647 NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847 		JBrowse link
G Alb albumin affects binding EXP Methylenebis(chloroaniline) binds to ALB protein CTD PMID:2019352 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 increases oxidation EXP CYP2B1 protein results in increased oxidation of Methylenebis(chloroaniline) CTD PMID:2908851 NCBI chr 1:90,646,098...90,669,762 JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases oxidation
multiple interactions 		ISO CYP3A4 protein results in increased oxidation of Methylenebis(chloroaniline)
alpha-naphthoflavone inhibits the reaction [CYP3A4 protein results in increased oxidation of Methylenebis(chloroaniline)]; Gestodene inhibits the reaction [CYP3A4 protein results in increased oxidation of Methylenebis(chloroaniline)]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased oxidation of Methylenebis(chloroaniline)] 		CTD PMID:1740010 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression ISO Methylenebis(chloroaniline) results in increased expression of GCLC mRNA CTD PMID:26198647 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression ISO Methylenebis(chloroaniline) results in increased expression of GCLM mRNA CTD PMID:26198647 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003 		JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 increases expression ISO Methylenebis(chloroaniline) results in increased expression of GPAT3 mRNA CTD PMID:26198647 NCBI chr14:9,018,762...9,072,552 JBrowse link
G Lif LIF, interleukin 6 family cytokine increases expression ISO Methylenebis(chloroaniline) results in increased expression of LIF mRNA CTD PMID:26198647 NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053 		JBrowse link
G Mpo myeloperoxidase affects metabolic processing ISO MPO protein affects the metabolism of Methylenebis(chloroaniline) CTD PMID:9288889 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Nat2 N-acetyltransferase 2 increases acetylation
affects binding 		ISO NAT2 protein results in increased acetylation of Methylenebis(chloroaniline); NAT2 protein results in increased acetylation of Methylenebis(chloroaniline) analog
Methylenebis(chloroaniline) binds to NAT2 protein 		CTD PMID:29180287 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 increases metabolic processing ISO PTGS1 protein results in increased metabolism of Methylenebis(chloroaniline) CTD PMID:11159734 NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases metabolic processing ISO PTGS2 protein results in increased metabolism of Methylenebis(chloroaniline) CTD PMID:11159734 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression ISO Methylenebis(chloroaniline) results in increased expression of SLC7A11 mRNA CTD PMID:26198647 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Methylenebis(chloroaniline) results in increased expression of SQSTM1 mRNA CTD PMID:26198647 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO Methylenebis(chloroaniline) results in increased expression of SRXN1 mRNA CTD PMID:26198647 NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765 		JBrowse link
4-amino-2,6-dinitrotoluene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aaas aladin WD repeat nucleoporin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AAAS mRNA CTD PMID:21346803 NCBI chr 7:135,342,901...135,362,545
Ensembl chr 7:135,342,901...135,362,545 		JBrowse link
G Abca8 ATP binding cassette subfamily A member 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ABCA8B mRNA CTD PMID:21346803 NCBI chr10:95,416,984...95,490,647
Ensembl chr10:95,416,205...95,490,452 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ABCC3 mRNA CTD PMID:21346803 NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ABCC4 mRNA CTD PMID:21346803 NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375 		JBrowse link
G Abce1 ATP binding cassette subfamily E member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ABCE1 mRNA CTD PMID:21346803 NCBI chr19:45,109,880...45,134,819
Ensembl chr19:45,109,906...45,134,819 		JBrowse link
G Abcf1 ATP binding cassette subfamily F member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ABCF1 mRNA CTD PMID:21346803 NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240 		JBrowse link
G Abcf2 ATP binding cassette subfamily F member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ABCF2 mRNA CTD PMID:21346803 NCBI chr 4:11,485,865...11,500,067
Ensembl chr 4:11,487,395...11,500,053 		JBrowse link
G Abtb3 ankyrin repeat and BTB domain containing 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ABTB3 mRNA CTD PMID:21346803 NCBI chr 7:19,922,883...20,199,740
Ensembl chr 7:19,923,814...20,198,110 		JBrowse link
G Acaa1a acetyl-CoA acyltransferase 1A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ACAA1 mRNA CTD PMID:21346803 NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:127,956,129...127,966,241 		JBrowse link
G Acaa2 acetyl-CoA acyltransferase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ACAA2 mRNA CTD PMID:21346803 NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420 		JBrowse link
G Aco2 aconitase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ACO2 mRNA CTD PMID:21346803 NCBI chr 7:115,265,816...115,308,931
Ensembl chr 7:115,265,791...115,308,892 		JBrowse link
G Actn3 actinin alpha 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ACTN3 mRNA CTD PMID:21346803 NCBI chr 1:211,588,473...211,604,401
Ensembl chr 1:211,588,474...211,604,401 		JBrowse link
G Adamts7 ADAM metallopeptidase with thrombospondin type 1 motif, 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ADAMTS7 mRNA CTD PMID:21346803 NCBI chr 8:99,584,529...99,624,132
Ensembl chr 8:99,584,529...99,624,132 		JBrowse link
G Adh6 alcohol dehydrogenase 6 (class V) affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ADH6 mRNA CTD PMID:21346803 NCBI chr 2:229,576,612...229,608,359
Ensembl chr 2:229,576,636...229,607,914 		JBrowse link
G Adprhl1 ADP-ribosylhydrolase like 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ADPRHL1 mRNA CTD PMID:21346803 NCBI chr16:82,985,355...83,017,240 JBrowse link
G Adprs ADP-ribosylserine hydrolase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ADPRS mRNA CTD PMID:21346803 NCBI chr 5:143,898,542...143,903,816
Ensembl chr 5:143,898,542...143,903,816 		JBrowse link
G Adsl adenylosuccinate lyase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ADSL mRNA CTD PMID:21346803 NCBI chr 7:114,359,440...114,383,618
Ensembl chr 7:114,359,440...114,384,872 		JBrowse link
G Afg3l2 AFG3 like matrix AAA peptidase subunit 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AFG3L2 mRNA CTD PMID:21346803 NCBI chr18:63,224,163...63,269,000
Ensembl chr18:63,224,163...63,269,000 		JBrowse link
G Ahsp alpha hemoglobin stabilizing protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AHSP mRNA CTD PMID:21346803 NCBI chr 1:192,310,306...192,315,943
Ensembl chr 1:192,310,244...192,315,942 		JBrowse link
G Aimp1 aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AIMP1 mRNA CTD PMID:21346803 NCBI chr 2:223,825,930...223,849,477
Ensembl chr 2:223,825,931...223,849,994 		JBrowse link
G Ak4 adenylate kinase 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AK4 mRNA CTD PMID:21346803 NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:121,154,572...121,214,401 		JBrowse link
G Akap5 A-kinase anchoring protein 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AKAP5 mRNA CTD PMID:21346803 NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AKR7A2 mRNA CTD PMID:21346803 NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:156,835,551...156,844,109 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AKR7A3 mRNA CTD PMID:21346803 NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153 		JBrowse link
G Akt1s1 AKT1 substrate 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AKT1S1 mRNA CTD PMID:21346803 NCBI chr 1:104,469,823...104,476,168
Ensembl chr 1:104,469,803...104,476,167 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ALDH1A1 mRNA CTD PMID:21346803 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ALDH1B1 mRNA CTD PMID:21346803 NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365 		JBrowse link
G Aldh1l1 aldehyde dehydrogenase 1 family, member L1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ALDH1L1 mRNA CTD PMID:21346803 NCBI chr 4:124,617,182...124,663,674
Ensembl chr 4:124,617,217...124,664,704 		JBrowse link
G Aldoa aldolase, fructose-bisphosphate A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ALDOA mRNA CTD PMID:21346803 NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211 		JBrowse link
G Alg12 ALG12, alpha-1,6-mannosyltransferase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ALG12 mRNA CTD PMID:21346803 NCBI chr 7:121,774,796...121,789,175
Ensembl chr 7:121,768,234...121,788,983 		JBrowse link
G Alg3 ALG3, alpha-1,3- mannosyltransferase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ALG3 mRNA CTD PMID:21346803 NCBI chr11:93,804,859...93,810,403
Ensembl chr11:93,804,891...93,812,060 		JBrowse link
G Amy2a3 amylase 2a3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AMY2A3 mRNA CTD PMID:21346803 NCBI chr 2:204,005,840...204,014,412
Ensembl chr 2:204,005,840...204,014,413 		JBrowse link
G Angptl4 angiopoietin-like 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ANGPTL4 mRNA CTD PMID:21346803 NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681 		JBrowse link
G Ankrd39 ankyrin repeat domain 39 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ANKRD39 mRNA CTD PMID:21346803 NCBI chr 9:46,277,659...46,286,050
Ensembl chr 9:46,279,952...46,286,043 		JBrowse link
G Anxa7 annexin A7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ANXA7 mRNA CTD PMID:21346803 NCBI chr15:3,869,180...3,897,827
Ensembl chr15:3,870,974...3,898,891 		JBrowse link
G Ap1g1 adaptor related protein complex 1 subunit gamma 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AP1G1 mRNA CTD PMID:21346803 NCBI chr19:54,654,101...54,740,586
Ensembl chr19:54,620,807...54,740,586 		JBrowse link
G Ap1m1 adaptor related protein complex 1 subunit mu 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AP1M1 mRNA CTD PMID:21346803 NCBI chr16:17,620,910...17,636,431
Ensembl chr16:17,616,187...17,636,462 		JBrowse link
G Ap3d1 adaptor related protein complex 3 subunit delta 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AP3D1 mRNA CTD PMID:21346803 NCBI chr 7:9,620,909...9,656,350
Ensembl chr 7:9,620,968...9,656,342 		JBrowse link
G Aqp2 aquaporin 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AQP2 mRNA CTD PMID:21346803 NCBI chr 7:132,590,286...132,595,321
Ensembl chr 7:132,590,225...132,595,319 		JBrowse link
G Aqp8 aquaporin 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of AQP8 mRNA CTD PMID:21346803 NCBI chr 1:187,424,314...187,430,243
Ensembl chr 1:187,424,417...187,430,242 		JBrowse link
G Arhgap32 Rho GTPase activating protein 32 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ARHGAP32 mRNA CTD PMID:21346803 NCBI chr 8:38,679,368...38,939,960
Ensembl chr 8:38,684,484...38,939,960 		JBrowse link
G Arid3b AT-rich interaction domain 3B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ARID3B mRNA CTD PMID:21346803 NCBI chr 8:67,089,141...67,136,764
Ensembl chr 8:67,083,802...67,152,245 		JBrowse link
G Ash2l ASH2 like histone lysine methyltransferase complex subunit affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ASH2L mRNA CTD PMID:21346803 NCBI chr16:72,943,527...72,966,791
Ensembl chr16:72,944,949...72,967,839 		JBrowse link
G Atad1 ATPase family, AAA domain containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATAD1 mRNA CTD PMID:21346803 NCBI chr 1:239,957,329...240,023,792
Ensembl chr 1:239,957,882...240,009,822 		JBrowse link
G Atad3a ATPase family, AAA domain containing 3A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATAD3A mRNA CTD PMID:21346803 NCBI chr 5:171,632,545...171,652,725
Ensembl chr 5:171,632,547...171,652,725 		JBrowse link
G Ate1 arginyltransferase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATE1 mRNA CTD PMID:21346803 NCBI chr 1:194,391,843...194,514,284
Ensembl chr 1:194,391,843...194,511,348 		JBrowse link
G Atf6 activating transcription factor 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATF6 mRNA CTD PMID:21346803 NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033 		JBrowse link
G Atg7 autophagy related 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATG7 mRNA CTD PMID:21346803 NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319 		JBrowse link
G Atic 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATIC mRNA CTD PMID:21346803 NCBI chr 9:80,614,311...80,634,360
Ensembl chr 9:80,614,283...80,635,756 		JBrowse link
G Atp2a2 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATP2A2 mRNA CTD PMID:21346803 NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934 		JBrowse link
G Atp6v0a1 ATPase H+ transporting V0 subunit a1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATP6V0A1 mRNA CTD PMID:21346803 NCBI chr10:86,436,089...86,490,185
Ensembl chr10:86,436,141...86,490,181 		JBrowse link
G Atp6v0e2 ATPase, H+ transporting V0 subunit e2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATP6V0E2 mRNA CTD PMID:21346803 NCBI chr 4:78,815,771...78,818,919
Ensembl chr 4:78,813,129...78,819,680 		JBrowse link
G Atp8b2 ATPase phospholipid transporting 8B2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ATP8B2 mRNA CTD PMID:21346803 NCBI chr 2:177,676,205...177,699,575
Ensembl chr 2:177,676,208...177,699,575 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BACH1 mRNA CTD PMID:21346803 NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277 		JBrowse link
G Banf1 barrier to autointegration nuclear assembly factor 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BANF1 mRNA CTD PMID:21346803 NCBI chr 1:212,101,523...212,103,568
Ensembl chr 1:212,101,523...212,103,552 		JBrowse link
G Baz1b bromodomain adjacent to zinc finger domain, 1B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BAZ1B mRNA CTD PMID:21346803 NCBI chr12:27,068,541...27,126,511
Ensembl chr12:27,068,541...27,126,511 		JBrowse link
G Bbx BBX high mobility group box domain containing affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BBX mRNA CTD PMID:21346803 NCBI chr11:63,850,034...64,097,700
Ensembl chr11:63,850,018...64,093,265 		JBrowse link
G Bcat2 branched chain amino acid transaminase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BCAT2 mRNA CTD PMID:21346803 NCBI chr 1:105,175,157...105,196,474
Ensembl chr 1:105,176,977...105,196,463 		JBrowse link
G Bcl7c BAF chromatin remodeling complex subunit BCL7C affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BCL7C mRNA CTD PMID:21346803 NCBI chr 1:191,703,432...191,754,751
Ensembl chr 1:191,691,089...191,754,641 		JBrowse link
G Bdkrb2 bradykinin receptor B2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BDKRB2 mRNA CTD PMID:21346803 NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:130,237,255...130,267,209 		JBrowse link
G Bmf Bcl2 modifying factor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BMF mRNA CTD PMID:21346803 NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258 		JBrowse link
G Bop1 BOP1 ribosomal biogenesis factor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BOP1 mRNA CTD PMID:21346803 NCBI chr 7:110,052,716...110,076,529
Ensembl chr 7:110,052,720...110,076,529 		JBrowse link
G Bpifb2 BPI fold containing family B, member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BPIFB2 mRNA CTD PMID:21346803 NCBI chr 3:162,818,223...162,837,219
Ensembl chr 3:162,818,223...162,837,210 		JBrowse link
G Bpnt1 3'(2'), 5'-bisphosphate nucleotidase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BPNT1 mRNA CTD PMID:21346803 NCBI chr13:99,397,127...99,425,056
Ensembl chr13:99,400,115...99,425,053 		JBrowse link
G Brd1 bromodomain containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BRD1 mRNA CTD PMID:21346803 NCBI chr 7:121,653,859...121,701,700
Ensembl chr 7:121,653,859...121,701,700 		JBrowse link
G Brf2 BRF2 general transcription factor 3B subunit affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BRF2 mRNA CTD PMID:21346803 NCBI chr16:71,626,146...71,635,909
Ensembl chr16:71,623,238...71,635,903 		JBrowse link
G Bsn bassoon (presynaptic cytomatrix protein) affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BSN mRNA CTD PMID:21346803 NCBI chr 8:117,663,447...117,754,412
Ensembl chr 8:117,670,334...117,754,412 		JBrowse link
G Bspry B-box and SPRY domain containing affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BSPRY mRNA CTD PMID:21346803 NCBI chr 5:80,942,974...80,965,157
Ensembl chr 5:80,942,979...80,988,154 		JBrowse link
G Btbd9 BTB domain containing 9 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BTBD9 mRNA CTD PMID:21346803 NCBI chr20:8,287,813...8,645,437
Ensembl chr20:8,290,456...8,641,292 		JBrowse link
G Bysl bystin-like affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of BYSL mRNA CTD PMID:21346803 NCBI chr 9:20,880,341...20,890,092
Ensembl chr 9:20,880,026...20,890,900 		JBrowse link
G C1qc complement C1q C chain affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of C1QC mRNA CTD PMID:21346803 NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468 		JBrowse link
G Ca11 carbonic anhydrase 11 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CAR11 mRNA CTD PMID:21346803 NCBI chr 1:105,306,347...105,311,651
Ensembl chr 1:105,302,289...105,311,832 		JBrowse link
G Cad carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CAD mRNA CTD PMID:21346803 NCBI chr 6:31,012,091...31,035,098
Ensembl chr 6:31,012,091...31,035,297 		JBrowse link
G Capns1 calpain, small subunit 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CAPNS1 mRNA CTD PMID:21346803 NCBI chr 1:94,572,083...94,582,332
Ensembl chr 1:94,572,083...94,583,368 		JBrowse link
G Carm1 coactivator-associated arginine methyltransferase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CARM1 mRNA CTD PMID:21346803 NCBI chr 8:28,373,370...28,418,056
Ensembl chr 8:28,373,362...28,418,056 		JBrowse link
G Cast calpastatin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CAST mRNA CTD PMID:21346803 NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:5,707,640...5,817,180 		JBrowse link
G Catsper2 cation channel, sperm associated 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CATSPER2 mRNA CTD PMID:21346803 NCBI chr 3:128,822,387...128,842,501
Ensembl chr 3:128,822,391...128,842,261 		JBrowse link
G Cavin1 caveolae associated protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CAVIN1 mRNA CTD PMID:21346803 NCBI chr10:86,384,401...86,398,240
Ensembl chr10:86,384,401...86,396,383 		JBrowse link
G Cbarp CACN subunit beta associated regulatory protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CBARP mRNA CTD PMID:21346803 NCBI chr 7:10,217,314...10,225,855
Ensembl chr 7:10,217,328...10,225,854 		JBrowse link
G Cblb Cbl proto-oncogene B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CBLB mRNA CTD PMID:21346803 NCBI chr11:62,058,829...62,225,904
Ensembl chr11:62,061,653...62,225,778 		JBrowse link
G Cbr1 carbonyl reductase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CBR1 mRNA CTD PMID:21346803 NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104 		JBrowse link
G Cc2d1b coiled-coil and C2 domain containing 1B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CC2D1B mRNA CTD PMID:21346803 NCBI chr 5:128,581,962...128,596,045
Ensembl chr 5:128,581,994...128,596,022 		JBrowse link
G Ccdc92 coiled-coil domain containing 92 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CCDC92 mRNA CTD PMID:21346803 NCBI chr12:37,457,676...37,484,080
Ensembl chr12:37,457,068...37,484,327 		JBrowse link
G Ccl9 C-C motif chemokine ligand 9 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CCL6 mRNA CTD PMID:21346803 NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877 		JBrowse link
G Ccr5 C-C motif chemokine receptor 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CCR5 mRNA CTD PMID:21346803 NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:132,629,683...132,637,594 		JBrowse link
G Cct2 chaperonin containing TCP1 subunit 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CCT2 mRNA CTD PMID:21346803 NCBI chr 7:54,578,654...54,591,428
Ensembl chr 7:54,578,663...54,592,977 		JBrowse link
G Cct3 chaperonin containing TCP1 subunit 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CCT3 mRNA CTD PMID:21346803 NCBI chr 2:176,063,529...176,088,180
Ensembl chr 2:176,063,526...176,089,925 		JBrowse link
G Cct6a chaperonin containing TCP1 subunit 6A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CCT6A mRNA CTD PMID:21346803 NCBI chr12:32,508,842...32,519,072
Ensembl chr12:32,508,675...32,519,119 		JBrowse link
G Cd83 CD83 molecule affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CD83 mRNA CTD PMID:21346803 NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047 		JBrowse link
G Cdc42ep4 CDC42 effector protein 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CDC42EP4 mRNA CTD PMID:21346803 NCBI chr10:99,271,750...99,298,551
Ensembl chr10:99,267,540...99,300,168 		JBrowse link
G Cdc42ep5 CDC42 effector protein 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CDC42EP5 mRNA CTD PMID:21346803 NCBI chr 1:79,108,036...79,110,550 JBrowse link
G Cdk4 cyclin-dependent kinase 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CDK4 mRNA CTD PMID:21346803 NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163 		JBrowse link
G Cers5 ceramide synthase 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CERS5 mRNA CTD PMID:21346803 NCBI chr 7:132,738,834...132,776,920
Ensembl chr 7:132,738,834...132,776,786 		JBrowse link
G Chchd6 coiled-coil-helix-coiled-coil-helix domain containing 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CHCHD6 mRNA CTD PMID:21346803 NCBI chr 4:123,360,729...123,581,429
Ensembl chr 4:123,349,187...123,581,421 		JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CHD2 mRNA CTD PMID:21346803 NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335 		JBrowse link
G Chmp6 charged multivesicular body protein 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CHMP6 mRNA CTD PMID:21346803 NCBI chr10:105,690,400...105,696,070
Ensembl chr10:105,690,398...105,696,333 		JBrowse link
G Chordc1 cysteine and histidine rich domain containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CHORDC1 mRNA CTD PMID:21346803 NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696 		JBrowse link
G Cirbp cold inducible RNA binding protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CIRBP mRNA CTD PMID:21346803 NCBI chr 7:10,184,515...10,189,623 JBrowse link
G Ckap4 cytoskeleton-associated protein 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CKAP4 mRNA CTD PMID:21346803 NCBI chr 7:21,118,527...21,126,624
Ensembl chr 7:21,118,085...21,126,624 		JBrowse link
G Clcf1 cardiotrophin-like cytokine factor 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CLCF1 mRNA CTD PMID:21346803 NCBI chr 1:210,937,763...210,947,064
Ensembl chr 1:210,937,255...210,947,064 		JBrowse link
G Clip1 CAP-GLY domain containing linker protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CLIP1 mRNA CTD PMID:21346803 NCBI chr12:38,571,533...38,678,779
Ensembl chr12:38,571,834...38,678,779 		JBrowse link
G Cltb clathrin, light chain B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CLTB mRNA CTD PMID:21346803 NCBI chr17:10,006,416...10,024,278
Ensembl chr17:10,006,656...10,024,915 		JBrowse link
G Cnot4 CCR4-NOT transcription complex, subunit 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CNOT4 mRNA CTD PMID:21346803 NCBI chr 4:64,679,903...64,781,432
Ensembl chr 4:64,679,904...64,738,083 		JBrowse link
G Comt catechol-O-methyltransferase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of COMT mRNA CTD PMID:21346803 NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533 		JBrowse link
G Comtd1 catechol-O-methyltransferase domain containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of COMTD1 mRNA CTD PMID:21346803 NCBI chr15:2,509,121...2,512,232
Ensembl chr15:2,509,032...2,512,232 		JBrowse link
G Coq8b coenzyme Q8B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of COQ8B mRNA CTD PMID:21346803 NCBI chr 1:91,653,241...91,676,822
Ensembl chr 1:91,654,225...91,676,819 		JBrowse link
G Coro1a coronin 1A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CORO1A mRNA CTD PMID:21346803 NCBI chr 1:190,726,129...190,731,133
Ensembl chr 1:190,726,130...190,731,102 		JBrowse link
G Creld1 cysteine-rich with EGF-like domains 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CRELD1 mRNA CTD PMID:21346803 NCBI chr 4:148,187,510...148,197,120
Ensembl chr 4:148,187,265...148,197,116 		JBrowse link
G Creld2 cysteine-rich with EGF-like domains 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CRELD2 mRNA CTD PMID:21346803 NCBI chr 7:121,788,754...121,796,230
Ensembl chr 7:121,788,745...121,796,228 		JBrowse link
G Cryl1 crystallin, lambda 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CRYL1 mRNA CTD PMID:21346803 NCBI chr15:35,542,628...35,661,563
Ensembl chr15:35,542,628...35,661,563 		JBrowse link
G Cse1l chromosome segregation 1 like affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CSE1L mRNA CTD PMID:21346803 NCBI chr 3:176,060,183...176,097,909
Ensembl chr 3:176,060,215...176,108,734 		JBrowse link
G Csnk1e casein kinase 1, epsilon affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CSNK1E mRNA CTD PMID:21346803 NCBI chr 7:112,863,726...112,887,338
Ensembl chr 7:112,863,731...112,884,101 		JBrowse link
G Cstf3 cleavage stimulation factor subunit 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CSTF3 mRNA CTD PMID:21346803 NCBI chr 3:111,421,291...111,492,539
Ensembl chr 3:111,421,234...111,497,046 		JBrowse link
G Cul2 cullin 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CUL2 mRNA CTD PMID:21346803 NCBI chr17:58,864,274...58,905,447
Ensembl chr17:58,864,274...58,905,132 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CYP8B1 mRNA CTD PMID:21346803 NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689 		JBrowse link
G Dap death-associated protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DAP mRNA CTD PMID:21346803 NCBI chr 2:83,910,113...83,962,673
Ensembl chr 2:83,910,060...83,962,673 		JBrowse link
G Dapk2 death-associated protein kinase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DAPK2 mRNA CTD PMID:21346803 NCBI chr 8:75,601,621...75,720,619
Ensembl chr 8:75,601,634...75,720,617 		JBrowse link
G Dcaf4 DDB1 and CUL4 associated factor 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of WDR21 mRNA CTD PMID:21346803 NCBI chr 6:108,885,970...108,912,116
Ensembl chr 6:108,885,932...108,912,110 		JBrowse link
G Dcakd dephospho-CoA kinase domain containing affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DCAKD mRNA CTD PMID:21346803 NCBI chr10:88,457,829...88,489,011
Ensembl chr10:88,457,829...88,480,118 		JBrowse link
G Ddah1 dimethylarginine dimethylaminohydrolase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DDAH1 mRNA CTD PMID:21346803 NCBI chr 2:237,327,812...237,460,624
Ensembl chr 2:237,327,766...237,460,626 		JBrowse link
G Ddit4l DNA-damage-inducible transcript 4-like affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DDIT4L mRNA CTD PMID:21346803 NCBI chr 2:228,800,831...228,804,478
Ensembl chr 2:228,801,705...228,806,225 		JBrowse link
G Ddx18 DEAD-box helicase 18 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DDX18 mRNA CTD PMID:21346803 NCBI chr13:35,282,391...35,296,038
Ensembl chr13:35,282,467...35,295,972 		JBrowse link
G Ddx21 DExD-box helicase 21 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DDX21 mRNA CTD PMID:21346803 NCBI chr20:31,077,044...31,097,238
Ensembl chr20:31,077,045...31,097,238 		JBrowse link
G Ddx24 DEAD-box helicase 24 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DDX24 mRNA CTD PMID:21346803 NCBI chr 6:128,329,554...128,346,818
Ensembl chr 6:128,329,554...128,349,625 		JBrowse link
G Ddx39b DExD-box helicase 39B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DDX39B mRNA CTD PMID:21346803 NCBI chr20:3,577,200...3,589,651
Ensembl chr20:3,576,734...3,589,651 		JBrowse link
G Det1 DET1 partner of COP1 E3 ubiquitin ligase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DET1 mRNA CTD PMID:21346803 NCBI chr 1:142,159,120...142,175,366
Ensembl chr 1:142,127,876...142,175,336 		JBrowse link
G Dhcr7 7-dehydrocholesterol reductase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DHCR7 mRNA CTD PMID:21346803 NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382 		JBrowse link
G Dhodh dihydroorotate dehydrogenase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DHODH mRNA CTD PMID:21346803 NCBI chr19:54,460,636...54,483,049
Ensembl chr19:54,468,690...54,514,496 		JBrowse link
G Dhx36 DEAH-box helicase 36 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DHX36 mRNA CTD PMID:21346803 NCBI chr 2:149,006,089...149,044,192
Ensembl chr 2:149,006,089...149,044,191 		JBrowse link
G Disp1 dispatched RND transporter family member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DISP1 mRNA CTD PMID:21346803 NCBI chr13:97,252,574...97,398,329
Ensembl chr13:97,252,574...97,398,460 		JBrowse link
G Dkc1 dyskerin pseudouridine synthase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DKC1 mRNA CTD PMID:21346803 NCBI chr  X:157,751,651...157,757,796
Ensembl chr  Y:380,743...385,405
Ensembl chr  X:380,743...385,405 		JBrowse link
G Dlat dihydrolipoamide S-acetyltransferase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DLAT mRNA CTD PMID:21346803 NCBI chr 8:59,875,537...59,900,947
Ensembl chr 8:59,868,214...59,900,818
Ensembl chr 1:59,868,214...59,900,818 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DNAJB1 mRNA CTD PMID:21346803 NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416 		JBrowse link
G Dnajc11 DnaJ heat shock protein family (Hsp40) member C11 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DNAJC11 mRNA CTD PMID:21346803 NCBI chr 5:167,724,776...167,770,032
Ensembl chr 5:167,724,717...167,770,694 		JBrowse link
G Dnajc2 DnaJ heat shock protein family (Hsp40) member C2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DNAJC2 mRNA CTD PMID:21346803 NCBI chr 4:14,162,490...14,189,662
Ensembl chr 4:14,163,838...14,192,846 		JBrowse link
G Dnm1l dynamin 1-like affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DNM1L mRNA CTD PMID:21346803 NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420 		JBrowse link
G Dph5 diphthamide biosynthesis 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DPH5 mRNA CTD PMID:21346803 NCBI chr 2:206,489,556...206,540,590
Ensembl chr 2:206,489,556...206,523,556 		JBrowse link
G Drosha drosha ribonuclease III affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DROSHA mRNA CTD PMID:21346803 NCBI chr 2:63,591,885...63,703,688
Ensembl chr 2:63,591,968...63,703,687 		JBrowse link
G Dusp13b dual specificity phosphatase 13B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DUSP13B mRNA CTD PMID:21346803 NCBI chr15:2,616,761...2,624,434
Ensembl chr15:2,609,049...2,624,887 		JBrowse link
G Dynll1 dynein light chain LC8-type 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of DYNLL1 mRNA CTD PMID:21346803 NCBI chr12:46,945,291...46,976,867
Ensembl chr12:46,973,050...46,976,861 		JBrowse link
G Ebna1bp2 EBNA1 binding protein 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EBNA1BP2 mRNA CTD PMID:21346803 NCBI chr 5:137,433,534...137,438,100
Ensembl chr 5:137,433,226...137,438,637 		JBrowse link
G Eef2k eukaryotic elongation factor-2 kinase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EEF2K mRNA CTD PMID:21346803 NCBI chr 1:184,824,420...184,888,048
Ensembl chr 1:184,824,420...184,888,048 		JBrowse link
G Egfl8 EGF-like-domain, multiple 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NG3 mRNA CTD PMID:21346803 NCBI chr20:4,137,531...4,140,632
Ensembl chr20:4,138,053...4,141,681 		JBrowse link
G Ehmt1 euchromatic histone lysine methyltransferase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EHMT1 mRNA CTD PMID:21346803 NCBI chr 3:27,978,888...28,127,178
Ensembl chr 3:27,978,888...28,127,349 		JBrowse link
G Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EIF2AK2 mRNA CTD PMID:21346803 NCBI chr 6:21,941,147...21,977,115
Ensembl chr 6:21,952,631...21,977,116 		JBrowse link
G Eif2b2 eukaryotic translation initiation factor 2B subunit beta affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EIF2B2 mRNA CTD PMID:21346803 NCBI chr 6:110,597,979...110,604,403
Ensembl chr 6:110,597,729...110,604,403 		JBrowse link
G Eif2b3 eukaryotic translation initiation factor 2B subunit gamma affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EIF2B3 mRNA CTD PMID:21346803 NCBI chr 5:135,728,764...135,795,276
Ensembl chr 5:135,728,959...135,799,914 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EIF2S1 mRNA CTD PMID:21346803 NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649 		JBrowse link
G Eif3b eukaryotic translation initiation factor 3, subunit B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EIF3B mRNA CTD PMID:21346803 NCBI chr12:19,310,308...19,334,768
Ensembl chr12:19,310,311...19,334,939 		JBrowse link
G Eif4a1 eukaryotic translation initiation factor 4A1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EIF4A1 mRNA CTD PMID:21346803 NCBI chr10:54,883,093...54,888,602
Ensembl chr10:54,883,093...54,888,602 		JBrowse link
G Elp6 elongator acetyltransferase complex subunit 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ELP6 mRNA CTD PMID:21346803 NCBI chr 8:119,158,380...119,173,483
Ensembl chr 8:119,158,396...119,174,244 		JBrowse link
G Eng endoglin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ENG mRNA CTD PMID:21346803 NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:36,326,202...36,370,933 		JBrowse link
G Ep400 E1A binding protein p400 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EP400 mRNA CTD PMID:21346803 NCBI chr12:51,551,665...51,658,635
Ensembl chr12:51,551,695...51,658,634 		JBrowse link
G Epas1 endothelial PAS domain protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EPAS1 mRNA CTD PMID:21346803 NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729 		JBrowse link
G Ephx1 epoxide hydrolase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EPHX1 mRNA CTD PMID:21346803 NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ERCC1 mRNA CTD PMID:21346803 NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120 		JBrowse link
G Eya3 EYA transcriptional coactivator and phosphatase 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of EYA3 mRNA CTD PMID:21346803 NCBI chr 5:150,090,535...150,218,855
Ensembl chr 5:150,137,256...150,218,852 		JBrowse link
G Farsb phenylalanyl-tRNA synthetase subunit beta affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FARSB mRNA CTD PMID:21346803 NCBI chr 9:87,336,321...87,395,546
Ensembl chr 9:87,336,326...87,395,505 		JBrowse link
G Fat1 FAT atypical cadherin 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FAT1 mRNA CTD PMID:21346803 NCBI chr16:53,909,759...54,029,175
Ensembl chr16:53,909,556...54,028,609 		JBrowse link
G Fbxo21 F-box protein 21 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FBXO21 mRNA CTD PMID:21346803 NCBI chr12:44,231,918...44,266,035
Ensembl chr12:44,231,923...44,266,035 		JBrowse link
G Fcer2 Fc epsilon receptor II affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FCER2A mRNA CTD PMID:21346803 NCBI chr12:6,540,697...6,552,364
Ensembl chr12:6,540,703...6,549,374 		JBrowse link
G Fcgr3a Fc gamma receptor 3A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FCGR3A mRNA CTD PMID:21346803 NCBI chr13:85,782,636...85,792,656
Ensembl chr13:85,782,490...85,792,651 		JBrowse link
G Fdps farnesyl diphosphate synthase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FDPS mRNA CTD PMID:21346803 NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:176,795,192...176,807,136 		JBrowse link
G Fdxr ferredoxin reductase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FDXR mRNA CTD PMID:21346803 NCBI chr10:101,006,845...101,015,582
Ensembl chr10:101,006,849...101,015,542 		JBrowse link
G Fech ferrochelatase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FECH mRNA CTD PMID:21346803 NCBI chr18:60,215,325...60,248,525
Ensembl chr18:60,215,325...60,249,546 		JBrowse link
G Fkbp11 FKBP prolyl isomerase 11 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FKBP11 mRNA CTD PMID:21346803 NCBI chr 7:131,750,828...131,757,784
Ensembl chr 7:131,750,672...131,770,123 		JBrowse link
G Fkbp8 FKBP prolyl isomerase 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FKBP8 mRNA CTD PMID:21346803 NCBI chr16:18,929,581...18,936,621
Ensembl chr16:18,929,582...18,936,543 		JBrowse link
G Flot1 flotillin 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FLOT1 mRNA CTD PMID:21346803 NCBI chr20:2,922,662...2,932,906
Ensembl chr20:2,922,655...2,932,771 		JBrowse link
G Fnbp1 formin binding protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FNBP1 mRNA CTD PMID:21346803 NCBI chr 3:34,706,814...34,826,770
Ensembl chr 3:34,706,814...34,822,117 		JBrowse link
G Foxn3 forkhead box N3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of CHES1 mRNA CTD PMID:21346803 NCBI chr 6:124,191,695...124,572,070
Ensembl chr 6:124,195,701...124,572,040 		JBrowse link
G Ftsj1 FtsJ RNA 2'-O-methyltransferase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FTSJ1 mRNA CTD PMID:21346803 NCBI chr  X:16,915,087...16,929,426
Ensembl chr  X:16,916,033...16,923,999 		JBrowse link
G Ftsj3 FtsJ RNA 2'-O-methyltransferase 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of FTSJ3 mRNA CTD PMID:21346803 NCBI chr10:91,680,735...91,687,475
Ensembl chr10:91,680,753...91,687,179 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of G6PDX mRNA CTD PMID:21346803 NCBI chr  X:157,352,364...157,372,144
Ensembl chr  X:157,352,373...157,372,144 		JBrowse link
G Gaa alpha glucosidase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GAA mRNA CTD PMID:21346803 NCBI chr10:105,028,106...105,045,365
Ensembl chr10:105,028,307...105,045,366 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GAPDH mRNA CTD PMID:21346803 NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377 		JBrowse link
G Gars1 glycyl-tRNA synthetase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GARS1 mRNA CTD PMID:21346803 NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876 		JBrowse link
G Gart phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GART mRNA CTD PMID:21346803 NCBI chr11:44,351,841...44,377,086
Ensembl chr11:44,351,851...44,377,086 		JBrowse link
G Gbp2 guanylate binding protein 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GBP2 mRNA CTD PMID:21346803 NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GCLC mRNA CTD PMID:21346803 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gdf15 growth differentiation factor 15 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GDF15 mRNA CTD PMID:21346803 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GGT1 mRNA CTD PMID:21346803 NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050 		JBrowse link
G Glyatl2 glycine-N-acyltransferase-like 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KEG1 mRNA CTD PMID:21346803 NCBI chr 1:219,232,154...219,265,142
Ensembl chr 1:219,232,103...219,266,322 		JBrowse link
G Gnl3l G protein nucleolar 3 like affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GNL3L mRNA CTD PMID:21346803 NCBI chr  X:23,404,324...23,437,501
Ensembl chr  X:23,404,324...23,439,315 		JBrowse link
G Gosr2 golgi SNAP receptor complex member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GOSR2 mRNA CTD PMID:21346803 NCBI chr10:89,085,323...89,105,665
Ensembl chr10:89,086,331...89,105,637 		JBrowse link
G Gpat4 glycerol-3-phosphate acyltransferase 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GPAT4 mRNA CTD PMID:21346803 NCBI chr16:75,515,935...75,555,431
Ensembl chr16:75,521,640...75,557,847 		JBrowse link
G Gpi glucose-6-phosphate isomerase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GPI mRNA CTD PMID:21346803 NCBI chr 1:95,965,389...95,996,932
Ensembl chr 1:95,965,396...95,993,261 		JBrowse link
G Gpn2 GPN-loop GTPase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GPN2 mRNA CTD PMID:21346803 NCBI chr 5:151,093,279...151,101,114
Ensembl chr 5:151,093,418...151,101,111 		JBrowse link
G Grb7 growth factor receptor bound protein 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GRB7 mRNA CTD PMID:21346803 NCBI chr10:83,936,538...83,949,344
Ensembl chr10:83,939,299...83,949,382 		JBrowse link
G Grin2c glutamate ionotropic receptor NMDA type subunit 2C affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GRIN2C mRNA CTD PMID:21346803 NCBI chr10:100,987,410...101,006,064
Ensembl chr10:100,987,513...101,005,409 		JBrowse link
G Grm2 glutamate metabotropic receptor 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GRM2 mRNA CTD PMID:21346803 NCBI chr 8:116,158,810...116,171,857
Ensembl chr 8:116,158,810...116,171,857 		JBrowse link
G Grm3 glutamate metabotropic receptor 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GRM3 mRNA CTD PMID:21346803 NCBI chr 4:25,319,218...25,600,721
Ensembl chr 4:25,319,942...25,564,764 		JBrowse link
G Gsr glutathione-disulfide reductase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GSR mRNA CTD PMID:21346803 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394 		JBrowse link
G Gss glutathione synthetase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GSS mRNA CTD PMID:21346803 NCBI chr 3:164,508,005...164,538,343
Ensembl chr 3:164,508,005...164,538,306 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GSTM1 mRNA CTD PMID:21346803 NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GSTM4 mRNA CTD PMID:21346803 NCBI chr 2:198,356,114...198,373,487
Ensembl chr 2:198,358,744...198,373,638 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GSTP1 mRNA; 4-amino-2,6-dinitrotoluene affects the expression of GSTP2 mRNA CTD PMID:21346803 NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705 		JBrowse link
G Gtf2h1 general transcription factor IIH subunit 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GTF2H1 mRNA CTD PMID:21346803 NCBI chr 1:106,457,692...106,485,729
Ensembl chr 1:106,457,394...106,485,727 		JBrowse link
G Gtf3a general transcription factor III A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GTF3A mRNA CTD PMID:21346803 NCBI chr12:13,250,643...13,258,587
Ensembl chr12:13,250,644...13,258,587 		JBrowse link
G Gtpbp4 GTP binding protein 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GTPBP4 mRNA CTD PMID:21346803 NCBI chr17:65,997,472...66,019,530
Ensembl chr17:66,276,566...66,289,637 		JBrowse link
G Gzmb granzyme B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GZMB mRNA CTD PMID:21346803 NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469 		JBrowse link
G Gzmc granzyme C affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of GZMC mRNA CTD PMID:21346803 NCBI chr15:34,437,312...34,440,006
Ensembl chr15:34,437,317...34,440,048 		JBrowse link
G H1f0 H1.0 linker histone affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of H1F0 mRNA CTD PMID:21346803 NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006 		JBrowse link
G H1f4 H1.4 linker histone, cluster member affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of H1F4 mRNA CTD PMID:21346803 NCBI chr17:41,914,425...41,915,206
Ensembl chr17:41,914,431...41,916,129 		JBrowse link
G Hbe2 hemoglobin, epsilon 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HBE2 mRNA CTD PMID:21346803 NCBI chr 1:167,691,174...167,692,802
Ensembl chr 1:167,683,760...167,706,139 		JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HCK mRNA CTD PMID:21346803 NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935 		JBrowse link
G Hcn2 hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HCN2 mRNA CTD PMID:21346803 NCBI chr 7:10,620,422...10,639,457
Ensembl chr 7:10,620,422...10,639,457 		JBrowse link
G Hdac10 histone deacetylase 10 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HDAC10 mRNA CTD PMID:21346803 NCBI chr 7:122,078,768...122,084,457
Ensembl chr 7:122,078,768...122,083,870 		JBrowse link
G Hdc histidine decarboxylase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HDC mRNA CTD PMID:21346803 NCBI chr 3:134,300,628...134,318,704
Ensembl chr 3:134,300,632...134,318,711 		JBrowse link
G Heatr1 HEAT repeat containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HEATR1 mRNA CTD PMID:21346803 NCBI chr17:62,745,008...62,785,609
Ensembl chr17:62,745,008...62,785,186 		JBrowse link
G Hemk1 HemK methyltransferase family member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HEMK1 mRNA CTD PMID:21346803 NCBI chr 8:116,878,317...116,889,342
Ensembl chr 8:116,878,318...116,888,873 		JBrowse link
G Hes6 hes family bHLH transcription factor 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HES6 mRNA CTD PMID:21346803 NCBI chr 9:99,449,375...99,451,343
Ensembl chr 9:99,449,371...99,451,096 		JBrowse link
G Hgh1 HGH1 homolog affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HGH1 mRNA CTD PMID:21346803 NCBI chr 7:109,972,079...109,975,398
Ensembl chr 7:109,972,609...109,975,395 		JBrowse link
G Hk3 hexokinase 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HK3 mRNA CTD PMID:21346803 NCBI chr17:9,602,119...9,620,038
Ensembl chr17:9,605,016...9,620,037 		JBrowse link
G Hmgb1 high mobility group box 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HMGB1 mRNA CTD PMID:21346803 NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HMGCR mRNA CTD PMID:21346803 NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533 		JBrowse link
G Hmox1 heme oxygenase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HMOX1 mRNA CTD PMID:21346803 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hopx HOP homeobox affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HOPX mRNA CTD PMID:21346803 NCBI chr14:31,410,235...31,437,189
Ensembl chr14:31,410,221...31,437,188 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSP90AA1 mRNA CTD PMID:21346803 NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSP90AB1 mRNA CTD PMID:21346803 NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926 		JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSP90B1 mRNA CTD PMID:21346803 NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:22,997,962...23,012,293 		JBrowse link
G Hspa8 heat shock protein family A (Hsp70) member 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSPA8 mRNA CTD PMID:21346803 NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSPB1 mRNA CTD PMID:21346803 NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSPB8 mRNA CTD PMID:21346803 NCBI chr12:45,835,899...45,866,449
Ensembl chr12:45,837,066...45,851,937 		JBrowse link
G Hspbp1 HSPA (Hsp70) binding protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSPBP1 mRNA CTD PMID:21346803 NCBI chr 1:78,194,067...78,217,836
Ensembl chr 1:78,189,305...78,217,835 		JBrowse link
G Hspd1 heat shock protein family D (Hsp60) member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSPD1 mRNA CTD PMID:21346803 NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037 		JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HSPH1 mRNA CTD PMID:21346803 NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of HTATIP2 mRNA CTD PMID:21346803 NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815 		JBrowse link
G Iars1 isoleucyl-tRNA synthetase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IARS1 mRNA CTD PMID:21346803 NCBI chr17:15,147,357...15,193,716
Ensembl chr17:15,147,357...15,193,652 		JBrowse link
G Icam1 intercellular adhesion molecule 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ICAM1 mRNA CTD PMID:21346803 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Ide insulin degrading enzyme affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IDE mRNA CTD PMID:21346803 NCBI chr 1:244,415,495...244,516,925
Ensembl chr 1:244,416,343...244,514,526 		JBrowse link
G Ifrd2 interferon-related developmental regulator 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IFRD2 mRNA CTD PMID:21346803 NCBI chr 8:117,139,612...117,144,834
Ensembl chr 8:117,139,550...117,144,836 		JBrowse link
G Ift81 intraflagellar transport 81 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IFT81 mRNA CTD PMID:21346803 NCBI chr12:39,618,559...39,697,971
Ensembl chr12:39,618,651...39,697,962 		JBrowse link
G Ihh Indian hedgehog signaling molecule affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IHH mRNA CTD PMID:21346803 NCBI chr 9:83,952,986...83,959,203
Ensembl chr 9:83,952,986...83,959,203 		JBrowse link
G Il17rb interleukin 17 receptor B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IL17RB mRNA CTD PMID:21346803 NCBI chr16:5,186,961...5,200,657
Ensembl chr16:5,186,961...5,200,694 		JBrowse link
G Il1b interleukin 1 beta affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IL1B mRNA CTD PMID:21346803 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il6r interleukin 6 receptor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IL6RA mRNA CTD PMID:21346803 NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221 		JBrowse link
G Ilf2 interleukin enhancer binding factor 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ILF2 mRNA CTD PMID:21346803 NCBI chr 2:178,256,927...178,268,773
Ensembl chr 2:178,248,585...178,268,920 		JBrowse link
G Ilf3 interleukin enhancer binding factor 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ILF3 mRNA CTD PMID:21346803 NCBI chr 8:28,198,454...28,236,634
Ensembl chr 8:28,198,543...28,236,612 		JBrowse link
G Impdh1 inosine monophosphate dehydrogenase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IMPDH1 mRNA CTD PMID:21346803 NCBI chr 4:58,767,230...58,782,825
Ensembl chr 4:58,767,230...58,783,124 		JBrowse link
G Impdh2 inosine monophosphate dehydrogenase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IMPDH2 mRNA CTD PMID:21346803 NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873 		JBrowse link
G Ipo13 importin 13 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IPO13 mRNA CTD PMID:21346803 NCBI chr 5:136,719,204...136,740,118
Ensembl chr 5:136,719,204...136,741,847 		JBrowse link
G Ipo4 importin 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IPO4 mRNA CTD PMID:21346803 NCBI chr15:33,087,321...33,097,241
Ensembl chr15:33,087,321...33,097,241 		JBrowse link
G Irf2 interferon regulatory factor 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IRF2 mRNA CTD PMID:21346803 NCBI chr16:52,171,855...52,283,620
Ensembl chr16:52,164,442...52,282,627 		JBrowse link
G Irf5 interferon regulatory factor 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IRF5 mRNA CTD PMID:21346803 NCBI chr 4:59,092,914...59,104,596
Ensembl chr 4:59,081,357...59,112,552 		JBrowse link
G Irf9 interferon regulatory factor 9 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IRF9 mRNA CTD PMID:21346803 NCBI chr15:33,065,422...33,071,881
Ensembl chr15:33,065,659...33,071,879 		JBrowse link
G Irgm immunity-related GTPase M affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of IRGM mRNA CTD PMID:21346803 NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,732,961...33,743,228 		JBrowse link
G Itpr1 inositol 1,4,5-trisphosphate receptor, type 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ITPR1 mRNA CTD PMID:21346803 NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504 		JBrowse link
G Jmjd6 jumonji domain containing 6, arginine demethylase and lysine hydroxylase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of JMJD6 mRNA CTD PMID:21346803 NCBI chr10:102,539,935...102,545,986
Ensembl chr10:102,539,894...102,545,986 		JBrowse link
G Katnal1 katanin catalytic subunit A1 like 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KATNAL1 mRNA CTD PMID:21346803 NCBI chr12:11,130,935...11,192,330
Ensembl chr12:11,139,110...11,194,396 		JBrowse link
G Kcnh3 potassium voltage-gated channel subfamily H member 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KCNH3 mRNA CTD PMID:21346803 NCBI chr 7:132,244,492...132,262,725
Ensembl chr 7:132,244,880...132,262,721 		JBrowse link
G Kctd5 potassium channel tetramerization domain containing 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KCTD5 mRNA CTD PMID:21346803 NCBI chr10:13,583,781...13,609,762
Ensembl chr10:13,583,781...13,610,062 		JBrowse link
G Kdm6b lysine demethylase 6B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KDM6B mRNA CTD PMID:21346803 NCBI chr10:54,619,520...54,641,014
Ensembl chr10:54,619,544...54,629,610 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KEAP1 mRNA CTD PMID:21346803 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042 		JBrowse link
G Kif3b kinesin family member 3B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KIF3B mRNA CTD PMID:21346803 NCBI chr 3:162,218,621...162,258,191
Ensembl chr 3:162,218,682...162,258,581 		JBrowse link
G Kifap3 kinesin-associated protein 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KIFAP3 mRNA CTD PMID:21346803 NCBI chr13:78,660,849...78,797,821
Ensembl chr13:78,660,871...78,797,820 		JBrowse link
G Klc1 kinesin light chain 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KLC1 mRNA CTD PMID:21346803 NCBI chr 6:136,644,592...136,690,399
Ensembl chr 6:136,644,307...136,689,760 		JBrowse link
G Klhl2 kelch-like family member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KLHL2 mRNA CTD PMID:21346803 NCBI chr16:29,627,171...29,739,782
Ensembl chr16:29,627,237...29,739,957 		JBrowse link
G Krt18 keratin 18 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KRT18 mRNA CTD PMID:21346803 NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848 		JBrowse link
G Krt8 keratin 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of KRT8 mRNA CTD PMID:21346803 NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403 		JBrowse link
G Lama3 laminin subunit alpha 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LAMA3 mRNA CTD PMID:21346803 NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449 		JBrowse link
G Lama5 laminin subunit alpha 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LAMA5 mRNA CTD PMID:21346803 NCBI chr 3:187,647,904...187,695,974
Ensembl chr 3:187,647,904...187,696,173 		JBrowse link
G Larp1 La ribonucleoprotein 1, translational regulator affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LARP1 mRNA CTD PMID:21346803 NCBI chr10:42,691,833...42,746,816
Ensembl chr10:42,691,600...42,746,816 		JBrowse link
G Lmna lamin A/C affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LMNA mRNA CTD PMID:21346803 NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072 		JBrowse link
G Lpxn leupaxin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LPXN mRNA CTD PMID:21346803 NCBI chr 1:219,353,319...219,387,743
Ensembl chr 1:219,353,708...219,387,742 		JBrowse link
G Lrfn3 leucine rich repeat and fibronectin type III domain containing 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LRFN3 mRNA CTD PMID:21346803 NCBI chr 1:94,744,315...94,751,001
Ensembl chr 1:94,744,321...94,751,178 		JBrowse link
G Lrrc8c leucine rich repeat containing 8 VRAC subunit C affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LRRC8C mRNA CTD PMID:21346803 NCBI chr14:4,528,721...4,621,259
Ensembl chr14:4,531,823...4,620,049 		JBrowse link
G Lsp1 lymphocyte-specific protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LSP1 mRNA CTD PMID:21346803 NCBI chr 1:207,044,157...207,077,891
Ensembl chr 1:207,044,159...207,077,893 		JBrowse link
G Ltb lymphotoxin beta affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LTB mRNA CTD PMID:21346803 NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,632,210...3,634,054 		JBrowse link
G Ly86 lymphocyte antigen 86 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of LY86 mRNA CTD PMID:21346803 NCBI chr17:27,621,313...27,705,336
Ensembl chr17:27,621,313...27,692,743 		JBrowse link
G Macroh2a1 macroH2A.1 histone affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MACROH2A1 mRNA CTD PMID:21346803 NCBI chr17:8,484,340...8,547,268
Ensembl chr17:8,484,246...8,547,257 		JBrowse link
G Mafg MAF bZIP transcription factor G affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MAFG mRNA CTD PMID:21346803 NCBI chr10:106,401,633...106,410,159 JBrowse link
G Map3k1 mitogen-activated protein kinase kinase kinase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MAP3K1 mRNA CTD PMID:21346803 NCBI chr 2:45,081,889...45,150,555
Ensembl chr 2:45,081,889...45,149,897 		JBrowse link
G Mb myoglobin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MB mRNA CTD PMID:21346803 NCBI chr 7:110,640,511...110,647,742
Ensembl chr 7:110,640,512...110,647,958 		JBrowse link
G Mbd3 methyl-CpG binding domain protein 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MBD3 mRNA CTD PMID:21346803 NCBI chr 7:9,961,053...9,970,845
Ensembl chr 7:9,963,797...9,970,265 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MCM7 mRNA CTD PMID:21346803 NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771 		JBrowse link
G Mfn2 mitofusin 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MFN2 mRNA CTD PMID:21346803 NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MGST2 mRNA CTD PMID:21346803 NCBI chr 2:137,821,787...137,866,664
Ensembl chr 2:137,836,140...137,866,661 		JBrowse link
G Mlh3 mutL homolog 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MLH3 mRNA CTD PMID:21346803 NCBI chr 6:110,612,535...110,649,408
Ensembl chr 6:110,612,535...110,648,999 		JBrowse link
G Mocs1 molybdenum cofactor synthesis 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MOCS1 mRNA CTD PMID:21346803 NCBI chr 9:19,045,223...19,071,628
Ensembl chr 9:19,045,223...19,065,449 		JBrowse link
G Mrpl12 mitochondrial ribosomal protein L12 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MRPL12 mRNA CTD PMID:21346803 NCBI chr10:106,256,746...106,261,249
Ensembl chr10:106,256,547...106,263,088 		JBrowse link
G Mrpl24 mitochondrial ribosomal protein L24 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MRPL24 mRNA CTD PMID:21346803 NCBI chr 2:175,680,872...175,687,107
Ensembl chr 2:175,681,070...175,688,660 		JBrowse link
G Mrpl38 mitochondrial ribosomal protein L38 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MRPL38 mRNA CTD PMID:21346803 NCBI chr10:101,864,242...101,871,048
Ensembl chr10:101,863,318...101,871,048 		JBrowse link
G Mrpl4 mitochondrial ribosomal protein L4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MRPL4 mRNA CTD PMID:21346803 NCBI chr 8:27,815,771...27,821,786
Ensembl chr 8:27,815,740...27,821,780 		JBrowse link
G Mrpl40 mitochondrial ribosomal protein L40 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MRPL40 mRNA CTD PMID:21346803 NCBI chr11:95,637,751...95,643,587
Ensembl chr11:95,637,712...95,643,586 		JBrowse link
G Mrps18b mitochondrial ribosomal protein S18B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MRPS18B mRNA CTD PMID:21346803 NCBI chr20:2,842,978...2,849,065
Ensembl chr20:2,842,528...2,849,065 		JBrowse link
G Mrps27 mitochondrial ribosomal protein S27 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MRPS27 mRNA CTD PMID:21346803 NCBI chr 2:32,474,178...32,542,741
Ensembl chr 2:32,473,965...32,542,738 		JBrowse link
G Ms4a6a membrane spanning 4-domains A6A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MS4A6A mRNA CTD PMID:21346803 NCBI chr 1:217,826,261...217,839,606
Ensembl chr 1:217,826,261...217,850,013 		JBrowse link
G Ms4a6b membrane-spanning 4-domains, subfamily A, member 6B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MS4A6B mRNA CTD PMID:21346803 NCBI chr 1:217,705,785...217,727,719
Ensembl chr 1:217,705,961...217,727,450 		JBrowse link
G Msh5 mutS homolog 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MSH5 mRNA CTD PMID:21346803 NCBI chr20:3,779,180...3,797,996
Ensembl chr20:3,781,578...3,797,994 		JBrowse link
G Mt1a metallothionein 1A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MT1A mRNA CTD PMID:21346803 NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr  X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200 		JBrowse link
G Mtmr2 myotubularin related protein 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MTMR2 mRNA CTD PMID:21346803 NCBI chr 8:18,899,303...18,949,767
Ensembl chr 8:18,928,126...18,949,766 		JBrowse link
G Mtmr9 myotubularin related protein 9 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MTMR9 mRNA CTD PMID:21346803 NCBI chr15:41,945,102...41,967,136
Ensembl chr15:41,945,105...41,967,136 		JBrowse link
G Mtss1 MTSS I-BAR domain containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MTSS1 mRNA CTD PMID:21346803 NCBI chr 7:92,378,228...92,517,444
Ensembl chr 7:92,378,238...92,517,303 		JBrowse link
G Mvd mevalonate diphosphate decarboxylase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MVD mRNA CTD PMID:21346803 NCBI chr19:67,404,911...67,414,974
Ensembl chr19:67,404,911...67,422,366 		JBrowse link
G Mybbp1a MYB binding protein 1a affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MYBBP1A mRNA CTD PMID:21346803 NCBI chr10:57,555,458...57,565,819
Ensembl chr10:57,555,452...57,566,041 		JBrowse link
G Myh7b myosin heavy chain 7B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MYH7B mRNA CTD PMID:21346803 NCBI chr 3:164,537,211...164,582,441
Ensembl chr 3:164,558,340...164,582,094 		JBrowse link
G Myo1e myosin IE affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MYO1E mRNA CTD PMID:21346803 NCBI chr 8:79,768,828...79,961,048
Ensembl chr 8:79,753,596...79,961,045 		JBrowse link
G Myo1f myosin IF affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of MYO1F mRNA CTD PMID:21346803 NCBI chr 7:15,065,530...15,116,087
Ensembl chr 7:15,065,530...15,116,087 		JBrowse link
G Naa10 N(alpha)-acetyltransferase 10, NatA catalytic subunit affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NAA10 mRNA CTD PMID:21346803 NCBI chr  X:156,807,378...156,812,632
Ensembl chr  X:156,807,378...156,812,574 		JBrowse link
G Naa15 N(alpha)-acetyltransferase 15, NatA auxiliary subunit affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NAA15 mRNA CTD PMID:21346803 NCBI chr 2:137,608,883...137,671,618
Ensembl chr 2:137,608,797...137,671,619 		JBrowse link
G Nadsyn1 NAD synthetase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NADSYN1 mRNA CTD PMID:21346803 NCBI chr 1:208,410,914...208,439,242
Ensembl chr 1:208,410,914...208,439,207 		JBrowse link
G Nap1l1 nucleosome assembly protein 1-like 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NAP1L1 mRNA CTD PMID:21346803 NCBI chr 7:48,819,464...48,844,108
Ensembl chr 7:48,819,477...48,844,104 		JBrowse link
G Nat8 N-acetyltransferase 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NAT8 mRNA CTD PMID:21346803 NCBI chr 4:119,836,986...119,837,764
Ensembl chr 4:119,835,645...119,843,159 		JBrowse link
G Ncor2 nuclear receptor co-repressor 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NCOR2 mRNA CTD PMID:21346803 NCBI chr12:37,127,736...37,289,612
Ensembl chr12:37,127,686...37,289,612 		JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NDUFAF4 mRNA CTD PMID:21346803 NCBI chr 5:43,401,795...43,406,967 JBrowse link
G Nek4 NIMA-related kinase 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NEK4 mRNA CTD PMID:21346803 NCBI chr16:6,151,292...6,200,280
Ensembl chr16:6,151,368...6,198,450 		JBrowse link
G Nek6 NIMA-related kinase 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NEK6 mRNA CTD PMID:21346803 NCBI chr 3:42,693,994...42,766,026
Ensembl chr 3:42,693,971...42,767,773 		JBrowse link
G Nek8 NIMA-related kinase 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NEK8 mRNA CTD PMID:21346803 NCBI chr10:63,558,940...63,570,954
Ensembl chr10:63,558,788...63,570,488 		JBrowse link
G Nelfe negative elongation factor complex member E affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NELFE mRNA CTD PMID:21346803 NCBI chr20:3,981,259...3,987,016
Ensembl chr20:3,981,261...3,986,922 		JBrowse link
G Nfia nuclear factor I/A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NFIA mRNA CTD PMID:21346803 NCBI chr 5:117,359,006...117,897,391
Ensembl chr 5:117,359,077...117,891,395 		JBrowse link
G Nfib nuclear factor I/B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NFIB mRNA CTD PMID:21346803 NCBI chr 5:101,805,168...102,020,618
Ensembl chr 5:101,805,168...102,019,945 		JBrowse link
G Nhp2 NHP2 ribonucleoprotein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NOLA2 mRNA CTD PMID:21346803 NCBI chr10:36,378,020...36,381,362
Ensembl chr10:36,377,997...36,381,354 		JBrowse link
G Nle1 notchless homolog 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NLE1 mRNA CTD PMID:21346803 NCBI chr10:68,331,609...68,342,562
Ensembl chr10:68,331,609...68,340,386 		JBrowse link
G Nme6 NME/NM23 nucleoside diphosphate kinase 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NME6 mRNA CTD PMID:21346803 NCBI chr 8:118,708,092...118,717,756
Ensembl chr 8:118,711,036...118,718,288 		JBrowse link
G Nol8 nucleolar protein 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NOL8 mRNA CTD PMID:21346803 NCBI chr17:15,196,881...15,220,265
Ensembl chr17:15,196,881...15,220,202 		JBrowse link
G Nol9 nucleolar protein 9 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NOL9 mRNA CTD PMID:21346803 NCBI chr 5:167,829,249...167,849,364
Ensembl chr 5:167,829,264...167,849,366 		JBrowse link
G Nolc1 nucleolar and coiled-body phosphoprotein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NOLC1 mRNA CTD PMID:21346803 NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:254,870,319...254,881,069 		JBrowse link
G Nop56 NOP56 ribonucleoprotein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NOP56 mRNA CTD PMID:21346803 NCBI chr 3:137,926,187...137,934,971
Ensembl chr 3:137,929,646...137,934,959 		JBrowse link
G Np4 defensin NP-4 precursor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NP4 mRNA CTD PMID:21346803 NCBI chr16:77,197,061...77,199,713
Ensembl chr16:77,121,639...77,122,502
Ensembl chr16:77,121,639...77,122,502 		JBrowse link
G Npepps aminopeptidase puromycin sensitive affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NPEPPS mRNA CTD PMID:21346803 NCBI chr10:82,687,869...82,770,363
Ensembl chr10:82,687,871...82,770,363 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NQO1 mRNA CTD PMID:21346803 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NR0B2 mRNA CTD PMID:21346803 NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NR1I3 mRNA CTD PMID:21346803 NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370 		JBrowse link
G Nrros negative regulator of reactive oxygen species affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NRROS mRNA CTD PMID:21346803 NCBI chr11:82,133,608...82,151,160
Ensembl chr11:82,133,144...82,151,308 		JBrowse link
G Nsfl1c NSFL1 cofactor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NSFL1C mRNA CTD PMID:21346803 NCBI chr 3:160,438,708...160,463,261
Ensembl chr 3:160,438,708...160,463,228 		JBrowse link
G Nsun5 NOP2/Sun RNA methyltransferase 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NSUN5 mRNA CTD PMID:21346803 NCBI chr12:26,930,204...26,935,887
Ensembl chr12:26,930,863...26,936,130 		JBrowse link
G Nt5dc2 5'-nucleotidase domain containing 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NT5DC2 mRNA CTD PMID:21346803 NCBI chr16:6,328,925...6,336,978
Ensembl chr16:6,328,523...6,336,980 		JBrowse link
G Nuak2 NUAK family kinase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NUAK2 mRNA CTD PMID:21346803 NCBI chr13:46,305,744...46,322,755
Ensembl chr13:46,305,975...46,322,748 		JBrowse link
G Nudt7 nudix hydrolase 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NUDT7 mRNA CTD PMID:21346803 NCBI chr19:59,034,808...59,049,148
Ensembl chr19:59,034,839...59,063,994 		JBrowse link
G Nup153 nucleoporin 153 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NUP153 mRNA CTD PMID:21346803 NCBI chr17:18,178,434...18,231,109
Ensembl chr17:18,178,456...18,231,109 		JBrowse link
G Nup205 nucleoporin 205 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NUP205 mRNA CTD PMID:21346803 NCBI chr 4:64,822,051...64,887,996
Ensembl chr 4:64,822,065...64,887,988 		JBrowse link
G Nup210 nucleoporin 210 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NUP210 mRNA CTD PMID:21346803 NCBI chr 4:125,068,736...125,167,238
Ensembl chr 4:125,068,736...125,167,047 		JBrowse link
G Nutf2 nuclear transport factor 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of NTF2 mRNA CTD PMID:21346803 NCBI chr19:50,662,168...50,683,457
Ensembl chr19:50,662,394...50,683,454 		JBrowse link
G Oat ornithine aminotransferase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OAT mRNA CTD PMID:21346803 NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754 		JBrowse link
G Odc1 ornithine decarboxylase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ODC1 mRNA CTD PMID:21346803 NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146 		JBrowse link
G Or10d1g olfactory receptor family 10 subfamily D member 1G affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OR10D1G mRNA CTD PMID:21346803 NCBI chr 8:48,040,566...48,047,353
Ensembl chr 8:48,040,878...48,041,813 		JBrowse link
G Or2d36b olfactory receptor family 2 subfamily D member 36B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OR2D36B mRNA CTD PMID:21346803 NCBI chr 1:170,342,043...170,342,987
Ensembl chr 1:170,342,043...170,342,987 		JBrowse link
G Or2t48e olfactory receptor family 2 subfamily T member 48E affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OR2T48E mRNA CTD PMID:21346803 NCBI chr10:43,190,786...43,191,715 JBrowse link
G Or52a5b olfactory receptor family 52 subfamily A member 5B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OR52A5 mRNA CTD PMID:21346803 NCBI chr 1:167,572,790...167,573,740 JBrowse link
G Or8g52 olfactory receptor family 8 subfamily G member 52 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OR8G52 mRNA CTD PMID:21346803 NCBI chr 8:48,968,911...48,969,849
Ensembl chr 8:48,968,911...48,969,849 		JBrowse link
G Or9i1b olfactory receptor family 9 subfamily I member 1B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OR9I1B mRNA CTD PMID:21346803 NCBI chr 1:220,520,734...220,521,684
Ensembl chr 1:220,520,734...220,521,684 		JBrowse link
G Osbp oxysterol binding protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OSBP mRNA CTD PMID:21346803 NCBI chr 1:218,313,455...218,343,263
Ensembl chr 1:218,313,148...218,343,258 		JBrowse link
G Osgin1 oxidative stress induced growth inhibitor 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of OSGIN1 mRNA CTD PMID:21346803 NCBI chr19:64,380,336...64,409,165
Ensembl chr19:64,401,173...64,409,162 		JBrowse link
G Pa2g4 proliferation-associated 2G4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PA2G4 mRNA CTD PMID:21346803 NCBI chr 7:1,569,326...1,576,794
Ensembl chr 7:1,569,327...1,576,802 		JBrowse link
G Pabpc4 poly(A) binding protein, cytoplasmic 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PABPC4 mRNA CTD PMID:21346803 NCBI chr 5:140,847,835...140,864,089
Ensembl chr 5:140,848,225...140,864,087 		JBrowse link
G Panx2 pannexin 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PANX2 mRNA CTD PMID:21346803 NCBI chr 7:122,018,937...122,032,009
Ensembl chr 7:122,018,937...122,032,004 		JBrowse link
G Papss1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PAPSS1 mRNA CTD PMID:21346803 NCBI chr 2:222,646,103...222,788,475
Ensembl chr 2:222,714,487...222,788,670 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PARP1 mRNA CTD PMID:21346803 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Parp16 poly (ADP-ribose) polymerase family, member 16 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PARP16 mRNA CTD PMID:21346803 NCBI chr 8:74,626,399...74,644,610
Ensembl chr 8:74,622,878...74,644,612 		JBrowse link
G Pars2 prolyl-tRNA synthetase 2, mitochondrial affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PARS2 mRNA CTD PMID:21346803 NCBI chr 5:126,662,882...126,667,981
Ensembl chr 5:126,657,700...126,676,455 		JBrowse link
G Pcgf1 polycomb group ring finger 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PCGF1 mRNA CTD PMID:21346803 NCBI chr 4:117,140,144...117,144,729
Ensembl chr 4:117,142,061...117,145,040 		JBrowse link
G Pdap1 PDGFA associated protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PDAP1 mRNA CTD PMID:21346803 NCBI chr12:14,584,414...14,594,641
Ensembl chr12:14,584,398...14,594,641 		JBrowse link
G Pdcd11 programmed cell death 11 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PDCD11 mRNA CTD PMID:21346803 NCBI chr 1:255,922,198...255,963,336
Ensembl chr 1:255,922,225...255,963,336 		JBrowse link
G Pde4dip phosphodiesterase 4D interacting protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PDE4DIP mRNA CTD PMID:21346803 NCBI chr 2:187,982,002...188,178,937
Ensembl chr 2:187,981,878...188,178,869 		JBrowse link
G Pdia4 protein disulfide isomerase family A, member 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PDIA4 mRNA CTD PMID:21346803 NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:78,134,144...78,153,191 		JBrowse link
G Pdia5 protein disulfide isomerase family A, member 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PDIA5 mRNA CTD PMID:21346803 NCBI chr11:78,777,436...78,892,370
Ensembl chr11:78,777,419...78,864,329 		JBrowse link
G Pdlim5 PDZ and LIM domain 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PDLIM5 mRNA CTD PMID:21346803 NCBI chr 2:233,625,478...233,793,582
Ensembl chr 2:233,628,503...233,793,528 		JBrowse link
G Pef1 penta-EF hand domain containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PEF1 mRNA CTD PMID:21346803 NCBI chr 5:147,735,973...147,759,239
Ensembl chr 5:147,735,976...147,761,092 		JBrowse link
G Pigl phosphatidylinositol glycan anchor biosynthesis, class L affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PIGL mRNA CTD PMID:21346803 NCBI chr10:47,641,478...47,699,200
Ensembl chr10:47,641,098...47,699,453 		JBrowse link
G Pigv phosphatidylinositol glycan anchor biosynthesis, class V affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PIGV mRNA CTD PMID:21346803 NCBI chr 5:151,173,486...151,185,748
Ensembl chr 5:151,173,044...151,185,376 		JBrowse link
G Pir pirin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PIR mRNA CTD PMID:21346803 NCBI chr  X:33,740,428...33,851,049
Ensembl chr  X:33,740,429...33,851,049 		JBrowse link
G Pitrm1 pitrilysin metallopeptidase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PITRM1 mRNA CTD PMID:21346803 NCBI chr17:68,705,699...68,737,350
Ensembl chr17:68,705,699...68,749,717 		JBrowse link
G Pla2g2e phospholipase A2, group IIE affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLA2G2E mRNA CTD PMID:21346803 NCBI chr 5:156,404,639...156,410,421
Ensembl chr 5:156,404,639...156,410,408 		JBrowse link
G Plaat3 phospholipase A and acyltransferase 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLAAT3 mRNA CTD PMID:21346803 NCBI chr 1:214,211,755...214,245,551
Ensembl chr 1:214,211,791...214,246,763 		JBrowse link
G Plac8 placenta associated 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLAC8 mRNA CTD PMID:21346803 NCBI chr14:9,356,950...9,378,586
Ensembl chr14:9,356,972...9,378,572 		JBrowse link
G Plek2 pleckstrin 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLEK2 mRNA CTD PMID:21346803 NCBI chr 6:103,434,156...103,452,457
Ensembl chr 6:103,434,156...103,452,371 		JBrowse link
G Plekha6 pleckstrin homology domain containing A6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLEKHA6 mRNA CTD PMID:21346803 NCBI chr13:47,166,899...47,307,003
Ensembl chr13:47,167,160...47,307,003 		JBrowse link
G Plk3 polo-like kinase 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLK3 mRNA CTD PMID:21346803 NCBI chr 5:135,843,725...135,848,900
Ensembl chr 5:135,843,725...135,848,900 		JBrowse link
G Plpp2 phospholipid phosphatase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLPP2 mRNA CTD PMID:21346803 NCBI chr 7:10,826,534...10,834,628
Ensembl chr 7:10,826,549...10,834,627 		JBrowse link
G Plxna2 plexin A2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PLXNA2 mRNA CTD PMID:21346803 NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453 		JBrowse link
G Polr2m RNA polymerase II subunit M affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of POLR2M mRNA CTD PMID:21346803 NCBI chr 8:81,012,770...81,020,201
Ensembl chr 8:81,012,771...81,020,302 		JBrowse link
G Polr3c RNA polymerase III subunit C affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of POLR3C mRNA CTD PMID:21346803 NCBI chr 2:186,935,038...186,950,962
Ensembl chr 2:186,935,038...186,950,962 		JBrowse link
G Polr3d RNA polymerase III subunit D affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of POLR3D mRNA CTD PMID:21346803 NCBI chr15:51,921,283...51,925,952
Ensembl chr15:51,921,283...51,925,691 		JBrowse link
G Pomgnt1 protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of POMGNT1 mRNA CTD PMID:21346803 NCBI chr 5:134,870,971...134,880,864
Ensembl chr 5:134,870,975...134,880,863 		JBrowse link
G Ppfibp2 PPFIA binding protein 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PPFIBP2 mRNA CTD PMID:21346803 NCBI chr 1:170,916,649...171,062,096
Ensembl chr 1:170,916,649...171,065,618 		JBrowse link
G Ppil3 peptidylprolyl isomerase like 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PPIL3 mRNA CTD PMID:21346803 NCBI chr 9:67,460,594...67,474,325
Ensembl chr 9:67,460,595...67,474,251 		JBrowse link
G Ppm1g protein phosphatase, Mg2+/Mn2+ dependent, 1G affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PPM1G mRNA CTD PMID:21346803 NCBI chr 6:30,873,531...30,893,735
Ensembl chr 6:30,873,481...30,893,732 		JBrowse link
G Ppp1r14b protein phosphatase 1, regulatory (inhibitor) subunit 14B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PPP1R14B mRNA CTD PMID:21346803 NCBI chr 1:213,594,416...213,596,527
Ensembl chr12:21,088,517...21,101,431
Ensembl chr 1:21,088,517...21,101,431 		JBrowse link
G Ppp2r1a protein phosphatase 2 scaffold subunit A alpha affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PPP2R1A mRNA CTD PMID:21346803 NCBI chr 1:69,213,198...69,232,441
Ensembl chr 1:69,213,038...69,238,242 		JBrowse link
G Ppp3ca protein phosphatase 3 catalytic subunit alpha affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PPP3CA mRNA CTD PMID:21346803 NCBI chr 2:227,839,058...228,113,560
Ensembl chr 2:227,839,062...228,113,554 		JBrowse link
G Prdx6 peroxiredoxin 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PRDX6 mRNA CTD PMID:21346803 NCBI chr13:76,062,082...76,072,631
Ensembl chr13:76,061,554...76,072,657 		JBrowse link
G Prkag3 protein kinase AMP-activated non-catalytic subunit gamma 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PRKAG3 mRNA CTD PMID:21346803 NCBI chr 9:83,744,385...83,753,629
Ensembl chr 9:83,744,385...83,753,729 		JBrowse link
G Prkca protein kinase C, alpha affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PRKCA mRNA CTD PMID:21346803 NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572 		JBrowse link
G Prkce protein kinase C, epsilon affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PRKCE mRNA CTD PMID:21346803 NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288 		JBrowse link
G Prkcz protein kinase C, zeta affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PRKCZ mRNA CTD PMID:21346803 NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674 		JBrowse link
G Prmt5 protein arginine methyltransferase 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PRMT5 mRNA CTD PMID:21346803 NCBI chr15:31,938,927...31,948,318
Ensembl chr15:31,938,719...31,948,426 		JBrowse link
G Prpf19 pre-mRNA processing factor 19 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PRPF19 mRNA CTD PMID:21346803 NCBI chr 1:216,966,104...216,977,549
Ensembl chr 1:216,966,462...216,980,506 		JBrowse link
G Psmc4 proteasome 26S subunit, ATPase 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PSMC4 mRNA CTD PMID:21346803 NCBI chr 1:92,476,690...92,485,268
Ensembl chr 1:92,476,690...92,485,060 		JBrowse link
G Pter phosphotriesterase related affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PTER mRNA CTD PMID:21346803 NCBI chr17:80,967,463...81,028,707
Ensembl chr17:80,967,477...81,030,099 		JBrowse link
G Ptger3 prostaglandin E receptor 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PTGER3 mRNA CTD PMID:21346803 NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:249,264,985...249,409,846 		JBrowse link
G Ptges2 prostaglandin E synthase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PTGES2 mRNA CTD PMID:21346803 NCBI chr 3:36,088,246...36,095,430
Ensembl chr 3:36,088,246...36,097,694 		JBrowse link
G Ptprh protein tyrosine phosphatase, receptor type, H affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PTPRH mRNA CTD PMID:21346803 NCBI chr 1:78,272,414...78,318,977
Ensembl chr 1:78,271,276...78,318,977 		JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PTTG1 mRNA CTD PMID:21346803 NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309 		JBrowse link
G Pus1 pseudouridine synthase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PUS1 mRNA CTD PMID:21346803 NCBI chr12:51,539,659...51,548,975
Ensembl chr12:51,540,212...51,548,973 		JBrowse link
G Pvr PVR cell adhesion molecule affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PVR mRNA CTD PMID:21346803 NCBI chr 1:88,689,235...88,704,641
Ensembl chr 1:88,688,981...88,704,630 		JBrowse link
G Pwp1 PWP1 homolog, endonuclein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PWP1 mRNA CTD PMID:21346803 NCBI chr 7:19,870,465...19,886,463
Ensembl chr 7:19,866,927...19,886,463 		JBrowse link
G Pxylp1 2-phosphoxylose phosphatase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PXYLP1 mRNA CTD PMID:21346803 NCBI chr 8:106,299,303...106,364,603
Ensembl chr 8:106,299,304...106,364,603 		JBrowse link
G Pycard PYD and CARD domain containing affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of PYCARD mRNA CTD PMID:21346803 NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419 		JBrowse link
G Qrsl1 glutaminyl-tRNA amidotransferase subunit QRSL1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of QRSL1 mRNA CTD PMID:21346803 NCBI chr20:48,939,858...48,964,812
Ensembl chr20:48,939,858...48,964,812 		JBrowse link
G Qtrt1 queuine tRNA-ribosyltransferase catalytic subunit 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of QTRT1 mRNA CTD PMID:21346803 NCBI chr 8:28,239,993...28,249,983
Ensembl chr 8:28,242,472...28,250,398 		JBrowse link
G Rab10 RAB10, member RAS oncogene family affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RAB10 mRNA CTD PMID:21346803 NCBI chr 6:31,974,858...32,039,554
Ensembl chr 6:31,986,921...32,039,733 		JBrowse link
G Rabggta Rab geranylgeranyltransferase subunit alpha affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RABGGTA mRNA CTD PMID:21346803 NCBI chr15:33,176,268...33,183,320
Ensembl chr15:33,176,099...33,183,271 		JBrowse link
G Rac1 Rac family small GTPase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RAC1 mRNA CTD PMID:21346803 NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109 		JBrowse link
G Rae1 ribonucleic acid export 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RAE1 mRNA CTD PMID:21346803 NCBI chr 3:182,197,432...182,212,381
Ensembl chr 3:182,197,459...182,213,135 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RAF1 mRNA CTD PMID:21346803 NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813 		JBrowse link
G Ralgapa1 Ral GTPase activating protein catalytic subunit alpha 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RALGAPA1 mRNA CTD PMID:21346803 NCBI chr 6:78,712,554...78,987,486
Ensembl chr 6:78,701,832...78,987,486 		JBrowse link
G Raph1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RAPH1 mRNA CTD PMID:21346803 NCBI chr 9:69,397,272...69,484,174
Ensembl chr 9:69,401,517...69,484,019 		JBrowse link
G Rarres1 retinoic acid receptor responder 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RARRES1 mRNA CTD PMID:21346803 NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:154,059,761...154,094,024 		JBrowse link
G Rasd2 RASD family, member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RASD2 mRNA CTD PMID:21346803 NCBI chr19:13,600,028...13,610,753
Ensembl chr19:13,599,986...13,610,753 		JBrowse link
G Rbm19 RNA binding motif protein 19 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RBM19 mRNA CTD PMID:21346803 NCBI chr12:42,026,277...42,111,530
Ensembl chr12:42,026,278...42,111,530 		JBrowse link
G Rcan2 regulator of calcineurin 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RCAN2 mRNA CTD PMID:21346803 NCBI chr 9:24,456,861...24,674,234
Ensembl chr 9:24,456,861...24,672,189 		JBrowse link
G Rcc1l RCC1 like affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RCC1L mRNA CTD PMID:21346803 NCBI chr12:28,179,205...28,210,462
Ensembl chr12:28,180,154...28,215,151 		JBrowse link
G Rcc2 regulator of chromosome condensation 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RCC2 mRNA CTD PMID:21346803 NCBI chr 5:158,277,476...158,300,294
Ensembl chr 5:158,277,476...158,300,294 		JBrowse link
G Rcor1 REST corepressor 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RCOR1 mRNA CTD PMID:21346803 NCBI chr 6:135,890,851...135,967,367
Ensembl chr 6:135,890,851...135,967,367 		JBrowse link
G Rcor2 REST corepressor 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RCOR2 mRNA CTD PMID:21346803 NCBI chr 1:213,882,585...213,890,022
Ensembl chr 1:213,878,519...213,890,022 		JBrowse link
G Reep6 receptor accessory protein 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of REEP6 mRNA CTD PMID:21346803 NCBI chr 7:10,024,601...10,031,507
Ensembl chr 7:10,024,602...10,031,740 		JBrowse link
G Rexo2 RNA exonuclease 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of REXO2 mRNA CTD PMID:21346803 NCBI chr 8:57,708,420...57,720,142
Ensembl chr 8:57,707,558...57,720,142 		JBrowse link
G Rgs11 regulator of G-protein signaling 11 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RGS11 mRNA CTD PMID:21346803 NCBI chr10:15,727,279...15,735,536
Ensembl chr10:15,727,279...15,735,536 		JBrowse link
G Rhbdf1 rhomboid 5 homolog 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RHBDF1 mRNA CTD PMID:21346803 NCBI chr10:15,911,282...15,924,214
Ensembl chr10:15,911,308...15,924,214 		JBrowse link
G Rhbg Rh family B glycoprotein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RHBG mRNA CTD PMID:21346803 NCBI chr 2:176,002,886...176,015,201
Ensembl chr 2:176,002,887...176,015,609 		JBrowse link
G Ribc1 RIB43A domain with coiled-coils 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RIBC1 mRNA CTD PMID:21346803 NCBI chr  X:24,571,126...24,583,170
Ensembl chr  X:24,570,499...24,582,789 		JBrowse link
G Rin2 Ras and Rab interactor 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RIN2 mRNA CTD PMID:21346803 NCBI chr 3:153,540,147...153,756,897
Ensembl chr 3:153,540,214...153,756,897 		JBrowse link
G Riok3 RIO kinase 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RIOK3 mRNA CTD PMID:21346803 NCBI chr18:3,602,535...3,628,108
Ensembl chr18:3,602,535...3,628,108 		JBrowse link
G Riox2 ribosomal oxygenase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RIOX2 mRNA CTD PMID:21346803 NCBI chr11:54,327,311...54,353,989
Ensembl chr11:54,330,605...54,353,752 		JBrowse link
G Ropn1 rhophilin associated tail protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ROPN1 mRNA CTD PMID:21346803 NCBI chr11:79,603,053...79,632,344
Ensembl chr11:79,603,055...79,632,344 		JBrowse link
G Ros1 ROS proto-oncogene 1 , receptor tyrosine kinase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of H4C8 mRNA CTD PMID:21346803 NCBI chr20:31,975,328...32,126,675
Ensembl chr20:31,975,329...32,126,547 		JBrowse link
G Rpf2 ribosome production factor 2 homolog affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RPF2 mRNA CTD PMID:21346803 NCBI chr20:45,184,511...45,205,983
Ensembl chr20:45,184,512...45,206,001 		JBrowse link
G Rpl37 ribosomal protein L37 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RPL37 mRNA CTD PMID:21346803 NCBI chr 2:55,942,827...55,944,905
Ensembl chr 2:55,942,945...55,944,900 		JBrowse link
G Rpp38 ribonuclease P/MRP subunit p38 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RPP38 mRNA CTD PMID:21346803 NCBI chr17:79,823,237...79,826,908
Ensembl chr17:79,822,980...79,869,245 		JBrowse link
G Rps5 ribosomal protein S5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RPS5 mRNA CTD PMID:21346803 NCBI chr 1:82,610,965...82,615,262
Ensembl chr 1:82,610,965...82,615,262 		JBrowse link
G Rsbn1 round spermatid basic protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RSBN1 mRNA CTD PMID:21346803 NCBI chr 2:194,105,058...194,159,142
Ensembl chr 2:194,105,061...194,159,142 		JBrowse link
G RT1-Da RT1 class II, locus Da affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RT1-DA mRNA CTD PMID:21346803 NCBI chr20:4,515,393...4,520,387
Ensembl chr20:4,513,908...4,520,383 		JBrowse link
G RT1-S3 RT1 class Ib, locus S3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RT1-S3 mRNA CTD PMID:21346803 NCBI chr20:2,675,463...2,680,229 JBrowse link
G RT1-T24-1 RT1 class I, locus T24, gene 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RT1-T24-1 mRNA CTD PMID:21346803 NCBI chr20:2,766,304...2,779,680
Ensembl chr20:2,766,319...2,780,951 		JBrowse link
G Rtp4 receptor (chemosensory) transporter protein 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RTP4 mRNA CTD PMID:21346803 NCBI chr11:90,741,992...90,840,061
Ensembl chr11:90,741,992...90,753,851 		JBrowse link
G Runx3 RUNX family transcription factor 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RUNX3 mRNA CTD PMID:21346803 NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:152,644,270...152,702,835 		JBrowse link
G Ruvbl1 RuvB-like AAA ATPase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RUVBL1 mRNA CTD PMID:21346803 NCBI chr 4:122,489,754...122,524,666
Ensembl chr 4:122,489,680...122,524,665 		JBrowse link
G Ruvbl2 RuvB-like AAA ATPase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of RUVBL2 mRNA CTD PMID:21346803 NCBI chr 1:105,038,487...105,051,851
Ensembl chr 1:105,038,174...105,051,720 		JBrowse link
G S100g S100 calcium binding protein G affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of S100G mRNA CTD PMID:21346803 NCBI chr  X:35,337,636...35,340,205
Ensembl chr  X:35,337,675...35,340,205 		JBrowse link
G Sacs sacsin molecular chaperone affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SACS mRNA CTD PMID:21346803 NCBI chr15:39,461,853...39,546,419
Ensembl chr15:39,472,905...39,546,419 		JBrowse link
G Sart1 spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SART1 mRNA CTD PMID:21346803 NCBI chr 1:212,119,824...212,128,517
Ensembl chr 1:212,104,557...212,128,486 		JBrowse link
G Sbno1 strawberry notch homolog 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SBNO1 mRNA CTD PMID:21346803 NCBI chr12:37,835,306...37,895,861
Ensembl chr12:37,846,514...37,891,231 		JBrowse link
G Scgb1a1 secretoglobin family 1A member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SCGB1A1 mRNA CTD PMID:21346803 NCBI chr 1:215,406,138...215,409,686
Ensembl chr 1:215,406,138...215,409,686 		JBrowse link
G Scly selenocysteine lyase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SCLY mRNA CTD PMID:21346803 NCBI chr 9:99,337,796...99,358,487
Ensembl chr 9:99,327,873...99,358,487 		JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SCNN1A mRNA CTD PMID:21346803 NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405 		JBrowse link
G Sdad1 SDA1 domain containing 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SDAD1 mRNA CTD PMID:21346803 NCBI chr14:16,025,726...16,052,565
Ensembl chr14:16,025,727...16,055,359 		JBrowse link
G Selenbp1 selenium binding protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SELENBP1 mRNA CTD PMID:21346803 NCBI chr 2:185,183,022...185,193,612
Ensembl chr 2:185,183,004...185,194,295 		JBrowse link
G Senp3 SUMO specific peptidase 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SENP3 mRNA CTD PMID:21346803 NCBI chr10:54,889,445...54,898,359
Ensembl chr10:54,888,847...54,898,227 		JBrowse link
G Serpina6 serpin family A member 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SERPINA6 mRNA CTD PMID:21346803 NCBI chr 6:128,544,828...128,555,064
Ensembl chr 6:128,544,831...128,555,139 		JBrowse link
G Set Set nuclear proto-oncogene affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SET mRNA CTD PMID:21346803 NCBI chr 3:33,732,319...33,743,433 JBrowse link
G Sf1 splicing factor 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SF1 mRNA CTD PMID:21346803 NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:213,099,260...213,113,590 		JBrowse link
G Sf3a1 splicing factor 3A subunit 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SF3A1 mRNA CTD PMID:21346803 NCBI chr14:83,254,971...83,275,720
Ensembl chr14:83,254,971...83,275,720 		JBrowse link
G Sf3b4 splicing factor 3B subunit 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SF3B4 mRNA CTD PMID:21346803 NCBI chr 2:186,421,667...186,426,419
Ensembl chr 2:186,421,636...186,426,833 		JBrowse link
G Sfpq splicing factor proline and glutamine rich affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SFPQ mRNA CTD PMID:21346803 NCBI chr 5:144,621,678...144,637,930
Ensembl chr 5:144,622,476...144,637,926 		JBrowse link
G Sfxn4 sideroflexin 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SFXN4 mRNA CTD PMID:21346803 NCBI chr 1:269,962,527...269,984,849
Ensembl chr 1:269,962,535...269,984,836 		JBrowse link
G Shmt2 serine hydroxymethyltransferase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SHMT2 mRNA CTD PMID:21346803 NCBI chr 7:65,244,247...65,249,580
Ensembl chr 7:65,244,247...65,249,567 		JBrowse link
G Sin3a SIN3 transcription regulator family member A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SIN3A mRNA CTD PMID:21346803 NCBI chr 8:66,377,471...66,432,150
Ensembl chr 8:66,381,657...66,434,542 		JBrowse link
G Slc18a3 solute carrier family 18 member A3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC18A3 mRNA CTD PMID:21346803 NCBI chr16:7,719,953...7,722,814 JBrowse link
G Slc19a1 solute carrier family 19 member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC19A1 mRNA CTD PMID:21346803 NCBI chr20:11,583,928...11,601,959
Ensembl chr20:11,583,929...11,601,488 		JBrowse link
G Slc27a4 solute carrier family 27 member 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC27A4 mRNA CTD PMID:21346803 NCBI chr 3:33,472,903...33,485,824
Ensembl chr 3:33,472,903...33,485,824 		JBrowse link
G Slc30a6 solute carrier family 30 member 6 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC30A6 mRNA CTD PMID:21346803 NCBI chr 6:26,772,804...26,802,656
Ensembl chr 6:26,772,804...26,802,656 		JBrowse link
G Slc3a2 solute carrier family 3 member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC3A2 mRNA CTD PMID:21346803 NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064 		JBrowse link
G Slc41a1 solute carrier family 41 member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC41A1 mRNA CTD PMID:21346803 NCBI chr13:45,822,999...45,843,364
Ensembl chr13:45,822,999...45,843,657 		JBrowse link
G Slc41a2 solute carrier family 41 member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC41A2 mRNA CTD PMID:21346803 NCBI chr 7:22,271,298...22,378,764
Ensembl chr 7:22,271,313...22,378,764 		JBrowse link
G Slc4a2 solute carrier family 4 member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC4A2 mRNA CTD PMID:21346803 NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:11,628,862...11,645,402 		JBrowse link
G Slc4a4 solute carrier family 4 member 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLC4A4 mRNA CTD PMID:21346803 NCBI chr14:19,125,394...19,577,379
Ensembl chr14:19,129,264...19,577,435 		JBrowse link
G Slpi secretory leukocyte peptidase inhibitor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SLPI mRNA CTD PMID:21346803 NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822 		JBrowse link
G Smarca2 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SMARCA2 mRNA CTD PMID:21346803 NCBI chr 1:233,617,277...233,784,908
Ensembl chr 1:233,617,366...233,784,869 		JBrowse link
G Smc1a structural maintenance of chromosomes 1A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SMC1A mRNA CTD PMID:21346803 NCBI chr  X:24,582,732...24,627,462
Ensembl chr  X:24,582,690...24,627,462 		JBrowse link
G Smyd5 SMYD family member 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SMYD5 mRNA CTD PMID:21346803 NCBI chr 4:119,527,115...119,541,580
Ensembl chr 4:119,527,113...119,541,838 		JBrowse link
G Snrpa small nuclear ribonucleoprotein polypeptide A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SNRPA mRNA CTD PMID:21346803 NCBI chr 1:91,609,419...91,618,119
Ensembl chr 1:91,609,420...91,618,042 		JBrowse link
G Snx27 sorting nexin 27 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SNX27 mRNA CTD PMID:21346803 NCBI chr 2:184,824,930...184,907,931
Ensembl chr 2:184,806,844...184,907,931 		JBrowse link
G Sphk2 sphingosine kinase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SPHK2 mRNA CTD PMID:21346803 NCBI chr 1:105,317,332...105,324,985
Ensembl chr 1:105,317,333...105,321,637 		JBrowse link
G Spn sialophorin affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SPN mRNA CTD PMID:21346803 NCBI chr 1:191,177,449...191,190,115
Ensembl chr 1:191,178,096...191,187,852 		JBrowse link
G Sptan1 spectrin, alpha, non-erythrocytic 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SPTAN1 mRNA CTD PMID:21346803 NCBI chr 3:33,639,020...33,703,890
Ensembl chr 3:33,607,210...33,703,889 		JBrowse link
G Sqstm1 sequestosome 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SQSTM1 mRNA CTD PMID:21346803 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Srfbp1 serum response factor binding protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SRFBP1 mRNA CTD PMID:21346803 NCBI chr18:48,118,740...48,139,824
Ensembl chr18:48,117,375...48,140,864 		JBrowse link
G Srm spermidine synthase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SRM mRNA CTD PMID:21346803 NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705 		JBrowse link
G Stau1 staufen double-stranded RNA binding protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of STAU1 mRNA CTD PMID:21346803 NCBI chr 3:176,099,053...176,144,947
Ensembl chr 3:176,099,053...176,144,947 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of STIP1 mRNA CTD PMID:21346803 NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:213,638,641...213,657,654 		JBrowse link
G Stk35 serine/threonine kinase 35 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of STK35 mRNA CTD PMID:21346803 NCBI chr 3:137,465,884...137,498,554
Ensembl chr 3:137,470,110...137,498,940 		JBrowse link
G Stxbp5 syntaxin binding protein 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of STXBP5 mRNA CTD PMID:21346803 NCBI chr 1:6,002,738...6,155,528
Ensembl chr 1:6,002,738...6,155,528 		JBrowse link
G Styxl1 serine/threonine/tyrosine interacting-like 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of STYXL1 mRNA CTD PMID:21346803 NCBI chr12:26,544,059...26,576,365
Ensembl chr12:26,544,067...26,576,366 		JBrowse link
G Supt6h SPT6 homolog, histone chaperone and transcription elongation factor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SUPT6H mRNA CTD PMID:21346803 NCBI chr10:63,601,990...63,638,851
Ensembl chr10:63,601,993...63,638,851 		JBrowse link
G Sympk symplekin scaffold protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SYMPK mRNA CTD PMID:21346803 NCBI chr 1:87,800,416...87,828,727
Ensembl chr 1:87,799,853...87,828,727 		JBrowse link
G Syt5 synaptotagmin 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of SYT5 mRNA CTD PMID:21346803 NCBI chr 1:78,320,034...78,327,750
Ensembl chr 1:78,320,034...78,327,746 		JBrowse link
G Tarbp2 Tarbp2 subunit of RISC loading complex affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TARBP2 mRNA CTD PMID:21346803 NCBI chr 7:135,527,710...135,532,826
Ensembl chr 7:135,527,589...135,533,323 		JBrowse link
G Tbl1x transducin (beta)-like 1 X-linked affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TBL1X mRNA CTD PMID:21346803 NCBI chr  X:45,452,983...45,609,532
Ensembl chr  X:45,454,482...45,609,525 		JBrowse link
G Tbrg4 transforming growth factor beta regulator 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TBRG4 mRNA CTD PMID:21346803 NCBI chr14:85,696,738...85,704,691
Ensembl chr14:85,695,893...85,704,659 		JBrowse link
G Tcea3 transcription elongation factor A3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TCEA3 mRNA CTD PMID:21346803 NCBI chr 5:153,760,401...153,792,934
Ensembl chr 5:153,760,407...153,792,930 		JBrowse link
G Tcp1 t-complex 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TCP1 mRNA CTD PMID:21346803 NCBI chr 1:50,376,848...50,384,527
Ensembl chr 1:50,376,848...50,384,527 		JBrowse link
G Tdrd3 tudor domain containing 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TDRD3 mRNA CTD PMID:21346803 NCBI chr15:69,748,754...69,911,605
Ensembl chr15:69,749,217...69,884,656 		JBrowse link
G Tent4b terminal nucleotidyltransferase 4B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TENT4B mRNA CTD PMID:21346803 NCBI chr19:34,984,244...35,042,423
Ensembl chr19:34,980,296...35,042,399 		JBrowse link
G Tfb1m transcription factor B1, mitochondrial affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TFB1M mRNA CTD PMID:21346803 NCBI chr 1:46,520,510...46,567,004
Ensembl chr 1:46,524,435...46,566,948 		JBrowse link
G Tfg trafficking from ER to golgi regulator affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TFG mRNA CTD PMID:21346803 NCBI chr11:57,354,607...57,381,071
Ensembl chr11:57,354,687...57,382,267 		JBrowse link
G Tfrc transferrin receptor affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TFRC mRNA CTD PMID:21346803 NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318 		JBrowse link
G Tgm1 transglutaminase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TGM1 mRNA CTD PMID:21346803 NCBI chr15:33,160,985...33,175,632
Ensembl chr15:33,160,987...33,174,463 		JBrowse link
G Thap12 THAP domain containing 12 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of THAP12 mRNA CTD PMID:21346803 NCBI chr 1:162,414,781...162,430,560
Ensembl chr 1:162,414,723...162,430,551 		JBrowse link
G Thap7 THAP domain containing 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of THAP7 mRNA CTD PMID:21346803 NCBI chr11:96,986,720...96,990,375
Ensembl chr11:96,987,275...96,990,371 		JBrowse link
G Thop1 thimet oligopeptidase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of THOP1 mRNA CTD PMID:21346803 NCBI chr 7:9,283,617...9,295,957
Ensembl chr 7:9,283,617...9,295,957 		JBrowse link
G Thtpa thiamine triphosphatase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of THTPA mRNA CTD PMID:21346803 NCBI chr15:32,536,297...32,541,537
Ensembl chr15:32,537,497...32,541,535 		JBrowse link
G Timm9 translocase of inner mitochondrial membrane 9 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TIMM9 mRNA CTD PMID:21346803 NCBI chr 6:95,346,065...95,358,895
Ensembl chr 6:95,346,065...95,358,895 		JBrowse link
G Tiparp TCDD-inducible poly(ADP-ribose) polymerase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TIPARP mRNA CTD PMID:21346803 NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:152,063,751...152,090,406 		JBrowse link
G Tmem69 transmembrane protein 69 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TMEM69 mRNA CTD PMID:21346803 NCBI chr 5:135,241,557...135,247,323
Ensembl chr 5:135,241,560...135,247,215 		JBrowse link
G Tmem97 transmembrane protein 97 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TMEM97 mRNA CTD PMID:21346803 NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818 		JBrowse link
G Tmod4 tropomodulin 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TMOD4 mRNA CTD PMID:21346803 NCBI chr 2:185,384,547...185,389,549
Ensembl chr 2:185,384,795...185,389,992 		JBrowse link
G Tnfaip1 TNF alpha induced protein 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TNFAIP1 mRNA CTD PMID:21346803 NCBI chr10:63,915,824...63,930,514
Ensembl chr10:63,915,825...63,930,514 		JBrowse link
G Tomm40 translocase of outer mitochondrial membrane 40 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TOMM40 mRNA CTD PMID:21346803 NCBI chr 1:88,486,745...88,498,833
Ensembl chr 1:88,486,758...88,499,671 		JBrowse link
G Tp53 tumor protein p53 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TP53 mRNA CTD PMID:21346803 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Tpp2 tripeptidyl peptidase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TPP2 mRNA CTD PMID:21346803 NCBI chr 9:53,538,788...53,620,253
Ensembl chr 9:53,538,313...53,620,251 		JBrowse link
G Trak2 trafficking kinesin protein 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TRAK2 mRNA CTD PMID:21346803 NCBI chr 9:67,842,680...67,909,786
Ensembl chr 9:67,842,683...67,908,158 		JBrowse link
G Trim28 tripartite motif-containing 28 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TRIM28 mRNA CTD PMID:21346803 NCBI chr 1:82,724,842...82,731,566
Ensembl chr 1:82,724,838...82,731,572 		JBrowse link
G Trim37 tripartite motif-containing 37 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TRIM37 mRNA CTD PMID:21346803 NCBI chr10:72,440,672...72,572,831
Ensembl chr10:72,440,644...72,572,828 		JBrowse link
G Trim69 tripartite motif-containing 69 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TRIM69 mRNA CTD PMID:21346803 NCBI chr 3:129,565,060...129,585,629
Ensembl chr 3:129,564,934...129,585,629 		JBrowse link
G Trmt1 tRNA methyltransferase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TRMT1 mRNA CTD PMID:21346803 NCBI chr19:40,361,583...40,374,971
Ensembl chr19:40,361,583...40,374,622 		JBrowse link
G Trmt2a tRNA methyltransferase 2 homolog A affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TRMT2A mRNA CTD PMID:21346803 NCBI chr11:96,241,998...96,246,719
Ensembl chr11:96,242,001...96,246,609 		JBrowse link
G Trub1 TruB pseudouridine synthase family member 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TRUB1 mRNA CTD PMID:21346803 NCBI chr 1:266,518,510...266,559,633
Ensembl chr 1:266,520,637...266,581,178 		JBrowse link
G Tsen2 tRNA splicing endonuclease subunit 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TSEN2 mRNA CTD PMID:21346803 NCBI chr 4:150,275,389...150,310,846
Ensembl chr 4:150,275,501...150,313,013 		JBrowse link
G Tsku tsukushi, small leucine rich proteoglycan affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TSKU mRNA CTD PMID:21346803 NCBI chr 1:162,071,459...162,082,972
Ensembl chr 1:162,064,126...162,089,272 		JBrowse link
G Ttll12 tubulin tyrosine ligase like 12 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TTLL12 mRNA CTD PMID:21346803 NCBI chr 7:116,612,609...116,631,244
Ensembl chr 7:116,612,609...116,631,577 		JBrowse link
G Tuba1c tubulin, alpha 1C affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TUBA1C mRNA CTD PMID:21346803 NCBI chr 7:131,636,974...132,078,589
Ensembl chr 7:132,070,536...132,079,311 		JBrowse link
G Txnrd1 thioredoxin reductase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TXNRD1 mRNA CTD PMID:21346803 NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817 		JBrowse link
G Tymp thymidine phosphorylase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of TYMP mRNA CTD PMID:21346803 NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003 		JBrowse link
G Ubl7 ubiquitin-like 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UBL7 mRNA CTD PMID:21346803 NCBI chr 8:67,217,151...67,236,224
Ensembl chr 8:67,216,527...67,236,224 		JBrowse link
G Ubqln4 ubiquilin 4 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UBQLN4 mRNA CTD PMID:21346803 NCBI chr 2:176,310,524...176,325,724
Ensembl chr 2:176,310,568...176,325,924 		JBrowse link
G Ugdh UDP-glucose 6-dehydrogenase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UGDH mRNA CTD PMID:21346803 NCBI chr14:43,202,480...43,226,002
Ensembl chr14:43,202,356...43,226,629 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UGP2 mRNA CTD PMID:21346803 NCBI chr14:99,657,637...99,698,573
Ensembl chr14:99,657,639...99,698,002 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UGT1A2 mRNA CTD PMID:21346803 NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Ugt1a6a UDP glucuronosyltransferase family 1 member A6a affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UGT1A6 mRNA CTD PMID:21346803 NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Umps uridine monophosphate synthetase affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UMPS mRNA CTD PMID:21346803 NCBI chr11:80,311,269...80,321,678
Ensembl chr11:80,311,214...80,327,828 		JBrowse link
G Usp10 ubiquitin specific peptidase 10 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of USP10 mRNA CTD PMID:21346803 NCBI chr19:64,881,255...64,923,522
Ensembl chr19:64,881,315...64,923,519 		JBrowse link
G Usp14 ubiquitin specific peptidase 14 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of USP14 mRNA CTD PMID:21346803 NCBI chr18:1,292,745...1,330,867
Ensembl chr18:1,292,745...1,330,336 		JBrowse link
G Usp39 ubiquitin specific peptidase 39 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of USP39 mRNA CTD PMID:21346803 NCBI chr 4:105,932,140...105,964,551
Ensembl chr 4:105,932,140...105,964,551 		JBrowse link
G Usp7 ubiquitin specific peptidase 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of USP7 mRNA CTD PMID:21346803 NCBI chr10:7,335,508...7,432,018
Ensembl chr10:7,367,604...7,432,013 		JBrowse link
G Utp14a UTP14A small subunit processome component affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UTP14A mRNA CTD PMID:21346803 NCBI chr  X:132,317,163...132,342,524
Ensembl chr  X:132,317,159...132,342,523 		JBrowse link
G Utp4 UTP4 small subunit processome component affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of UTP4 mRNA CTD PMID:21346803 NCBI chr19:51,696,437...51,730,323
Ensembl chr19:51,701,739...51,730,325 		JBrowse link
G Vars2 valyl-tRNA synthetase 2, mitochondrial affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of VARS2 mRNA CTD PMID:21346803 NCBI chr20:3,081,869...3,092,907
Ensembl chr20:3,081,893...3,092,901 		JBrowse link
G Vdac1 voltage-dependent anion channel 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of VDAC1 mRNA CTD PMID:21346803 NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541 		JBrowse link
G Vegfb vascular endothelial growth factor B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of VEGFB mRNA CTD PMID:21346803 NCBI chr 1:213,601,570...213,607,254
Ensembl chr 1:213,600,966...213,607,152 		JBrowse link
G Wars1 tryptophanyl-tRNA synthetase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of WARS1 mRNA CTD PMID:21346803 NCBI chr 6:133,540,463...133,571,645
Ensembl chr 6:133,539,744...133,571,645 		JBrowse link
G Wdr12 WD repeat domain 12 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of WDR12 mRNA CTD PMID:21346803 NCBI chr 9:68,969,547...68,996,811
Ensembl chr 9:68,969,547...68,996,811 		JBrowse link
G Wdr36 WD repeat domain 36 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of WDR36 mRNA CTD PMID:21346803 NCBI chr18:24,747,812...24,783,704
Ensembl chr18:24,747,832...24,783,110 		JBrowse link
G Wdr46 WD repeat domain 46 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of WDR46 mRNA CTD PMID:21346803 NCBI chr20:4,939,721...4,947,619
Ensembl chr20:4,939,732...4,947,741 		JBrowse link
G Wnk1 WNK lysine deficient protein kinase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of WNK1 mRNA CTD PMID:21346803 NCBI chr 4:154,800,590...154,926,147
Ensembl chr 4:154,800,590...154,926,147 		JBrowse link
G Wnt2 Wnt family member 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of WNT2 mRNA CTD PMID:21346803 NCBI chr 4:47,294,300...47,340,284
Ensembl chr 4:47,294,300...47,421,976 		JBrowse link
G Xpo1 exportin 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of XPO1 mRNA CTD PMID:21346803 NCBI chr14:101,434,450...101,476,705
Ensembl chr14:101,434,517...101,476,714 		JBrowse link
G Xrcc5 X-ray repair cross complementing 5 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of XRCC5 mRNA CTD PMID:21346803 NCBI chr 9:81,404,507...81,493,293
Ensembl chr 9:81,375,863...81,493,293 		JBrowse link
G Xrn1 5'-3' exoribonuclease 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of XRN1 mRNA CTD PMID:21346803 NCBI chr 8:105,407,785...105,516,967
Ensembl chr 8:105,407,785...105,512,321 		JBrowse link
G Yars1 tyrosyl-tRNA synthetase 1 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of YARS1 mRNA CTD PMID:21346803 NCBI chr 5:146,820,163...146,848,377
Ensembl chr 5:146,819,358...146,848,377 		JBrowse link
G Yars2 tyrosyl-tRNA synthetase 2 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of YARS2 mRNA CTD PMID:21346803 NCBI chr11:98,136,530...98,142,320
Ensembl chr11:98,115,386...98,142,668 		JBrowse link
G Ywhag tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of YWHAG mRNA CTD PMID:21346803 NCBI chr12:26,381,106...26,409,466
Ensembl chr12:26,380,816...26,409,465 		JBrowse link
G Zbtb16 zinc finger and BTB domain containing 16 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZBTB16 mRNA CTD PMID:21346803 NCBI chr 8:57,885,886...58,073,507
Ensembl chr 8:57,891,081...58,073,507 		JBrowse link
G Zbtb43 zinc finger and BTB domain containing 43 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZBTB43 mRNA CTD PMID:21346803 NCBI chr 3:37,142,210...37,161,524
Ensembl chr 3:37,141,354...37,162,238 		JBrowse link
G Zc3h7b zinc finger CCCH-type containing 7B affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZC3H7B mRNA CTD PMID:21346803 NCBI chr 7:115,142,245...115,190,513
Ensembl chr 7:115,142,420...115,190,513 		JBrowse link
G Zc3h8 zinc finger CCCH type containing 8 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZC3H8 mRNA CTD PMID:21346803 NCBI chr 3:136,629,998...136,646,998
Ensembl chr 3:136,629,999...136,646,952 		JBrowse link
G Zdhhc23 zinc finger DHHC-type palmitoyltransferase 23 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZDHHC23 mRNA CTD PMID:21346803 NCBI chr11:70,224,581...70,240,971
Ensembl chr11:70,225,045...70,240,102 		JBrowse link
G Zdhhc7 zinc finger DHHC-type palmitoyltransferase 7 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZDHHC7 mRNA CTD PMID:21346803 NCBI chr19:65,048,140...65,065,286
Ensembl chr19:65,037,310...65,065,286 		JBrowse link
G Zfp593 zinc finger protein 593 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZNF593 mRNA CTD PMID:21346803 NCBI chr 5:151,746,396...151,748,724
Ensembl chr 5:151,746,396...151,748,891 		JBrowse link
G Zfp692 zinc finger protein 692 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZFP692 mRNA CTD PMID:21346803 NCBI chr10:42,988,946...42,997,009
Ensembl chr10:42,988,938...42,997,015 		JBrowse link
G Zmym3 zinc finger MYM-type containing 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZMYM3 mRNA CTD PMID:21346803 NCBI chr  X:70,568,573...70,584,221
Ensembl chr  X:70,568,573...70,584,768 		JBrowse link
G Zscan21 zinc finger and SCAN domain containing 21 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZSCAN21 mRNA CTD PMID:21346803 NCBI chr12:22,112,204...22,142,506
Ensembl chr12:22,117,311...22,128,783 		JBrowse link
G Zswim3 zinc finger, SWIM-type containing 3 affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZSWIM3 mRNA CTD PMID:21346803 NCBI chr 3:173,962,078...173,977,360
Ensembl chr 3:173,941,801...173,977,692 		JBrowse link
G Zwint ZW10 interacting kinetochore protein affects expression EXP 4-amino-2,6-dinitrotoluene affects the expression of ZWINT mRNA CTD PMID:21346803 NCBI chr20:15,502,559...15,953,701
Ensembl chr20:15,937,396...15,953,203 		JBrowse link
4-aminophenol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO 4-aminophenol results in decreased phosphorylation of AKT1 protein CTD PMID:22162043 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Alb albumin multiple interactions EXP [4-nitrophenol co-treated with 4-aminophenol co-treated with 4-nitroaniline] results in increased expression of ALB protein CTD PMID:20429802 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G Capn2 calpain 2 decreases activity
decreases expression 		EXP 4-aminophenol results in decreased activity of CAPN2 protein
4-aminophenol results in decreased expression of CAPN2 protein 		CTD PMID:17567590 NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625 		JBrowse link
G Casp12 caspase 12 multiple interactions EXP 4-aminophenol results in increased activity of and results in increased cleavage of CASP12 protein; 4-aminophenol results in increased cleavage of and results in increased activity of CASP12 protein; PD 150606 inhibits the reaction [4-aminophenol results in increased activity of and results in increased cleavage of CASP12 protein] CTD PMID:17567590 PMID:17567592 NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol CTD PMID:20369854 NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO 4-aminophenol results in increased expression of HMOX1 CTD PMID:26260164 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 increases expression EXP 4-aminophenol results in increased expression of HSP90B1 protein CTD PMID:17567590 PMID:17567592 NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:22,997,962...23,012,293 		JBrowse link
G Rnd1 Rho family GTPase 1 decreases expression EXP 4-aminophenol results in decreased expression of RND1 mRNA CTD PMID:23558518 NCBI chr 7:131,700,321...131,707,392
Ensembl chr 7:131,700,321...131,707,392 		JBrowse link
G Serpine1 serpin family E member 1 increases expression EXP 4-aminophenol results in increased expression of SERPINE1 mRNA CTD PMID:23558518 NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357 		JBrowse link
G Spp1 secreted phosphoprotein 1 decreases expression EXP 4-aminophenol results in decreased expression of SPP1 mRNA CTD PMID:23558518 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions
increases expression 		EXP PD 150606 inhibits the reaction [4-aminophenol results in increased expression of XBP1 protein]
4-aminophenol results in increased expression of XBP1 mRNA; 4-aminophenol results in increased expression of XBP1 protein 		CTD PMID:17567590 PMID:17567592 NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706 		JBrowse link
4-chloroaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G H2ax H2A.X variant histone increases phosphorylation ISO 4-chloroaniline results in increased phosphorylation of H2AX protein CTD PMID:34510228 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Nat1 N-acetyltransferase 1 increases acetylation ISO NAT1 protein results in increased acetylation of 4-chloroaniline CTD PMID:15627487 NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527 		JBrowse link
G Nat2 N-acetyltransferase 2 increases acetylation ISO NAT2 protein results in increased acetylation of 4-chloroaniline CTD PMID:15627487 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Tp53 tumor protein p53 affects expression ISO 4-chloroaniline affects the expression of TP53 mRNA CTD PMID:27825931 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
4-ethoxyaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO Phenetidine results in decreased expression of and results in decreased activity of PTGS2 protein CTD PMID:14592552 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
4-fluoroaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline CTD PMID:20369854 NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
4-Hexyloxyaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nat2 N-acetyltransferase 2 increases acetylation ISO NAT2 protein results in increased acetylation of 4-hexyloxyaniline CTD PMID:15627487 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
4-nitroaniline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin multiple interactions EXP [4-nitrophenol co-treated with 4-aminophenol co-treated with 4-nitroaniline] results in increased expression of ALB protein CTD PMID:20429802 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO BCL2 protein inhibits the reaction [resveratrol promotes the reaction [[CASP3 protein results in increased cleavage of aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide] which results in increased chemical synthesis of 4-nitroaniline]] CTD PMID:11577002 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G C1s complement C1s increases hydrolysis ISO C1S protein results in increased hydrolysis of 4-nitroaniline analog CTD PMID:3495295 NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO BCL2 protein inhibits the reaction [resveratrol promotes the reaction [[CASP3 protein results in increased cleavage of aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide] which results in increased chemical synthesis of 4-nitroaniline]]; resveratrol promotes the reaction [[CASP3 protein results in increased cleavage of aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide] which results in increased chemical synthesis of 4-nitroaniline] CTD PMID:11577002 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases activity
increases expression 		EXP 4-nitroaniline analog results in increased activity of CYP1A1 protein
4-nitroaniline analog results in increased expression of CYP1A1 protein 		CTD PMID:9545601 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases activity
increases expression 		EXP 4-nitroaniline analog results in increased activity of CYP1A2 protein
4-nitroaniline analog results in increased expression of CYP1A2 mRNA; 4-nitroaniline analog results in increased expression of CYP1A2 protein 		CTD PMID:7553614 PMID:9545601 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Dpp7 dipeptidylpeptidase 7 multiple interactions ISO [DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline]; Etoposide promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline]; Nigericin promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline]; UAMC00039 inhibits the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline] CTD PMID:16725115 NCBI chr 3:28,563,240...28,567,492
Ensembl chr 3:28,563,240...28,567,492 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Il1b interleukin 1 beta decreases expression ISO 4-nitroaniline results in decreased expression of IL1B mRNA CTD PMID:29594315 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO [4-nitroaniline co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672 		JBrowse link
G Klk1 kallikrein 1 affects metabolic processing
multiple interactions 		ISO KLK1 protein affects the metabolism of 4-nitroaniline analog
4-nitroaniline binds to and results in decreased activity of KLK1 protein 		CTD PMID:2330740 PMID:11151026 NCBI chr 1:103,779,152...103,783,270
Ensembl chr 1:103,779,164...103,783,270 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline] which results in increased expression of MPO protein modified form; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline CTD PMID:20199096 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
aclonifen term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO aclonifen results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370 		JBrowse link
aminoglutethimide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acp1 acid phosphatase 1 decreases expression ISO Aminoglutethimide results in decreased expression of ACP1 protein CTD PMID:26102013 NCBI chr 6:53,233,937...53,249,576
Ensembl chr 6:53,233,948...53,251,959 		JBrowse link
G Anp32b acidic nuclear phosphoprotein 32 family member B decreases expression ISO Aminoglutethimide results in decreased expression of ANP32B protein CTD PMID:26102013 NCBI chr 5:65,538,872...65,561,305
Ensembl chr 5:65,538,535...65,561,437 		JBrowse link
G Basp1 brain abundant, membrane attached signal protein 1 decreases expression ISO Aminoglutethimide results in decreased expression of BASP1 protein CTD PMID:26102013 NCBI chr 2:77,546,628...77,594,297
Ensembl chr 2:77,546,092...77,597,178 		JBrowse link
G Bcap31 B-cell receptor-associated protein 31 decreases expression ISO Aminoglutethimide results in decreased expression of BCAP31 protein CTD PMID:26102013 NCBI chr  X:156,548,911...156,581,002
Ensembl chr  X:156,548,911...156,579,371 		JBrowse link
G Cct4 chaperonin containing TCP1 subunit 4 increases expression ISO Aminoglutethimide results in increased expression of CCT4 protein CTD PMID:26102013 NCBI chr14:101,193,057...101,205,935
Ensembl chr14:101,192,772...101,205,770 		JBrowse link
G Cct6a chaperonin containing TCP1 subunit 6A decreases expression ISO Aminoglutethimide results in decreased expression of CCT6A protein CTD PMID:26102013 NCBI chr12:32,508,842...32,519,072
Ensembl chr12:32,508,675...32,519,119 		JBrowse link
G Cct7 chaperonin containing TCP1 subunit 7 decreases expression ISO Aminoglutethimide results in decreased expression of CCT7 protein CTD PMID:26102013 NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973 		JBrowse link
G Comt catechol-O-methyltransferase increases expression ISO Aminoglutethimide results in increased expression of COMT protein CTD PMID:26102013 NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533 		JBrowse link
G Cuta cutA divalent cation tolerance homolog decreases expression ISO Aminoglutethimide results in decreased expression of CUTA protein CTD PMID:26102013 NCBI chr20:5,024,816...5,026,446
Ensembl chr20:5,024,816...5,026,631 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 multiple interactions ISO Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA] CTD PMID:16935330 NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression ISO Aminoglutethimide results in decreased expression of CYP17A1 mRNA CTD PMID:16935330 NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions
increases activity
decreases activity 		ISO Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Aminoglutethimide inhibits the reaction [CYP19A1 protein affects the chemical synthesis of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine]; Aminoglutethimide inhibits the reaction [CYP19A1 protein affects the metabolism of Methadone]
Aminoglutethimide results in increased activity of CYP19A1 protein
Aminoglutethimide results in decreased activity of CYP19A1 protein 		CTD PMID:15242824 PMID:15968818 PMID:16935330 PMID:17910019 PMID:20087668 NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917 		JBrowse link
G Fshb follicle stimulating hormone subunit beta decreases expression
multiple interactions 		ISO Aminoglutethimide results in decreased expression of FSHB protein
Aminoglutethimide inhibits the reaction [[FSHB protein co-treated with LHB protein co-treated with Testosterone] results in increased abundance of Acetaldehyde] 		CTD PMID:9208491 PMID:22285649 NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072 		JBrowse link
G Gatd3a glutamine amidotransferase class 1 domain containing 3A increases expression ISO Aminoglutethimide results in increased expression of GATD3 protein CTD PMID:26102013 NCBI chr20:10,514,459...10,522,556
Ensembl chr20:10,514,443...10,522,555 		JBrowse link
G Gns glucosamine (N-acetyl)-6-sulfatase decreases expression ISO Aminoglutethimide results in decreased expression of GNS protein CTD PMID:26102013 NCBI chr 7:58,774,625...58,808,650
Ensembl chr 7:58,774,625...58,808,650 		JBrowse link
G Gpx1 glutathione peroxidase 1 increases expression ISO Aminoglutethimide results in increased expression of GPX1 protein CTD PMID:26102013 NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581 		JBrowse link
G Gsn gelsolin decreases expression ISO Aminoglutethimide results in decreased expression of GSN protein CTD PMID:26102013 NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:38,982,671...39,035,850 		JBrowse link
G H1f2 H1.2 linker histone, cluster member increases expression ISO Aminoglutethimide results in increased expression of H1-2 protein CTD PMID:26102013 NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317 		JBrowse link
G H2ac12 H2A clustered histone 12 increases expression ISO Aminoglutethimide results in increased expression of H2AC12 protein CTD PMID:26102013 NCBI chr17:47,182,193...47,182,658 JBrowse link
G H2az1 H2A.Z variant histone 1 increases expression ISO Aminoglutethimide results in increased expression of H2AZ1 protein CTD PMID:26102013 NCBI chr 2:229,026,464...229,031,411
Ensembl chr 2:229,028,843...229,031,411 		JBrowse link
G H2bc12 H2B clustered histone 12 increases expression ISO Aminoglutethimide results in increased expression of H2BC12 protein CTD PMID:26102013 NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816 		JBrowse link
G H3c13 H3 clustered histone 13 increases expression ISO Aminoglutethimide results in increased expression of H3C13 protein CTD PMID:26102013 NCBI chr17:41,959,540...41,960,009
Ensembl chr17:41,958,965...41,960,099 		JBrowse link
G Hmgb2 high mobility group box 2 decreases expression ISO Aminoglutethimide results in decreased expression of HMGB2 protein CTD PMID:26102013 NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860 		JBrowse link
G Hnrnph1 heterogeneous nuclear ribonucleoprotein H1 decreases expression ISO Aminoglutethimide results in decreased expression of HNRNPH1 protein CTD PMID:26102013 NCBI chr10:35,187,412...35,203,909
Ensembl chr10:35,193,890...35,203,906 		JBrowse link
G Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 multiple interactions ISO [Colforsin co-treated with Aminoglutethimide] results in decreased expression of HSD17B1 mRNA CTD PMID:16935330 NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210 		JBrowse link
G Hsd17b10 hydroxysteroid (17-beta) dehydrogenase 10 decreases expression ISO Aminoglutethimide results in decreased expression of HSD17B10 protein CTD PMID:26102013 NCBI chr  X:24,568,551...24,571,012
Ensembl chr  X:24,568,551...24,574,681 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 multiple interactions
decreases expression 		ISO Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of HSD17B4 mRNA]
Aminoglutethimide results in decreased expression of HSD17B4 mRNA 		CTD PMID:16935330 NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 decreases expression EXP Aminoglutethimide results in decreased expression of HSD17B7 mRNA CTD PMID:9231770 NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A increases expression ISO Aminoglutethimide results in increased expression of HSPA1A protein CTD PMID:26102013 NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979 		JBrowse link
G Hyou1 hypoxia up-regulated 1 increases expression ISO Aminoglutethimide results in increased expression of HYOU1 protein CTD PMID:26102013 NCBI chr 8:53,602,882...53,614,998
Ensembl chr 8:53,602,604...53,614,997 		JBrowse link
G Impdh2 inosine monophosphate dehydrogenase 2 decreases expression ISO Aminoglutethimide results in decreased expression of IMPDH2 protein CTD PMID:26102013 NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873 		JBrowse link
G Lhb luteinizing hormone subunit beta decreases expression
multiple interactions 		ISO Aminoglutethimide results in decreased expression of LHB protein
Aminoglutethimide inhibits the reaction [[FSHB protein co-treated with LHB protein co-treated with Testosterone] results in increased abundance of Acetaldehyde] 		CTD PMID:9208491 PMID:22285649 NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445 		JBrowse link
G Lmna lamin A/C decreases expression ISO Aminoglutethimide results in decreased expression of LMNA protein CTD PMID:26102013 NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072 		JBrowse link
G Lmnb2 lamin B2 decreases expression ISO Aminoglutethimide results in decreased expression of LMNB2 protein CTD PMID:26102013 NCBI chr 7:9,443,308...9,459,468
Ensembl chr 7:9,440,128...9,459,342 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 decreases expression ISO Aminoglutethimide results in decreased expression of MCM3 protein CTD PMID:26102013 NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide] which results in increased expression of MPO protein modified form; [Aminoglutethimide co-treated with Hydrogen Peroxide] results in increased oxidation of MPO protein; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide CTD PMID:20199096 PMID:26102013 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Myo18a myosin XVIIIa decreases expression ISO Aminoglutethimide results in decreased expression of MYO18A protein CTD PMID:26102013 NCBI chr10:63,152,303...63,253,543
Ensembl chr10:63,152,103...63,253,543 		JBrowse link
G Npm3 nucleophosmin/nucleoplasmin, 3 decreases expression ISO Aminoglutethimide results in decreased expression of NPM3 protein CTD PMID:26102013 NCBI chr 1:254,544,664...254,546,649
Ensembl chr 1:254,544,664...254,546,649 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases activity ISO Aminoglutethimide results in increased activity of NR1I2 protein CTD PMID:21068194 NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380 		JBrowse link
G Nup210 nucleoporin 210 decreases expression ISO Aminoglutethimide results in decreased expression of NUP210 protein CTD PMID:26102013 NCBI chr 4:125,068,736...125,167,238
Ensembl chr 4:125,068,736...125,167,047 		JBrowse link
G Pgr progesterone receptor multiple interactions
decreases expression 		ISO [Aminoglutethimide co-treated with 17 alpha-Hydroxyprogesterone Caproate] results in decreased expression of PGR protein
Aminoglutethimide results in decreased expression of PGR protein 		CTD PMID:8565696 PMID:9208491 NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271 		JBrowse link
G Pitpnb phosphatidylinositol transfer protein, beta increases expression ISO Aminoglutethimide results in increased expression of PITPNB protein CTD PMID:26102013 NCBI chr12:50,909,140...50,958,193
Ensembl chr12:50,909,143...50,958,140 		JBrowse link
G Ppp1ca protein phosphatase 1 catalytic subunit alpha decreases expression ISO Aminoglutethimide results in decreased expression of PPP1CA protein CTD PMID:26102013 NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:210,914,567...210,918,193 		JBrowse link
G Prdx3 peroxiredoxin 3 increases expression ISO Aminoglutethimide results in increased expression of PRDX3 protein CTD PMID:26102013 NCBI chr 1:269,987,691...270,000,111
Ensembl chr 1:269,987,685...270,000,300 		JBrowse link
G Psmb4 proteasome 20S subunit beta 4 decreases expression ISO Aminoglutethimide results in decreased expression of PSMB4 protein CTD PMID:26102013 NCBI chr 2:185,131,787...185,134,561
Ensembl chr 2:185,131,786...185,135,287 		JBrowse link
G Rtraf RNA transcription, translation and transport factor decreases expression ISO Aminoglutethimide results in decreased expression of RTRAF protein CTD PMID:26102013 NCBI chr15:4,482,699...4,507,115
Ensembl chr15:4,480,966...4,507,115 		JBrowse link
G Spp1 secreted phosphoprotein 1 decreases expression EXP Aminoglutethimide results in decreased expression of SPP1 mRNA CTD PMID:23558518 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820 		JBrowse link
G Ssb small RNA binding exonuclease protection factor La decreases expression ISO Aminoglutethimide results in decreased expression of SSB protein CTD PMID:26102013 NCBI chr 3:75,024,385...75,034,016
Ensembl chr 3:75,024,474...75,034,031 		JBrowse link
G Star steroidogenic acute regulatory protein decreases expression
increases expression 		ISO Aminoglutethimide results in decreased expression of STAR mRNA
Aminoglutethimide results in increased expression of STAR mRNA 		CTD PMID:10960482 PMID:16935330 NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447 		JBrowse link
G Tpt1 tumor protein, translationally-controlled 1 decreases expression ISO Aminoglutethimide results in decreased expression of TPT1 protein CTD PMID:26102013 NCBI chr15:57,562,217...57,568,968
Ensembl chr15:57,566,067...57,569,554 		JBrowse link
G Ubc ubiquitin C increases expression ISO Aminoglutethimide results in increased expression of UBC protein CTD PMID:26102013 NCBI chr12:36,899,673...36,905,275
Ensembl chr12:36,900,127...36,905,275 		JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K decreases expression ISO Aminoglutethimide results in decreased expression of UBE2K protein CTD PMID:26102013 NCBI chr14:43,011,681...43,077,825
Ensembl chr14:43,011,681...43,072,462 		JBrowse link
G Wdr1 WD repeat domain 1 increases expression ISO Aminoglutethimide results in increased expression of WDR1 protein CTD PMID:26102013 NCBI chr14:76,470,238...76,504,086
Ensembl chr14:76,470,176...76,504,080 		JBrowse link
G Ywhaq tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta increases expression ISO Aminoglutethimide results in increased expression of YWHAQ protein CTD PMID:26102013 NCBI chr 6:46,664,358...46,694,875
Ensembl chr 6:46,664,358...46,694,875 		JBrowse link
AZD8186 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO AZD8186 results in decreased phosphorylation of AKT1 protein CTD PMID:26853465 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Akt1s1 AKT1 substrate 1 affects phosphorylation ISO AZD8186 affects the phosphorylation of AKT1S1 protein CTD PMID:26853465 NCBI chr 1:104,469,823...104,476,168
Ensembl chr 1:104,469,803...104,476,167 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta affects expression
multiple interactions 		ISO AZD8186 affects the expression of MAP1LC3B protein modified form
bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form] 		CTD PMID:26853465 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
benzidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO benzidine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847 		JBrowse link
G Bik BCL2-interacting killer increases expression ISO benzidine results in increased expression of BIK mRNA CTD PMID:26198647 NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression ISO benzidine results in increased expression of GCLC mRNA CTD PMID:26198647 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression ISO benzidine results in increased expression of GCLM mRNA CTD PMID:26198647 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003 		JBrowse link
G H2ax H2A.X variant histone increases phosphorylation
multiple interactions 		EXP
ISO 		benzidine results in increased phosphorylation of H2AX protein
[NAT1 polymorphism affects the susceptibility to benzidine] which affects the expression of H2AX 		CTD PMID:37097310 PMID:37527026 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hprt1 hypoxanthine phosphoribosyltransferase 1 multiple interactions ISO [NAT1 polymorphism affects the susceptibility to benzidine] which affects the mutagenesis of HPRT1 CTD PMID:37097310 NCBI chr  X:137,655,744...137,687,718
Ensembl chr  X:137,655,680...137,687,712 		JBrowse link
G Lpo lactoperoxidase increases metabolic processing ISO LPO protein results in increased metabolism of benzidine CTD PMID:15606142 NCBI chr10:73,104,170...73,124,683
Ensembl chr10:73,104,188...73,123,456 		JBrowse link
G Mki67 marker of proliferation Ki-67 increases expression EXP benzidine results in increased expression of MKI67 protein CTD PMID:37527026 NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593 		JBrowse link
G Mpo myeloperoxidase affects metabolic processing ISO MPO protein affects the metabolism of benzidine CTD PMID:9288889 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056 		JBrowse link
G Nat1 N-acetyltransferase 1 increases activity
multiple interactions
affects response to substance
affects acetylation
increases metabolic processing 		ISO NAT1 protein results in increased activity of benzidine
[NAT1 polymorphism affects the susceptibility to benzidine] which affects the expression of H2AX; [NAT1 polymorphism affects the susceptibility to benzidine] which affects the mutagenesis of HPRT1
NAT1 polymorphism affects the acetylation of benzidine
NAT1 protein results in increased metabolism of benzidine 		CTD PMID:15450435 PMID:33136180 PMID:37097310 NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527 		JBrowse link
G Nat2 N-acetyltransferase 2 affects response to substance ISO NAT2 gene polymorphism affects the susceptibility to benzidine CTD PMID:16003747 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 increases metabolic processing ISO PTGS1 protein results in increased metabolism of benzidine CTD PMID:11159734 NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases metabolic processing ISO PTGS2 protein results in increased metabolism of benzidine CTD PMID:11159734 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression ISO benzidine results in increased expression of SLC7A11 mRNA CTD PMID:26198647 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO benzidine results in increased expression of SQSTM1 mRNA CTD PMID:26198647 NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750 		JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO benzidine results in increased expression of SRXN1 mRNA CTD PMID:26198647 NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765 		JBrowse link
G Tp53 tumor protein p53 increases expression ISO benzidine results in increased expression of TP53 protein mutant form CTD PMID:15748509 PMID:17690521 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases metabolic processing ISO UGT2B7 protein results in increased metabolism of benzidine CTD PMID:15615884 NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451 		JBrowse link
benzocaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl4 C-C motif chemokine ligand 4 increases expression ISO Benzocaine results in increased expression of CCL4 protein CTD PMID:18353026 NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein CTD PMID:15588918 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein CTD PMID:15588918 NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580 		JBrowse link
G Il18 interleukin 18 increases activity ISO Benzocaine results in increased activity of IL18 protein CTD PMID:15840424 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1a interleukin 1 alpha increases activity ISO Benzocaine results in increased activity of IL1A protein CTD PMID:15840424 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Benzocaine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein CTD PMID:15588918 NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672 		JBrowse link
BI-2536 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp8 caspase 8 increases activity ISO BI 2536 results in increased activity of CASP8 protein CTD PMID:24403256 NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Notch1 notch receptor 1 multiple interactions ISO BI 2536 inhibits the reaction [Arsenic Trioxide results in decreased expression of NOTCH1 protein]; BI 2536 inhibits the reaction [Nocodazole results in decreased expression of NOTCH1 protein] CTD PMID:31597699 NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613 		JBrowse link
G Plk1 polo-like kinase 1 decreases activity
multiple interactions 		ISO BI 2536 results in decreased activity of PLK1 protein
BI 2536 inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of PLK1 protein] 		CTD PMID:24748653 PMID:31597699 NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:186,147,658...186,157,637 		JBrowse link
bromfenac term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO bromfenac results in decreased activity of ABCB11 protein CTD PMID:22646477 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases activity ISO bromfenac results in decreased activity of ABCC2 protein CTD PMID:22646477 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Bmp6 bone morphogenetic protein 6 increases expression ISO bromfenac results in increased expression of BMP6 mRNA CTD PMID:32816093 NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases metabolic processing ISO CYP1A2 protein results in increased metabolism of bromfenac metabolite CTD PMID:31815452 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 increases hydroxylation ISO CYP2C19 protein results in increased hydroxylation of bromfenac CTD PMID:31815452 NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases hydroxylation ISO CYP2C8 protein results in increased hydroxylation of bromfenac CTD PMID:31815452
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing ISO CYP3A4 protein results in increased metabolism of bromfenac metabolite CTD PMID:31815452 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Ereg epiregulin increases expression ISO bromfenac results in increased expression of EREG mRNA CTD PMID:32816093 NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260 		JBrowse link
G Il1a interleukin 1 alpha increases expression ISO bromfenac results in increased expression of IL1A mRNA CTD PMID:32816093 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il1b interleukin 1 beta increases expression ISO bromfenac results in increased expression of IL1B mRNA CTD PMID:32816093 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase increases expression ISO bromfenac results in increased expression of MET mRNA CTD PMID:32816093 NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO bromfenac results in increased expression of PTGS2 mRNA CTD PMID:32816093 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression ISO bromfenac results in decreased expression of SLC7A11 mRNA CTD PMID:32816093 NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695 		JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO bromfenac results in increased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases metabolic processing
multiple interactions 		ISO UGT2B7 protein results in increased metabolism of bromfenac
[UGT2B7 protein results in increased metabolism of bromfenac] which results in increased abundance of bromfenac metabolite; Mefenamic Acid inhibits the reaction [[UGT2B7 protein results in increased metabolism of bromfenac] which results in increased abundance of bromfenac metabolite]; Mefenamic Acid inhibits the reaction [UGT2B7 protein results in increased metabolism of bromfenac] 		CTD PMID:31815452 PMID:38331335 NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451 		JBrowse link
bromhexine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO Bromhexine results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Bromhexine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019 		JBrowse link
butamben term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor affects binding EXP butamben binds to AR protein CTD PMID:14565775 NCBI chr  X:67,135,317...67,304,476
Ensembl chr  X:67,135,317...67,304,467 		JBrowse link
G Med1 mediator complex subunit 1 multiple interactions ISO butamben promotes the reaction [NR1I2.L protein binds to MED1 protein]; butamben promotes the reaction [NR1I2.S protein binds to MED1 protein] CTD PMID:12198127 NCBI chr10:83,641,851...83,685,560
Ensembl chr10:83,641,862...83,685,545 		JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO butamben promotes the reaction [NR1I2.L protein binds to NCOA1 protein]; butamben promotes the reaction [NR1I2.S protein binds to NCOA1 protein] CTD PMID:12198127 NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924 		JBrowse link
G Ncoa2 nuclear receptor coactivator 2 multiple interactions ISO butamben promotes the reaction [NR1I2.L protein binds to NCOA2 protein] CTD PMID:12198127 NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776 		JBrowse link
G Ncoa3 nuclear receptor coactivator 3 multiple interactions ISO butamben promotes the reaction [NR1I2.L protein binds to NCOA3 protein] CTD PMID:12198127 NCBI chr 3:175,157,824...175,237,831
Ensembl chr 3:175,157,821...175,240,631 		JBrowse link
cisapride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO Cisapride results in decreased activity of ABCB11 protein CTD PMID:23956101 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant multiple interactions ISO Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] CTD PMID:31150804 NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929 		JBrowse link
G Ctsk cathepsin K multiple interactions ISO Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] CTD PMID:31150804 NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
affects metabolic processing
affects chemical synthesis
decreases activity 		ISO Cisapride inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
CYP3A4 protein affects the metabolism of Cisapride
CYP3A4 protein affects the chemical synthesis of Cisapride metabolite
Cisapride results in decreased activity of CYP3A4 protein 		CTD PMID:11717173 PMID:15306208 PMID:19299527 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Dcstamp dendrocyte expressed seven transmembrane protein multiple interactions ISO Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA] CTD PMID:31150804 NCBI chr 7:72,692,364...72,706,983
Ensembl chr 7:72,671,477...72,707,009 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] CTD PMID:31150804 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 multiple interactions
decreases activity
affects localization
affects binding 		ISO beta-Cyclodextrins analog inhibits the reaction [Cisapride results in decreased activity of KCNH2 protein]; Cisapride binds to and results in decreased activity of KCNH2 protein; Cisapride inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Cisapride affects the localization of KCNH2 protein mutant form
Cisapride binds to KCNH2 protein 		CTD PMID:9395068 PMID:10531299 PMID:11005845 PMID:11741928 PMID:12388285 More... NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 multiple interactions ISO Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] CTD PMID:31150804 NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990 		JBrowse link
G Scn5a sodium voltage-gated channel alpha subunit 5 increases localization ISO Cisapride results in increased localization of SCN5A protein mutant form CTD PMID:16301357 NCBI chr 8:128,098,613...128,196,515
Ensembl chr 8:128,098,613...128,196,470 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Cisapride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] CTD PMID:31150804 NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479 		JBrowse link
clenbuterol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acadm acyl-CoA dehydrogenase medium chain increases expression ISO Clenbuterol results in increased expression of ACADM mRNA CTD PMID:17446185 NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:245,518,693...245,542,864 		JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions
increases activity 		ISO
EXP 		[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]
Clenbuterol results in increased activity of ADRB2 protein 		CTD PMID:16007677 PMID:18552870 PMID:34601065 NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803 		JBrowse link
G Adrb3 adrenoceptor beta 3 multiple interactions EXP Clenbuterol binds to and results in increased activity of ADRB3 protein CTD PMID:7815362 NCBI chr16:71,544,603...71,547,410
Ensembl chr16:71,542,567...71,547,420 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions EXP Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]] CTD PMID:15710352 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions EXP Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]] CTD PMID:15710352 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149 		JBrowse link
G Esrra estrogen related receptor, alpha increases expression ISO Clenbuterol results in increased expression of ESRRA mRNA CTD PMID:17446185 NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811 		JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions EXP Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]; Clenbuterol inhibits the reaction [Reserpine results in increased expression of GAD1 mRNA]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]] CTD PMID:8774452 NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759 		JBrowse link
G Il10 interleukin 10 multiple interactions
affects expression 		ISO
EXP 		Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein]
Clenbuterol affects the expression of IL10 protein 		CTD PMID:15021963 PMID:15502056 NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580 		JBrowse link
G Il18 interleukin 18 increases expression ISO Clenbuterol results in increased expression of IL18 mRNA; Clenbuterol results in increased expression of IL18 protein CTD PMID:15178407 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286 		JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] CTD PMID:15021963 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il6 interleukin 6 multiple interactions EXP Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] CTD PMID:15021963 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] CTD PMID:15502056 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072 		JBrowse link
G Odc1 ornithine decarboxylase 1 multiple interactions
increases stability
increases activity 		ISO Alprenolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Metoprolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Propranolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]
Clenbuterol results in increased stability of ODC1 protein 		CTD PMID:10353628 NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146 		JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 increases expression ISO Clenbuterol results in increased expression of PDK4 mRNA CTD PMID:17446185 NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions 		ISO
EXP 		Clenbuterol results in increased expression of PPARGC1A mRNA
Propranolol inhibits the reaction [Clenbuterol results in increased expression of PPARGC1A mRNA] 		CTD PMID:17446185 NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP Clenbuterol affects the reaction [Lipopolysaccharides affects the localization of RELA protein] CTD PMID:15710352 NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Tfam transcription factor A, mitochondrial increases expression ISO Clenbuterol results in increased expression of TFAM mRNA CTD PMID:17446185 NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,355,363...17,369,877 		JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] CTD PMID:15021963 PMID:15710352 NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303 		JBrowse link
G Ucp1 uncoupling protein 1 increases expression ISO Clenbuterol results in increased expression of UCP1 protein CTD PMID:10465291 NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420 		JBrowse link
co-trimoxazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ins2 insulin 2 increases secretion ISO Trimethoprim, Sulfamethoxazole Drug Combination results in increased secretion of INS protein modified form CTD PMID:14714756 NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805 		JBrowse link
dapsone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression EXP Dapsone metabolite results in decreased expression of ABCC2 protein CTD PMID:15863252 NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471 		JBrowse link
G Cat catalase decreases activity EXP Dapsone results in decreased activity of CAT protein CTD PMID:18602405 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in increased expression of CCL3 mRNA] CTD PMID:21765237 NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of CXCR4 mRNA] CTD PMID:21440447 NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases activity ISO Dapsone results in increased activity of CYP1A1 protein CTD PMID:12451431 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO CYP2B6 protein results in increased metabolism of and results in increased susceptibility to Dapsone CTD PMID:19998329 NCBI chr 1:90,780,468...90,859,852 JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO CYP2C19 protein results in increased metabolism of and results in increased susceptibility to Dapsone CTD PMID:19998329 NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases metabolic processing ISO CYP2C8 protein results in increased metabolism of Dapsone CTD PMID:17286541
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions ISO CYP2D6 protein results in increased metabolism of and results in increased susceptibility to Dapsone CTD PMID:19998329 NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
affects metabolic processing 		EXP
ISO 		[SOD2 co-treated with CYP3A4] affects the susceptibility to Dapsone
CYP3A4 protein affects the metabolism of Dapsone
CYP3A4 protein results in increased metabolism of and results in increased susceptibility to Dapsone 		CTD PMID:12920490 PMID:15327588 PMID:19501153 PMID:19998329 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Edn1 endothelin 1 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in increased expression of EDN1 mRNA] CTD PMID:21765237 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Elk4 ETS transcription factor ELK4 multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of ELK4 mRNA] CTD PMID:21440447 NCBI chr13:46,004,145...46,027,206
Ensembl chr13:46,004,182...46,027,199 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of FKBP5 mRNA] CTD PMID:21440447 NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases response to substance ISO G6PD protein mutant form results in increased susceptibility to Dapsone CTD PMID:7752092 NCBI chr  X:157,352,364...157,372,144
Ensembl chr  X:157,352,373...157,372,144 		JBrowse link
G Greb1 growth regulating estrogen receptor binding 1 multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of GREB1 mRNA] CTD PMID:21440447 NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in decreased expression of GSR protein]; Dapsone inhibits the reaction [Paraquat results in increased expression of GSR mRNA] CTD PMID:21765237 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in decreased expression of GSTP1 protein] CTD PMID:21765237 NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of IGF1R mRNA] CTD PMID:21440447 NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664 		JBrowse link
G Il1b interleukin 1 beta decreases expression ISO Dapsone results in decreased expression of IL1B mRNA CTD PMID:29594315 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Dapsone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of MAF mRNA] CTD PMID:21440447 NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378 		JBrowse link
G Mak male germ cell-associated kinase multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of MAK mRNA] CTD PMID:21440447 NCBI chr17:23,889,417...23,936,857
Ensembl chr17:23,889,516...23,936,855 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Dapsone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein] CTD PMID:21436242 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Dapsone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein] CTD PMID:21436242 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in increased expression of MMP9 protein] CTD PMID:21765237 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Nat2 N-acetyltransferase 2 increases acetylation ISO NAT2 protein results in increased acetylation of Dapsone CTD PMID:14528063 NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304 		JBrowse link
G Nkx3-1 NK3 homeobox 1 multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of NKX3-1 mRNA] CTD PMID:21440447 NCBI chr15:50,883,661...50,886,253
Ensembl chr15:50,883,597...50,886,251 		JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in increased expression of NOX4 mRNA] CTD PMID:20164675 PMID:21765237 NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of NR4A1 mRNA] CTD PMID:21440447 NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041 		JBrowse link
G Per1 period circadian regulator 1 multiple interactions ISO Dapsone analog inhibits the reaction [Metribolone results in increased expression of PER1 mRNA] CTD PMID:21440447 NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211 		JBrowse link
G Plcb2 phospholipase C, beta 2 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in increased phosphorylation of PLCB2 protein] CTD PMID:20164675 NCBI chr 3:126,134,925...126,158,303
Ensembl chr 3:126,138,736...126,158,221 		JBrowse link
G Prkd1 protein kinase D1 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in increased phosphorylation of PRKD1 protein] CTD PMID:21765237 NCBI chr 6:73,460,640...73,774,433
Ensembl chr 6:73,460,640...73,836,509 		JBrowse link
G Prmt1 protein arginine methyltransferase 1 decreases activity ISO Dapsone analog results in decreased activity of PRMT1 protein; Dapsone results in decreased activity of PRMT1 protein CTD PMID:21440447 NCBI chr 1:104,595,339...104,605,552
Ensembl chr 1:104,595,335...104,604,827 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Dapsone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of RELA protein] CTD PMID:21436242 NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Slc4a2 solute carrier family 4 member 2 decreases expression EXP Dapsone metabolite results in decreased expression of SLC4A2 protein CTD PMID:15863252 NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:11,628,862...11,645,402 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP
ISO 		[SOD2 co-treated with CYP3A4] affects the susceptibility to Dapsone
Dapsone inhibits the reaction [Paraquat results in decreased expression of SOD2 protein] 		CTD PMID:19501153 PMID:21765237 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Dapsone inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] CTD PMID:21765237 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
entinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A1bg alpha-1-B glycoprotein increases expression ISO entinostat results in increased expression of A1BG mRNA CTD PMID:27188386 NCBI chr 7:94,383,333...94,387,922
Ensembl chr 7:94,383,333...94,387,496 		JBrowse link
G Aak1 AP2 associated kinase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of AAK1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AAK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:120,845,012...121,009,170
Ensembl chr 4:120,858,557...121,004,236 		JBrowse link
G Aars1 alanyl-tRNA synthetase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of AARS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AARS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:55,906,694...55,930,499
Ensembl chr19:55,906,702...55,930,497 		JBrowse link
G Abat 4-aminobutyrate aminotransferase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA
entinostat results in increased expression of ABAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474 		JBrowse link
G Abca4 ATP binding cassette subfamily A member 4 increases expression ISO entinostat results in increased expression of ABCA4 mRNA CTD PMID:27188386 NCBI chr 2:212,849,470...212,986,730
Ensembl chr 2:212,755,803...212,986,729 		JBrowse link
G Abca5 ATP binding cassette subfamily A member 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA
entinostat results in decreased expression of ABCA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:95,739,610...95,808,633
Ensembl chr10:95,739,610...95,808,424 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 increases expression ISO entinostat results in increased expression of ABCB4 mRNA CTD PMID:27188386 NCBI chr 4:26,106,895...26,164,440 JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 increases expression ISO entinostat results in increased expression of ABCC4 mRNA CTD PMID:27188386 NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 increases expression ISO entinostat results in increased expression of ABCG1 mRNA CTD PMID:26272509 NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563 		JBrowse link
G Abhd14b abhydrolase domain containing 14b increases expression ISO entinostat results in increased expression of ABHD14B mRNA CTD PMID:27188386 NCBI chr 8:115,966,792...115,970,829
Ensembl chr 8:115,965,932...115,970,833 		JBrowse link
G Abhd15 abhydrolase domain containing 15 increases expression ISO entinostat results in increased expression of ABHD15 mRNA CTD PMID:27188386 NCBI chr10:62,861,335...62,866,726
Ensembl chr10:62,861,317...62,868,540 		JBrowse link
G Abhd3 abhydrolase domain containing 3, phospholipase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA
entinostat results in increased expression of ABHD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:1,996,010...2,051,311
Ensembl chr18:1,993,525...2,075,492 		JBrowse link
G Acad11 acyl-CoA dehydrogenase family, member 11 increases expression ISO entinostat results in increased expression of ACAD11 mRNA CTD PMID:26272509 NCBI chr 8:113,560,142...113,625,346
Ensembl chr 8:113,560,196...113,625,352 		JBrowse link
G Acadsb acyl-CoA dehydrogenase, short/branched chain increases expression
multiple interactions 		ISO entinostat results in increased expression of ACADSB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACADSB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:195,619,088...195,660,564
Ensembl chr 1:195,619,038...195,660,561 		JBrowse link
G Acap1 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACAP1 mRNA CTD PMID:27188386 NCBI chr10:55,104,040...55,119,280
Ensembl chr10:55,104,040...55,118,185 		JBrowse link
G Acat2 acetyl-CoA acetyltransferase 2 decreases expression ISO entinostat results in decreased expression of ACAT2 mRNA CTD PMID:27188386 NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095 		JBrowse link
G Acox1 acyl-CoA oxidase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ACOX1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136 		JBrowse link
G Acoxl acyl-CoA oxidase-like multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACOXL mRNA
entinostat results in increased expression of ACOXL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:135,514,340...135,820,291
Ensembl chr 3:135,514,275...135,820,291 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant increases expression
multiple interactions 		ISO entinostat results in increased expression of ACP5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ACSL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023 		JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of ACSM3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:183,564,652...183,591,328
Ensembl chr 1:183,564,635...183,591,437 		JBrowse link
G Acta1 actin, alpha 1, skeletal muscle multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTA1 mRNA
entinostat results in decreased expression of ACTA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:68,781,168...68,784,194
Ensembl chr19:68,781,168...68,786,178 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTA2 mRNA
entinostat results in decreased expression of ACTA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Actc1 actin, alpha, cardiac muscle 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ACTC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:121,266,291...121,271,827
Ensembl chr 3:121,266,291...121,271,827 		JBrowse link
G Actl6b actin-like 6B multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTL6B mRNA
entinostat results in increased expression of ACTL6B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:24,761,660...24,778,193
Ensembl chr12:24,761,693...24,778,151 		JBrowse link
G Actn1 actinin, alpha 1 increases expression ISO entinostat results in increased expression of ACTN1 mRNA CTD PMID:27188386 NCBI chr 6:104,731,485...104,826,312
Ensembl chr 6:104,731,485...104,826,172 		JBrowse link
G Acvr2b activin A receptor type 2B decreases expression ISO entinostat results in decreased expression of ACVR2B mRNA CTD PMID:27188386 NCBI chr 8:128,016,589...128,056,193
Ensembl chr 8:128,016,526...128,048,171 		JBrowse link
G Acvrl1 activin A receptor like type 1 increases expression ISO entinostat results in increased expression of ACVRL1 mRNA CTD PMID:27188386 NCBI chr 7:134,117,917...134,135,306
Ensembl chr 7:134,118,024...134,135,305 		JBrowse link
G Ada adenosine deaminase increases expression ISO entinostat results in increased expression of ADA mRNA CTD PMID:27188386 NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293 		JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552 		JBrowse link
G Adam28 ADAM metallopeptidase domain 28 increases expression ISO entinostat results in increased expression of ADAM28 mRNA CTD PMID:27188386 NCBI chr15:50,184,286...50,250,605
Ensembl chr15:50,127,516...50,250,526 		JBrowse link
G Adam8 ADAM metallopeptidase domain 8 increases expression ISO entinostat results in increased expression of ADAM8 mRNA CTD PMID:32870474 NCBI chr 1:204,206,206...204,218,988
Ensembl chr 1:204,206,199...204,218,485 		JBrowse link
G Adamts17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA
entinostat results in increased expression of ADAMTS17 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:129,856,062...130,178,430
Ensembl chr 1:129,856,074...130,176,844 		JBrowse link
G Adamts20 ADAM metallopeptidase with thrombospondin type 1 motif, 20 increases expression ISO entinostat results in increased expression of ADAMTS20 mRNA CTD PMID:27188386 NCBI chr 7:127,275,538...127,407,325
Ensembl chr 7:127,275,538...127,407,296 		JBrowse link
G Adamts9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ADAMTS9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876 		JBrowse link
G Adamtsl1 ADAMTS-like 1 increases expression ISO entinostat results in increased expression of ADAMTSL1 mRNA CTD PMID:27188386 NCBI chr 5:105,010,471...105,965,792
Ensembl chr 5:105,010,464...105,964,394 		JBrowse link
G Adamtsl3 ADAMTS-like 3 increases expression ISO entinostat results in increased expression of ADAMTSL3 mRNA CTD PMID:27188386 NCBI chr 1:145,698,004...146,006,195
Ensembl chr 1:145,698,004...146,006,195 		JBrowse link
G Adck2 aarF domain containing kinase 2 increases expression ISO entinostat results in increased expression of ADCK2 mRNA CTD PMID:27188386 NCBI chr 4:69,315,633...69,328,535
Ensembl chr 4:69,315,635...69,329,502 		JBrowse link
G Adcy2 adenylate cyclase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ADCY2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:36,204,054...36,650,645
Ensembl chr 1:36,204,054...36,650,645 		JBrowse link
G Adcy7 adenylate cyclase 7 increases expression ISO entinostat results in increased expression of ADCY7 mRNA CTD PMID:27188386 NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743 		JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 decreases expression ISO entinostat results in decreased expression of ADCYAP1 mRNA CTD PMID:27188386 NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383 		JBrowse link
G Adcyap1r1 ADCYAP receptor type I multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA
entinostat results in increased expression of ADCYAP1R1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:85,924,171...85,972,973
Ensembl chr 4:85,924,100...85,972,973 		JBrowse link
G Adgra2 adhesion G protein-coupled receptor A2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ADGRA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:71,635,814...71,674,275
Ensembl chr16:71,636,164...71,674,154 		JBrowse link
G Adgrb2 adhesion G protein-coupled receptor B2 increases expression ISO entinostat results in increased expression of ADGRB2 mRNA CTD PMID:27188386 NCBI chr 5:147,581,573...147,646,726
Ensembl chr 5:147,611,580...147,646,726 		JBrowse link
G Adgre5 adhesion G protein-coupled receptor E5 increases expression ISO entinostat results in increased expression of ADGRE5 mRNA CTD PMID:27188386 NCBI chr19:41,302,687...41,332,183
Ensembl chr19:41,303,213...41,324,641 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ADGRG1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124 		JBrowse link
G Adgrg2 adhesion G protein-coupled receptor G2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ADGRG2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:38,106,067...38,231,286
Ensembl chr  X:38,106,067...38,231,331 		JBrowse link
G Adgrg6 adhesion G protein-coupled receptor G6 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA
entinostat results in increased expression of ADGRG6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:10,633,004...10,774,685
Ensembl chr 1:10,631,829...10,774,023 		JBrowse link
G Adgrl1 adhesion G protein-coupled receptor L1 increases expression ISO entinostat results in increased expression of ADGRL1 mRNA CTD PMID:27188386 NCBI chr19:41,107,162...41,148,752
Ensembl chr19:41,109,117...41,148,896 		JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA
entinostat results in decreased expression of ADGRL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:26,690,891...27,458,132
Ensembl chr14:26,722,194...27,280,418 		JBrowse link
G Adi1 acireductone dioxygenase 1 decreases expression ISO entinostat results in decreased expression of ADI1 mRNA CTD PMID:27188386 NCBI chr 6:51,035,267...51,042,229
Ensembl chr 6:51,034,931...51,042,855 		JBrowse link
G Adora2b adenosine A2B receptor multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADORA2B mRNA
entinostat results in increased expression of ADORA2B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091 		JBrowse link
G Adra2a adrenoceptor alpha 2A increases expression
multiple interactions 		ISO entinostat results in increased expression of ADRA2A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871 		JBrowse link
G Adss1 adenylosuccinate synthase 1 increases expression ISO entinostat results in increased expression of ADSS1 mRNA CTD PMID:27188386 NCBI chr 6:137,500,549...137,523,087
Ensembl chr 6:137,501,001...137,523,086 		JBrowse link
G Afdn afadin, adherens junction formation factor decreases expression
multiple interactions 		ISO entinostat results in decreased expression of AFDN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:58,041,065...58,170,505
Ensembl chr 1:58,041,641...58,170,505 		JBrowse link
G Agbl5 AGBL carboxypeptidase 5 decreases expression ISO entinostat results in decreased expression of AGBL5 mRNA CTD PMID:27188386 NCBI chr 6:31,192,281...31,213,494
Ensembl chr 6:31,191,635...31,210,676 		JBrowse link
G Agmat agmatinase increases expression ISO entinostat results in increased expression of AGMAT mRNA CTD PMID:26272509 NCBI chr 5:159,326,680...159,357,300
Ensembl chr 5:159,343,160...159,357,299 		JBrowse link
G Ago4 argonaute RISC component 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGO4 mRNA
entinostat results in decreased expression of AGO4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:144,064,949...144,110,422
Ensembl chr 5:144,064,949...144,110,402 		JBrowse link
G Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of AGPAT2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AGPAT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:29,814,924...29,826,569
Ensembl chr 3:29,814,924...29,826,581 		JBrowse link
G Agtr2 angiotensin II receptor, type 2 decreases expression ISO entinostat results in decreased expression of AGTR2 mRNA CTD PMID:27188386 NCBI chr  X:116,914,320...116,918,504
Ensembl chr  X:116,913,656...116,918,745 		JBrowse link
G Ahi1 Abelson helper integration site 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of AHI1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AHI1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:17,580,859...17,711,775
Ensembl chr 1:17,582,006...17,711,774 		JBrowse link
G Ahnak AHNAK nucleoprotein increases expression ISO entinostat results in increased expression of AHNAK mRNA CTD PMID:27188386 NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675 		JBrowse link
G Ahnak2 AHNAK nucleoprotein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK2 mRNA
entinostat results in increased expression of AHNAK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:137,648,867...137,697,580
Ensembl chr 6:137,652,537...137,675,546 		JBrowse link
G Ahsa2 activator of HSP90 ATPase homolog 2 decreases expression ISO entinostat results in decreased expression of AHSA2P mRNA CTD PMID:26272509 NCBI chr14:101,677,447...101,688,706
Ensembl chr14:101,677,447...101,686,923 		JBrowse link
G Aif1 allograft inflammatory factor 1 increases expression ISO entinostat results in increased expression of AIF1 mRNA CTD PMID:27188386 NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO [fludarabine co-treated with entinostat] results in increased secretion of AIFM1 protein CTD PMID:15059916 NCBI chr  X:132,528,107...132,567,237
Ensembl chr  X:132,528,107...132,567,237 		JBrowse link
G Ajap1 adherens junctions associated protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA
entinostat results in increased expression of AJAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:169,190,477...169,302,938
Ensembl chr 5:169,190,477...169,304,515 		JBrowse link
G Ajuba ajuba LIM protein multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AJUBA mRNA
entinostat results in decreased expression of AJUBA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:31,989,796...32,000,042
Ensembl chr15:31,989,799...32,000,042 		JBrowse link
G Ak4 adenylate kinase 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AK4 mRNA
entinostat results in increased expression of AK4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:121,154,572...121,214,401 		JBrowse link
G Ak7 adenylate kinase 7 increases expression ISO entinostat results in increased expression of AK7 mRNA CTD PMID:27188386 NCBI chr 6:130,376,499...130,444,674
Ensembl chr 6:130,376,550...130,444,677 		JBrowse link
G Akap1 A-kinase anchoring protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of AKAP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:74,118,232...74,151,366
Ensembl chr10:74,119,124...74,138,190 		JBrowse link
G Akap14 A-kinase anchoring protein 14 increases expression ISO entinostat results in increased expression of AKAP14 mRNA CTD PMID:27188386 NCBI chr  X:121,261,195...121,276,376
Ensembl chr  X:121,259,899...121,276,376 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 decreases expression ISO entinostat results in decreased expression of AKR1C1 mRNA CTD PMID:27188386 NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 decreases expression ISO entinostat results in decreased expression of AKR1C2 mRNA CTD PMID:27188386 NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686 		JBrowse link
G Akt3 AKT serine/threonine kinase 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of AKT3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:91,475,839...91,758,060
Ensembl chr13:91,475,839...91,748,020 		JBrowse link
G Alb albumin increases expression ISO entinostat results in increased expression of ALB mRNA CTD PMID:25084468 PMID:27188386 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865 		JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA
entinostat results in decreased expression of ALDH1A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883 		JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression
multiple interactions 		ISO entinostat results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777 		JBrowse link
G Aldh1b1 aldehyde dehydrogenase 1 family, member B1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ALDH1B1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365 		JBrowse link
G Aldh1l2 aldehyde dehydrogenase 1 family, member L2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398 		JBrowse link
G Alkal2 ALK and LTK ligand 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ALKAL2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:53,223,204...53,232,794
Ensembl chr 6:53,223,341...53,233,011 		JBrowse link
G Alox15b arachidonate 15-lipoxygenase, type B increases expression ISO entinostat results in increased expression of ALOX15B mRNA CTD PMID:27188386 NCBI chr10:54,391,331...54,400,648
Ensembl chr10:54,391,302...54,400,648 		JBrowse link
G Alox5 arachidonate 5-lipoxygenase increases expression ISO entinostat results in increased expression of ALOX5 mRNA CTD PMID:27188386 NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126 		JBrowse link
G Alpk1 alpha-kinase 1 increases expression ISO entinostat results in increased expression of ALPK1 mRNA CTD PMID:26272509 NCBI chr 2:218,801,425...218,924,013
Ensembl chr 2:218,780,189...218,921,646 		JBrowse link
G Ambp alpha-1-microglobulin/bikunin precursor multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA
entinostat results in increased expression of AMBP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:81,583,621...81,593,938
Ensembl chr 5:81,583,622...81,593,850 		JBrowse link
G Amer1 APC membrane recruitment protein 1 decreases expression ISO entinostat results in decreased expression of AMER1 mRNA CTD PMID:27188386 NCBI chr  X:64,310,492...64,326,377
Ensembl chr  X:64,300,953...64,326,332 		JBrowse link
G Ang angiogenin increases expression
multiple interactions 		ISO entinostat results in increased expression of ANG mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106 		JBrowse link
G Angptl4 angiopoietin-like 4 increases expression ISO entinostat results in increased expression of ANGPTL4 mRNA CTD PMID:27188386 NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681 		JBrowse link
G Ank2 ankyrin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ANK2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:218,052,555...218,537,259 		JBrowse link
G Ank3 ankyrin 3 decreases expression ISO entinostat results in decreased expression of ANK3 mRNA CTD PMID:27188386 NCBI chr20:18,601,307...19,224,790
Ensembl chr20:18,601,826...19,084,879 		JBrowse link
G Ankdd1a ankyrin repeat and death domain containing 1A increases expression ISO entinostat results in increased expression of ANKDD1A mRNA CTD PMID:27188386 NCBI chr 8:74,912,707...74,938,870
Ensembl chr 8:74,916,011...74,937,863 		JBrowse link
G Ankef1 ankyrin repeat and EF-hand domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ANKEF1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKEF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:144,300,500...144,335,759
Ensembl chr 3:144,300,529...144,335,753 		JBrowse link
G Ankh ANKH inorganic pyrophosphate transport regulator increases expression
multiple interactions 		ISO entinostat results in increased expression of ANKH mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699 		JBrowse link
G Ankle1 ankyrin repeat and LEM domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ANKLE1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKLE1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:18,109,865...18,116,999
Ensembl chr16:18,110,476...18,114,244 		JBrowse link
G Ankrd10 ankyrin repeat domain 10 decreases expression ISO entinostat results in decreased expression of ANKRD10 mRNA CTD PMID:27188386 NCBI chr16:84,566,021...84,591,849
Ensembl chr16:84,568,506...84,591,846 		JBrowse link
G Ankrd28 ankyrin repeat domain 28 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD28 mRNA
entinostat results in decreased expression of ANKRD28 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:6,924,868...7,056,593
Ensembl chr16:6,924,882...7,056,593 		JBrowse link
G Ankrd33b ankyrin repeat domain 33B increases expression ISO entinostat results in increased expression of ANKRD33B mRNA CTD PMID:27188386 NCBI chr 2:83,988,505...84,070,311
Ensembl chr 2:83,993,974...84,070,936 		JBrowse link
G Ankrd35 ankyrin repeat domain 35 decreases expression ISO entinostat results in decreased expression of ANKRD35 mRNA CTD PMID:27188386 NCBI chr 2:186,895,896...186,915,903
Ensembl chr 2:186,895,945...186,915,902 		JBrowse link
G Ankrd37 ankyrin repeat domain 37 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ANKRD37 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545 		JBrowse link
G Ankrd44 ankyrin repeat domain 44 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ANKRD44 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD44 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:63,621,193...63,921,999
Ensembl chr 9:63,555,869...63,921,940 		JBrowse link
G Ankrd55 ankyrin repeat domain 55 increases expression ISO entinostat results in increased expression of ANKRD55 mRNA CTD PMID:27188386 NCBI chr 2:45,617,011...45,717,086
Ensembl chr 2:45,617,177...45,717,057 		JBrowse link
G Ankrd6 ankyrin repeat domain 6 increases expression ISO entinostat results in increased expression of ANKRD6 mRNA CTD PMID:27188386 NCBI chr 5:51,999,225...52,139,623
Ensembl chr 5:51,999,221...52,139,594 		JBrowse link
G Anks1b ankyrin repeat and sterile alpha motif domain containing 1B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ANKS1B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:26,200,649...27,366,552
Ensembl chr 7:26,201,240...27,364,943 		JBrowse link
G Ano3 anoctamin 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA
entinostat results in increased expression of ANO3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:117,690,242...118,004,695
Ensembl chr 3:117,692,103...118,004,675 		JBrowse link
G Ano4 anoctamin 4 increases expression ISO entinostat results in increased expression of ANO4 mRNA CTD PMID:27188386 NCBI chr 7:25,216,389...25,625,811
Ensembl chr 7:25,216,389...25,625,746 		JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA
entinostat results in increased expression of ANTXR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:121,148,103...121,336,892 		JBrowse link
G Antxr2 ANTXR cell adhesion molecule 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ANTXR2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANTXR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168 		JBrowse link
G Anxa1 annexin A1 decreases expression ISO entinostat results in decreased expression of ANXA1 mRNA CTD PMID:26272509 NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831 		JBrowse link
G Anxa11 annexin A11 increases expression ISO entinostat results in increased expression of ANXA11 mRNA CTD PMID:27188386 NCBI chr16:1,419,627...1,464,590
Ensembl chr16:1,418,351...1,464,839 		JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631 		JBrowse link
G Anxa4 annexin A4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA
entinostat results in increased expression of ANXA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:120,741,750...120,798,534
Ensembl chr 4:120,741,750...120,798,513 		JBrowse link
G Anxa5 annexin A5 increases expression ISO entinostat results in increased expression of ANXA5 mRNA CTD PMID:27188386 NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:121,242,136...121,281,400 		JBrowse link
G Anxa9 annexin A9 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA
entinostat results in increased expression of ANXA9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:185,562,174...185,572,560
Ensembl chr 2:185,562,174...185,572,560 		JBrowse link
G Aopep aminopeptidase O increases expression ISO entinostat results in increased expression of AOPEP mRNA CTD PMID:27188386 NCBI chr17:1,817,001...2,133,008
Ensembl chr17:1,817,001...2,133,104 		JBrowse link
G Ap1m2 adaptor related protein complex 1 subunit mu 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA
entinostat results in increased expression of AP1M2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:28,114,748...28,132,767
Ensembl chr 8:28,114,748...28,132,642 		JBrowse link
G Ap1s3 adaptor related protein complex 1 subunit sigma 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of AP1S3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1S3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:88,399,109...88,458,396
Ensembl chr 9:88,399,109...88,488,089 		JBrowse link
G Ap3b2 adaptor related protein complex 3 subunit beta 2 decreases expression ISO entinostat results in decreased expression of AP3B2 mRNA CTD PMID:27188386 NCBI chr 1:144,821,819...144,854,533
Ensembl chr 1:144,821,819...144,854,432 		JBrowse link
G Ap3m1 adaptor related protein complex 3 subunit mu 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AP3M1 mRNA
entinostat results in decreased expression of AP3M1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:3,285,591...3,314,139
Ensembl chr15:3,295,444...3,313,104 		JBrowse link
G Apba2 amyloid beta precursor protein binding family A member 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of APBA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:127,465,026...127,698,124
Ensembl chr 1:127,465,009...127,698,117 		JBrowse link
G Apbb2 amyloid beta precursor protein binding family B member 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APBB2 mRNA
entinostat results in increased expression of APBB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:41,849,638...42,232,930
Ensembl chr14:41,911,785...42,232,280 		JBrowse link
G Apcdd1 APC down-regulated 1 increases expression ISO entinostat results in increased expression of APCDD1 mRNA CTD PMID:27188386 NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356 		JBrowse link
G Apela apelin receptor early endogenous ligand increases expression ISO entinostat results in increased expression of APELA mRNA CTD PMID:26272509 NCBI chr16:29,460,855...29,469,962
Ensembl chr16:29,460,812...29,469,955 		JBrowse link
G Aph1b aph-1 homolog B, gamma secretase subunit multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APH1B mRNA
entinostat results in increased expression of APH1B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,310,380...76,334,146
Ensembl chr 8:76,310,380...76,331,428 		JBrowse link
G Apln apelin decreases expression ISO entinostat results in decreased expression of APLN mRNA CTD PMID:32870474 NCBI chr  X:132,058,739...132,091,518
Ensembl chr  X:132,081,759...132,091,246 		JBrowse link
G Apoe apolipoprotein E multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOE mRNA
entinostat results in increased expression of APOE mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855 		JBrowse link
G Apold1 apolipoprotein L domain containing 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APOLD1 mRNA
entinostat results in decreased expression of APOLD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:169,499,728...169,557,075
Ensembl chr 4:169,549,679...169,559,176 		JBrowse link
G Arap1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 increases expression ISO entinostat results in increased expression of ARAP1 mRNA CTD PMID:27188386 NCBI chr 1:165,160,701...165,226,219
Ensembl chr 1:165,160,678...165,226,218 		JBrowse link
G Arhgap24 Rho GTPase activating protein 24 increases expression ISO entinostat results in increased expression of ARHGAP24 mRNA CTD PMID:27188386 NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950 		JBrowse link
G Arhgap26 Rho GTPase activating protein 26 increases expression ISO entinostat results in increased expression of ARHGAP26 mRNA CTD PMID:27188386 NCBI chr18:30,702,602...31,489,047
Ensembl chr18:31,089,787...31,489,047 		JBrowse link
G Arhgap29 Rho GTPase activating protein 29 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP29 mRNA
entinostat results in decreased expression of ARHGAP29 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:212,744,626...212,816,710
Ensembl chr 2:212,755,803...212,986,729 		JBrowse link
G Arhgap42 Rho GTPase activating protein 42 increases expression
multiple interactions 		ISO entinostat results in increased expression of ARHGAP42 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP42 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:14,436,478...14,666,588
Ensembl chr 8:14,419,256...14,666,385 		JBrowse link
G Arhgap45 Rho GTPase activating protein 45 increases expression ISO entinostat results in increased expression of ARHGAP45 mRNA CTD PMID:27188386 NCBI chr 7:10,325,515...10,340,955
Ensembl chr 7:10,325,539...10,341,890 		JBrowse link
G Arhgap5 Rho GTPase activating protein 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA
entinostat results in decreased expression of ARHGAP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636 		JBrowse link
G Arhgap9 Rho GTPase activating protein 9 increases expression
multiple interactions 		ISO entinostat results in increased expression of ARHGAP9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,034,023...65,042,336
Ensembl chr 7:65,034,144...65,042,336 		JBrowse link
G Arhgdib Rho GDP dissociation inhibitor beta increases expression ISO entinostat results in increased expression of ARHGDIB mRNA CTD PMID:27188386 NCBI chr 4:171,554,139...171,573,057
Ensembl chr 4:171,554,140...171,573,068 		JBrowse link
G Arhgef26 Rho guanine nucleotide exchange factor 26 increases expression ISO entinostat results in increased expression of ARHGEF26 mRNA CTD PMID:27188386 NCBI chr 2:148,889,405...149,000,538
Ensembl chr 2:148,889,423...149,000,538 		JBrowse link
G Arhgef3 Rho guanine nucleotide exchange factor 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF3 mRNA
entinostat results in increased expression of ARHGEF3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:2,308,311...2,588,634
Ensembl chr16:2,308,400...2,588,819 		JBrowse link
G Arhgef37 Rho guanine nucleotide exchange factor 37 increases expression ISO entinostat results in increased expression of ARHGEF37 mRNA CTD PMID:27188386 NCBI chr18:57,205,621...57,271,284
Ensembl chr18:57,230,117...57,271,031 		JBrowse link
G Ark2c arkadia (RNF111) C-terminal like ring finger ubiquitin ligase 2C decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ARK2C mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARK2C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:73,259,736...73,375,987
Ensembl chr18:73,264,901...73,375,987 		JBrowse link
G Arl3 ARF like GTPase 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL3 mRNA
entinostat results in decreased expression of ARL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:255,342,078...255,388,087
Ensembl chr 1:255,342,076...255,388,279 		JBrowse link
G Arl4c ARF like GTPase 4C decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ARL4C mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL4C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:96,748,075...96,751,510
Ensembl chr 9:96,745,069...96,752,772 		JBrowse link
G Arl5b ARF like GTPase 5B increases expression
multiple interactions 		ISO entinostat results in increased expression of ARL5B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARL5B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:82,864,315...82,888,458
Ensembl chr17:82,864,287...82,890,646 		JBrowse link
G Armcx4 armadillo repeat containing, X-linked 4 decreases expression ISO entinostat results in decreased expression of ARMCX4 mRNA CTD PMID:27188386 NCBI chr  X:102,153,743...102,164,173
Ensembl chr  X:102,153,800...102,164,633 		JBrowse link
G Armh4 armadillo-like helical domain containing 4 decreases expression ISO entinostat results in decreased expression of ARMH4 mRNA CTD PMID:27188386 NCBI chr15:25,455,478...25,556,569
Ensembl chr15:25,455,297...25,556,534 		JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA
entinostat results in decreased expression of ARNT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997 		JBrowse link
G Arpin actin-related protein 2/3 complex inhibitor decreases expression ISO entinostat results in decreased expression of ARPIN mRNA CTD PMID:27188386 NCBI chr 1:143,273,590...143,282,426
Ensembl chr 1:143,273,590...143,282,532 		JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859 		JBrowse link
G Arrdc4 arrestin domain containing 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ARRDC4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:131,779,436...131,793,438
Ensembl chr 1:131,779,437...131,793,565 		JBrowse link
G Arsi arylsulfatase family, member I increases expression ISO entinostat results in increased expression of ARSI mRNA CTD PMID:27188386 NCBI chr18:56,634,556...56,642,168
Ensembl chr18:56,625,487...56,642,168 		JBrowse link
G Arx aristaless related homeobox multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA
entinostat results in decreased expression of ARX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:62,010,097...62,022,009
Ensembl chr  X:62,010,097...62,022,002 		JBrowse link
G Asap3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASAP3 mRNA
entinostat results in increased expression of ASAP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:153,716,988...153,757,787
Ensembl chr 5:153,716,988...153,757,787 		JBrowse link
G Asb4 ankyrin repeat and SOCS box-containing 4 increases expression ISO entinostat results in increased expression of ASB4 mRNA CTD PMID:27188386 NCBI chr 4:34,473,527...34,511,163
Ensembl chr 4:34,473,408...34,512,888 		JBrowse link
G Asic1 acid sensing ion channel subunit 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ASIC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:132,698,723...132,707,832 		JBrowse link
G Asmtl acetylserotonin O-methyltransferase-like increases expression ISO entinostat results in increased expression of ASMTL mRNA CTD PMID:27188386 NCBI chr12:21,429,119...21,431,847
Ensembl chr12:21,429,171...21,431,847 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) multiple interactions
decreases expression
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA
entinostat results in decreased expression of ASNS mRNA
entinostat results in increased expression of ASNS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050 		JBrowse link
G Asphd1 aspartate beta-hydroxylase domain containing 1 increases expression ISO entinostat results in increased expression of ASPHD1 mRNA CTD PMID:27188386 NCBI chr 1:190,983,506...190,987,440
Ensembl chr 1:190,983,506...190,987,440 		JBrowse link
G Aspn asporin increases expression ISO entinostat results in increased expression of ASPN mRNA CTD PMID:27188386 NCBI chr17:15,286,338...15,310,567
Ensembl chr17:15,287,065...15,310,632 		JBrowse link
G Ass1 argininosuccinate synthase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA
entinostat results in increased expression of ASS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627 		JBrowse link
G Astn1 astrotactin 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA
entinostat results in decreased expression of ASTN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:73,070,754...73,388,902
Ensembl chr13:73,071,267...73,388,895 		JBrowse link
G Asxl3 ASXL transcriptional regulator 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ASXL3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASXL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:13,868,223...14,040,867
Ensembl chr18:13,868,674...14,037,373 		JBrowse link
G Atad2b ATPase family, AAA domain containing 2B decreases expression ISO entinostat results in decreased expression of ATAD2B mRNA CTD PMID:27188386 NCBI chr 6:33,646,075...33,789,532
Ensembl chr 6:33,646,075...33,789,532 		JBrowse link
G Atf5 activating transcription factor 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of ATF5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183 		JBrowse link
G Atl1 atlastin GTPase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL1 mRNA
entinostat results in decreased expression of ATL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:94,113,149...94,210,955
Ensembl chr 6:94,112,877...94,211,219 		JBrowse link
G Atosb atos homolog B multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATOSB mRNA
entinostat results in decreased expression of ATOSB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:62,056,654...62,070,338
Ensembl chr 5:62,056,654...62,064,613 		JBrowse link
G Atp10d ATPase phospholipid transporting 10D (putative) increases expression ISO entinostat results in increased expression of ATP10D mRNA CTD PMID:27188386 NCBI chr14:36,265,696...36,366,460
Ensembl chr14:36,265,696...36,366,460 		JBrowse link
G Atp1b2 ATPase Na+/K+ transporting subunit beta 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ATP1B2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP1B2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:54,817,473...54,823,708
Ensembl chr10:54,817,476...54,823,708 		JBrowse link
G Atp23 ATP23 metallopeptidase and ATP synthase assembly factor homolog increases expression
multiple interactions 		ISO entinostat results in increased expression of ATP23 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:64,600,100...64,615,240
Ensembl chr 7:64,600,100...64,615,392 		JBrowse link
G Atp2a3 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2A3 mRNA
entinostat results in increased expression of ATP2A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:58,079,710...58,111,279
Ensembl chr10:58,079,852...58,111,278 		JBrowse link
G Atp2c2 ATPase secretory pathway Ca2+ transporting 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA
entinostat results in increased expression of ATP2C2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:64,662,729...64,719,998
Ensembl chr19:64,662,715...64,719,996 		JBrowse link
G Atp6ap1l ATPase H+ transporting accessory protein 1 like increases expression ISO entinostat results in increased expression of ATP6AP1L mRNA CTD PMID:27188386 NCBI chr 2:23,772,724...23,814,913
Ensembl chr 2:23,772,745...23,814,618 		JBrowse link
G Atp6v0a2 ATPase H+ transporting V0 subunit a2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA
entinostat results in decreased expression of ATP6V0A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:37,608,211...37,640,860
Ensembl chr12:37,472,813...37,640,860 		JBrowse link
G Atp6v1c2 ATPase H+ transporting V1 subunit C2 increases expression ISO entinostat results in increased expression of ATP6V1C2 mRNA CTD PMID:27188386 NCBI chr 6:45,809,269...45,872,914
Ensembl chr 6:45,809,271...45,848,747 		JBrowse link
G Atp7a ATPase copper transporting alpha decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ATP7A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP7A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:75,159,635...75,267,094
Ensembl chr  X:75,159,782...75,267,093 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027 		JBrowse link
G Atp8b3 ATPase phospholipid transporting 8B3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA
entinostat results in increased expression of ATP8B3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:9,823,496...9,846,137
Ensembl chr 7:9,826,275...9,846,195 		JBrowse link
G Atp8b4 ATPase phospholipid transporting 8B4 (putative) increases expression ISO entinostat results in increased expression of ATP8B4 mRNA CTD PMID:27188386 NCBI chr 3:134,008,367...134,212,394
Ensembl chr 3:134,009,580...134,210,260 		JBrowse link
G Aven apoptosis and caspase activation inhibitor decreases expression ISO entinostat results in decreased expression of AVEN mRNA CTD PMID:27188386 NCBI chr 3:119,753,395...119,886,009
Ensembl chr 3:119,872,661...119,886,008 		JBrowse link
G B2m beta-2 microglobulin increases expression ISO entinostat results in increased expression of B2M mRNA CTD PMID:27188386 NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356 		JBrowse link
G B3galnt1 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GALNT1 mRNA
entinostat results in decreased expression of B3GALNT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:156,157,234...156,187,037
Ensembl chr 2:156,156,265...156,188,404 		JBrowse link
G B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of B3GNT5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:94,645,480...94,657,584
Ensembl chr11:94,645,480...94,660,514 		JBrowse link
G B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 increases expression
multiple interactions 		ISO entinostat results in increased expression of B3GNT7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:94,404,197...94,408,148
Ensembl chr 9:94,404,135...94,408,147 		JBrowse link
G B3gnt9 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 increases expression ISO entinostat results in increased expression of B3GNT9 mRNA CTD PMID:27188386 NCBI chr19:50,039,649...50,042,206
Ensembl chr19:50,030,866...50,043,339 		JBrowse link
G B4galt2 beta-1,4-galactosyltransferase 2 decreases expression ISO entinostat results in decreased expression of B4GALT2 mRNA CTD PMID:27188386 NCBI chr 5:136,697,981...136,707,783
Ensembl chr 5:136,697,981...136,710,422 		JBrowse link
G Baalc BAALC binder of MAP3K1 and KLF4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAALC mRNA
entinostat results in decreased expression of BAALC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:71,803,640...71,877,608
Ensembl chr 7:71,774,898...71,879,261 		JBrowse link
G Bace1 beta-secretase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BACE1 mRNA
entinostat results in decreased expression of BACE1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:55,038,823...55,064,918 		JBrowse link
G Bace2 beta-secretase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA
entinostat results in increased expression of BACE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:50,176,852...50,258,948
Ensembl chr11:50,176,621...50,259,008 		JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions EXP [Azacitidine co-treated with entinostat] results in increased expression of BAD mRNA CTD PMID:21224363 NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034 		JBrowse link
G Bag2 BAG cochaperone 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
entinostat results in increased expression of BAG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression 		EXP
ISO 		[Azacitidine co-treated with entinostat] results in increased expression of BAK1 mRNA
entinostat results in increased expression of BAK1 protein 		CTD PMID:21041383 PMID:21224363 NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions 		ISO entinostat results in increased expression of BAMBI mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:58,816,438...58,821,003
Ensembl chr17:58,816,442...58,821,247 		JBrowse link
G Bank1 B-cell scaffold protein with ankyrin repeats 1 increases expression ISO entinostat results in increased expression of BANK1 mRNA CTD PMID:27188386 NCBI chr 2:227,203,998...227,474,008
Ensembl chr 2:227,203,998...227,474,037 		JBrowse link
G Batf3 basic leucine zipper ATF-like transcription factor 3 increases expression ISO entinostat results in increased expression of BATF3 mRNA CTD PMID:27188386 NCBI chr13:105,220,782...105,232,365
Ensembl chr13:105,220,390...105,232,369 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression ISO entinostat results in increased expression of BAX protein CTD PMID:21041383 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Baz2b bromodomain adjacent to zinc finger domain, 2B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of BAZ2B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAZ2B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:64,792,984...65,034,547
Ensembl chr 3:64,794,001...65,001,781 		JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression 		ISO entinostat promotes the reaction [Etoposide results in increased expression of BBC3 protein]; Etoposide promotes the reaction [entinostat results in increased expression of BBC3 protein] CTD PMID:25699604 NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666 		JBrowse link
G Bbip1 BBSome interacting protein 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BBIP1 mRNA
entinostat results in decreased expression of BBIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:262,950,459...262,964,410
Ensembl chr 1:262,950,462...262,964,394 		JBrowse link
G Bbs9 Bardet-Biedl syndrome 9 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA
entinostat results in increased expression of BBS9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:29,288,846...29,713,889
Ensembl chr 8:29,289,997...29,713,880 		JBrowse link
G Bche butyrylcholinesterase decreases expression
multiple interactions 		ISO entinostat results in decreased expression of BCHE mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCHE mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760 		JBrowse link
G Bcl11a BCL11 transcription factor A multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA
entinostat results in increased expression of BCL11A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:102,230,147...102,325,289
Ensembl chr14:102,231,113...102,325,623 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions 		ISO entinostat results in decreased expression of BCL2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA
entinostat results in decreased expression of BCL2 protein 		CTD PMID:21041383 PMID:26272509 PMID:27188386 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO entinostat results in decreased expression of BCL2L1 protein CTD PMID:21041383 NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907 		JBrowse link
G Bcl2l11 Bcl2-like 11 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of BCL2L11 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695 		JBrowse link
G Bcl2l14 Bcl2-like 14 decreases expression ISO entinostat results in decreased expression of BCL2L14 mRNA CTD PMID:27188386 NCBI chr 4:168,948,919...168,989,450
Ensembl chr 4:168,948,946...168,990,079 		JBrowse link
G Bco1 beta-carotene oxygenase 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of BCO1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:62,058,061...62,094,923
Ensembl chr19:62,058,089...62,094,917 		JBrowse link
G Bcor BCL6 co-repressor increases expression ISO entinostat results in increased expression of BCOR mRNA CTD PMID:27188386 NCBI chr  X:13,282,431...13,402,254
Ensembl chr  X:13,360,376...13,402,254 		JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDH1 mRNA
entinostat results in increased expression of BDH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636 		JBrowse link
G Bend3 BEN domain containing 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND3 mRNA
entinostat results in increased expression of BEND3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:48,562,383...48,599,194
Ensembl chr20:48,576,311...48,596,808 		JBrowse link
G Bend4 BEN domain containing 4 increases expression ISO entinostat results in increased expression of BEND4 mRNA CTD PMID:27188386 NCBI chr14:41,106,206...41,142,572
Ensembl chr14:41,106,763...41,136,979 		JBrowse link
G Bend5 BEN domain containing 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND5 mRNA
entinostat results in decreased expression of BEND5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:131,519,214...131,565,228
Ensembl chr 5:131,519,214...131,762,906 		JBrowse link
G Bend6 BEN domain containing 6 increases expression ISO entinostat results in increased expression of BEND6 mRNA CTD PMID:27188386 NCBI chr 9:43,576,982...43,631,437
Ensembl chr 9:43,576,982...43,631,194 		JBrowse link
G Best2 bestrophin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of BEST2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEST2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:40,047,191...40,053,216
Ensembl chr19:40,047,191...40,053,216 		JBrowse link
G Best4 bestrophin 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of BEST4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,858,774...135,865,624
Ensembl chr 5:135,860,018...135,863,707 		JBrowse link
G Bex5l1 brain expressed X-linked 5 like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA
entinostat results in increased expression of BEX5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:119,181,370...119,202,904 JBrowse link
G Bhlhe22 basic helix-loop-helix family, member e22 decreases expression ISO entinostat results in decreased expression of BHLHE22 mRNA CTD PMID:27188386 NCBI chr 2:102,402,622...102,405,732
Ensembl chr 2:102,400,164...102,420,508 		JBrowse link
G Bicd1 BICD cargo adaptor 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BICD1 mRNA
entinostat results in increased expression of BICD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:184,208,891...184,362,840
Ensembl chr 4:184,210,363...184,357,391 		JBrowse link
G Bik BCL2-interacting killer multiple interactions
increases expression 		EXP
ISO 		[Azacitidine co-treated with entinostat] results in increased expression of BIK mRNA
entinostat results in increased expression of BIK mRNA 		CTD PMID:21224363 PMID:27188386 NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 increases expression ISO entinostat results in increased expression of BIRC3 mRNA CTD PMID:27188386 NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO entinostat results in decreased expression of BIRC5 protein CTD PMID:29845424 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Blvrb biliverdin reductase B increases expression
multiple interactions 		ISO entinostat results in increased expression of BLVRB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BLVRB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:91,866,258...91,883,921
Ensembl chr 1:91,866,258...91,884,225 		JBrowse link
G Bmal1 basic helix-loop-helix ARNT like 1 increases expression ISO entinostat results in increased expression of BMAL1 mRNA CTD PMID:27188386 NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739 		JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA
entinostat results in increased expression of BMP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760 		JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
entinostat results in increased expression of BMP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189 		JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA
entinostat results in increased expression of BMP7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137 		JBrowse link
G Bmp8b bone morphogenetic protein 8b increases expression ISO entinostat results in increased expression of BMP8B mRNA CTD PMID:27188386 NCBI chr 5:140,671,117...140,696,450
Ensembl chr 5:140,671,211...140,696,448 		JBrowse link
G Bmper BMP-binding endothelial regulator multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA
entinostat results in increased expression of BMPER mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359 		JBrowse link
G Bmpr1b bone morphogenetic protein receptor type 1B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of BMPR1B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BMPR1B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311 		JBrowse link
G Bnc2 basonuclin zinc finger protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA
entinostat results in increased expression of BNC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:103,724,934...104,061,890
Ensembl chr 5:103,724,934...104,125,428 		JBrowse link
G Bok BCL2 family apoptosis regulator BOK multiple interactions EXP [Azacitidine co-treated with entinostat] results in increased expression of BOK mRNA CTD PMID:21224363 NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833 		JBrowse link
G Brd10 bromodomain containing 10 decreases expression ISO entinostat results in decreased expression of BRD10 mRNA CTD PMID:27188386 NCBI chr 1:236,904,520...236,984,414
Ensembl chr 1:236,904,520...236,983,923 		JBrowse link
G Bri3bp Bri3 binding protein multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRI3BP mRNA
entinostat results in increased expression of BRI3BP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:36,838,098...36,849,919
Ensembl chr12:36,838,098...36,849,919 		JBrowse link
G Brinp1 BMP/retinoic acid inducible neural specific 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of BRINP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:87,363,621...87,565,580
Ensembl chr 5:87,364,050...87,508,256 		JBrowse link
G Brwd1 bromodomain and WD repeat domain containing 1 decreases expression ISO entinostat results in decreased expression of BRWD1 mRNA CTD PMID:27188386 NCBI chr11:48,756,174...48,853,692
Ensembl chr11:48,756,811...48,848,256 		JBrowse link
G Bspry B-box and SPRY domain containing multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA
entinostat results in increased expression of BSPRY mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:80,942,974...80,965,157
Ensembl chr 5:80,942,979...80,988,154 		JBrowse link
G C10h16orf89 similar to human chromosome 16 open reading frame 89 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C16ORF89 mRNA
entinostat results in increased expression of C16ORF89 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:10,856,320...10,877,515
Ensembl chr10:10,868,419...10,877,515 		JBrowse link
G C11h3orf52 similar to human chromosome 3 open reading frame 52 increases expression
multiple interactions 		ISO entinostat results in increased expression of C3ORF52 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:68,629,570...68,654,874
Ensembl chr11:68,629,570...68,654,868 		JBrowse link
G C12h12orf76 similar to human chromosome 12 open reading frame 76 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of C12ORF76 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF76 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:47,452,148...47,456,832
Ensembl chr12:47,452,016...47,456,829 		JBrowse link
G C13h1orf105 similar to human chromosome 1 open reading frame 105 increases expression ISO entinostat results in increased expression of C1ORF105 mRNA CTD PMID:27188386 NCBI chr13:76,846,595...76,889,660
Ensembl chr13:76,846,597...76,889,595 		JBrowse link
G C13h1orf53 similar to human chromosome 1 open reading frame 53 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA
entinostat results in decreased expression of C1ORF53 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:52,965,244...52,970,432
Ensembl chr13:52,965,244...52,970,607 		JBrowse link
G C17h5orf24 similar to human chromosome 5 open reading frame 24 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C5ORF24 mRNA
entinostat results in decreased expression of C5ORF24 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:8,928,209...8,938,126
Ensembl chr17:8,929,936...8,932,379 		JBrowse link
G C1h19orf33 similar to human chromosome 19 open reading frame 33 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA
entinostat results in increased expression of C19ORF33 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:93,677,305...93,678,141
Ensembl chr 1:93,677,305...93,678,141 		JBrowse link
G C1h19orf84 similar to human chromosome 19 open reading frame 84 increases expression ISO entinostat results in increased expression of C19ORF84 mRNA CTD PMID:27188386 NCBI chr 1:102,971,969...102,973,907
Ensembl chr 1:102,971,947...102,973,905 		JBrowse link
G C1qtnf2 C1q and TNF related 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1QTNF2 mRNA
entinostat results in increased expression of C1QTNF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:28,443,326...28,460,400
Ensembl chr10:28,443,425...28,460,395 		JBrowse link
G C20h21orf58 similar to human chromosome 21 open reading frame 58 multiple interactions
affects expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C21ORF58 mRNA
entinostat affects the expression of C21ORF58 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:12,165,853...12,187,271
Ensembl chr20:12,174,928...12,186,503 		JBrowse link
G C2h4orf33 similar to human chromosome 4 open reading frame 33 increases expression ISO entinostat results in increased expression of C4ORF33 mRNA CTD PMID:27188386 NCBI chr 2:126,692,176...126,769,183
Ensembl chr 2:126,697,854...126,746,878 		JBrowse link
G C3 complement C3 increases expression
multiple interactions 		ISO entinostat results in increased expression of C3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339 		JBrowse link
G C3h11orf96 similar to human chromosome 11 open reading frame 96 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA
entinostat results in increased expression of C11ORF96 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:100,375,474...100,376,717
Ensembl chr 3:100,351,199...100,378,346 		JBrowse link
G C3h15orf48 similar to human chromosome 15 open reading frame 48 increases expression ISO entinostat results in increased expression of COXFA4L3 mRNA CTD PMID:27188386 NCBI chr 3:130,173,535...130,177,088
Ensembl chr 3:130,173,416...130,177,089 		JBrowse link
G C4h2orf68 similar to human chromosome 2 open reading frame 68 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA
entinostat results in decreased expression of C2ORF68 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:105,960,543...105,966,509
Ensembl chr 4:105,960,751...105,966,508 		JBrowse link
G C5 complement C5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of C5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:38,668,174...38,759,468
Ensembl chr 3:38,668,174...38,759,468 		JBrowse link
G C5h1orf94 similar to human chromosome 1 open reading frame 94 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1ORF94 mRNA
entinostat results in increased expression of C1ORF94 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:145,566,517...145,610,294
Ensembl chr 5:145,552,750...145,610,294 		JBrowse link
G C5h8orf34 similar to human chromosome 8 open reading frame 34 increases expression
multiple interactions 		ISO entinostat results in increased expression of C8ORF34 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:12,021,000...12,560,212
Ensembl chr 5:12,021,007...12,559,772 		JBrowse link
G C5h8orf88 similar to human chromosome 8 open reading frame 88 increases expression ISO entinostat results in increased expression of C8ORF88 mRNA CTD PMID:27188386 NCBI chr 5:33,127,385...33,152,914
Ensembl chr 5:33,126,632...33,174,768 		JBrowse link
G C6h14orf132 similar to human chromosome 14 open reading frame 132 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C14ORF132 mRNA
entinostat results in increased expression of C14ORF132 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:130,130,176...130,163,153
Ensembl chr 6:130,130,794...130,158,762 		JBrowse link
G C7h12orf56 similar to human chromosome 12 open reading frame 56 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA
entinostat results in increased expression of C12ORF56 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:59,055,283...59,106,900
Ensembl chr 7:59,056,310...59,106,407 		JBrowse link
G C7h8orf76 similar to human chromosome 8 open reading frame 76 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of C8ORF76 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C8ORF76 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:91,448,422...91,459,284
Ensembl chr 7:91,443,270...91,462,404 		JBrowse link
G C7h8orf82 similar to human chromosome 8 open reading frame 82 decreases expression ISO entinostat results in decreased expression of C8ORF82 mRNA CTD PMID:27188386 NCBI chr 7:110,324,408...110,326,752
Ensembl chr 7:110,324,409...110,326,752 		JBrowse link
G C8h11orf87 similar to human chromosome 11 open reading frame 87 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF87 mRNA
entinostat results in increased expression of C11ORF87 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:61,958,626...61,966,119
Ensembl chr 8:61,957,676...61,968,365 		JBrowse link
G C9h2orf49 similar to human chromosome 2 open reading frame 49 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF49 mRNA
entinostat results in decreased expression of C2ORF49 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:52,863,565...52,874,234
Ensembl chr 9:52,863,542...52,874,234 		JBrowse link
G C9h2orf88 similar to human chromosome 2 open reading frame 88 increases expression ISO entinostat results in increased expression of AKAP19 mRNA CTD PMID:27188386 NCBI chr 9:56,037,234...56,076,793
Ensembl chr 9:56,031,114...56,131,839 		JBrowse link
G C9h6orf132 similar to human chromosome 6 open reading frame 132 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C6ORF132 mRNA
entinostat results in increased expression of C6ORF132 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:21,022,482...21,058,942
Ensembl chr 9:21,023,092...21,059,125 		JBrowse link
G C9h6orf141 similar to human chromosome 6 open reading frame 141 decreases expression ISO entinostat results in decreased expression of C6ORF141 mRNA CTD PMID:26272509 NCBI chr 9:27,521,466...27,525,644
Ensembl chr 9:27,521,466...27,525,644 		JBrowse link
G Ca12 carbonic anhydrase 12 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA
entinostat results in increased expression of CA12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465 		JBrowse link
G Ca13 carbonic anhydrase 13 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA
entinostat results in increased expression of CA13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:88,649,643...88,680,763
Ensembl chr 2:88,649,625...88,680,763 		JBrowse link
G Ca4 carbonic anhydrase 4 increases expression ISO entinostat results in increased expression of CA4 mRNA CTD PMID:27188386 NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916 		JBrowse link
G Cacna1a calcium voltage-gated channel subunit alpha1 A increases expression ISO entinostat results in increased expression of CACNA1A mRNA CTD PMID:27188386 NCBI chr19:40,425,560...40,724,810
Ensembl chr19:40,425,560...40,724,599 		JBrowse link
G Cacna1g calcium voltage-gated channel subunit alpha1 G increases expression ISO entinostat results in increased expression of CACNA1G mRNA CTD PMID:27188386 NCBI chr10:79,851,886...79,919,926
Ensembl chr10:79,851,896...79,919,634 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 decreases expression
increases expression
multiple interactions 		ISO entinostat results in decreased expression of CACNA2D1 mRNA
entinostat results in increased expression of CACNA2D1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:19,902,324...20,330,287
Ensembl chr 4:19,905,764...20,330,147 		JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA CTD PMID:27188386 NCBI chr17:82,473,097...82,818,564
Ensembl chr17:82,473,129...82,818,564 		JBrowse link
G Cacng8 calcium voltage-gated channel auxiliary subunit gamma 8 increases expression ISO entinostat results in increased expression of CACNG8 mRNA CTD PMID:27188386 NCBI chr 1:74,670,767...74,691,003
Ensembl chr 1:74,669,766...74,694,015 		JBrowse link
G Cadm4 cell adhesion molecule 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CADM4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:89,203,089...89,225,345
Ensembl chr 1:89,202,554...89,225,345 		JBrowse link
G Calb1 calbindin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CALB1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases expression
multiple interactions 		ISO entinostat results in increased expression of CALCA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529 		JBrowse link
G Calcrl calcitonin receptor like receptor increases expression ISO entinostat results in increased expression of CALCRL mRNA CTD PMID:27188386 NCBI chr 3:89,835,071...89,932,616
Ensembl chr 3:89,835,077...89,887,350 		JBrowse link
G Calhm6 calcium homeostasis modulator family member 6 decreases expression ISO entinostat results in decreased expression of CALHM6 mRNA CTD PMID:27188386 NCBI chr20:26,638,721...26,640,466
Ensembl chr20:26,638,722...26,640,408 		JBrowse link
G Calml4 calmodulin-like 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CALML4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:72,218,870...72,230,650
Ensembl chr 8:72,218,613...72,230,650 		JBrowse link
G Caln1 calneuron 1 increases expression ISO entinostat results in increased expression of CALN1 mRNA CTD PMID:27188386 NCBI chr12:31,447,964...31,939,847 JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA
entinostat results in decreased expression of CAMK2N1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:155,958,116...155,959,897
Ensembl chr 5:155,957,878...155,961,058 		JBrowse link
G Cand1 cullin-associated and neddylation-dissociated 1 decreases expression ISO entinostat results in decreased expression of CAND1 mRNA CTD PMID:26272509 NCBI chr 7:56,566,765...56,604,653
Ensembl chr 7:56,551,394...56,604,655 		JBrowse link
G Cap2 cyclase associated actin cytoskeleton regulatory protein 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAP2 mRNA
entinostat results in decreased expression of CAP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:18,260,462...18,409,681
Ensembl chr17:18,261,646...18,409,563 		JBrowse link
G Capg capping actin protein, gelsolin like increases expression ISO entinostat results in increased expression of CAPG mRNA CTD PMID:27188386 NCBI chr 4:106,152,912...106,170,010
Ensembl chr 4:106,152,890...106,170,672 		JBrowse link
G Capn6 calpain 6 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA
entinostat results in decreased expression of CAPN6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:112,177,467...112,202,178
Ensembl chr  X:112,177,467...112,202,178 		JBrowse link
G Capn9 calpain 9 decreases expression ISO entinostat results in decreased expression of CAPN9 mRNA CTD PMID:27188386 NCBI chr19:69,446,847...69,483,810
Ensembl chr19:69,446,847...69,483,810 		JBrowse link
G Card10 caspase recruitment domain family, member 10 increases expression ISO entinostat results in increased expression of CARD10 mRNA CTD PMID:27188386 NCBI chr 7:112,210,944...112,252,044
Ensembl chr 7:112,210,776...112,239,806 		JBrowse link
G Card19 caspase recruitment domain family, member 19 increases expression
multiple interactions 		ISO entinostat results in increased expression of CARD19 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARD19 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:15,638,973...15,651,720
Ensembl chr17:15,639,012...15,651,720 		JBrowse link
G Cars1 cysteinyl-tRNA synthetase 1 decreases expression
increases expression
multiple interactions 		ISO entinostat results in decreased expression of CARS1 mRNA
entinostat results in increased expression of CARS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407 		JBrowse link
G Cartpt CART prepropeptide decreases expression ISO entinostat results in decreased expression of CARTPT mRNA CTD PMID:27188386 NCBI chr 2:32,989,215...32,991,794
Ensembl chr 2:32,989,215...32,999,712 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases expression
increases activity 		ISO entinostat results in increased cleavage of and results in increased activity of CASP3 protein; TNFSF10 protein promotes the reaction [entinostat results in increased activity of CASP3 protein]
entinostat results in increased cleavage of CASP3 protein
entinostat results in increased expression of CASP3 protein
MC1568 inhibits the reaction [entinostat results in increased activity of CASP3 protein] 		CTD PMID:21041383 PMID:25068794 PMID:26251326 PMID:29845424 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp6 caspase 6 increases expression ISO entinostat results in increased expression of CASP6 protein CTD PMID:29845424 NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726 		JBrowse link
G Casp8 caspase 8 increases expression
multiple interactions 		ISO entinostat results in increased expression of CASP8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699 		JBrowse link
G Casp9 caspase 9 increases cleavage ISO entinostat results in increased cleavage of CASP9 protein CTD PMID:29845424 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cast calpastatin decreases expression
increases expression 		ISO entinostat results in decreased expression of CAST mRNA
entinostat results in increased expression of CAST mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:5,707,640...5,817,180 		JBrowse link
G Cav2 caveolin 2 increases expression ISO entinostat results in increased expression of CAV2 mRNA CTD PMID:27188386 NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:46,582,096...46,591,425 		JBrowse link
G Cavin1 caveolae associated protein 1 increases expression ISO entinostat results in increased expression of CAVIN1 mRNA CTD PMID:27188386 NCBI chr10:86,384,401...86,398,240
Ensembl chr10:86,384,401...86,396,383 		JBrowse link
G Cbfb core-binding factor subunit beta decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CBFB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBFB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:49,955,133...50,002,661
Ensembl chr19:49,959,096...50,002,657 		JBrowse link
G Cblc Cbl proto-oncogene C increases expression
multiple interactions 		ISO entinostat results in increased expression of CBLC mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:88,567,930...88,584,709
Ensembl chr 1:88,567,932...88,584,709 		JBrowse link
G Cbln1 cerebellin 1 precursor multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLN1 mRNA
entinostat results in increased expression of CBLN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:35,782,151...35,785,960
Ensembl chr19:35,781,952...35,785,960 		JBrowse link
G Cbln2 cerebellin 2 precursor decreases expression ISO entinostat results in decreased expression of CBLN2 mRNA CTD PMID:27188386 NCBI chr18:82,215,210...82,222,648
Ensembl chr18:82,215,220...82,222,648 		JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBR3 mRNA
entinostat results in increased expression of CBR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558 		JBrowse link
G Cbs cystathionine beta synthase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBS mRNA
entinostat results in increased expression of CBS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,709,395...9,734,066 		JBrowse link
G Cbx5 chromobox 5 decreases expression ISO entinostat results in decreased expression of CBX5 mRNA CTD PMID:27188386 NCBI chr 7:136,203,827...136,254,575
Ensembl chr 7:136,211,649...136,229,118 		JBrowse link
G Ccdc121 coiled-coil domain containing 121 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC121 mRNA
entinostat results in decreased expression of CCDC121 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:30,690,831...30,693,437
Ensembl chr 6:30,690,831...30,693,437 		JBrowse link
G Ccdc13 coiled-coil domain containing 13 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC13 mRNA
entinostat results in increased expression of CCDC13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:130,335,797...130,391,658
Ensembl chr 8:130,335,204...130,377,096 		JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:58,963,196...58,992,962
Ensembl chr 4:58,962,908...58,992,975 		JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:106,135,827...106,142,413
Ensembl chr 6:106,134,333...106,144,441 		JBrowse link
G Ccdc50 coiled-coil domain containing 50 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC50 mRNA
entinostat results in decreased expression of CCDC50 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:86,837,624...86,900,164
Ensembl chr11:86,837,624...86,899,980 		JBrowse link
G Ccdc69 coiled-coil domain containing 69 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA
entinostat results in increased expression of CCDC69 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:39,673,984...39,701,080
Ensembl chr10:39,673,985...39,700,579 		JBrowse link
G Ccdc80 coiled-coil domain containing 80 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC80 mRNA
entinostat results in decreased expression of CCDC80 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:69,191,188...69,224,844
Ensembl chr11:69,191,189...69,224,844 		JBrowse link
G Ccdc92 coiled-coil domain containing 92 multiple interactions
increases expression
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC92 mRNA
entinostat results in increased expression of CCDC92 mRNA
entinostat results in decreased expression of CCDC92 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:37,457,676...37,484,080
Ensembl chr12:37,457,068...37,484,327 		JBrowse link
G Cckbr cholecystokinin B receptor multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA
entinostat results in decreased expression of CCKBR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases expression ISO entinostat results in increased expression of CCL2 mRNA CTD PMID:27188386 NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875 		JBrowse link
G Ccl26 C-C motif chemokine ligand 26 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA
entinostat results in increased expression of CCL26 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:26,745,972...26,750,924 JBrowse link
G Ccm2l CCM2 like scaffold protein increases expression
multiple interactions 		ISO entinostat results in increased expression of CCM2L mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCM2L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:161,993,717...162,009,372
Ensembl chr 3:161,859,312...162,009,371 		JBrowse link
G Ccna2 cyclin A2 multiple interactions ISO [fludarabine co-treated with entinostat] results in decreased expression of CCNA2 protein CTD PMID:15059916 NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701 		JBrowse link
G Ccnd1 cyclin D1 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of CCND1 mRNA
TNFSF10 protein promotes the reaction [entinostat results in decreased expression of CCND1 protein]
[fludarabine co-treated with entinostat] results in decreased expression of CCND1 protein; [fludarabine co-treated with entinostat] results in decreased phosphorylation of and results in increased degradation of CCND1 protein; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCND1 mRNA 		CTD PMID:15059916 PMID:21041383 PMID:26272509 PMID:27188386 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [fludarabine co-treated with entinostat] results in decreased expression of CCNE1 protein CTD PMID:15059916 NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822 		JBrowse link
G Ccne2 cyclin E2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNE2 mRNA
entinostat results in decreased expression of CCNE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882 		JBrowse link
G Ccng2 cyclin G2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA
entinostat results in decreased expression of CCNG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206 		JBrowse link
G Ccnj cyclin J decreases expression ISO entinostat results in decreased expression of CCNJ mRNA CTD PMID:27188386 NCBI chr 1:249,608,991...249,626,798
Ensembl chr 1:249,608,969...249,626,794 		JBrowse link
G Ccnt1 cyclin T1 decreases expression ISO entinostat results in decreased expression of CCNT1 mRNA CTD PMID:27188386 NCBI chr 7:131,566,176...131,596,988
Ensembl chr 7:131,566,176...131,596,938 		JBrowse link
G Ccnt2 cyclin T2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CCNT2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:41,804,007...41,845,641
Ensembl chr13:41,804,046...41,844,488 		JBrowse link
G Ccr10 C-C motif chemokine receptor 10 increases expression ISO entinostat results in increased expression of CCR10 mRNA CTD PMID:27188386 NCBI chr10:86,608,836...86,611,273
Ensembl chr10:86,608,836...86,611,273 		JBrowse link
G Cd109 CD109 molecule increases expression
multiple interactions 		ISO entinostat results in increased expression of CD109 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD109 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:88,334,736...88,449,463
Ensembl chr 8:88,334,736...88,449,462 		JBrowse link
G Cd19 CD19 molecule increases expression
multiple interactions 		ISO entinostat results in increased expression of CD19 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD19 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:190,417,853...190,424,494
Ensembl chr 1:190,417,853...190,424,355 		JBrowse link
G Cd200 Cd200 molecule decreases expression ISO entinostat results in decreased expression of CD200 mRNA CTD PMID:27188386 NCBI chr11:68,916,200...68,943,570
Ensembl chr11:68,916,224...68,943,569 		JBrowse link
G Cd24 CD24 molecule increases expression
multiple interactions 		ISO entinostat results in increased expression of CD24 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785 		JBrowse link
G Cd302 CD302 molecule increases expression ISO entinostat results in increased expression of CD302 mRNA CTD PMID:27188386 NCBI chr 3:65,131,017...65,164,737
Ensembl chr 3:65,113,102...65,164,737 		JBrowse link
G Cd36 CD36 molecule increases expression ISO entinostat results in increased expression of CD36 mRNA CTD PMID:27188386 NCBI chr 4:18,209,088...18,302,142 JBrowse link
G Cd40 CD40 molecule increases expression ISO entinostat results in increased expression of CD40 mRNA CTD PMID:27188386 NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847 		JBrowse link
G Cd44 CD44 molecule increases expression
multiple interactions 		ISO entinostat results in increased expression of CD44 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424 		JBrowse link
G Cd52 CD52 molecule increases expression ISO entinostat results in increased expression of CD52 mRNA CTD PMID:27188386 NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086 		JBrowse link
G Cd70 Cd70 molecule increases expression ISO entinostat results in increased expression of CD70 mRNA CTD PMID:27188386 NCBI chr 9:2,093,540...2,096,692
Ensembl chr 9:2,086,848...2,096,692 		JBrowse link
G Cd74 CD74 molecule increases expression ISO entinostat results in increased expression of CD74 mRNA CTD PMID:27188386 NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410 		JBrowse link
G Cd83 CD83 molecule increases expression ISO entinostat results in increased expression of CD83 mRNA CTD PMID:27188386 NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047 		JBrowse link
G Cd9 CD9 molecule increases expression
multiple interactions 		ISO entinostat results in increased expression of CD9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444 		JBrowse link
G Cd99l2 CD99 molecule-like 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD99L2 mRNA
entinostat results in decreased expression of CD99L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:6,861,242...6,906,838
Ensembl chr15:6,864,268...6,906,952 		JBrowse link
G Cda cytidine deaminase increases expression
multiple interactions 		ISO entinostat results in increased expression of CDA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541 		JBrowse link
G Cdc14a cell division cycle 14A multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC14A mRNA
entinostat results in decreased expression of CDC14A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:206,910,475...207,070,537
Ensembl chr 2:206,910,475...207,091,722 		JBrowse link
G Cdc25a cell division cycle 25A decreases expression ISO entinostat results in decreased expression of CDC25A mRNA CTD PMID:27188386 NCBI chr 8:118,742,824...118,761,190
Ensembl chr 8:118,742,426...118,761,188 		JBrowse link
G Cdc42ep5 CDC42 effector protein 5 increases expression ISO entinostat results in increased expression of CDC42EP5 mRNA CTD PMID:26272509 NCBI chr 1:79,108,036...79,110,550 JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO entinostat results in decreased expression of CDC42SE2 mRNA CTD PMID:27188386 NCBI chr10:39,337,269...39,405,772
Ensembl chr 1:100,424,547...100,424,801
Ensembl chr10:100,424,547...100,424,801 		JBrowse link
G Cdca7l cell division cycle associated 7 like increases expression
multiple interactions 		ISO entinostat results in increased expression of CDCA7L mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCA7L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:144,936,885...144,982,844
Ensembl chr 6:144,908,171...144,982,843 		JBrowse link
G Cdcp1 CUB domain containing protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CDCP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:131,706,140...131,742,799
Ensembl chr 8:131,706,140...131,742,877 		JBrowse link
G Cdh1 cadherin 1 increases expression
decreases expression
multiple interactions 		ISO entinostat results in increased expression of CDH1 mRNA; entinostat results in increased expression of CDH1 protein
entinostat results in decreased expression of CDH1 mRNA; entinostat results in decreased expression of CDH1 protein
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:29845424 NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh11 cadherin 11 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH11 mRNA
entinostat results in decreased expression of CDH11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:2,152,961...2,312,140
Ensembl chr19:2,154,840...2,312,140 		JBrowse link
G Cdh12 cadherin 12 decreases expression ISO entinostat results in decreased expression of CDH12 mRNA CTD PMID:27188386 NCBI chr 2:72,201,859...73,436,039
Ensembl chr 2:72,886,532...73,436,039 		JBrowse link
G Cdh18 cadherin 18 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA
entinostat results in increased expression of CDH18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:74,548,681...75,550,720
Ensembl chr 2:75,075,595...75,550,720 		JBrowse link
G Cdh2 cadherin 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CDH2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288 		JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:51,303,414...51,353,900
Ensembl chr19:51,300,083...51,354,257 		JBrowse link
G Cdh6 cadherin 6 decreases expression
increases expression 		ISO entinostat results in decreased expression of CDH6 mRNA
entinostat results in increased expression of CDH6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:63,801,630...63,952,309
Ensembl chr 2:63,806,135...63,952,287 		JBrowse link
G Cdh8 cadherin 8 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CDH8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:5,494,552...5,901,950
Ensembl chr19:5,500,221...5,902,627 		JBrowse link
G Cdh9 cadherin 9 increases expression
multiple interactions 		ISO entinostat results in increased expression of CDH9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:67,954,708...68,094,371
Ensembl chr 2:67,955,166...68,094,365 		JBrowse link
G Cdk12 cyclin-dependent kinase 12 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK12 mRNA CTD PMID:27188386 NCBI chr10:83,697,174...83,793,676
Ensembl chr10:83,767,206...83,777,183
Ensembl chr10:83,767,206...83,777,183 		JBrowse link
G Cdkl2 cyclin dependent kinase like 2 increases expression ISO entinostat results in increased expression of CDKL2 mRNA CTD PMID:26272509 PMID:27188386 NCBI chr14:16,312,154...16,347,524
Ensembl chr14:16,312,932...16,347,523 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression 		ISO
EXP 		2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [entinostat results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [entinostat results in increased expression of CDKN1A protein]; entinostat promotes the reaction [decitabine results in increased expression of CDKN1A protein]; entinostat promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [entinostat results in increased expression of CDKN1A protein]
TNFSF10 protein promotes the reaction [entinostat results in increased expression of CDKN1A protein]
[Azacitidine co-treated with entinostat] results in increased expression of CDKN1A mRNA
entinostat results in decreased expression of CDKN1A protein
entinostat results in increased expression of CDKN1A mRNA; entinostat results in increased expression of CDKN1A protein 		CTD PMID:18223691 PMID:20421217 PMID:21041383 PMID:21224363 PMID:25699604 More... NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO [fludarabine co-treated with entinostat] results in decreased expression of CDKN1B protein CTD PMID:15059916 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions EXP [Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene; [Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA CTD PMID:21224363 NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248 		JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO entinostat results in increased expression of CDKN2B mRNA CTD PMID:27188386 NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855 		JBrowse link
G Cdkn3 cyclin-dependent kinase inhibitor 3 increases expression ISO entinostat results in increased expression of CDKN3 mRNA CTD PMID:27188386 NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722 		JBrowse link
G Cdv3 carnitine deficiency-associated gene expressed in ventricle 3 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDV3 mRNA CTD PMID:27188386 NCBI chr 8:112,812,898...112,826,073
Ensembl chr 8:112,813,952...112,826,056 		JBrowse link
G Cdyl chromodomain Y-like increases expression
multiple interactions 		ISO entinostat results in increased expression of CDYL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDYL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:29,188,697...29,409,805
Ensembl chr17:29,188,698...29,409,757 		JBrowse link
G Ceacam1 CEA cell adhesion molecule 1 increases expression ISO entinostat results in increased expression of CEACAM1 mRNA CTD PMID:27188386 NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA
entinostat results in increased expression of CEBPB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072 		JBrowse link
G Cebpz CCAAT/enhancer binding protein zeta multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPZ mRNA
entinostat results in increased expression of CEBPZ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:21,872,071...21,889,755
Ensembl chr 6:21,872,025...21,889,749 		JBrowse link
G Celf1 CUGBP, Elav-like family member 1 decreases expression ISO entinostat results in decreased expression of CELF1 mRNA CTD PMID:27188386 NCBI chr 3:97,380,407...97,455,253
Ensembl chr 3:97,380,424...97,452,791 		JBrowse link
G Celf2 CUGBP, Elav-like family member 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF2 mRNA
entinostat results in decreased expression of CELF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:75,813,928...76,639,300
Ensembl chr17:75,813,704...76,636,362 		JBrowse link
G Celf4 CUGBP, Elav-like family member 4 decreases expression ISO entinostat results in decreased expression of CELF4 mRNA CTD PMID:27188386 NCBI chr18:17,061,284...17,339,747
Ensembl chr18:17,061,293...17,339,571 		JBrowse link
G Cenpv centromere protein V decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CENPV mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPV mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:47,713,778...47,746,800
Ensembl chr10:47,713,778...47,727,679 		JBrowse link
G Cep112 centrosomal protein 112 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP112 mRNA
entinostat results in decreased expression of CEP112 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:93,865,630...94,332,679
Ensembl chr10:93,865,699...94,332,680 		JBrowse link
G Cep120 centrosomal protein 120 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP120 mRNA
entinostat results in decreased expression of CEP120 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:49,326,266...49,388,380
Ensembl chr18:49,326,266...49,388,243 		JBrowse link
G Cep126 centrosomal protein 126 increases expression ISO entinostat results in increased expression of CEP126 mRNA CTD PMID:27188386 NCBI chr 8:13,485,211...13,552,711
Ensembl chr 8:13,490,685...13,552,221 		JBrowse link
G Cep41 centrosomal protein 41 decreases expression ISO entinostat results in decreased expression of CEP41 mRNA CTD PMID:26272509 NCBI chr 4:60,238,602...60,279,670
Ensembl chr 4:60,239,539...60,254,419 		JBrowse link
G Cep70 centrosomal protein 70 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP70 mRNA
entinostat results in decreased expression of CEP70 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:108,689,562...108,742,620
Ensembl chr 8:108,689,671...108,742,617 		JBrowse link
G Cep85l centrosomal protein 85-like increases expression
multiple interactions 		ISO entinostat results in increased expression of CEP85L mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:33,111,114...33,282,182
Ensembl chr20:33,115,438...33,282,238 		JBrowse link
G Ces1d carboxylesterase 1D increases expression ISO entinostat results in increased expression of CES1 mRNA CTD PMID:27188386 NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449 		JBrowse link
G Cfap251 cilia and flagella associated protein 251 increases expression ISO entinostat results in increased expression of CFAP251 mRNA CTD PMID:27188386 NCBI chr12:38,923,154...38,997,881
Ensembl chr12:38,922,330...38,954,783 		JBrowse link
G Cfap44 cilia and flagella associated protein 44 increases expression ISO entinostat results in increased expression of CFAP44 mRNA CTD PMID:27188386 NCBI chr11:69,704,997...69,789,998
Ensembl chr11:69,705,719...69,789,905 		JBrowse link
G Cfap52 cilia and flagella associated protein 52 increases expression ISO entinostat results in increased expression of CFAP52 mRNA CTD PMID:27188386 NCBI chr10:53,112,692...53,153,844
Ensembl chr10:53,112,693...53,153,844 		JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression ISO entinostat results in decreased expression of CFAP91 mRNA CTD PMID:26272509 NCBI chr11:75,919,129...75,962,786
Ensembl chr11:75,919,142...75,962,785 		JBrowse link
G Cfap95 cilia and flagella associated protein 95 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA
entinostat results in increased expression of CFAP95 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:230,558,329...230,669,479
Ensembl chr 1:230,558,331...230,669,479 		JBrowse link
G Cfd complement factor D increases expression
multiple interactions 		ISO entinostat results in increased expression of CFD mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:10,463,773...10,465,496
Ensembl chr 7:10,463,775...10,465,572 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CFLAR mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434 		JBrowse link
G Cgas cyclic GMP-AMP synthase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGAS mRNA
entinostat results in increased expression of CGAS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:88,172,559...88,187,538
Ensembl chr 8:88,174,512...88,185,859 		JBrowse link
G Cgnl1 cingulin-like 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CGNL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:81,154,169...81,305,598
Ensembl chr 8:81,140,091...81,305,747 		JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO entinostat results in increased expression of CGREF1 mRNA CTD PMID:27188386 NCBI chr 6:31,151,795...31,163,801
Ensembl chr 6:31,151,795...31,163,800 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of CHAC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA
entinostat results in decreased expression of CHAC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361 		JBrowse link
G Chac2 ChaC glutathione specific gamma-glutamylcyclotransferase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of CHAC2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:108,921,669...108,929,215
Ensembl chr14:108,921,341...108,929,469 		JBrowse link
G Chchd10 coiled-coil-helix-coiled-coil-helix domain containing 10 increases expression
multiple interactions 		ISO entinostat results in increased expression of CHCHD10 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHCHD10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:12,725,274...12,730,295
Ensembl chr20:12,725,277...12,745,677 		JBrowse link
G Chek1 checkpoint kinase 1 decreases expression ISO entinostat results in decreased expression of CHEK1 protein CTD PMID:34665271 NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359 		JBrowse link
G Chga chromogranin A multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA
entinostat results in increased expression of CHGA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237 		JBrowse link
G Chodl chondrolectin multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
entinostat results in increased expression of CHODL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:31,141,030...31,163,342
Ensembl chr11:31,141,021...31,163,334 		JBrowse link
G Chp2 calcineurin-like EF hand protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHP2 mRNA
entinostat results in increased expression of CHP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:186,189,090...186,203,663
Ensembl chr 1:186,185,151...186,203,667 		JBrowse link
G Chrdl1 chordin-like 1 increases expression ISO entinostat results in increased expression of CHRDL1 mRNA CTD PMID:27188386 NCBI chr  X:111,685,864...111,789,684
Ensembl chr  X:111,685,866...111,789,661 		JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of CHRM3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304 		JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
entinostat results in increased expression of CHRNA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:64,297,755...64,311,412 		JBrowse link
G Chrna9 cholinergic receptor nicotinic alpha 9 subunit increases expression ISO entinostat results in increased expression of CHRNA9 mRNA CTD PMID:27188386 NCBI chr14:42,588,948...42,595,669
Ensembl chr14:42,588,948...42,595,669 		JBrowse link
G Chrnb1 cholinergic receptor nicotinic beta 1 subunit increases expression ISO entinostat results in increased expression of CHRNB1 mRNA CTD PMID:27188386 NCBI chr10:54,999,943...55,015,137
Ensembl chr10:55,002,788...55,015,107 		JBrowse link
G Chrnb4 cholinergic receptor nicotinic beta 4 subunit increases expression
multiple interactions 		ISO entinostat results in increased expression of CHRNB4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNB4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:64,312,644...64,333,319
Ensembl chr 8:64,313,669...64,333,248 		JBrowse link
G Chst15 carbohydrate sulfotransferase 15 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA
entinostat results in increased expression of CHST15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444 		JBrowse link
G Chst2 carbohydrate sulfotransferase 2 increases expression ISO entinostat results in increased expression of CHST2 mRNA CTD PMID:27188386 NCBI chr 8:104,839,716...104,845,961
Ensembl chr 8:104,831,292...104,860,301 		JBrowse link
G Chst4 carbohydrate sulfotransferase 4 increases expression
multiple interactions 		ISO entinostat results in increased expression of CHST4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:54,900,914...54,911,735
Ensembl chr19:54,882,719...54,916,648 		JBrowse link
G Chst9 carbohydrate sulfotransferase 9 increases expression
multiple interactions 		ISO entinostat results in increased expression of CHST9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:6,850,874...7,125,222
Ensembl chr18:6,851,831...7,125,161 		JBrowse link
G Ciart circadian associated repressor of transcription decreases expression ISO entinostat results in decreased expression of CIART mRNA CTD PMID:32870474 NCBI chr 2:186,108,744...186,113,778
Ensembl chr 2:186,108,752...186,112,246 		JBrowse link
G Cilp2 cartilage intermediate layer protein 2 increases expression ISO entinostat results in increased expression of CILP2 mRNA CTD PMID:27188386 NCBI chr16:19,573,821...19,581,100
Ensembl chr16:19,573,908...19,581,100 		JBrowse link
G Cimap1b ciliary microtubule associated protein 1B increases expression ISO entinostat results in increased expression of CIMAP1B mRNA CTD PMID:27188386 NCBI chr 7:122,323,860...122,326,921
Ensembl chr 7:122,323,860...122,326,876 		JBrowse link
G Cimap3 ciliary microtubule associated protein 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of CIMAP3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:196,164,103...196,181,466
Ensembl chr 2:196,163,275...196,181,604 		JBrowse link
G Cish cytokine inducible SH2-containing protein multiple interactions ISO entinostat inhibits the reaction [IL3 protein results in increased expression of CISH mRNA] CTD PMID:25769527 NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA
entinostat results in increased expression of CITED2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782 		JBrowse link
G Clasp2 cytoplasmic linker associated protein 2 decreases expression ISO entinostat results in decreased expression of CLASP2 mRNA CTD PMID:27188386 NCBI chr 8:122,555,532...122,736,934
Ensembl chr 8:122,555,524...122,737,587 		JBrowse link
G Clcnkb chloride voltage-gated channel Kb increases expression ISO entinostat results in increased expression of CLCNKB mRNA CTD PMID:27188386 NCBI chr 5:158,993,073...159,005,618
Ensembl chr 5:158,993,074...159,004,900 		JBrowse link
G Cldn1 claudin 1 increases expression ISO entinostat results in increased expression of CLDN1 mRNA CTD PMID:26272509 NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529 		JBrowse link
G Cldn10 claudin 10 increases expression ISO entinostat results in increased expression of CLDN10 mRNA CTD PMID:27188386 NCBI chr15:102,269,858...102,361,589
Ensembl chr15:102,269,858...102,361,589 		JBrowse link
G Cldn11 claudin 11 increases expression ISO entinostat results in increased expression of CLDN11 mRNA CTD PMID:27188386 NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539 		JBrowse link
G Cldn23 claudin 23 increases expression
multiple interactions 		ISO entinostat results in increased expression of CLDN23 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:63,117,045...63,118,769
Ensembl chr16:63,116,781...63,118,957 		JBrowse link
G Cldn6 claudin 6 increases expression
multiple interactions 		ISO entinostat results in increased expression of CLDN6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581 		JBrowse link
G Cldn7 claudin 7 increases expression
multiple interactions 		ISO entinostat results in increased expression of CLDN7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905 		JBrowse link
G Clec11a C-type lectin domain containing 11A increases expression ISO entinostat results in increased expression of CLEC11A mRNA CTD PMID:27188386 NCBI chr 1:103,938,029...103,941,170
Ensembl chr 1:103,935,185...103,946,784 		JBrowse link
G Clec12a C-type lectin domain family 12, member A increases expression ISO entinostat results in increased expression of CLEC12A mRNA CTD PMID:27188386 NCBI chr 4:164,484,162...164,502,793
Ensembl chr 4:164,484,162...164,510,233 		JBrowse link
G Clec18a C-type lectin domain family 18, member A multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA
entinostat results in decreased expression of CLEC18A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:55,947,625...55,964,505
Ensembl chr19:55,947,223...55,965,323 		JBrowse link
G Clgn calmegin increases expression ISO entinostat results in increased expression of CLGN mRNA CTD PMID:27188386 NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325 		JBrowse link
G Clic3 chloride intracellular channel 3 increases expression ISO entinostat results in increased expression of CLIC3 mRNA CTD PMID:27188386 NCBI chr 3:28,670,176...28,672,166
Ensembl chr 3:28,670,229...28,675,723 		JBrowse link
G Clic4 chloride intracellular channel 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC4 mRNA
entinostat results in increased expression of CLIC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:152,737,371...152,797,118
Ensembl chr 5:152,737,371...152,797,118 		JBrowse link
G Clic6 chloride intracellular channel 6 increases expression
multiple interactions 		ISO entinostat results in increased expression of CLIC6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:45,223,715...45,266,261
Ensembl chr11:45,223,669...45,267,344 		JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CLIP4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLIP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:29,359,628...29,449,365
NCBI chr 6:29,349,245...29,351,890
Ensembl chr 6:29,348,918...29,449,271 		JBrowse link
G Clmn calmin increases expression ISO entinostat results in increased expression of CLMN mRNA CTD PMID:27188386 NCBI chr 6:129,470,613...129,572,079
Ensembl chr 6:129,478,149...129,572,027 		JBrowse link
G Clp1 cleavage factor polyribonucleotide kinase subunit 1 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA CTD PMID:27188386 NCBI chr 3:90,213,461...90,217,165
Ensembl chr 3:90,213,465...90,217,538 		JBrowse link
G Clpb ClpB family mitochondrial disaggregase increases expression ISO entinostat results in increased expression of CLPB mRNA CTD PMID:27188386 NCBI chr 1:165,440,705...165,563,514
Ensembl chr 1:165,440,861...165,583,815 		JBrowse link
G Clrn3 clarin 3 decreases expression ISO entinostat results in decreased expression of CLRN3 mRNA CTD PMID:27188386 NCBI chr 1:199,748,863...199,764,486
Ensembl chr 1:199,748,864...199,764,486 		JBrowse link
G Clu clusterin multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA
entinostat results in increased expression of CLU mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860 		JBrowse link
G Clul1 clusterin like 1 increases expression ISO entinostat results in increased expression of CLUL1 mRNA CTD PMID:27188386 NCBI chr 9:120,791,105...120,816,680
Ensembl chr 9:120,791,105...120,816,680 		JBrowse link
G Cmklr1 chemerin chemokine-like receptor 1 increases expression ISO entinostat results in increased expression of CMKLR1 mRNA CTD PMID:32870474 NCBI chr12:48,634,929...48,687,833
Ensembl chr12:48,634,003...48,691,458 		JBrowse link
G Cmtm5 CKLF-like MARVEL transmembrane domain containing 5 increases expression ISO entinostat results in increased expression of CMTM5 mRNA CTD PMID:27188386 NCBI chr15:32,382,171...32,385,288
Ensembl chr15:32,382,608...32,385,271 		JBrowse link
G Cmtm8 CKLF-like MARVEL transmembrane domain containing 8 increases expression ISO entinostat results in increased expression of CMTM8 mRNA CTD PMID:27188386 NCBI chr 8:123,360,168...123,425,291
Ensembl chr 8:123,360,170...123,425,276 		JBrowse link
G Cnfn cornifelin increases expression ISO entinostat results in increased expression of CNFN mRNA CTD PMID:27188386 NCBI chr 1:90,079,409...90,081,556
Ensembl chr 1:90,078,552...90,081,556 		JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA
entinostat results in decreased expression of CNKSR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:40,722,843...40,971,730
Ensembl chr  X:40,722,996...40,965,604 		JBrowse link
G Cnmd chondromodulin multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA
entinostat results in increased expression of CNMD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:61,450,617...61,475,382
Ensembl chr15:61,450,450...61,475,350 		JBrowse link
G Cnn1 calponin 1 increases expression ISO entinostat results in increased expression of CNN1 mRNA CTD PMID:27188386 NCBI chr 8:28,908,437...28,917,099
Ensembl chr 8:28,908,330...28,919,482 		JBrowse link
G Cnn2 calponin 2 increases expression ISO entinostat results in increased expression of CNN2 mRNA CTD PMID:32870474 NCBI chr 7:10,363,141...10,370,312
Ensembl chr 7:10,363,102...10,370,312 		JBrowse link
G Cnot3 CCR4-NOT transcription complex, subunit 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CNOT3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:74,471,284...74,487,527
Ensembl chr 1:74,470,566...74,487,527 		JBrowse link
G Cnpy2 canopy FGF signaling regulator 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of CNPY2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNPY2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:1,332,293...1,338,081
Ensembl chr 7:1,334,335...1,340,333 		JBrowse link
G Cnr1 cannabinoid receptor 1 decreases expression ISO entinostat results in decreased expression of CNR1 mRNA CTD PMID:27188386 NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252 		JBrowse link
G Cnrip1 cannabinoid receptor interacting protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA
entinostat results in increased expression of CNRIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:95,664,435...95,707,062
Ensembl chr14:95,664,774...95,694,371 		JBrowse link
G Cntn1 contactin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CNTN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391 		JBrowse link
G Cntrl centriolin decreases expression ISO entinostat results in decreased expression of CNTRL mRNA CTD PMID:27188386 NCBI chr 3:38,825,575...38,897,835
Ensembl chr 3:38,825,624...38,897,833 		JBrowse link
G Cobl cordon-bleu WH2 repeat protein multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA
entinostat results in increased expression of COBL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:91,041,721...91,274,272
Ensembl chr14:91,041,721...91,274,257 		JBrowse link
G Col10a1 collagen type X alpha 1 chain decreases expression ISO entinostat results in decreased expression of COL10A1 protein CTD PMID:26251326 NCBI chr20:39,737,536...39,744,518
Ensembl chr20:39,716,822...39,751,440 		JBrowse link
G Col11a1 collagen type XI alpha 1 chain multiple interactions
decreases expression
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COL11A1 mRNA
entinostat results in decreased expression of COL11A1 mRNA
entinostat results in increased expression of COL11A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264 		JBrowse link
G Col11a2 collagen type XI alpha 2 chain increases expression ISO entinostat results in increased expression of COL11A2 mRNA CTD PMID:27188386 NCBI chr20:4,788,829...4,818,492
Ensembl chr20:4,788,829...4,817,648 		JBrowse link
G Col13a1 collagen type XIII alpha 1 chain increases expression
multiple interactions 		ISO entinostat results in increased expression of COL13A1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL13A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:30,326,744...30,466,800
Ensembl chr20:30,326,744...30,466,800 		JBrowse link
G Col14a1 collagen type XIV alpha 1 chain increases expression
multiple interactions 		ISO entinostat results in increased expression of COL14A1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938 		JBrowse link
G Col16a1 collagen type XVI alpha 1 chain increases expression ISO entinostat results in increased expression of COL16A1 mRNA CTD PMID:27188386 NCBI chr 5:147,672,559...147,727,007
Ensembl chr 5:147,672,601...147,727,011 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions
decreases expression
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA
entinostat results in decreased expression of COL1A1 protein
entinostat results in increased expression of COL1A1 mRNA 		CTD PMID:26251326 PMID:26272509 PMID:27188386 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460 		JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression
multiple interactions 		ISO entinostat results in increased expression of COL1A2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995 		JBrowse link
G Col22a1 collagen type XXII alpha 1 chain increases expression ISO entinostat results in increased expression of COL22A1 mRNA CTD PMID:27188386 NCBI chr 7:105,619,776...105,857,246
Ensembl chr 7:105,619,757...105,856,960 		JBrowse link
G Col2a1 collagen type II alpha 1 chain multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COL2A1 mRNA
entinostat results in decreased expression of COL2A1 protein
entinostat results in decreased expression of COL2A1 mRNA 		CTD PMID:26251326 PMID:26272509 PMID:27188386 NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627 		JBrowse link
G Col5a1 collagen type V alpha 1 chain increases expression ISO entinostat results in increased expression of COL5A1 mRNA CTD PMID:27188386 NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020 		JBrowse link
G Col5a3 collagen type V alpha 3 chain increases expression
multiple interactions 		ISO entinostat results in increased expression of COL5A3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:27,580,768...27,626,002
Ensembl chr 8:27,580,768...27,626,122 		JBrowse link
G Col6a1 collagen type VI alpha 1 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA
entinostat results in increased expression of COL6A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA
entinostat results in increased expression of COL6A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990 		JBrowse link
G Col8a2 collagen type VIII alpha 2 chain increases expression
multiple interactions 		ISO entinostat results in increased expression of COL8A2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL8A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:143,870,754...143,897,372
Ensembl chr 5:143,870,742...143,897,884 		JBrowse link
G Col9a1 collagen type IX alpha 1 chain decreases expression
multiple interactions 		ISO entinostat results in decreased expression of COL9A1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COL9A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:34,081,364...34,164,552
Ensembl chr 9:34,003,905...34,164,543 		JBrowse link
G Col9a2 collagen type IX alpha 2 chain increases expression ISO entinostat results in increased expression of COL9A2 mRNA CTD PMID:27188386 NCBI chr 5:139,892,798...139,910,131
Ensembl chr 5:139,892,798...139,909,855 		JBrowse link
G Col9a3 collagen type IX alpha 3 chain increases expression
multiple interactions 		ISO entinostat results in increased expression of COL9A3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:188,089,337...188,112,034
Ensembl chr 3:188,089,403...188,112,270 		JBrowse link
G Colec12 collectin sub-family member 12 increases expression ISO entinostat results in increased expression of COLEC12 mRNA CTD PMID:26272509 NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297 		JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA
entinostat results in decreased expression of COLGALT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:67,073,551...67,178,194
Ensembl chr13:67,073,551...67,178,194 		JBrowse link
G Comtd1 catechol-O-methyltransferase domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA
entinostat results in increased expression of COMTD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:2,509,121...2,512,232
Ensembl chr15:2,509,032...2,512,232 		JBrowse link
G Copz2 COPI coat complex subunit zeta 2 increases expression ISO entinostat results in increased expression of COPZ2 mRNA CTD PMID:27188386 NCBI chr10:82,328,888...82,341,959
Ensembl chr10:82,328,660...82,341,959 		JBrowse link
G Coro2a coronin 2A multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA
entinostat results in increased expression of CORO2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:65,623,823...65,654,602 		JBrowse link
G Cox11 cytochrome c oxidase copper chaperone COX11 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of COX11 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COX11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:75,955,825...75,962,398
Ensembl chr10:75,955,783...75,963,489 		JBrowse link
G Cpeb1 cytoplasmic polyadenylation element binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB1 mRNA
entinostat results in increased expression of CPEB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:144,709,278...144,817,388
Ensembl chr 1:144,709,691...144,815,880 		JBrowse link
G Cpeb3 cytoplasmic polyadenylation element binding protein 3 increases expression ISO entinostat results in increased expression of CPEB3 mRNA CTD PMID:27188386 NCBI chr 1:244,161,690...244,343,765
Ensembl chr 1:244,161,690...244,343,561 		JBrowse link
G Cpm carboxypeptidase M increases expression ISO entinostat results in increased expression of CPM mRNA CTD PMID:27188386 NCBI chr 7:55,111,599...55,172,114
Ensembl chr 7:55,111,599...55,172,114 		JBrowse link
G Cpne2 copine 2 increases expression ISO entinostat results in increased expression of CPNE2 mRNA CTD PMID:27188386 NCBI chr19:10,440,245...10,477,783
Ensembl chr19:10,434,647...10,477,783 		JBrowse link
G Cpne4 copine 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA
entinostat results in increased expression of CPNE4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:114,056,152...114,531,855
Ensembl chr 8:113,993,703...114,531,855 		JBrowse link
G Cpped1 calcineurin-like phosphoesterase domain containing 1 increases expression ISO entinostat results in increased expression of CPPED1 mRNA CTD PMID:27188386 NCBI chr10:4,135,601...4,328,039
Ensembl chr10:4,208,463...4,231,065 		JBrowse link
G Cps1 carbamoyl-phosphate synthase 1 increases expression ISO entinostat results in increased expression of CPS1 mRNA CTD PMID:27188386 NCBI chr 9:76,063,863...76,186,739
Ensembl chr 9:76,000,754...76,186,734 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A increases expression
multiple interactions 		ISO entinostat results in increased expression of CPT1A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326 		JBrowse link
G Cpvl carboxypeptidase, vitellogenic-like increases expression ISO entinostat results in increased expression of CPVL mRNA CTD PMID:27188386 NCBI chr 4:84,311,853...84,422,098
Ensembl chr 4:84,311,854...84,416,033 		JBrowse link
G Cpxm2 carboxypeptidase X (M14 family), member 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA
entinostat results in increased expression of CPXM2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,266,930...196,377,350
Ensembl chr 1:196,266,930...196,377,347 		JBrowse link
G Cr1l complement C3b/C4b receptor 1 like multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA
entinostat results in increased expression of CR1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:109,138,132...109,189,068
Ensembl chr13:109,103,235...109,188,869 		JBrowse link
G Cr2 complement C3d receptor 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA
entinostat results in increased expression of CR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:109,207,034...109,244,980
Ensembl chr13:109,213,867...109,244,552 		JBrowse link
G Crabp1 cellular retinoic acid binding protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CRABP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:64,047,060...64,055,470 		JBrowse link
G Cracr2a calcium release activated channel regulator 2A increases expression ISO entinostat results in increased expression of CRACR2A mRNA CTD PMID:27188386 NCBI chr 4:162,094,247...162,207,926
Ensembl chr 4:162,110,929...162,221,529 		JBrowse link
G Creb5 cAMP responsive element binding protein 5 multiple interactions
increases expression
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREB5 mRNA
entinostat results in increased expression of CREB5 mRNA
entinostat results in decreased expression of CREB5 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:32870474 NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793 		JBrowse link
G Crebrf CREB3 regulatory factor decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CREBRF mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREBRF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:16,903,607...16,967,450
Ensembl chr10:16,903,547...16,966,430 		JBrowse link
G Creg1 cellular repressor of E1A-stimulated genes 1 increases expression ISO entinostat results in increased expression of CREG1 mRNA CTD PMID:27188386 NCBI chr13:80,552,779...80,565,272
Ensembl chr13:80,549,933...80,565,272 		JBrowse link
G Crip1 cysteine rich protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CRIP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:138,047,801...138,055,672
Ensembl chr 6:138,047,801...138,055,672 		JBrowse link
G Cripto cripto, EGF-CFC family member increases expression ISO entinostat results in increased expression of CRIPTO mRNA CTD PMID:26272509 NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948 		JBrowse link
G Crlf1 cytokine receptor-like factor 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CRLF1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRLF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:18,958,695...18,970,026
Ensembl chr16:18,957,956...18,969,970 		JBrowse link
G Crot carnitine O-octanoyltransferase multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CROT mRNA
entinostat results in decreased expression of CROT mRNA 		CTD PMID:27188386 NCBI chr 4:26,031,729...26,088,057
Ensembl chr 4:26,052,516...26,088,064 		JBrowse link
G Crtac1 cartilage acidic protein 1 increases expression ISO entinostat results in increased expression of CRTAC1 mRNA CTD PMID:27188386 NCBI chr 1:251,040,963...251,182,920
Ensembl chr 1:251,028,143...251,182,689 		JBrowse link
G Cryab crystallin, alpha B increases expression ISO entinostat results in increased expression of CRYAB mRNA CTD PMID:27188386 NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528 		JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CRYBG1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:49,007,673...49,204,040
Ensembl chr20:49,007,929...49,204,047 		JBrowse link
G Crybg2 crystallin beta-gamma domain containing 2 increases expression ISO entinostat results in increased expression of CRYBG2 mRNA CTD PMID:27188386 NCBI chr 5:151,570,154...151,602,164
Ensembl chr 5:151,570,540...151,602,163 		JBrowse link
G Crybg3 crystallin beta-gamma domain containing 3 decreases expression ISO entinostat results in decreased expression of CRYBG3 mRNA CTD PMID:27188386 NCBI chr11:54,218,399...54,330,962
Ensembl chr11:54,208,444...54,330,960 		JBrowse link
G Cryl1 crystallin, lambda 1 increases expression ISO entinostat results in increased expression of CRYL1 mRNA CTD PMID:27188386 NCBI chr15:35,542,628...35,661,563
Ensembl chr15:35,542,628...35,661,563 		JBrowse link
G Crym crystallin, mu multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYM mRNA
entinostat results in increased expression of CRYM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:183,991,752...184,006,923
Ensembl chr 1:183,991,745...184,006,962 		JBrowse link
G Csad cysteine sulfinic acid decarboxylase increases expression ISO entinostat results in increased expression of CSAD mRNA CTD PMID:27188386 NCBI chr 7:135,187,175...135,216,495
Ensembl chr 7:135,187,175...135,215,581 		JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha increases expression ISO entinostat results in increased expression of CSF2RA mRNA CTD PMID:27188386 NCBI chr14:113,219...118,808
Ensembl chr14:113,225...118,117 		JBrowse link
G Csrnp3 cysteine and serine rich nuclear protein 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA
entinostat results in decreased expression of CSRNP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:70,906,587...71,102,596
Ensembl chr 3:70,906,380...71,094,009 		JBrowse link
G Csrp1 cysteine and glycine-rich protein 1 increases expression ISO entinostat results in increased expression of CSRP1 mRNA CTD PMID:27188386 NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139 		JBrowse link
G Cst6 cystatin E/M multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST6 mRNA
entinostat results in increased expression of CST6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:212,084,676...212,086,384
Ensembl chr 1:212,084,676...212,086,384 		JBrowse link
G Ctbp2 C-terminal binding protein 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of CTBP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTBP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:197,208,536...197,348,802
Ensembl chr 1:197,212,133...197,254,261 		JBrowse link
G Ctbs chitobiase increases expression ISO entinostat results in increased expression of CTBS mRNA CTD PMID:27188386 NCBI chr 2:238,000,800...238,015,368
Ensembl chr 2:238,000,842...238,015,475 		JBrowse link
G Ctcfl1 CCCTC-binding factor like 1 increases expression ISO entinostat results in increased expression of CTCFL mRNA CTD PMID:27188386 NCBI chr 3:182,286,637...182,309,272
Ensembl chr 3:182,286,637...182,309,272 		JBrowse link
G Cth cystathionine gamma-lyase increases expression ISO entinostat results in increased expression of CTH mRNA CTD PMID:26272509 NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066 		JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 increases expression ISO entinostat results in increased expression of CTHRC1 mRNA CTD PMID:26272509 PMID:27188386 NCBI chr 7:72,007,372...72,017,654
Ensembl chr 7:72,007,372...72,017,654 		JBrowse link
G Ctnna2 catenin alpha 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CTNNA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNNA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:110,852,265...112,001,351
Ensembl chr 4:110,852,265...112,001,365 		JBrowse link
G Ctnnbip1 catenin, beta-interacting protein 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CTNNBIP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNNBIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:165,245,019...165,293,994
Ensembl chr 5:165,245,098...165,293,991 		JBrowse link
G Ctnnd2 catenin delta 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CTNND2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:82,879,469...83,727,409
Ensembl chr 2:82,879,469...83,727,409 		JBrowse link
G Ctsb cathepsin B increases expression ISO entinostat results in increased expression of CTSB mRNA CTD PMID:27188386 NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478 		JBrowse link
G Ctsc cathepsin C increases expression
multiple interactions 		ISO entinostat results in increased expression of CTSC mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:151,441,032...151,474,082 		JBrowse link
G Ctsh cathepsin H increases expression ISO entinostat results in increased expression of CTSH mRNA CTD PMID:27188386 NCBI chr 8:99,488,756...99,507,639
Ensembl chr 8:99,488,874...99,509,181 		JBrowse link
G Ctxn3 cortexin 3 increases expression ISO entinostat results in increased expression of CTXN3 mRNA CTD PMID:27188386 NCBI chr18:53,129,505...53,138,694
Ensembl chr18:53,129,489...53,138,693 		JBrowse link
G Cubn cubilin increases expression ISO entinostat results in increased expression of CUBN mRNA CTD PMID:27188386 NCBI chr17:81,293,619...81,501,694
Ensembl chr17:81,293,619...81,501,694 		JBrowse link
G Cul3 cullin 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA
entinostat results in decreased expression of CUL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:89,040,987...89,118,775
Ensembl chr 9:89,040,987...89,118,427 		JBrowse link
G Cuzd1 CUB and zona pellucida-like domains 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CUZD1 mRNA
entinostat results in increased expression of CUZD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:195,519,609...195,532,733
Ensembl chr 1:195,519,609...195,532,733 		JBrowse link
G Cx3cr1 C-X3-C motif chemokine receptor 1 increases expression ISO entinostat results in increased expression of CX3CR1 mRNA CTD PMID:27188386 NCBI chr 8:128,661,294...128,679,048
Ensembl chr 8:128,654,833...128,685,983 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO entinostat results in increased expression of CXCL10 mRNA CTD PMID:27188386 NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 increases expression
multiple interactions 		ISO entinostat results in increased expression of CXCL12 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA 		CTD PMID:26272509 PMID:27188386 PMID:32870474 NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA
entinostat results in decreased expression of CXCR4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459 		JBrowse link
G Cxxc4 CXXC finger protein 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of CXXC4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXXC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:225,329,044...225,363,347 JBrowse link
G Cxxc5 CXXC finger protein 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA
entinostat results in increased expression of CXXC5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635 		JBrowse link
G Cyb561 cytochrome b-561 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB561 mRNA
entinostat results in increased expression of CYB561 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:91,377,866...91,388,548
Ensembl chr10:91,377,866...91,385,097 		JBrowse link
G Cybrd1 cytochrome b reductase 1 increases expression ISO entinostat results in increased expression of CYBRD1 mRNA CTD PMID:27188386 NCBI chr 3:76,342,231...76,369,846
Ensembl chr 3:76,342,404...76,370,061 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [fludarabine co-treated with entinostat] results in increased secretion of CYCS protein CTD PMID:15059916 NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816 		JBrowse link
G Cyfip1 cytoplasmic FMR1 interacting protein 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CYFIP1 mRNA
entinostat results in decreased expression of CYFIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:115,842,754...115,935,163
Ensembl chr 1:115,846,661...115,951,292 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA
entinostat results in increased expression of CYP1A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 increases expression ISO entinostat results in increased expression of CYP24A1 mRNA CTD PMID:27188386 NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083 		JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of CYP26A1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP26A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657 		JBrowse link
G Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA
entinostat results in increased expression of CYP2S1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073 		JBrowse link
G Cyp4x1 cytochrome P450, family 4, subfamily x, polypeptide 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP4X1 mRNA
entinostat results in increased expression of CYP4X1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:133,888,439...133,923,254
Ensembl chr 5:133,888,439...133,919,642 		JBrowse link
G Cyren cell cycle regulator of NHEJ decreases expression ISO entinostat results in decreased expression of CYREN mRNA CTD PMID:26272509 NCBI chr 4:64,514,477...64,519,896
Ensembl chr 4:64,514,477...64,518,742 		JBrowse link
G Cyria CYFIP related Rac1 interactor A increases expression
multiple interactions 		ISO entinostat results in increased expression of CYRIA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860 		JBrowse link
G Cystm1 cysteine-rich transmembrane module containing 1 increases expression ISO entinostat results in increased expression of CYSTM1 mRNA CTD PMID:27188386 NCBI chr18:28,219,861...28,287,574
Ensembl chr18:28,220,004...28,287,574 		JBrowse link
G Cyth1 cytohesin 1 decreases expression ISO entinostat results in decreased expression of CYTH1 mRNA CTD PMID:27188386 NCBI chr10:103,901,376...103,984,496
Ensembl chr10:103,864,804...103,984,383 		JBrowse link
G Daam2 dishevelled associated activator of morphogenesis 2 increases expression ISO entinostat results in increased expression of DAAM2 mRNA CTD PMID:27188386 NCBI chr 9:18,926,620...19,044,672
Ensembl chr 9:18,926,623...19,044,671 		JBrowse link
G Dach1 dachshund family transcription factor 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DACH1 mRNA
entinostat results in decreased expression of DACH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:80,936,063...81,317,746
Ensembl chr15:80,936,063...81,317,627 		JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA
entinostat results in increased expression of DACT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053 		JBrowse link
G Dazap2 DAZ associated protein 2 increases expression ISO entinostat results in increased expression of DAZAP2 mRNA CTD PMID:27188386 NCBI chr 7:133,593,503...133,599,044
Ensembl chr 7:133,593,512...133,599,047 		JBrowse link
G Dazl deleted in azoospermia-like multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
entinostat results in decreased expression of DAZL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:18,193,363...18,210,100
Ensembl chr 9:18,193,363...18,210,100 		JBrowse link
G Dbp D-box binding PAR bZIP transcription factor multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DBP mRNA CTD PMID:27188386 NCBI chr 1:105,312,256...105,317,205
Ensembl chr 1:105,312,108...105,317,205 		JBrowse link
G Dcaf4 DDB1 and CUL4 associated factor 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA
entinostat results in increased expression of DCAF4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:108,885,970...108,912,116
Ensembl chr 6:108,885,932...108,912,110 		JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA
entinostat results in increased expression of DCC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541 		JBrowse link
G Dcdc1-ps1 doublecortin domain containing 1, pseudogene 1 increases expression ISO entinostat results in increased expression of DCDC1 mRNA CTD PMID:27188386 NCBI chr 3:112,940,793...113,351,417
Ensembl chr 3:113,277,854...113,351,719 		JBrowse link
G Dclk1 doublecortin-like kinase 1 multiple interactions
decreases expression
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA
entinostat results in decreased expression of DCLK1 mRNA
entinostat results in increased expression of DCLK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:141,571,983...141,861,090 		JBrowse link
G Dclk2 doublecortin-like kinase 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA
entinostat results in decreased expression of DCLK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:174,506,660...174,636,353
Ensembl chr 2:174,506,660...174,636,192 		JBrowse link
G Dcn decorin increases expression ISO entinostat results in increased expression of DCN mRNA CTD PMID:27188386 NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926 		JBrowse link
G Dcxr dicarbonyl and L-xylulose reductase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCXR mRNA
entinostat results in increased expression of DCXR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:106,504,730...106,506,619 JBrowse link
G Ddah2 DDAH family member 2, ADMA-independent decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DDAH2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDAH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:3,766,115...3,769,161
Ensembl chr20:3,766,120...3,769,183 		JBrowse link
G Ddc dopa decarboxylase decreases expression ISO entinostat results in decreased expression of DDC mRNA CTD PMID:27188386 NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 decreases expression ISO entinostat results in decreased expression of DDIT3 mRNA CTD PMID:32870474 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509 		JBrowse link
G Ddit4l DNA-damage-inducible transcript 4-like decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DDIT4L mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:228,800,831...228,804,478
Ensembl chr 2:228,801,705...228,806,225 		JBrowse link
G Ddx17 DEAD-box helicase 17 decreases expression ISO entinostat results in decreased expression of DDX17 mRNA CTD PMID:27188386 NCBI chr 7:112,971,522...112,989,747
Ensembl chr 7:112,971,523...112,989,747 		JBrowse link
G Def6 DEF6 guanine nucleotide exchange factor multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEF6 mRNA
entinostat results in increased expression of DEF6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:6,270,323...6,291,724
Ensembl chr20:6,269,357...6,291,771 		JBrowse link
G Defa5 defensin alpha 5 decreases expression ISO entinostat results in decreased expression of DEFA5 mRNA CTD PMID:27188386 NCBI chr16:77,044,994...77,047,318
Ensembl chr16:77,044,994...77,047,318 		JBrowse link
G Defb1 defensin beta 1 decreases expression ISO entinostat results in decreased expression of DEFB1 mRNA CTD PMID:27188386 NCBI chr16:77,001,326...77,016,068
Ensembl chr16:77,001,326...77,016,068 		JBrowse link
G Degs1 delta(4)-desaturase, sphingolipid 1 increases expression ISO entinostat results in increased expression of DEGS1 mRNA CTD PMID:26272509 PMID:27188386 NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302 		JBrowse link
G Dennd11 DENN domain containing 11 decreases expression ISO entinostat results in decreased expression of DENND11 mRNA CTD PMID:27188386 NCBI chr 4:70,163,869...70,232,731
Ensembl chr 4:70,163,869...70,195,800 		JBrowse link
G Dennd1a DENN domain containing 1A decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DENND1A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:41,974,502...42,461,816
Ensembl chr 3:41,974,502...42,461,886 		JBrowse link
G Dennd1b DENN domain containing 1B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DENND1B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:53,096,717...53,324,372
Ensembl chr13:53,092,261...53,324,369 		JBrowse link
G Dennd1c DENN domain containing 1C increases expression ISO entinostat results in increased expression of DENND1C mRNA CTD PMID:27188386 NCBI chr 9:1,991,035...2,003,330
Ensembl chr 9:1,991,039...2,003,151 		JBrowse link
G Dennd2a DENN domain containing 2A multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA
entinostat results in decreased expression of DENND2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:69,199,814...69,299,128
Ensembl chr 4:69,199,814...69,298,984 		JBrowse link
G Dennd2c DENN domain containing 2C multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND2C mRNA
entinostat results in increased expression of DENND2C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:193,310,822...193,378,986
Ensembl chr 2:193,335,230...193,378,978 		JBrowse link
G Depdc7 DEP domain containing 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA
entinostat results in increased expression of DEPDC7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:111,554,701...111,575,979
Ensembl chr 3:111,554,706...111,575,979 		JBrowse link
G Deptor DEP domain containing MTOR-interacting protein increases expression
multiple interactions 		ISO entinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041 		JBrowse link
G Dgke diacylglycerol kinase epsilon increases expression ISO entinostat results in increased expression of DGKE mRNA CTD PMID:27188386 NCBI chr10:74,348,931...74,374,509
Ensembl chr10:74,350,246...74,374,478 		JBrowse link
G Dgkh diacylglycerol kinase, eta increases expression ISO entinostat results in increased expression of DGKH mRNA CTD PMID:27188386 NCBI chr15:60,390,279...60,559,777
Ensembl chr15:60,402,004...60,560,218 		JBrowse link
G Dgkk diacylglycerol kinase kappa multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DGKK mRNA
entinostat results in increased expression of DGKK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:18,253,849...18,385,805
Ensembl chr  X:18,256,463...18,385,640 		JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA
entinostat results in increased expression of DHRS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588 		JBrowse link
G Dhrs3 dehydrogenase/reductase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA
entinostat results in increased expression of DHRS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653 		JBrowse link
G Dhx30 DExH-box helicase 30 decreases expression ISO entinostat results in decreased expression of DHX30 mRNA CTD PMID:27188386 NCBI chr 8:118,943,186...118,975,319
Ensembl chr 8:118,943,187...118,975,592 		JBrowse link
G Dhx58 DEXH-box helicase 58 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHX58 mRNA
entinostat results in increased expression of DHX58 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:86,120,677...86,132,095
Ensembl chr10:86,120,677...86,131,844 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions ISO [fludarabine co-treated with entinostat] results in increased secretion of DIABLO protein CTD PMID:15059916 NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265 		JBrowse link
G Diaph2 diaphanous-related formin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:96,700,535...97,528,080
Ensembl chr  X:96,700,726...97,528,080 		JBrowse link
G Dido1 death inducer-obliterator 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DIDO1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIDO1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:188,150,100...188,203,445
Ensembl chr 3:188,150,100...188,194,823 		JBrowse link
G Dio1 iodothyronine deiodinase 1 decreases expression ISO entinostat results in decreased expression of DIO1 mRNA CTD PMID:27188386 NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771 		JBrowse link
G Dio3 iodothyronine deiodinase 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIO3 mRNA
entinostat results in decreased expression of DIO3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985 		JBrowse link
G Dipk1a divergent protein kinase domain 1A increases expression ISO entinostat results in increased expression of DIPK1A mRNA CTD PMID:27188386 NCBI chr14:1,917,353...1,988,188
Ensembl chr14:1,917,324...1,988,678 		JBrowse link
G Dipk1c divergent protein kinase domain 1C decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:80,362,854...80,384,774
Ensembl chr18:80,362,982...80,386,551 		JBrowse link
G Diras3 DIRAS family GTPase 3 increases expression ISO entinostat results in increased expression of DIRAS3 mRNA CTD PMID:27188386 NCBI chr 6:136,346,157...136,347,371
Ensembl chr 6:136,346,154...136,348,376 		JBrowse link
G Dis3 DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DIS3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:82,231,922...82,258,299
Ensembl chr15:82,231,283...82,258,333 		JBrowse link
G Disp1 dispatched RND transporter family member 1 increases expression ISO entinostat results in increased expression of DISP1 mRNA CTD PMID:27188386 NCBI chr13:97,252,574...97,398,329
Ensembl chr13:97,252,574...97,398,460 		JBrowse link
G Dlg3 discs large MAGUK scaffold protein 3 decreases expression ISO entinostat results in decreased expression of DLG3 mRNA CTD PMID:27188386 NCBI chr  X:69,899,694...69,951,928
Ensembl chr  X:69,900,003...69,950,696 		JBrowse link
G Dlk1 delta like non-canonical Notch ligand 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA
entinostat results in decreased expression of DLK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529 		JBrowse link
G Dll1 delta like canonical Notch ligand 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA
entinostat results in decreased expression of DLL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:64,985,161...64,993,274
Ensembl chr 1:64,985,161...64,993,276 		JBrowse link
G Dlx4 distal-less homeobox 4 increases expression ISO entinostat results in increased expression of DLX4 mRNA CTD PMID:27188386 NCBI chr10:80,581,878...80,587,272
Ensembl chr10:80,582,303...80,587,294 		JBrowse link
G Dlx6 distal-less homeobox 6 decreases expression ISO entinostat results in decreased expression of DLX6 mRNA CTD PMID:26272509 NCBI chr 4:35,951,005...35,956,354
Ensembl chr 4:35,951,005...35,956,354 		JBrowse link
G Dmac2l distal membrane arm assembly component 2 like multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMAC2L mRNA
entinostat results in decreased expression of DMAC2L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:93,941,690...93,960,662 		JBrowse link
G Dmc1 DNA meiotic recombinase 1 increases expression ISO entinostat results in increased expression of DMC1 mRNA CTD PMID:27188386 NCBI chr 7:113,005,278...113,047,854
Ensembl chr 7:113,005,281...113,047,854 		JBrowse link
G Dmrt1 doublesex and mab-3 related transcription factor 1 increases expression ISO entinostat results in increased expression of DMRT1 mRNA CTD PMID:27188386 NCBI chr 1:232,569,179...232,667,646
Ensembl chr 1:232,569,072...232,668,370 		JBrowse link
G Dmrt3 doublesex and mab-3 related transcription factor 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DMRT3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMRT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:232,670,642...232,690,557
Ensembl chr 1:232,675,059...232,688,833 		JBrowse link
G Dmxl1 Dmx-like 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of DMXL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMXL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:45,179,505...45,349,999
Ensembl chr18:45,179,551...45,356,406 		JBrowse link
G Dnai1 dynein, axonemal, intermediate chain 1 increases expression ISO entinostat results in increased expression of DNAI1 mRNA CTD PMID:27188386 NCBI chr 5:61,526,079...61,596,806
Ensembl chr 5:61,525,999...61,596,810 		JBrowse link
G Dnajb12 DnaJ heat shock protein family (Hsp40) member B12 increases expression ISO entinostat results in increased expression of DNAJB12 mRNA CTD PMID:27188386 NCBI chr20:28,371,180...28,389,390
Ensembl chr20:28,371,199...28,389,389 		JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 increases expression
multiple interactions 		ISO entinostat results in increased expression of DNAJB6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:6,010,081...6,232,052
Ensembl chr 4:6,128,070...6,232,005 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of DNAJC18 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNAJC18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:27,543,438...27,577,535
Ensembl chr18:27,543,438...27,577,535 		JBrowse link
G Dnase1l3 deoxyribonuclease 1L3 increases expression ISO entinostat results in increased expression of DNASE1L3 mRNA CTD PMID:27188386 NCBI chr15:19,351,683...19,378,536
Ensembl chr15:19,352,493...19,378,531 		JBrowse link
G Dnase2 deoxyribonuclease 2, lysosomal increases expression ISO entinostat results in increased expression of DNASE2 mRNA CTD PMID:27188386 NCBI chr19:40,149,505...40,152,225
Ensembl chr19:40,149,505...40,152,225 		JBrowse link
G Dner delta/notch-like EGF repeat containing increases expression
multiple interactions 		ISO entinostat results in increased expression of DNER mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568 		JBrowse link
G Dnm1 dynamin 1 increases expression ISO entinostat results in increased expression of DNM1 mRNA CTD PMID:27188386 NCBI chr 3:36,002,535...36,055,220
Ensembl chr 3:36,002,064...36,046,289 		JBrowse link
G Dnm3 dynamin 3 increases expression ISO entinostat results in increased expression of DNM3 mRNA CTD PMID:27188386 NCBI chr13:76,892,381...77,371,346
Ensembl chr13:76,892,171...77,371,350 		JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions EXP [Azacitidine co-treated with entinostat] results in decreased expression of DNMT1 protein CTD PMID:21224363 NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119 		JBrowse link
G Dnmt3b DNA methyltransferase 3 beta increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of DNMT3B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNMT3B mRNA
entinostat results in decreased expression of DNMT3B protein 		CTD PMID:19679824 PMID:26272509 PMID:27188386 NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313 		JBrowse link
G Doc2a double C2 domain alpha multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOC2A mRNA CTD PMID:27188386 NCBI chr 1:190,887,306...190,893,057
Ensembl chr 1:190,888,214...190,893,384 		JBrowse link
G Dock2 dedicator of cytokinesis 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK2 mRNA
entinostat results in increased expression of DOCK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:19,331,412...19,748,987
Ensembl chr10:19,331,412...19,748,969 		JBrowse link
G Dock5 dedicator of cytokinesis 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA
entinostat results in increased expression of DOCK5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:46,155,124...46,334,127
Ensembl chr15:46,155,125...46,334,042 		JBrowse link
G Dock6 dedicator of cytokinesis 6 increases expression ISO entinostat results in increased expression of DOCK6 mRNA CTD PMID:27188386 NCBI chr 8:28,618,523...28,670,741
Ensembl chr 8:28,618,523...28,670,648 		JBrowse link
G Dock7 dedicator of cytokinesis 7 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA
entinostat results in decreased expression of DOCK7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:118,714,863...118,898,362
Ensembl chr 5:118,714,863...118,898,335 		JBrowse link
G Dok6 docking protein 6 decreases expression ISO entinostat results in decreased expression of DOK6 mRNA CTD PMID:27188386 NCBI chr18:84,847,491...85,290,647
Ensembl chr18:84,847,491...85,290,647 		JBrowse link
G Dpep3 dipeptidase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPEP3 mRNA
entinostat results in increased expression of DPEP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:50,778,079...50,786,451
Ensembl chr19:50,777,579...50,783,741 		JBrowse link
G Dpp4 dipeptidylpeptidase 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPP4 mRNA
entinostat results in increased expression of DPP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422 		JBrowse link
G Dppa2 developmental pluripotency-associated 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of DPPA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:66,008,002...66,020,044
Ensembl chr11:66,011,628...66,020,994 		JBrowse link
G Dppa5 developmental pluripotency associated 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA
entinostat results in increased expression of DPPA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:88,095,627...88,097,936
Ensembl chr 1:14,260,684...14,261,146 		JBrowse link
G Dpt dermatopontin increases expression ISO entinostat results in increased expression of DPT mRNA CTD PMID:27188386 NCBI chr13:79,656,341...79,684,759
Ensembl chr13:79,655,985...79,684,758 		JBrowse link
G Dram1 DNA-damage regulated autophagy modulator 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRAM1 mRNA
entinostat results in increased expression of DRAM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:24,630,233...24,665,270
Ensembl chr 7:24,630,238...24,664,354 		JBrowse link
G Drc12 dynein regulatory complex subunit 12 homolog increases expression ISO entinostat results in increased expression of DRC12 mRNA CTD PMID:27188386 NCBI chr 8:53,468,344...53,481,168
Ensembl chr 8:53,472,849...53,486,567 		JBrowse link
G Dsg4 desmoglein 4 increases expression ISO entinostat results in increased expression of DSG4 mRNA CTD PMID:27188386 NCBI chr18:11,995,902...12,032,908
Ensembl chr18:11,995,902...12,032,908 		JBrowse link
G Duox2 dual oxidase 2 increases expression ISO entinostat results in increased expression of DUOX2 mRNA CTD PMID:27188386 NCBI chr 3:129,680,543...129,698,886
Ensembl chr 3:129,680,546...129,699,203 		JBrowse link
G Dusp10 dual specificity phosphatase 10 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA
entinostat results in increased expression of DUSP10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304 		JBrowse link
G Dusp16 dual specificity phosphatase 16 decreases expression ISO entinostat results in decreased expression of DUSP16 mRNA CTD PMID:27188386 NCBI chr 4:169,278,118...169,361,508
Ensembl chr 4:169,278,118...169,361,508 		JBrowse link
G Dusp23 dual specificity phosphatase 23 increases expression ISO entinostat results in increased expression of DUSP23 mRNA CTD PMID:27188386 NCBI chr13:87,630,245...87,632,400
Ensembl chr13:87,630,245...87,632,400 		JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO entinostat results in decreased expression of DUSP4 mRNA CTD PMID:27188386 NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700 		JBrowse link
G Dusp5 dual specificity phosphatase 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of DUSP5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417 		JBrowse link
G Dync1li1 dynein cytoplasmic 1 light intermediate chain 1 decreases expression ISO entinostat results in decreased expression of DYNC1LI1 mRNA CTD PMID:27188386 NCBI chr 8:123,254,823...123,288,496
Ensembl chr 8:123,254,859...123,289,167 		JBrowse link
G Eaf2 ELL associated factor 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA
entinostat results in increased expression of EAF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:77,465,585...77,509,993
Ensembl chr11:77,406,020...77,509,993 		JBrowse link
G Ears2 glutamyl-tRNA synthetase 2, mitochondrial multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EARS2 mRNA
entinostat results in increased expression of EARS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:186,025,740...186,057,165 JBrowse link
G Ebf2 EBF transcription factor 2 decreases expression ISO entinostat results in decreased expression of EBF2 mRNA CTD PMID:27188386 NCBI chr15:45,610,949...45,809,828
Ensembl chr15:45,610,949...45,809,822 		JBrowse link
G Ebf3 EBF transcription factor 3 decreases expression ISO entinostat results in decreased expression of EBF3 mRNA CTD PMID:27188386 NCBI chr 1:201,426,446...201,544,444
Ensembl chr 1:201,426,450...201,544,305 		JBrowse link
G Ebi3 Epstein-Barr virus induced 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA
entinostat results in increased expression of EBI3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:861,441...874,731
Ensembl chr 9:870,792...874,973 		JBrowse link
G Ebpl EBP like increases expression ISO entinostat results in increased expression of EBPL mRNA CTD PMID:27188386 NCBI chr15:39,684,140...39,707,537
Ensembl chr15:39,684,140...39,707,537 		JBrowse link
G Ece1 endothelin converting enzyme 1 increases expression ISO entinostat results in increased expression of ECE1 mRNA CTD PMID:27188386 NCBI chr 5:155,361,031...155,462,723
Ensembl chr 5:155,360,639...155,462,719 		JBrowse link
G Echdc2 enoyl CoA hydratase domain containing 2 increases expression ISO entinostat results in increased expression of ECHDC2 mRNA CTD PMID:27188386 NCBI chr 5:128,144,241...128,163,611
Ensembl chr 5:128,144,425...128,163,610 		JBrowse link
G Eci2 enoyl-CoA delta isomerase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ECI2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ECI2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:30,056,274...30,092,169
Ensembl chr17:30,076,524...30,092,161 		JBrowse link
G Ecm2 extracellular matrix protein 2 decreases expression ISO entinostat results in decreased expression of ECM2 mRNA CTD PMID:27188386 NCBI chr17:15,326,359...15,358,938
Ensembl chr17:15,326,359...15,358,855 		JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ECPAS mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:78,398,449...78,509,077
Ensembl chr 5:78,398,718...78,512,908 		JBrowse link
G Ecrg4 ECRG4 augurin precursor increases expression
multiple interactions 		ISO entinostat results in increased expression of ECRG4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ECRG4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:53,485,040...53,504,691
Ensembl chr 9:53,485,040...53,504,703 		JBrowse link
G Eda ectodysplasin-A increases expression ISO entinostat results in increased expression of EDA mRNA CTD PMID:27188386 NCBI chr  X:69,118,577...69,520,274
Ensembl chr  X:69,118,796...69,520,274 		JBrowse link
G Edn1 endothelin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA
entinostat results in increased expression of EDN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
entinostat results in increased expression of EDNRB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765 		JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 increases expression ISO entinostat results in increased expression of EEF1A1 mRNA CTD PMID:27015953 NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072 		JBrowse link
G Eef1a2 eukaryotic translation elongation factor 1 alpha 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of EEF1A2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EEF1A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:188,643,455...188,652,633
Ensembl chr 3:188,643,458...188,677,712 		JBrowse link
G Efhb EF hand domain family, member B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of EFHB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:6,608,791...6,680,104
Ensembl chr 9:6,608,794...6,678,827 		JBrowse link
G Efhc2 EF-hand domain containing 2 increases expression ISO entinostat results in increased expression of EFHC2 mRNA CTD PMID:27188386 NCBI chr  X:7,943,603...8,144,073
Ensembl chr  X:7,943,725...8,144,215 		JBrowse link
G Efhd1 EF-hand domain family, member D1 increases expression ISO entinostat results in increased expression of EFHD1 mRNA CTD PMID:27188386 NCBI chr 9:95,386,155...95,432,800
Ensembl chr 9:95,386,169...95,432,798 		JBrowse link
G Efna1 ephrin A1 increases expression
multiple interactions 		ISO entinostat results in increased expression of EFNA1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726 		JBrowse link
G Efna5 ephrin A5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of EFNA5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:109,763,786...110,042,396
Ensembl chr 9:109,767,252...110,042,348 		JBrowse link
G Efnb2 ephrin B2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of EFNB2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208 		JBrowse link
G Efr3a EFR3 homolog A increases expression ISO entinostat results in increased expression of EFR3A mRNA CTD PMID:27188386 NCBI chr 7:99,441,764...99,522,454
Ensembl chr 7:99,441,767...99,522,454 		JBrowse link
G Egf epidermal growth factor decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of EGF mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA
entinostat results in increased expression of EGF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297 		JBrowse link
G Egfl7 EGF-like-domain, multiple 7 increases expression ISO entinostat results in increased expression of EGFL7 mRNA CTD PMID:27188386 NCBI chr 3:29,802,481...29,814,966
Ensembl chr 3:29,802,690...29,814,951 		JBrowse link
G Egflam EGF-like, fibronectin type III and laminin G domains increases expression ISO entinostat results in increased expression of EGFLAM mRNA CTD PMID:27188386 NCBI chr 2:58,029,934...58,204,010
Ensembl chr 2:58,029,935...58,203,643 		JBrowse link
G Egln1 egl-9 family hypoxia-inducible factor 1 decreases expression ISO entinostat results in decreased expression of EGLN1 mRNA CTD PMID:27188386 NCBI chr19:69,765,276...69,804,681 JBrowse link
G Egr1 early growth response 1 decreases expression ISO entinostat results in decreased expression of EGR1 mRNA CTD PMID:26272509 NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843 		JBrowse link
G Egr3 early growth response 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of EGR3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:51,560,482...51,565,778
Ensembl chr15:51,560,344...51,565,712 		JBrowse link
G Egr4 early growth response 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGR4 mRNA
entinostat results in decreased expression of EGR4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:119,605,358...119,607,817
Ensembl chr 4:119,605,357...119,608,368 		JBrowse link
G Ehbp1l1 EH domain binding protein 1-like 1 increases expression ISO entinostat results in increased expression of EHBP1L1 mRNA CTD PMID:27188386 NCBI chr 1:212,423,444...212,444,357
Ensembl chr 1:212,423,447...212,443,598 		JBrowse link
G Ehd2 EH-domain containing 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of EHD2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EHD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:85,767,757...85,786,974
Ensembl chr 1:85,768,667...85,786,943 		JBrowse link
G Ehd4 EH-domain containing 4 increases expression ISO entinostat results in increased expression of EHD4 mRNA CTD PMID:27188386 NCBI chr 3:127,511,973...127,575,856
Ensembl chr 3:127,511,954...127,576,072 		JBrowse link
G Eif2ak4 eukaryotic translation initiation factor 2 alpha kinase 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF2AK4 mRNA
entinostat results in increased expression of EIF2AK4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:125,810,207...125,895,574
Ensembl chr 3:125,810,060...125,895,574 		JBrowse link
G Eif3m eukaryotic translation initiation factor 3, subunit M decreases expression ISO entinostat results in decreased expression of EIF3M mRNA CTD PMID:26272509 NCBI chr 3:111,879,589...111,897,193
Ensembl chr 3:111,870,925...111,897,193 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF4EBP1 mRNA
entinostat results in increased expression of EIF4EBP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874 		JBrowse link
G Elapor1 endosome-lysosome associated apoptosis and autophagy regulator 1 increases expression ISO entinostat results in increased expression of ELAPOR1 mRNA CTD PMID:27188386 NCBI chr 2:198,777,323...198,856,497
Ensembl chr 2:198,777,323...198,856,497 		JBrowse link
G Elavl2 ELAV like RNA binding protein 2 decreases expression ISO entinostat results in decreased expression of ELAVL2 mRNA CTD PMID:27188386 NCBI chr 5:111,076,705...111,202,341
Ensembl chr 5:111,076,705...111,224,918 		JBrowse link
G Elavl3 ELAV like RNA binding protein 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of ELAVL3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELAVL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:28,823,120...28,859,395
Ensembl chr 8:28,825,707...28,859,659 		JBrowse link
G Elf3 E74 like ETS transcription factor 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA
entinostat results in increased expression of ELF3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:49,242,265...49,247,102
Ensembl chr13:49,242,267...49,247,380 		JBrowse link
G Elf4 E74 like ETS transcription factor 4 increases expression
multiple interactions 		ISO entinostat results in increased expression of ELF4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:132,465,290...132,508,175
Ensembl chr  X:132,468,539...132,478,689 		JBrowse link
G Elfn2 extracellular leucine-rich repeat and fibronectin type III domain containing 2 increases expression ISO entinostat results in increased expression of ELFN2 mRNA CTD PMID:32870474 NCBI chr 7:112,101,998...112,153,280
Ensembl chr 7:112,074,331...112,153,451 		JBrowse link
G Elk3 ETS transcription factor ELK3 increases expression
multiple interactions 		ISO entinostat results in increased expression of ELK3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:29,655,676...29,718,163
Ensembl chr 7:29,655,693...29,691,661 		JBrowse link
G Ell2 elongation factor for RNA polymerase II 2 increases expression ISO entinostat results in increased expression of ELL2 mRNA CTD PMID:27188386 NCBI chr 2:6,910,446...6,990,654
Ensembl chr 2:6,921,771...7,016,199 		JBrowse link
G Ell3 elongation factor for RNA polymerase II 3 increases expression ISO entinostat results in increased expression of ELL3 mRNA CTD PMID:26272509 NCBI chr 3:128,866,755...128,870,896
Ensembl chr 3:128,864,777...128,870,852 		JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:63,194,539...63,251,526
Ensembl chr 8:63,137,295...63,251,322 		JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 increases expression ISO entinostat results in increased expression of ELOVL2 mRNA CTD PMID:27188386 NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,750,350...23,790,601 		JBrowse link
G Elp4 elongator acetyltransferase complex subunit 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA
entinostat results in decreased expression of ELP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:112,617,020...112,839,963
Ensembl chr 3:112,617,035...112,839,963 		JBrowse link
G Emilin2 elastin microfibril interfacer 2 increases expression ISO entinostat results in increased expression of EMILIN2 mRNA CTD PMID:27188386 NCBI chr 9:118,607,312...118,667,087
Ensembl chr 9:118,606,891...118,666,957 		JBrowse link
G Eml6 EMAP like 6 increases expression ISO entinostat results in increased expression of EML6 mRNA CTD PMID:27188386 NCBI chr14:107,651,893...108,006,792
Ensembl chr14:107,699,400...108,005,409 		JBrowse link
G Emp1 epithelial membrane protein 1 increases expression ISO entinostat results in increased expression of EMP1 mRNA CTD PMID:27188386 NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365 		JBrowse link
G Emp2 epithelial membrane protein 2 increases expression ISO entinostat results in increased expression of EMP2 mRNA CTD PMID:27188386 NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,866,922...5,901,532 		JBrowse link
G Emsy EMSY transcriptional repressor, BRCA2 interacting multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMSY mRNA
entinostat results in decreased expression of EMSY mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:162,295,167...162,364,742
Ensembl chr 1:162,295,169...162,364,707 		JBrowse link
G Emx2 empty spiracles homeobox 2 decreases expression ISO entinostat results in decreased expression of EMX2 mRNA CTD PMID:26272509 NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:268,612,663...268,619,671 		JBrowse link
G Endod1 endonuclease domain containing 1 increases expression ISO entinostat results in increased expression of ENDOD1 mRNA CTD PMID:27188386 NCBI chr 8:19,490,615...19,520,007
Ensembl chr 8:19,490,615...19,520,007 		JBrowse link
G Eno2 enolase 2 increases expression ISO entinostat results in increased expression of ENO2 mRNA CTD PMID:22613180 NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220 		JBrowse link
G Eno3 enolase 3 increases expression ISO entinostat results in increased expression of ENO3 mRNA CTD PMID:27188386 NCBI chr10:55,868,880...55,876,099
Ensembl chr10:55,866,101...55,874,540 		JBrowse link
G Enpep glutamyl aminopeptidase decreases expression ISO entinostat results in decreased expression of ENPEP mRNA CTD PMID:26272509 NCBI chr 2:220,456,258...220,526,218
Ensembl chr 2:220,456,278...220,526,218 		JBrowse link
G Enpp4 ectonucleotide pyrophosphatase/phosphodiesterase 4 increases expression ISO entinostat results in increased expression of ENPP4 mRNA CTD PMID:27188386 NCBI chr 9:24,386,351...24,396,248
Ensembl chr 9:24,360,272...24,396,152 		JBrowse link
G Enpp5 ectonucleotide pyrophosphatase/phosphodiesterase family member 5 increases expression ISO entinostat results in increased expression of ENPP5 mRNA CTD PMID:27188386 NCBI chr 9:24,407,574...24,415,029
Ensembl chr 9:24,408,218...24,414,867 		JBrowse link
G Enpp6 ectonucleotide pyrophosphatase/phosphodiesterase 6 increases expression ISO entinostat results in increased expression of ENPP6 mRNA CTD PMID:27188386 NCBI chr16:51,898,557...52,026,789
Ensembl chr16:51,898,557...52,026,728 		JBrowse link
G Ensa endosulfine alpha decreases expression ISO entinostat results in decreased expression of ENSA mRNA CTD PMID:27188386 NCBI chr 2:185,874,500...185,881,838
Ensembl chr 2:185,874,500...185,881,838 		JBrowse link
G Entpd1 ectonucleoside triphosphate diphosphohydrolase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENTPD1 mRNA
entinostat results in increased expression of ENTPD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:249,374,810...249,502,310
Ensembl chr 1:249,374,836...249,502,317 		JBrowse link
G Eogt EGF domain specific O-linked N-acetylglucosamine transferase increases expression
multiple interactions 		ISO entinostat results in increased expression of EOGT mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:131,275,587...131,313,243
Ensembl chr 4:131,276,573...131,311,926 		JBrowse link
G Ep300 E1A binding protein p300 multiple interactions ISO entinostat promotes the reaction [EP300 protein binds to RELA protein] CTD PMID:20421217 NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574 		JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:116,502,864...116,707,274
Ensembl chr 9:116,462,807...116,707,274 		JBrowse link
G Epb41l4b erythrocyte membrane protein band 4.1 like 4B multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA
entinostat results in increased expression of EPB41L4B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:76,486,886...76,647,752
Ensembl chr 5:76,486,902...76,647,752 		JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA
entinostat results in increased expression of EPB41L5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:33,221,705...33,321,400
Ensembl chr13:33,223,589...33,321,133 		JBrowse link
G Epc1 enhancer of polycomb homolog 1 decreases expression ISO entinostat results in decreased expression of EPC1 mRNA CTD PMID:27188386 NCBI chr17:59,198,513...59,289,535
Ensembl chr17:59,197,677...59,289,519 		JBrowse link
G Epc2 enhancer of polycomb homolog 2 decreases expression ISO entinostat results in decreased expression of EPC2 mRNA CTD PMID:27188386 NCBI chr 3:54,276,187...54,376,373
Ensembl chr 3:54,276,239...54,376,916 		JBrowse link
G Epcam epithelial cell adhesion molecule multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA
entinostat results in increased expression of EPCAM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702 		JBrowse link
G Epha1 Eph receptor A1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA
entinostat results in increased expression of EPHA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:72,213,022...72,227,543
Ensembl chr 4:72,213,037...72,227,474 		JBrowse link
G Epha2 Eph receptor A2 increases expression ISO entinostat results in increased expression of EPHA2 mRNA CTD PMID:32870474 NCBI chr 5:158,888,629...158,917,100
Ensembl chr 5:158,888,629...158,917,234 		JBrowse link
G Epha3 Eph receptor A3 decreases expression ISO entinostat results in decreased expression of EPHA3 mRNA CTD PMID:27188386 NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425 		JBrowse link
G Epha4 Eph receptor A4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of EPHA4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755 		JBrowse link
G Epha7 Eph receptor A7 increases expression
multiple interactions 		ISO entinostat results in increased expression of EPHA7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:47,771,776...47,925,189
Ensembl chr 5:47,771,865...47,925,058 		JBrowse link
G Epha8 Eph receptor A8 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA8 mRNA
entinostat results in increased expression of EPHA8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:154,449,566...154,476,966
Ensembl chr 5:154,449,566...154,476,966 		JBrowse link
G Ephx3 epoxide hydrolase 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of EPHX3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:11,857,367...11,862,674
Ensembl chr 7:11,857,367...11,862,674 		JBrowse link
G Epor erythropoietin receptor multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPOR mRNA
entinostat results in increased expression of EPOR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:28,765,738...28,770,371
Ensembl chr 8:28,765,746...28,770,322 		JBrowse link
G Eps8l2 EPS8 signaling adaptor L2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA
entinostat results in increased expression of EPS8L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,875,825...205,901,109
Ensembl chr 1:205,875,801...205,901,101 		JBrowse link
G Epyc epiphycan increases expression ISO entinostat results in increased expression of EPYC mRNA CTD PMID:27188386 NCBI chr 7:34,323,332...34,360,845
Ensembl chr 7:34,323,273...34,361,032 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 decreases expression
increases expression
multiple interactions 		ISO entinostat results in decreased expression of ERAP1 mRNA
entinostat results in increased expression of ERAP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:5,666,436...5,740,056 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
entinostat results in increased expression of ERBB3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120 		JBrowse link
G Erc1 ELKS/RAB6-interacting/CAST family member 1 increases expression ISO entinostat results in increased expression of ERC1 mRNA CTD PMID:27188386 NCBI chr 4:154,435,936...154,727,987
Ensembl chr 4:154,435,944...154,727,987 		JBrowse link
G Erfe erythroferrone increases expression
multiple interactions 		ISO entinostat results in increased expression of ERFE mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERFE mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:99,404,512...99,412,383
Ensembl chr 9:99,404,514...99,412,383 		JBrowse link
G Erich1 glutamate-rich 1 increases expression ISO entinostat results in increased expression of ERICH1 mRNA CTD PMID:27188386 NCBI chr16:82,203,536...82,271,361
Ensembl chr16:82,203,610...82,272,989 		JBrowse link
G Erp27 endoplasmic reticulum protein 27 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ERP27 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERP27 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,535,845...171,552,848
Ensembl chr 4:171,535,847...171,553,072 		JBrowse link
G Erp44 endoplasmic reticulum protein 44 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ERP44 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERP44 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:67,313,245...67,406,207
Ensembl chr 5:67,312,098...67,406,444 		JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of ESRP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:29,224,831...29,279,381
Ensembl chr 5:29,225,360...29,279,278 		JBrowse link
G Esrp2 epithelial splicing regulatory protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA
entinostat results in increased expression of ESRP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:50,944,401...50,951,919
Ensembl chr19:50,944,401...50,951,568 		JBrowse link
G Esx1 ESX homeobox 1 increases expression ISO entinostat results in increased expression of ESX1 mRNA CTD PMID:27188386 NCBI chr  X:105,241,568...105,246,733 JBrowse link
G Esyt3 extended synaptotagmin 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESYT3 mRNA
entinostat results in increased expression of ESYT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:108,749,761...108,796,630
Ensembl chr 8:108,750,489...108,796,572 		JBrowse link
G Etl4 enhancer trap locus 4 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1217 mRNA CTD PMID:27188386 NCBI chr17:87,749,486...88,213,158
Ensembl chr17:87,403,819...88,213,158 		JBrowse link
G Etnk1 ethanolamine kinase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA
entinostat results in increased expression of ETNK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:177,857,001...177,901,278
Ensembl chr 4:177,856,960...177,924,721 		JBrowse link
G Etnppl ethanolamine-phosphate phospho-lyase increases expression
multiple interactions 		ISO entinostat results in increased expression of ETNPPL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNPPL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:221,847,210...221,868,827
Ensembl chr 2:221,847,250...221,866,357 		JBrowse link
G Etv1 ETS variant transcription factor 1 decreases expression ISO entinostat results in decreased expression of ETV1 mRNA CTD PMID:27188386 NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:61,317,429...61,408,959 		JBrowse link
G Etv4 ETS variant transcription factor 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETV4 mRNA
entinostat results in increased expression of ETV4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:87,206,977...87,222,202
Ensembl chr10:87,206,977...87,222,318 		JBrowse link
G Exosc6 exosome component 6 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EXOSC6 mRNA CTD PMID:27188386 NCBI chr19:55,931,523...55,932,937
Ensembl chr19:55,931,523...55,932,937 		JBrowse link
G Exph5 exophilin 5 increases expression ISO entinostat results in increased expression of EXPH5 mRNA CTD PMID:27188386 NCBI chr 8:62,595,116...62,671,575
Ensembl chr 8:62,595,116...62,671,575 		JBrowse link
G Eya4 EYA transcriptional coactivator and phosphatase 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EYA4 mRNA
entinostat results in decreased expression of EYA4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:23,991,431...24,235,132
Ensembl chr 1:23,991,431...24,235,131 		JBrowse link
G Ezr ezrin increases expression
multiple interactions 		ISO entinostat results in increased expression of EZR mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:49,373,035...49,416,573 		JBrowse link
G F12 coagulation factor XII increases expression ISO entinostat results in increased expression of F12 mRNA CTD PMID:27188386 NCBI chr17:9,212,819...9,220,664
Ensembl chr17:9,212,819...9,220,664 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of F2RL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954 		JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of F2RL2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:28,706,501...28,712,473 		JBrowse link
G F5 coagulation factor V increases expression
multiple interactions 		ISO entinostat results in increased expression of F5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:79,046,657...79,116,247
Ensembl chr13:79,046,448...79,116,247 		JBrowse link
G Fa2h fatty acid 2-hydroxylase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FA2H mRNA
entinostat results in increased expression of FA2H mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:56,222,240...56,273,480
Ensembl chr19:56,222,242...56,273,623 		JBrowse link
G Fabp1 fatty acid binding protein 1 decreases expression ISO entinostat results in decreased expression of FABP1 mRNA CTD PMID:27188386 NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113 		JBrowse link
G Fabp3 fatty acid binding protein 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA
entinostat results in increased expression of FABP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881 		JBrowse link
G Fabp6 fatty acid binding protein 6 decreases expression ISO entinostat results in decreased expression of FABP6 mRNA CTD PMID:27188386 NCBI chr10:28,565,054...28,569,727
Ensembl chr10:28,565,054...28,573,058 		JBrowse link
G Faim Fas apoptotic inhibitory molecule decreases expression ISO entinostat results in decreased expression of FAIM mRNA CTD PMID:27188386 NCBI chr 8:108,423,259...108,445,365
Ensembl chr 8:108,423,221...108,440,151 		JBrowse link
G Fam110c family with sequence similarity 110, member C increases expression
multiple interactions 		ISO entinostat results in increased expression of FAM110C mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:53,366,013...53,372,270
Ensembl chr 6:53,352,870...53,401,117 		JBrowse link
G Fam111a FAM111 trypsin like peptidase A increases expression ISO entinostat results in increased expression of FAM111A mRNA CTD PMID:27188386 NCBI chr 1:219,065,542...219,081,213
Ensembl chr 1:219,065,601...219,081,211 		JBrowse link
G Fam114a1 family with sequence similarity 114, member A1 increases expression
multiple interactions 		ISO entinostat results in increased expression of FAM114A1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM114A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:43,629,349...43,699,800
Ensembl chr14:43,629,375...43,699,800 		JBrowse link
G Fam149a family with sequence similarity 149, member A increases expression ISO entinostat results in increased expression of FAM149A mRNA CTD PMID:27188386 NCBI chr16:53,587,841...53,647,072
Ensembl chr16:53,587,841...53,647,072 		JBrowse link
G Fam162a family with sequence similarity 162, member A increases expression
multiple interactions 		ISO entinostat results in increased expression of FAM162A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:78,186,260...78,215,186
Ensembl chr11:78,185,852...78,216,560 		JBrowse link
G Fam163a family with sequence similarity 163, member A increases expression ISO entinostat results in increased expression of FAM163A mRNA CTD PMID:27188386 NCBI chr13:70,813,129...70,891,410
Ensembl chr13:70,813,134...70,891,316 		JBrowse link
G Fam181b family with sequence similarity 181, member B increases expression
multiple interactions 		ISO entinostat results in increased expression of FAM181B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM181B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:156,578,821...156,580,318
Ensembl chr 1:156,491,094...156,595,845 		JBrowse link
G Fam20a FAM20A, golgi associated secretory pathway pseudokinase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM20A mRNA
entinostat results in increased expression of FAM20A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:95,136,799...95,197,176
Ensembl chr10:95,142,458...95,197,053 		JBrowse link
G Fam20c FAM20C, golgi associated secretory pathway kinase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM20C mRNA
entinostat results in increased expression of FAM20C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:20,940,654...20,999,072
Ensembl chr12:20,940,654...20,998,318 		JBrowse link
G Fam210b family with sequence similarity 210, member B increases expression ISO entinostat results in increased expression of FAM210B mRNA CTD PMID:27188386 NCBI chr 3:181,536,665...181,546,830
Ensembl chr 3:181,536,673...181,546,834 		JBrowse link
G Fam222a family with sequence similarity 222, member A multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA
entinostat results in decreased expression of FAM222A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:47,647,221...47,693,703
Ensembl chr12:47,647,405...47,693,703 		JBrowse link
G Fam241a family with sequence similarity 241 member A multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA
entinostat results in increased expression of FAM241A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:219,019,025...219,049,648
Ensembl chr 2:219,018,241...219,049,770 		JBrowse link
G Fam24b family with sequence similarity 24 member B increases expression
multiple interactions 		ISO entinostat results in increased expression of FAM24B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM24B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:195,542,729...195,546,140
Ensembl chr 1:195,542,729...195,546,140 		JBrowse link
G Fam3b FAM3 metabolism regulating signaling molecule B increases expression
multiple interactions 		ISO entinostat results in increased expression of FAM3B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:50,300,926...50,333,296
Ensembl chr11:50,300,926...50,347,339 		JBrowse link
G Fam43a family with sequence similarity 43, member A increases expression
multiple interactions 		ISO entinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297 		JBrowse link
G Fam43b family with sequence similarity 43, member B increases expression ISO entinostat results in increased expression of FAM43B mRNA CTD PMID:27188386 NCBI chr 5:155,893,961...155,896,359
Ensembl chr 5:155,893,968...155,898,755 		JBrowse link
G Fam50b family with sequence similarity 50, member B increases expression ISO entinostat results in increased expression of FAM50B mRNA CTD PMID:27188386 NCBI chr17:30,379,796...30,399,399
Ensembl chr17:30,379,171...30,399,651 		JBrowse link
G Fam78a family with sequence similarity 78, member A multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM78A mRNA
entinostat results in increased expression of FAM78A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:35,753,712...35,771,600
Ensembl chr 3:35,753,712...35,770,448 		JBrowse link
G Fank1 fibronectin type III and ankyrin repeat domains 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA
entinostat results in decreased expression of FANK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:198,007,496...198,114,790
Ensembl chr 1:198,007,547...198,115,561 		JBrowse link
G Far2 fatty acyl CoA reductase 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FAR2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:182,705,499...182,819,290
Ensembl chr 4:182,705,381...182,825,279 		JBrowse link
G Farp1 FERM, ARH/RhoGEF and pleckstrin domain protein 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FARP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FARP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:104,531,196...104,770,148
Ensembl chr15:104,531,813...104,770,147 		JBrowse link
G Farp2 FERM, ARH/RhoGEF and pleckstrin domain protein 2 increases expression ISO entinostat results in increased expression of FARP2 mRNA CTD PMID:27188386 NCBI chr 9:101,501,061...101,609,092
Ensembl chr 9:101,501,102...101,609,086 		JBrowse link
G Fas Fas cell surface death receptor increases expression ISO entinostat results in increased expression of FAS mRNA CTD PMID:27188386 NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104 		JBrowse link
G Fat3 FAT atypical cadherin 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FAT3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:20,972,840...21,555,679
Ensembl chr 8:20,972,840...21,555,240 		JBrowse link
G Faxc failed axon connections homolog, metaxin like GST domain containing decreases expression ISO entinostat results in decreased expression of FAXC mRNA CTD PMID:27188386 NCBI chr 5:40,277,167...40,336,503
Ensembl chr 5:40,277,135...40,344,076 		JBrowse link
G Fblim1 filamin binding LIM protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA
entinostat results in increased expression of FBLIM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:159,167,004...159,198,578
Ensembl chr 5:159,167,004...159,196,853 		JBrowse link
G Fbll1 fibrillarin-like 1 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of FBLL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLL1 mRNA
entinostat results in decreased expression of FBLL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:20,762,716...20,764,359
Ensembl chr10:20,761,581...20,764,670 		JBrowse link
G Fbln2 fibulin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of FBLN2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:125,261,464...125,321,030
Ensembl chr 4:125,261,607...125,321,029 		JBrowse link
G Fbln5 fibulin 5 increases expression ISO entinostat results in increased expression of FBLN5 mRNA CTD PMID:27188386 NCBI chr 6:126,664,100...126,742,847
Ensembl chr 6:126,664,100...126,746,296 		JBrowse link
G Fbln7 fibulin 7 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FBLN7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:136,564,825...136,601,205
Ensembl chr 3:136,564,917...136,601,198 		JBrowse link
G Fbn1 fibrillin 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FBN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:133,007,693...133,204,277
Ensembl chr 3:133,008,361...133,204,283 		JBrowse link
G Fbn2 fibrillin 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FBN2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:53,696,197...53,901,992
Ensembl chr18:53,697,708...53,902,191 		JBrowse link
G Fbxl13 F-box and leucine-rich repeat protein 13 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA
entinostat results in increased expression of FBXL13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:14,307,032...14,505,491
Ensembl chr 4:14,307,096...14,499,585 		JBrowse link
G Fbxl14 F-box and leucine-rich repeat protein 14 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA
entinostat results in decreased expression of FBXL14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:154,334,820...154,338,638
Ensembl chr 4:154,334,092...154,377,959 		JBrowse link
G Fbxl16 F-box and leucine-rich repeat protein 16 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL16 mRNA
entinostat results in increased expression of FBXL16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:15,333,996...15,346,253
Ensembl chr10:15,334,014...15,346,232 		JBrowse link
G Fbxl17 F-box and leucine-rich repeat protein 17 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA
entinostat results in decreased expression of FBXL17 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:110,227,609...110,666,184
Ensembl chr 9:110,227,609...110,653,980 		JBrowse link
G Fbxl21 F-box and leucine-rich repeat protein 21 increases expression
multiple interactions 		ISO entinostat results in increased expression of FBXL21P mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL21P mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:8,063,731...8,082,920
Ensembl chr17:8,066,565...8,078,644 		JBrowse link
G Fbxl3 F-box and leucine-rich repeat protein 3 decreases expression ISO entinostat results in decreased expression of FBXL3 mRNA CTD PMID:27188386 NCBI chr15:86,321,504...86,341,387
Ensembl chr15:86,321,504...86,341,387 		JBrowse link
G Fbxl8 F-box and leucine-rich repeat protein 8 increases expression ISO entinostat results in increased expression of FBXL8 mRNA CTD PMID:32870474 NCBI chr19:50,048,221...50,057,191
Ensembl chr19:50,052,393...50,057,453 		JBrowse link
G Fbxo16 F-box protein 16 increases expression ISO entinostat results in increased expression of FBXO16 mRNA CTD PMID:27188386 NCBI chr15:43,667,207...43,717,096
Ensembl chr15:43,667,855...43,734,346 		JBrowse link
G Fbxo2 F-box protein 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA
entinostat results in increased expression of FBXO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:163,875,757...163,881,508 		JBrowse link
G Fbxo9 f-box protein 9 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA
entinostat results in decreased expression of FBXO9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:87,838,787...87,864,362
Ensembl chr 8:87,838,789...87,864,504 		JBrowse link
G Fcf1 Fcf1 rRNA-processing protein decreases expression ISO entinostat results in decreased expression of FCF1 mRNA CTD PMID:27188386 NCBI chr 6:110,348,854...110,360,715
Ensembl chr 6:110,348,845...110,372,221 		JBrowse link
G Fdft1 farnesyl diphosphate farnesyl transferase 1 decreases expression ISO entinostat results in decreased expression of FDFT1 mRNA CTD PMID:27188386 NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168 		JBrowse link
G Fdxr ferredoxin reductase increases expression
multiple interactions 		ISO entinostat results in increased expression of FDXR mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FDXR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:101,006,845...101,015,582
Ensembl chr10:101,006,849...101,015,542 		JBrowse link
G Fech ferrochelatase increases expression ISO entinostat results in increased expression of FECH mRNA CTD PMID:27188386 NCBI chr18:60,215,325...60,248,525
Ensembl chr18:60,215,325...60,249,546 		JBrowse link
G Fer1l4 fer-1-like family member 4 increases expression ISO entinostat results in increased expression of FER1L4 mRNA CTD PMID:27188386 NCBI chr 3:164,996,183...165,031,719
Ensembl chr 3:164,996,183...165,031,719 		JBrowse link
G Fermt1 FERM domain containing kindlin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of FERMT1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:140,624,434...140,666,419
Ensembl chr 3:140,624,434...140,666,419 		JBrowse link
G Fermt3 FERM domain containing kindlin 3 decreases expression ISO entinostat results in decreased expression of FERMT3 mRNA CTD PMID:27188386 NCBI chr 1:213,618,691...213,636,889
Ensembl chr 1:213,618,208...213,636,273 		JBrowse link
G Fezf2 Fez family zinc finger 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA
entinostat results in decreased expression of FEZF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:15,199,045...15,207,982
Ensembl chr15:15,204,193...15,207,982 		JBrowse link
G Fgd5 FYVE, RhoGEF and PH domain containing 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGD5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:126,054,201...126,151,698
Ensembl chr 4:126,054,210...126,151,697 		JBrowse link
G Fgf11 fibroblast growth factor 11 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF11 mRNA
entinostat results in increased expression of FGF11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:55,015,232...55,020,773
Ensembl chr10:55,016,411...55,020,454 		JBrowse link
G Fgf18 fibroblast growth factor 18 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGF18 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:18,210,240...18,241,929
Ensembl chr10:18,210,512...18,240,933 		JBrowse link
G Fgf19 fibroblast growth factor 19 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGF19 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267 		JBrowse link
G Fgf2 fibroblast growth factor 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGF2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493 		JBrowse link
G Fgf4 fibroblast growth factor 4 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGF4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:209,453,229...209,457,085
Ensembl chr 1:209,453,229...209,457,085 		JBrowse link
G Fgf8 fibroblast growth factor 8 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA
entinostat results in decreased expression of FGF8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605 		JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA
entinostat results in decreased expression of FGF9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926 		JBrowse link
G Fgfbp3 fibroblast growth factor binding protein 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGFBP3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:244,056,569...244,058,574
Ensembl chr 1:244,056,307...244,065,654 		JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGFR1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855 		JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of FGFR3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209 		JBrowse link
G Fhl1 four and a half LIM domains 1 increases expression ISO entinostat results in increased expression of FHL1 mRNA CTD PMID:27188386 NCBI chr  X:139,592,794...139,652,290
Ensembl chr  X:139,592,604...139,652,282 		JBrowse link
G Fhod1 formin homology 2 domain containing 1 increases expression ISO entinostat results in increased expression of FHOD1 mRNA CTD PMID:27188386 NCBI chr19:50,116,415...50,135,868
Ensembl chr19:50,116,415...50,135,330 		JBrowse link
G Fibcd1 fibrinogen C domain containing 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FIBCD1 mRNA
entinostat results in increased expression of FIBCD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:35,490,459...35,524,142
Ensembl chr 3:35,490,459...35,524,142 		JBrowse link
G Fibin fin bud initiation factor homolog increases expression ISO entinostat results in increased expression of FIBIN mRNA CTD PMID:32870474 NCBI chr 3:117,396,973...117,399,244
Ensembl chr 3:117,391,724...117,399,479 		JBrowse link
G Filip1 filamin A interacting protein 1 decreases expression ISO entinostat results in decreased expression of FILIP1 mRNA CTD PMID:26272509 NCBI chr 8:89,641,509...89,836,772
Ensembl chr 8:89,644,579...89,802,771 		JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FJX1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:109,229,223...109,231,324
Ensembl chr 3:109,227,170...109,232,479 		JBrowse link
G Fkbp11 FKBP prolyl isomerase 11 increases expression
multiple interactions 		ISO entinostat results in increased expression of FKBP11 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:131,750,828...131,757,784
Ensembl chr 7:131,750,672...131,770,123 		JBrowse link
G Fkbp14 FKBP prolyl isomerase 14 increases expression ISO entinostat results in increased expression of FKBP14 mRNA CTD PMID:27188386 NCBI chr 4:85,035,840...85,051,917
Ensembl chr 4:85,037,145...85,051,808 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of FKBP5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118 		JBrowse link
G Fkbp7 FKBP prolyl isomerase 7 increases expression ISO entinostat results in increased expression of FKBP7 mRNA CTD PMID:27188386 NCBI chr 3:82,016,647...82,030,913
Ensembl chr 3:82,016,513...82,028,573 		JBrowse link
G Fkbp9 FKBP prolyl isomerase 9 increases expression ISO entinostat results in increased expression of FKBP9 mRNA CTD PMID:27188386 NCBI chr 4:87,436,439...87,486,909
Ensembl chr 4:87,436,478...87,508,940 		JBrowse link
G Flnb filamin B multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA
entinostat results in increased expression of FLNB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:19,392,212...19,525,278
Ensembl chr15:19,392,216...19,525,209 		JBrowse link
G Flrt1 fibronectin leucine rich transmembrane protein 1 increases expression ISO entinostat results in increased expression of FLRT1 mRNA CTD PMID:27188386 NCBI chr 1:213,704,983...213,782,958
Ensembl chr 1:213,704,038...213,782,981 		JBrowse link
G Flrt2 fibronectin leucine rich transmembrane protein 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FLRT2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004 		JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of FLT1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750 		JBrowse link
G Fmc1 formation of mitochondrial complex V assembly factor 1 decreases expression ISO entinostat results in decreased expression of FMC1 mRNA CTD PMID:27188386 NCBI chr 4:68,241,009...68,249,045
Ensembl chr 4:68,241,009...68,268,534 		JBrowse link
G Fmn1 formin 1 increases expression ISO entinostat results in increased expression of FMN1 mRNA CTD PMID:27188386 NCBI chr 3:120,555,445...120,939,978
Ensembl chr 3:120,555,431...120,933,124 		JBrowse link
G Fmo4 flavin containing dimethylaniline monoxygenase 4 increases expression ISO entinostat results in increased expression of FMO4 mRNA CTD PMID:27188386 NCBI chr13:77,687,909...77,706,100
Ensembl chr13:77,687,909...77,706,100 		JBrowse link
G Fmo5 flavin containing dimethylaniline monoxygenase 5 decreases expression ISO entinostat results in decreased expression of FMO5 mRNA CTD PMID:27188386 NCBI chr 2:187,885,741...187,938,468
Ensembl chr 2:187,910,964...187,938,464 		JBrowse link
G Fmod fibromodulin increases expression ISO entinostat results in increased expression of FMOD mRNA CTD PMID:27188386 NCBI chr13:48,045,567...48,056,184
Ensembl chr13:47,990,774...48,056,183 		JBrowse link
G Fn1 fibronectin 1 increases expression ISO entinostat results in increased expression of FN1 mRNA CTD PMID:27188386 NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137 		JBrowse link
G Fndc1 fibronectin type III domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of FNDC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FNDC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:49,686,856...49,769,263
Ensembl chr 1:49,686,856...49,769,263 		JBrowse link
G Fndc3a fibronectin type III domain containing 3a decreases expression ISO entinostat results in decreased expression of FNDC3A mRNA CTD PMID:27188386 NCBI chr15:54,099,510...54,276,963
Ensembl chr15:54,099,510...54,276,407 		JBrowse link
G Fndc3b fibronectin type III domain containing 3B increases expression ISO entinostat results in increased expression of FNDC3B mRNA CTD PMID:27188386 NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:112,243,202...112,546,306 		JBrowse link
G Fntb farnesyltransferase, CAAX box, subunit beta increases expression ISO entinostat results in increased expression of FNTB mRNA CTD PMID:27188386 NCBI chr 6:101,269,657...101,352,716
Ensembl chr 6:101,269,671...101,352,716 		JBrowse link
G Folr1 folate receptor alpha decreases expression ISO entinostat results in decreased expression of FOLR1 mRNA CTD PMID:39237058 NCBI chr 1:165,631,462...165,650,430
Ensembl chr 1:165,631,462...165,642,669 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression ISO entinostat results in decreased expression of FOS mRNA CTD PMID:26272509 NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA
entinostat results in increased expression of FOSL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391 		JBrowse link
G Foxd1 forkhead box D1 increases expression ISO entinostat results in increased expression of FOXD1 mRNA CTD PMID:27188386 NCBI chr 2:31,436,802...31,439,222
Ensembl chr 2:31,436,813...31,439,399 		JBrowse link
G Foxd3 forkhead box D3 increases expression
multiple interactions 		ISO entinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:119,450,532...119,452,898
Ensembl chr 5:119,450,394...119,452,786 		JBrowse link
G Foxg1 forkhead box G1 decreases expression ISO entinostat results in decreased expression of FOXG1 mRNA CTD PMID:26272509 NCBI chr 6:72,401,582...72,404,392
Ensembl chr 6:72,394,239...72,427,392 		JBrowse link
G Foxh1 forkhead box H1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA
entinostat results in increased expression of FOXH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:110,268,608...110,272,105
Ensembl chr 7:110,268,612...110,270,692 		JBrowse link
G Foxj1 forkhead box J1 increases expression
multiple interactions 		ISO entinostat results in increased expression of FOXJ1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXJ1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:102,065,163...102,069,945
Ensembl chr10:102,065,170...102,069,241 		JBrowse link
G Foxl2 forkhead box L2 increases expression ISO entinostat results in increased expression of FOXL2 mRNA CTD PMID:27188386 NCBI chr 8:108,392,466...108,395,553
Ensembl chr 8:108,382,872...108,396,835 		JBrowse link
G Foxo1 forkhead box O1 increases expression
multiple interactions 		ISO entinostat results in increased expression of FOXO1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419 		JBrowse link
G Foxred2 FAD-dependent oxidoreductase domain containing 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of FOXRED2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXRED2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:111,402,322...111,419,056
Ensembl chr 7:111,402,322...111,417,988 		JBrowse link
G Fras1 Fraser extracellular matrix complex subunit 1 increases expression ISO entinostat results in increased expression of FRAS1 mRNA CTD PMID:27188386 NCBI chr14:13,095,370...13,506,895
Ensembl chr14:13,095,370...13,504,664 		JBrowse link
G Frat2 FRAT regulator of WNT signaling pathway 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of FRAT2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FRAT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:250,603,450...250,605,779
Ensembl chr 1:250,603,088...250,606,921 		JBrowse link
G Frmd4a FERM domain containing 4A decreases expression ISO entinostat results in decreased expression of FRMD4A mRNA CTD PMID:27188386 NCBI chr17:78,577,062...79,167,924
Ensembl chr17:78,579,277...79,167,663 		JBrowse link
G Frrs1l ferric-chelate reductase 1-like multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA
entinostat results in decreased expression of FRRS1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:76,451,101...76,485,319
Ensembl chr 5:76,451,101...76,485,316 		JBrowse link
G Fry FRY microtubule binding protein decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FRY mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRY mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603 		JBrowse link
G Fsd1l fibronectin type III and SPRY domain containing 1-like multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA CTD PMID:27188386 NCBI chr 5:73,052,565...73,130,292
Ensembl chr 5:73,054,274...73,130,292 		JBrowse link
G Fst follistatin multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FST mRNA CTD PMID:27188386 NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:47,856,345...47,863,491 		JBrowse link
G Fstl1 follistatin-like 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FSTL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSTL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:76,400,870...76,454,053
Ensembl chr11:76,391,315...76,455,126 		JBrowse link
G Ftx FTX transcript, XIST regulator increases expression ISO entinostat results in increased expression of FTX mRNA CTD PMID:26272509 NCBI chr  X:72,654,112...72,696,097 JBrowse link
G Fus Fus RNA binding protein decreases expression ISO entinostat results in decreased expression of FUS mRNA CTD PMID:27188386 NCBI chr 1:192,007,011...192,020,887
Ensembl chr 1:192,007,006...192,020,884 		JBrowse link
G Fut4 fucosyltransferase 4 increases expression
multiple interactions 		ISO entinostat results in increased expression of FUT4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436 		JBrowse link
G Fxr1 FMR1 autosomal homolog 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FXR1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FXR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:118,812,287...118,865,813
Ensembl chr 2:118,811,980...118,867,027 		JBrowse link
G Fxyd5 FXYD domain-containing ion transport regulator 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FXYD5 mRNA
entinostat results in increased expression of FXYD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:95,395,327...95,404,722
Ensembl chr 1:95,395,146...95,405,364 		JBrowse link
G Fxyd7 FXYD domain-containing ion transport regulator 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FXYD7 mRNA
entinostat results in increased expression of FXYD7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:95,405,071...95,414,407
Ensembl chr 1:95,405,225...95,414,345 		JBrowse link
G Fzd10 frizzled class receptor 10 increases expression ISO entinostat results in increased expression of FZD10 mRNA CTD PMID:26272509 NCBI chr12:33,734,364...33,737,559
Ensembl chr12:33,734,364...33,741,646 		JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA
entinostat results in decreased expression of FZD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:88,061,988...88,063,898
Ensembl chr10:88,061,667...88,065,396 		JBrowse link
G Fzd3 frizzled class receptor 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FZD3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:43,596,962...43,664,047
Ensembl chr15:43,596,965...43,663,960 		JBrowse link
G Fzd5 frizzled class receptor 5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of FZD5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612 		JBrowse link
G Fzd6 frizzled class receptor 6 increases expression ISO entinostat results in increased expression of FZD6 mRNA CTD PMID:27188386 NCBI chr 7:71,939,916...71,971,685
Ensembl chr 7:71,939,973...71,971,680 		JBrowse link
G Fzd7 frizzled class receptor 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA
entinostat results in increased expression of FZD7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585 		JBrowse link
G Fzd8 frizzled class receptor 8 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA
entinostat results in decreased expression of FZD8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961 		JBrowse link
G Gab1 GRB2-associated binding protein 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAB1 mRNA
entinostat results in decreased expression of GAB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:44,035,693...44,143,617
Ensembl chr19:44,035,063...44,143,617 		JBrowse link
G Gabbr2 gamma-aminobutyric acid type B receptor subunit 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABBR2 mRNA
entinostat results in increased expression of GABBR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:65,743,073...66,083,695
Ensembl chr 5:65,743,073...66,083,695 		JBrowse link
G Gabra5 gamma-aminobutyric acid type A receptor subunit alpha 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA
entinostat results in increased expression of GABRA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:117,404,446...117,517,424
Ensembl chr 1:117,404,494...117,516,635 		JBrowse link
G Gabrb1 gamma-aminobutyric acid type A receptor subunit beta1 increases expression ISO entinostat results in increased expression of GABRB1 mRNA CTD PMID:27188386 NCBI chr14:36,434,339...36,917,920
Ensembl chr14:36,434,352...36,902,893 		JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 increases expression ISO entinostat results in increased expression of GABRB2 mRNA CTD PMID:27188386 NCBI chr10:27,438,127...27,657,680
Ensembl chr10:27,438,238...27,655,171 		JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of GABRB3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
entinostat results in decreased expression of GABRB3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:117,602,772...117,838,230
Ensembl chr 1:117,431,842...117,836,725 		JBrowse link
G Gabrd gamma-aminobutyric acid type A receptor subunit delta increases expression ISO entinostat results in increased expression of GABRD mRNA CTD PMID:27188386 NCBI chr 5:171,240,813...171,252,709
Ensembl chr 5:171,240,789...171,253,094 		JBrowse link
G Gabrg3 gamma-aminobutyric acid type A receptor subunit gamma 3 increases expression ISO entinostat results in increased expression of GABRG3 mRNA CTD PMID:27188386 NCBI chr 1:116,763,332...117,386,770
Ensembl chr 1:116,763,129...117,382,536 		JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA
entinostat results in increased expression of GAD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759 		JBrowse link
G Gad2 glutamate decarboxylase 2 decreases expression ISO entinostat results in decreased expression of GAD2 mRNA CTD PMID:27188386 NCBI chr17:89,671,718...89,734,246
Ensembl chr17:89,671,716...89,941,089 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions 		ISO entinostat results in increased expression of GADD45B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718 		JBrowse link
G Gal galanin and GMAP prepropeptide increases expression
multiple interactions 		ISO entinostat results in increased expression of GAL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:210,079,709...210,084,572
Ensembl chr 1:210,079,702...210,084,229 		JBrowse link
G Galc galactosylceramidase decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GALC mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:123,182,636...123,252,024
Ensembl chr 6:123,182,643...123,245,578 		JBrowse link
G Galk1 galactokinase 1 increases expression ISO entinostat results in increased expression of GALK1 mRNA CTD PMID:27188386 NCBI chr10:101,742,067...101,746,244
Ensembl chr10:101,735,061...101,746,258 		JBrowse link
G Galnt10 polypeptide N-acetylgalactosaminyltransferase 10 increases expression ISO entinostat results in increased expression of GALNT10 mRNA CTD PMID:27188386 NCBI chr10:42,321,691...42,468,087
Ensembl chr10:42,322,161...42,468,087 		JBrowse link
G Galnt12 polypeptide N-acetylgalactosaminyltransferase 12 increases expression ISO entinostat results in increased expression of GALNT12 mRNA CTD PMID:27188386 NCBI chr 5:66,180,171...66,208,931
Ensembl chr 5:66,180,164...66,208,938 		JBrowse link
G Galnt14 polypeptide N-acetylgalactosaminyltransferase 14 increases expression ISO entinostat results in increased expression of GALNT14 mRNA CTD PMID:27188386 NCBI chr 6:27,507,878...27,724,033
Ensembl chr 6:27,507,627...27,724,031 		JBrowse link
G Galnt15 polypeptide N-acetylgalactosaminyltransferase 15 increases expression ISO entinostat results in increased expression of GALNT15 mRNA CTD PMID:32870474 NCBI chr16:7,233,524...7,273,290
Ensembl chr16:7,233,606...7,273,285 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
entinostat results in increased expression of GALNT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:71,150,559...71,187,321
Ensembl chr 3:71,150,571...71,174,323 		JBrowse link
G Galnt6 polypeptide N-acetylgalactosaminyltransferase 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT6 mRNA
entinostat results in increased expression of GALNT6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:133,668,612...133,715,909
Ensembl chr 7:133,668,615...133,698,439 		JBrowse link
G Galp galanin-like peptide increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of GALP mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALP mRNA
entinostat results in decreased expression of GALP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:76,717,110...76,741,056
Ensembl chr 1:76,717,110...76,735,354 		JBrowse link
G Gamt guanidinoacetate N-methyltransferase increases expression ISO entinostat results in increased expression of GAMT mRNA CTD PMID:27188386 NCBI chr 7:10,099,267...10,102,083
Ensembl chr 7:10,098,571...10,102,083 		JBrowse link
G Gap43 growth associated protein 43 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA
entinostat results in increased expression of GAP43 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797 		JBrowse link
G Garin5a golgi associated RAB2 interactor 5A increases expression
multiple interactions 		ISO entinostat results in increased expression of GARIN5A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARIN5A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:104,125,477...104,130,543
Ensembl chr 1:104,125,160...104,135,840 		JBrowse link
G Gas1 growth arrest-specific 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA
entinostat results in decreased expression of GAS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:4,487,716...4,490,701
Ensembl chr17:4,484,283...4,497,657 		JBrowse link
G Gas2l1 growth arrest-specific 2 like 1 increases expression ISO entinostat results in increased expression of GAS2L1 mRNA CTD PMID:27188386 NCBI chr14:84,169,398...84,175,514
Ensembl chr14:84,169,398...84,175,514 		JBrowse link
G Gas7 growth arrest specific 7 increases expression ISO entinostat results in increased expression of GAS7 mRNA CTD PMID:27188386 NCBI chr10:52,651,690...52,882,244
Ensembl chr10:52,651,690...52,882,244 		JBrowse link
G Gask1a golgi associated kinase 1A decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GASK1A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GASK1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:130,488,279...130,521,242
Ensembl chr 8:130,488,354...130,521,242 		JBrowse link
G Gata2 GATA binding protein 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of GATA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055 		JBrowse link
G Gata3 GATA binding protein 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
entinostat results in increased expression of GATA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670 		JBrowse link
G Gatm glycine amidinotransferase increases expression ISO entinostat results in increased expression of GATM mRNA CTD PMID:27188386 NCBI chr 3:130,112,508...130,137,664
Ensembl chr 3:130,112,509...130,129,355 		JBrowse link
G Gbe1 1,4-alpha-glucan branching enzyme 1 decreases expression ISO entinostat results in decreased expression of GBE1 mRNA CTD PMID:27188386 NCBI chr11:22,181,194...22,446,640
Ensembl chr11:22,181,103...22,446,638 		JBrowse link
G Gbgt1 globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 (FORS blood group) increases expression ISO entinostat results in increased expression of GBGT1 mRNA CTD PMID:27188386 NCBI chr 3:32,219,370...32,227,737 JBrowse link
G Gbp3 guanylate binding protein 3 increases expression ISO entinostat results in increased expression of GBP3 mRNA CTD PMID:27188386 NCBI chr 2:234,144,042...234,173,527
Ensembl chr 2:234,146,519...234,180,055 		JBrowse link
G Gbx2 gastrulation brain homeobox 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA
entinostat results in increased expression of GBX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:97,957,304...97,959,883
Ensembl chr 9:97,957,304...97,959,883 		JBrowse link
G Gca grancalcin increases expression ISO entinostat results in increased expression of GCA mRNA CTD PMID:27188386 NCBI chr 3:67,705,874...67,738,475
Ensembl chr 3:67,705,890...67,737,387 		JBrowse link
G Gcat glycine C-acetyltransferase decreases expression ISO entinostat results in decreased expression of GCAT mRNA CTD PMID:27188386 NCBI chr 7:112,475,572...112,481,920
Ensembl chr 7:112,475,496...112,482,664 		JBrowse link
G Gcc1 GRIP and coiled-coil domain containing 1 decreases expression ISO entinostat results in decreased expression of GCC1 mRNA CTD PMID:27188386 NCBI chr 4:57,996,261...58,008,126
Ensembl chr 4:57,996,267...58,002,185 		JBrowse link
G Gchfr GTP cyclohydrolase I feedback regulator multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA
entinostat results in increased expression of GCHFR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA
entinostat results in increased expression of GCLM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003 		JBrowse link
G Gdap1l1 ganglioside-induced differentiation-associated protein 1-like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA
entinostat results in increased expression of GDAP1L1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:172,529,523...172,549,128
Ensembl chr 3:172,509,564...172,549,125 		JBrowse link
G Gdf10 growth differentiation factor 10 decreases expression ISO entinostat results in decreased expression of GDF10 mRNA CTD PMID:26272509 NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,243,317...9,256,794 		JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA
entinostat results in increased expression of GDF15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022 		JBrowse link
G Gdpd2 glycerophosphodiester phosphodiesterase domain containing 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of GDPD2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDPD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:69,866,395...69,875,419
Ensembl chr  X:69,866,799...69,875,414 		JBrowse link
G Gdpd5 glycerophosphodiester phosphodiesterase domain containing 5 increases expression ISO entinostat results in increased expression of GDPD5 mRNA CTD PMID:27188386 NCBI chr 1:163,091,844...163,173,559
Ensembl chr 1:163,091,833...163,173,559 		JBrowse link
G Gfpt2 glutamine-fructose-6-phosphate transaminase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFPT2 mRNA
entinostat results in increased expression of GFPT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419 		JBrowse link
G Gfra1 GDNF family receptor alpha 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA
entinostat results in decreased expression of GFRA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:267,325,297...267,557,037
Ensembl chr 1:267,326,817...267,556,501 		JBrowse link
G Gfra3 GDNF family receptor alpha 3 increases expression ISO entinostat results in increased expression of GFRA3 mRNA CTD PMID:27188386 NCBI chr18:26,571,952...26,600,225
Ensembl chr18:26,571,921...26,600,225 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of GGT1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GGT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050 		JBrowse link
G Ghdc GH3 domain containing increases expression ISO entinostat results in increased expression of GHDC mRNA CTD PMID:27188386 NCBI chr10:86,193,920...86,198,141
Ensembl chr10:86,193,929...86,198,141 		JBrowse link
G Gigyf1 GRB10 interacting GYF protein 1 decreases expression ISO entinostat results in decreased expression of GIGYF1 mRNA CTD PMID:27188386 NCBI chr12:24,800,996...24,819,719
Ensembl chr12:24,802,865...24,811,800 		JBrowse link
G Ginm1 glycosylated integral membrane protein 1 increases expression ISO entinostat results in increased expression of GINM1 mRNA CTD PMID:27188386 NCBI chr 1:4,066,766...4,082,640
Ensembl chr 1:4,066,766...4,082,617 		JBrowse link
G Gip gastric inhibitory polypeptide increases expression ISO entinostat results in increased expression of GIP mRNA CTD PMID:27188386 NCBI chr10:81,465,070...81,473,216
Ensembl chr10:81,465,062...81,473,216 		JBrowse link
G Gja3 gap junction protein, alpha 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of GJA3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:35,296,946...35,322,405
Ensembl chr15:35,295,523...35,322,809 		JBrowse link
G Gja4 gap junction protein, alpha 4 decreases expression ISO entinostat results in decreased expression of GJA4 mRNA CTD PMID:27188386 NCBI chr 5:144,917,791...144,920,324
Ensembl chr 5:144,914,147...144,921,216 		JBrowse link
G Gjb1 gap junction protein, beta 1 decreases expression ISO entinostat results in decreased expression of GJB1 mRNA CTD PMID:27188386 NCBI chr  X:70,541,845...70,549,776
Ensembl chr  X:70,541,862...70,549,843 		JBrowse link
G Gjb2 gap junction protein, beta 2 increases expression ISO entinostat results in increased expression of GJB2 mRNA CTD PMID:27188386 NCBI chr15:35,375,977...35,393,817
Ensembl chr15:35,375,692...35,393,877 		JBrowse link
G Gjd3 gap junction protein, delta 3 increases expression ISO entinostat results in increased expression of GJD3 mRNA CTD PMID:27188386 NCBI chr10:84,429,923...84,432,011
Ensembl chr10:84,429,036...84,433,870 		JBrowse link
G Gkap1 G kinase anchoring protein 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GKAP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:6,389,377...6,429,091
Ensembl chr17:6,389,377...6,438,279 		JBrowse link
G Glb1l3 galactosidase, beta 1-like 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of GLB1L3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:33,454,914...33,496,641
Ensembl chr 8:33,454,914...33,496,641 		JBrowse link
G Glcci1 glucocorticoid induced 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GLCCI1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:37,274,271...37,601,898
Ensembl chr 4:37,529,364...37,599,802
Ensembl chr 4:37,529,364...37,599,802 		JBrowse link
G Gldn gliomedin increases expression ISO entinostat results in increased expression of GLDN mRNA CTD PMID:27188386 NCBI chr 8:63,575,270...63,619,346
Ensembl chr 8:63,575,270...63,619,346 		JBrowse link
G Glipr1 GLI pathogenesis-related 1 increases expression ISO entinostat results in increased expression of GLIPR1 mRNA CTD PMID:27188386 NCBI chr 7:49,373,579...49,399,190
Ensembl chr 7:49,373,581...49,384,640 		JBrowse link
G Glis3 GLIS family zinc finger 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA
entinostat results in decreased expression of GLIS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:235,389,567...235,809,416
Ensembl chr 1:235,392,651...235,809,221 		JBrowse link
G Glrb glycine receptor, beta multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLRB mRNA
entinostat results in decreased expression of GLRB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:168,432,736...168,505,614
Ensembl chr 2:168,432,736...168,505,614 		JBrowse link
G Glrx glutaredoxin increases expression ISO entinostat results in increased expression of GLRX mRNA CTD PMID:27188386 NCBI chr 2:7,073,737...7,083,548
Ensembl chr 2:7,073,759...7,083,543 		JBrowse link
G Gls2 glutaminase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of GLS2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:1,201,757...1,218,014
Ensembl chr 7:1,201,838...1,218,013 		JBrowse link
G Glt8d2 glycosyltransferase 8 domain containing 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of GLT8D2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLT8D2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:22,917,055...22,968,616
Ensembl chr 7:22,917,100...22,968,930 		JBrowse link
G Gm2a ganglioside GM2 activator increases expression ISO entinostat results in increased expression of GM2A mRNA CTD PMID:27188386 NCBI chr10:39,719,919...39,732,452
Ensembl chr10:39,719,938...39,732,451 		JBrowse link
G Gmppa GDP-mannose pyrophosphorylase A increases expression ISO entinostat results in increased expression of GMPPA mRNA CTD PMID:27188386 NCBI chr 9:84,375,373...84,382,917
Ensembl chr 9:84,375,425...84,382,916 		JBrowse link
G Gmpr guanosine monophosphate reductase increases expression ISO entinostat results in increased expression of GMPR mRNA CTD PMID:27188386 NCBI chr17:19,357,992...19,395,807
Ensembl chr17:19,357,992...19,431,655 		JBrowse link
G Gnas GNAS complex locus increases expression
multiple interactions 		ISO entinostat results in increased expression of GNAS mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536 		JBrowse link
G Gng2 G protein subunit gamma 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GNG2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:4,365,222...4,466,060
Ensembl chr15:4,365,135...4,466,059 		JBrowse link
G Gng7 G protein subunit gamma 7 increases expression ISO entinostat results in increased expression of GNG7 mRNA CTD PMID:27188386 NCBI chr 7:9,348,148...9,411,924
Ensembl chr 7:9,348,218...9,411,923 		JBrowse link
G Gng8 G protein subunit gamma 8 increases expression ISO entinostat results in increased expression of GNG8 mRNA CTD PMID:27188386 NCBI chr 1:86,692,609...86,696,463
Ensembl chr 1:86,692,642...86,696,408 		JBrowse link
G Gngt1 G protein subunit gamma transducin 1 increases expression ISO entinostat results in increased expression of GNGT1 mRNA CTD PMID:27188386 NCBI chr 4:32,960,945...32,963,930
Ensembl chr 4:32,960,945...32,963,930 		JBrowse link
G Golga1 golgin A1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GOLGA1 mRNA
entinostat results in decreased expression of GOLGA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:43,175,400...43,222,319
Ensembl chr 3:43,175,400...43,222,319 		JBrowse link
G Gpatch2 G patch domain containing 2 increases expression
decreases expression
multiple interactions 		ISO entinostat results in increased expression of GPATCH2 mRNA
entinostat results in decreased expression of GPATCH2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPATCH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:101,316,413...101,457,109
Ensembl chr13:101,316,413...101,457,109 		JBrowse link
G Gpc3 glypican 3 decreases expression
increases expression
multiple interactions 		ISO entinostat results in decreased expression of GPC3 mRNA
entinostat results in increased expression of GPC3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:136,789,770...137,157,598
Ensembl chr  X:136,789,770...137,157,639 		JBrowse link
G Gpc6 glypican 6 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GPC6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:100,437,415...101,435,038
Ensembl chr15:100,437,943...101,435,027 		JBrowse link
G Gpd1l glycerol-3-phosphate dehydrogenase 1 like multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA
entinostat results in increased expression of GPD1L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:123,469,282...123,498,948
Ensembl chr 8:123,466,667...123,498,908 		JBrowse link
G Gpha2 glycoprotein hormone subunit alpha 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of GPHA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPHA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:212,954,579...212,956,536
Ensembl chr 1:212,955,387...212,956,535 		JBrowse link
G Gpm6a glycoprotein m6a increases expression
multiple interactions 		ISO entinostat results in increased expression of GPM6A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:43,374,385...43,706,461
Ensembl chr16:43,374,385...43,706,705 		JBrowse link
G Gpm6b glycoprotein m6b multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6B mRNA
entinostat results in increased expression of GPM6B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:31,689,485...31,836,199
Ensembl chr  X:31,690,359...31,733,272 		JBrowse link
G Gpr143 G protein-coupled receptor 143 increases expression
multiple interactions 		ISO entinostat results in increased expression of GPR143 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR143 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:25,498,601...25,523,408
Ensembl chr  X:25,498,601...25,523,400 		JBrowse link
G Gpr155 G protein-coupled receptor 155 increases expression ISO entinostat results in increased expression of GPR155 mRNA CTD PMID:27188386 NCBI chr 3:78,623,931...78,677,803
Ensembl chr 3:78,607,976...78,677,803 		JBrowse link
G Gpr157 G protein-coupled receptor 157 increases expression ISO entinostat results in increased expression of GPR157 mRNA CTD PMID:27188386 NCBI chr 5:165,833,651...165,849,376
Ensembl chr 5:165,833,673...165,851,280 		JBrowse link
G Gpr160 G protein-coupled receptor 160 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR160 mRNA
entinostat results in increased expression of GPR160 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:114,414,084...114,491,590
Ensembl chr 2:114,410,261...114,474,790 		JBrowse link
G Gpr161 G protein-coupled receptor 161 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GPR161 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR161 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:80,111,271...80,156,517
Ensembl chr13:80,117,114...80,152,861 		JBrowse link
G Gpr173 G-protein coupled receptor 173 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA
entinostat results in decreased expression of GPR173 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:24,925,634...24,950,485
Ensembl chr  X:24,922,704...24,950,887 		JBrowse link
G Gpr176 G protein-coupled receptor 176 increases expression ISO entinostat results in increased expression of GPR176 mRNA CTD PMID:27188386 NCBI chr 3:125,690,750...125,791,172
Ensembl chr 3:125,690,751...125,791,172 		JBrowse link
G Gpr183 G protein-coupled receptor 183 decreases expression ISO entinostat results in decreased expression of GPR183 mRNA CTD PMID:33770205 NCBI chr15:105,445,129...105,457,192
Ensembl chr15:105,437,561...105,466,977 		JBrowse link
G Gpr22 G protein-coupled receptor 22 decreases expression ISO entinostat results in decreased expression of GPR22 mRNA CTD PMID:27188386 NCBI chr 6:54,037,998...54,044,994
Ensembl chr 6:54,037,552...54,045,020 		JBrowse link
G Gprc5a G protein-coupled receptor, class C, group 5, member A increases expression ISO entinostat results in increased expression of GPRC5A mRNA CTD PMID:27188386 NCBI chr 4:169,634,896...169,653,627
Ensembl chr 4:169,634,748...169,653,625 		JBrowse link
G Gpsm3 G-protein signaling modulator 3 increases expression ISO entinostat results in increased expression of GPSM3 mRNA CTD PMID:27188386 NCBI chr20:4,161,730...4,163,591
Ensembl chr20:4,161,730...4,189,072 		JBrowse link
G Gramd1c GRAM domain containing 1C increases expression ISO entinostat results in increased expression of GRAMD1C mRNA CTD PMID:27188386 NCBI chr11:70,139,076...70,224,478
Ensembl chr11:70,139,184...70,224,478 		JBrowse link
G Gramd2a GRAM domain containing 2A increases expression ISO entinostat results in increased expression of GRAMD2A mRNA CTD PMID:27188386 NCBI chr 8:68,975,529...69,013,575
Ensembl chr 8:69,003,807...69,013,573 		JBrowse link
G Gramd2b GRAM domain containing 2B increases expression ISO entinostat results in increased expression of GRAMD2B mRNA CTD PMID:27188386 NCBI chr18:52,082,128...52,180,056
Ensembl chr18:52,082,029...52,180,054 		JBrowse link
G Grb14 growth factor receptor bound protein 14 increases expression
multiple interactions 		ISO entinostat results in increased expression of GRB14 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRB14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:69,976,331...70,091,921
Ensembl chr 3:69,976,339...70,091,921 		JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression ISO entinostat results in increased expression of GREM1 mRNA CTD PMID:26272509 NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089 		JBrowse link
G Grem2 gremlin 2, DAN family BMP antagonist decreases expression ISO entinostat results in decreased expression of GREM2 mRNA CTD PMID:27188386 NCBI chr13:89,310,897...89,403,856
Ensembl chr13:89,310,662...89,404,312 		JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA
entinostat results in decreased expression of GRIA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309 		JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A increases expression
multiple interactions 		ISO entinostat results in increased expression of GRIN2A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIN2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378 		JBrowse link
G Grip1 glutamate receptor interacting protein 1 decreases expression ISO entinostat results in decreased expression of GRIP1 mRNA CTD PMID:27188386 NCBI chr 7:56,820,501...57,477,877
Ensembl chr 7:56,820,704...57,468,417 		JBrowse link
G Grk6 G protein-coupled receptor kinase 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRK6 mRNA
entinostat results in increased expression of GRK6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:9,182,160...9,198,380
Ensembl chr17:9,182,160...9,197,954 		JBrowse link
G Grm2 glutamate metabotropic receptor 2 decreases expression ISO entinostat results in decreased expression of GRM2 mRNA CTD PMID:27188386 NCBI chr 8:116,158,810...116,171,857
Ensembl chr 8:116,158,810...116,171,857 		JBrowse link
G Grp gastrin releasing peptide decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GRP mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:61,658,655...61,672,037
Ensembl chr18:61,658,250...61,672,037 		JBrowse link
G Gsdme gasdermin E multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSDME mRNA
entinostat results in decreased expression of GSDME mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525 		JBrowse link
G Gse1 Gse1 coiled-coil protein multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSE1 mRNA
entinostat results in increased expression of GSE1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:65,182,678...65,538,183
Ensembl chr19:65,446,263...65,538,176 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSK3B mRNA
entinostat results in decreased expression of GSK3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249 		JBrowse link
G Gsn gelsolin increases expression ISO entinostat results in increased expression of GSN mRNA CTD PMID:27188386 NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:38,982,671...39,035,850 		JBrowse link
G Gsto2 glutathione S-transferase omega 2 increases expression ISO entinostat results in increased expression of GSTO2 mRNA CTD PMID:27188386 NCBI chr 1:256,673,376...256,695,154
Ensembl chr 1:256,673,274...256,695,146 		JBrowse link
G Gsx1 GS homeobox 1 decreases expression ISO entinostat results in decreased expression of GSX1 mRNA CTD PMID:27188386 NCBI chr12:12,994,588...12,996,874
Ensembl chr12:12,994,588...12,996,874 		JBrowse link
G Gtf2ird2 GTF2I repeat domain containing 2 decreases expression ISO entinostat results in decreased expression of GTF2IRD2 mRNA CTD PMID:27188386 NCBI chr12:28,134,199...28,179,089
Ensembl chr12:28,133,792...28,172,876 		JBrowse link
G Gtsf1 gametocyte specific factor 1 increases expression ISO entinostat results in increased expression of GTSF1 mRNA CTD PMID:27188386 NCBI chr 7:136,417,793...136,436,849
Ensembl chr 7:136,417,793...136,436,094 		JBrowse link
G Guca1a guanylate cyclase activator 1A increases expression ISO entinostat results in increased expression of GUCA1A mRNA CTD PMID:27188386 NCBI chr 9:21,080,782...21,096,221
Ensembl chr 9:21,086,642...21,096,221 		JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1A1 mRNA CTD PMID:27188386 NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737 		JBrowse link
G Gucy1a2 guanylate cyclase 1 soluble subunit alpha 2 decreases expression ISO entinostat results in decreased expression of GUCY1A2 mRNA CTD PMID:27188386 NCBI chr 8:8,785,212...9,174,322
Ensembl chr 8:8,785,121...9,174,272 		JBrowse link
G Gucy1b1 guanylate cyclase 1 soluble subunit beta 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of GUCY1B1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987 		JBrowse link
G H1f4 H1.4 linker histone, cluster member decreases expression ISO entinostat results in decreased expression of H1-4 mRNA CTD PMID:27188386 NCBI chr17:41,914,425...41,915,206
Ensembl chr17:41,914,431...41,916,129 		JBrowse link
G H2ac6 H2A clustered histone 6 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of H2AC6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:47,403,701...47,404,167 JBrowse link
G H2aj H2A.J histone increases expression ISO entinostat results in increased expression of H2AJ mRNA CTD PMID:27188386 NCBI chr 4:171,406,922...171,407,406
Ensembl chr 4:171,406,177...171,408,845 		JBrowse link
G H2ax H2A.X variant histone increases phosphorylation ISO entinostat results in increased phosphorylation of H2AX protein CTD PMID:34665271 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G H2bc12 H2B clustered histone 12 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA
entinostat results in decreased expression of H2BC12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816 		JBrowse link
G H2bc14 H2B clustered histone 14 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of H2BC5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:47,488,627...47,489,008 JBrowse link
G H3c10 H3 clustered histone 10 decreases expression ISO entinostat results in decreased expression of H3C6 mRNA CTD PMID:27188386 NCBI chr17:41,996,216...41,997,128
Ensembl chr17:47,493,820...47,494,861
Ensembl chr17:47,493,820...47,494,861 		JBrowse link
G H3f4 H3.4 histone, cluster member multiple interactions
increases acetylation 		ISO [fludarabine co-treated with entinostat] results in increased acetylation of H3-4 protein
entinostat results in increased acetylation of H3-4 protein
entinostat promotes the reaction [H3F4 protein modified form binds to RHOX5 promoter]
entinostat results in increased acetylation of H3F4 protein 		CTD PMID:15059916 PMID:19679824 PMID:34665271 NCBI chr10:44,240,282...44,240,842 JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA
entinostat results in increased expression of HACD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:81,992,284...82,014,676
Ensembl chr17:81,992,292...82,014,592 		JBrowse link
G Hacd4 3-hydroxyacyl-CoA dehydratase 4 increases expression ISO entinostat results in increased expression of HACD4 mRNA CTD PMID:27188386 NCBI chr 5:107,935,514...107,961,271
Ensembl chr 5:107,934,937...107,962,836 		JBrowse link
G Hand1 heart and neural crest derivatives expressed 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of HAND1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:42,507,117...42,509,684
Ensembl chr10:42,507,122...42,509,684 		JBrowse link
G Hapln4 hyaluronan and proteoglycan link protein 4 increases expression ISO entinostat results in increased expression of HAPLN4 mRNA CTD PMID:27188386 NCBI chr16:19,367,041...19,375,173
Ensembl chr16:19,367,041...19,375,442 		JBrowse link
G Has3 hyaluronan synthase 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of HAS3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:51,668,276...51,691,042 JBrowse link
G Hbe1 hemoglobin subunit epsilon 1 decreases expression ISO entinostat results in decreased expression of HBE1 mRNA CTD PMID:27188386 NCBI chr 1:167,694,820...167,872,091
Ensembl chr 1:167,694,825...167,696,280 		JBrowse link
G Hbz hemoglobin subunit zeta decreases expression ISO entinostat results in decreased expression of HBZ mRNA CTD PMID:27188386 NCBI chr10:15,848,279...15,849,757
Ensembl chr10:15,848,289...15,849,768 		JBrowse link
G Hcfc1r1 host cell factor C1 regulator 1 increases expression ISO entinostat results in increased expression of HCFC1R1 mRNA CTD PMID:27188386 NCBI chr10:13,209,757...13,211,445
Ensembl chr10:13,209,558...13,211,443 		JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions 		ISO entinostat results in increased expression of HCK mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935 		JBrowse link
G Hcn4 hyperpolarization activated cyclic nucleotide-gated potassium channel 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCN4 mRNA
entinostat results in increased expression of HCN4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:68,118,062...68,155,482
Ensembl chr 8:68,118,062...68,155,495 		JBrowse link
G Hdac1 histone deacetylase 1 increases expression ISO entinostat results in increased expression of HDAC1 mRNA CTD PMID:27188386 NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387 		JBrowse link
G Hdac9 histone deacetylase 9 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDAC9 mRNA
entinostat results in decreased expression of HDAC9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:56,489,472...57,351,654
Ensembl chr 6:56,490,988...57,351,835 		JBrowse link
G Hdgfl3 HDGF like 3 decreases expression ISO entinostat results in decreased expression of HDGFL3 mRNA CTD PMID:27188386 NCBI chr 1:145,233,996...145,287,115
Ensembl chr 1:145,236,758...145,286,001 		JBrowse link
G Hdx highly divergent homeobox decreases expression ISO entinostat results in decreased expression of HDX mRNA CTD PMID:27188386 NCBI chr  X:80,739,615...80,881,621
Ensembl chr  X:80,739,615...80,881,512 		JBrowse link
G Hebp1 heme binding protein 1 increases expression ISO entinostat results in increased expression of HEBP1 mRNA CTD PMID:27188386 NCBI chr 4:169,705,665...169,735,199
Ensembl chr 4:169,705,668...169,735,199 		JBrowse link
G Heg1 heart development protein with EGF-like domains 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of HEG1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:80,512,096...80,600,150
Ensembl chr11:80,512,096...80,600,092 		JBrowse link
G Henmt1 HEN methyltransferase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of HENMT1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HENMT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:199,258,107...199,291,739
Ensembl chr 2:199,274,480...199,287,822 		JBrowse link
G Heph hephaestin multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEPH mRNA
entinostat results in decreased expression of HEPH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:65,160,628...65,412,457
Ensembl chr  X:65,305,773...65,412,453 		JBrowse link
G Herc6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC6 mRNA
entinostat results in increased expression of HERC6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:88,854,612...88,897,043
Ensembl chr 4:88,854,640...88,896,993 		JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of HES5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021 		JBrowse link
G Hesx1 HESX homeobox 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA
entinostat results in decreased expression of HESX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:2,198,589...2,200,694
Ensembl chr16:2,198,589...2,200,694 		JBrowse link
G Hexb hexosaminidase subunit beta increases expression ISO entinostat results in increased expression of HEXB mRNA CTD PMID:27188386 NCBI chr 2:30,218,608...30,238,771
Ensembl chr 2:30,218,608...30,238,771 		JBrowse link
G Hey1 hes-related family bHLH transcription factor with YRPW motif 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEY1 mRNA
entinostat results in decreased expression of HEY1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:95,003,935...95,006,457
Ensembl chr 2:95,002,943...95,007,624 		JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
entinostat results in increased expression of HEY2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:28,641,100...28,651,187
Ensembl chr 1:28,641,057...28,651,187 		JBrowse link
G Hfe homeostatic iron regulator increases expression ISO entinostat results in increased expression of HFE mRNA CTD PMID:27188386 NCBI chr17:41,841,302...41,849,359
Ensembl chr17:41,841,252...41,851,208 		JBrowse link
G Hgf hepatocyte growth factor increases expression ISO entinostat results in increased expression of HGF mRNA CTD PMID:27188386 NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851 		JBrowse link
G Hgsnat heparan-alpha-glucosaminide N-acetyltransferase multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA
entinostat results in decreased expression of HGSNAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:72,807,967...72,840,180
Ensembl chr16:72,807,849...72,840,176 		JBrowse link
G Hhat hedgehog acyltransferase multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HHAT mRNA
entinostat results in decreased expression of HHAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:106,558,635...106,814,723
Ensembl chr13:106,541,866...106,811,563 		JBrowse link
G Hhex hematopoietically expressed homeobox multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA
entinostat results in increased expression of HHEX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:244,602,945...244,608,532
Ensembl chr 1:244,602,825...244,608,604 		JBrowse link
G Hibadh 3-hydroxyisobutyrate dehydrogenase increases expression ISO entinostat results in increased expression of HIBADH mRNA CTD PMID:27188386 NCBI chr 4:82,979,759...83,077,819
Ensembl chr 4:82,979,765...83,111,242 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression
multiple interactions 		ISO entinostat results in decreased expression of HIF1A protein
TNFSF10 protein promotes the reaction [entinostat results in decreased expression of HIF1A protein] 		CTD PMID:21041383 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hira histone cell cycle regulator decreases expression ISO entinostat results in decreased expression of HIRA mRNA CTD PMID:27188386 NCBI chr11:95,528,831...95,637,565
Ensembl chr11:95,528,831...95,638,549 		JBrowse link
G Hivep2 HIVEP zinc finger 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP2 mRNA
entinostat results in decreased expression of HIVEP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:10,176,880...10,376,089
Ensembl chr 1:10,179,402...10,376,089 		JBrowse link
G Hivep3 HIVEP zinc finger 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of HIVEP3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:138,610,592...139,013,058
Ensembl chr 5:138,943,312...139,010,430 		JBrowse link
G Hk1 hexokinase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA
entinostat results in increased expression of HK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814 		JBrowse link
G Hlx H2.0-like homeobox decreases expression ISO entinostat results in decreased expression of HLX mRNA CTD PMID:27188386 NCBI chr13:98,811,852...98,817,264
Ensembl chr13:98,811,856...98,817,264 		JBrowse link
G Hmgb3 high mobility group box 3 decreases expression ISO entinostat results in decreased expression of HMGB3 mRNA CTD PMID:27188386 NCBI chr  X:154,341,106...154,346,087
Ensembl chr  X:154,340,935...154,346,097 		JBrowse link
G Hmgcll1 3-hydroxy-3-methylglutaryl-CoA lyase like 1 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of HMGCLL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA
entinostat results in decreased expression of HMGCLL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,637,708...85,799,759
Ensembl chr 8:85,637,958...85,767,740 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase decreases expression ISO entinostat results in decreased expression of HMGCR mRNA CTD PMID:27188386 NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA
entinostat results in decreased expression of HMGCS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802 		JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 increases expression ISO entinostat results in increased expression of HMGCS2 mRNA CTD PMID:27188386 NCBI chr 2:188,564,348...188,590,872
Ensembl chr 2:188,547,767...188,592,242 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA
entinostat results in increased expression of HMOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Hmx2 H6 family homeobox 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of HMX2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:195,749,284...195,758,347
Ensembl chr 1:195,749,284...195,756,945 		JBrowse link
G Hoga1 4-hydroxy-2-oxoglutarate aldolase 1 increases expression ISO entinostat results in increased expression of HOGA1 mRNA CTD PMID:27188386 NCBI chr 1:250,806,430...250,833,544
Ensembl chr 1:250,806,255...250,833,869 		JBrowse link
G Homez homeobox and leucine zipper encoding multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA
entinostat results in decreased expression of HOMEZ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:32,292,897...32,309,564
Ensembl chr15:32,291,048...32,321,319 		JBrowse link
G Hook1 hook microtubule-tethering protein 1 increases expression ISO entinostat results in increased expression of HOOK1 mRNA CTD PMID:27188386 NCBI chr 5:115,940,199...116,003,482
Ensembl chr 5:115,940,080...116,003,482 		JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA CTD PMID:27188386 NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209 		JBrowse link
G Hoxd1 homeo box D1 increases expression ISO entinostat results in increased expression of HOXD1 mRNA CTD PMID:27188386 NCBI chr 3:80,073,041...80,075,180
Ensembl chr 3:80,073,041...80,075,180 		JBrowse link
G Hoxd11 homeobox D11 increases expression ISO entinostat results in increased expression of HOXD11 mRNA CTD PMID:27188386 NCBI chr 3:79,992,394...79,994,688
Ensembl chr 3:79,992,394...79,994,688 		JBrowse link
G Hpcal4 hippocalcin-like 4 increases expression ISO entinostat results in increased expression of HPCAL4 mRNA CTD PMID:27188386 NCBI chr 5:140,739,577...140,751,529
Ensembl chr 5:140,739,635...140,751,530 		JBrowse link
G Hpdl 4-hydroxyphenylpyruvate dioxygenase-like multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA
entinostat results in increased expression of HPDL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,523,258...135,524,864
Ensembl chr 5:135,523,262...135,535,704 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression
multiple interactions 		ISO entinostat results in increased expression of HPGD mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831 		JBrowse link
G Hps1 HPS1, biogenesis of lysosomal organelles complex 3 subunit 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of HPS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:251,500,427...251,526,529
Ensembl chr 1:251,500,427...251,526,739 		JBrowse link
G Hpx hemopexin decreases expression ISO entinostat results in decreased expression of HPX mRNA CTD PMID:27188386 NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:169,344,583...169,352,156 		JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression
multiple interactions 		ISO entinostat results in increased expression of HRK mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:44,048,402...44,070,561
Ensembl chr12:44,048,402...44,070,561 		JBrowse link
G Hs1bp3 HCLS1 binding protein 3 increases expression ISO entinostat results in increased expression of HS1BP3 mRNA CTD PMID:27188386 NCBI chr 6:36,911,864...36,942,126
Ensembl chr 6:36,911,864...36,942,126 		JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185 		JBrowse link
G Hs3st5 heparan sulfate-glucosamine 3-sulfotransferase 5 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of HS3ST5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST5 mRNA
entinostat results in decreased expression of HS3ST5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:41,661,785...41,972,550
Ensembl chr20:41,773,601...41,972,542 		JBrowse link
G Hs6st2 heparan sulfate 6-O-sulfotransferase 2 increases expression ISO entinostat results in increased expression of HS6ST2 mRNA CTD PMID:27188386 NCBI chr  X:135,887,224...136,182,388
Ensembl chr  X:135,888,472...136,182,353 		JBrowse link
G Hs6st3 heparan sulfate 6-O-sulfotransferase 3 decreases expression ISO entinostat results in decreased expression of HS6ST3 mRNA CTD PMID:27188386 NCBI chr15:102,688,420...103,407,725
Ensembl chr15:102,688,365...103,408,384 		JBrowse link
G Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSD11B2 mRNA
entinostat results in increased expression of HSD11B2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 increases expression ISO entinostat results in increased expression of HSD17B6 mRNA CTD PMID:27188386 NCBI chr 7:831,407...850,950
Ensembl chr 7:831,421...850,873 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 increases expression ISO entinostat results in increased expression of HSD17B8 mRNA CTD PMID:27188386 NCBI chr20:4,828,571...4,830,635
Ensembl chr20:4,828,608...4,830,634 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 increases expression ISO entinostat results in increased expression of HSD3B1 mRNA CTD PMID:27188386 NCBI chr 2:188,858,574...188,864,694 JBrowse link
G Hsf2 heat shock transcription factor 2 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSF2 mRNA CTD PMID:27188386 NCBI chr20:37,366,301...37,393,922
Ensembl chr20:37,366,279...37,401,022 		JBrowse link
G Hspa12a heat shock protein family A (Hsp70) member 12A multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12A mRNA
entinostat results in increased expression of HSPA12A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:267,921,780...268,083,171
Ensembl chr 1:267,921,782...268,082,794 		JBrowse link
G Hspa12b heat shock protein family A (Hsp70) member 12B multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12B mRNA
entinostat results in increased expression of HSPA12B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:138,799,396...138,817,396
Ensembl chr 3:138,799,398...138,818,935 		JBrowse link
G Hspa2 heat shock protein family A (Hsp70) member 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA2 mRNA
entinostat results in increased expression of HSPA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,864,172...100,866,946
Ensembl chr 6:100,864,553...100,867,133 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA
entinostat results in increased expression of HSPA4L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:125,668,236...125,720,986 		JBrowse link
G Hspa9 heat shock protein family A (Hsp70) member 9 increases expression
multiple interactions 		ISO entinostat results in increased expression of HSPA9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,804,774...26,828,398 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPB8 mRNA
entinostat results in increased expression of HSPB8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:45,835,899...45,866,449
Ensembl chr12:45,837,066...45,851,937 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of HTATIP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTATIP2 mRNA
entinostat results in decreased expression of HTATIP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815 		JBrowse link
G Htr2c 5-hydroxytryptamine receptor 2C increases expression ISO entinostat results in increased expression of HTR2C mRNA CTD PMID:26272509 NCBI chr  X:115,453,190...115,682,325
Ensembl chr  X:115,452,842...115,682,324 		JBrowse link
G Htr3a 5-hydroxytryptamine receptor 3A multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTR3A mRNA
entinostat results in increased expression of HTR3A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:58,138,514...58,150,960
Ensembl chr 8:58,138,226...58,150,884 		JBrowse link
G Hyal1 hyaluronidase 1 increases expression ISO entinostat results in increased expression of HYAL1 mRNA CTD PMID:27188386 NCBI chr 8:117,129,311...117,133,162
Ensembl chr 8:117,129,277...117,133,146 		JBrowse link
G Hycc2 hyccin PI4KA lipid kinase complex subunit 2 decreases expression ISO entinostat results in decreased expression of HYCC2 mRNA CTD PMID:27188386 NCBI chr 9:67,551,064...67,623,353
Ensembl chr 9:67,551,064...67,587,186 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA
entinostat results in increased expression of ICAM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617 		JBrowse link
G Icam2 intercellular adhesion molecule 2 decreases expression ISO entinostat results in decreased expression of ICAM2 mRNA CTD PMID:27188386 NCBI chr10:91,808,449...91,819,319
Ensembl chr10:91,808,316...91,815,072 		JBrowse link
G Icam4 intercellular adhesion molecule 4, Landsteiner-Wiener blood group multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM4 mRNA
entinostat results in increased expression of ICAM4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:27,842,255...27,843,351
Ensembl chr 8:27,842,255...27,844,371 		JBrowse link
G Id3 inhibitor of DNA binding 3 increases expression ISO entinostat results in increased expression of ID3 mRNA CTD PMID:27188386 NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression
multiple interactions 		ISO entinostat results in increased expression of IDH3A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:63,867,882...63,887,223
Ensembl chr 8:63,867,820...63,887,223 		JBrowse link
G Idi1 isopentenyl-diphosphate delta isomerase 1 decreases expression ISO entinostat results in decreased expression of IDI1 mRNA CTD PMID:27188386 NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524 		JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of IDO1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:74,133,259...74,145,328
Ensembl chr16:74,133,259...74,145,328 		JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase increases expression
multiple interactions 		ISO entinostat results in increased expression of IFI30 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:18,709,570...18,713,635
Ensembl chr16:18,709,563...18,715,711 		JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA
entinostat results in increased expression of IFITM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776 		JBrowse link
G Ifitm3 interferon induced transmembrane protein 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of IFITM3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,540,649...205,541,758
Ensembl chr 1:205,481,168...205,547,920 		JBrowse link
G Ifng interferon gamma increases secretion ISO entinostat results in increased secretion of IFNG protein CTD PMID:19759901 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216 		JBrowse link
G Ifnlr1 interferon, lambda receptor 1 increases expression ISO entinostat results in increased expression of IFNLR1 mRNA CTD PMID:27188386 NCBI chr 5:153,203,597...153,225,911
Ensembl chr 5:153,203,597...153,225,911 		JBrowse link
G Ift57 intraflagellar transport 57 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA
entinostat results in decreased expression of IFT57 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:64,528,349...64,593,545
Ensembl chr11:64,528,349...64,593,545 		JBrowse link
G Igf2bp1 insulin-like growth factor 2 mRNA binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGF2BP1 mRNA
entinostat results in increased expression of IGF2BP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:81,405,021...81,447,814
Ensembl chr10:81,404,797...81,447,846 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA
entinostat results in decreased expression of IGFBP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944 		JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA
entinostat results in decreased expression of IGFBP5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390 		JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA
entinostat results in increased expression of IGFBP7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:31,091,681...31,151,623
Ensembl chr14:31,091,347...31,151,620 		JBrowse link
G Igfbpl1 insulin-like growth factor binding protein-like 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBPL1 mRNA
entinostat results in increased expression of IGFBPL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:64,872,056...64,887,461
Ensembl chr 5:64,872,057...64,887,461 		JBrowse link
G Igsf11 immunoglobulin superfamily, member 11 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF11 mRNA
entinostat results in decreased expression of IGSF11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:75,238,706...75,389,748
Ensembl chr11:75,236,545...75,390,425 		JBrowse link
G Ikbip IKBKB interacting protein increases expression ISO entinostat results in increased expression of IKBIP mRNA CTD PMID:27188386 NCBI chr 7:27,467,097...27,485,776
Ensembl chr 7:27,467,055...27,491,460 		JBrowse link
G Ikzf2 IKAROS family zinc finger 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of IKZF2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IKZF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:78,495,670...78,640,896
Ensembl chr 9:78,492,275...78,640,463 		JBrowse link
G Il10rb interleukin 10 receptor subunit beta increases expression ISO entinostat results in increased expression of IL10RB mRNA CTD PMID:27188386 NCBI chr11:44,132,471...44,154,062
Ensembl chr11:44,132,189...44,154,053 		JBrowse link
G Il11 interleukin 11 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL11 mRNA
entinostat results in increased expression of IL11 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:78,096,930...78,104,915 		JBrowse link
G Il17rb interleukin 17 receptor B decreases expression ISO entinostat results in decreased expression of IL17RB mRNA CTD PMID:27188386 NCBI chr16:5,186,961...5,200,657
Ensembl chr16:5,186,961...5,200,694 		JBrowse link
G Il17rd interleukin 17 receptor D decreases expression
multiple interactions 		ISO entinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:2,235,172...2,489,827
Ensembl chr16:2,235,169...2,301,850 		JBrowse link
G Il18r1 interleukin 18 receptor 1 increases expression ISO entinostat results in increased expression of IL18R1 mRNA CTD PMID:27188386 NCBI chr 9:50,223,274...50,257,370
Ensembl chr 9:50,223,200...50,257,367 		JBrowse link
G Il1a interleukin 1 alpha increases expression ISO entinostat results in increased expression of IL1A mRNA CTD PMID:27188386 NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013 		JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA
entinostat results in decreased expression of IL1RAPL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:55,322,779...56,827,486
Ensembl chr  X:55,328,964...56,826,613 		JBrowse link
G Il20rb interleukin 20 receptor subunit beta increases expression
multiple interactions 		ISO entinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:109,858,108...109,896,066
Ensembl chr 8:109,854,012...109,889,363 		JBrowse link
G Il27ra interleukin 27 receptor subunit alpha multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA
entinostat results in increased expression of IL27RA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:41,014,730...41,026,740
Ensembl chr19:41,014,730...41,026,760 		JBrowse link
G Il2rb interleukin 2 receptor subunit beta increases expression ISO entinostat results in increased expression of IL2RB mRNA CTD PMID:27188386 NCBI chr 7:111,913,828...111,928,537
Ensembl chr 7:111,913,828...111,928,537 		JBrowse link
G Il3 interleukin 3 multiple interactions ISO entinostat inhibits the reaction [IL3 protein results in increased expression of CISH mRNA] CTD PMID:25769527 NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810 		JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of IL6 protein
TNFSF10 protein promotes the reaction [entinostat results in decreased expression of IL6 protein] 		CTD PMID:21041383 NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610 		JBrowse link
G Il6r interleukin 6 receptor multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL6R mRNA
entinostat results in increased expression of IL6R mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221 		JBrowse link
G Ildr2 immunoglobulin-like domain containing receptor 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ILDR2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ILDR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:81,051,723...81,113,590
Ensembl chr13:81,051,647...81,109,861 		JBrowse link
G Impa2 inositol monophosphatase 2 increases expression ISO entinostat results in increased expression of IMPA2 mRNA CTD PMID:27188386 NCBI chr18:63,104,113...63,135,232
Ensembl chr18:63,104,083...63,137,543 		JBrowse link
G Inf2 inverted formin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of INF2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:137,470,259...137,497,039
Ensembl chr 6:137,470,286...137,497,039 		JBrowse link
G Ing3 inhibitor of growth family, member 3 decreases expression ISO entinostat results in decreased expression of ING3 mRNA CTD PMID:27188386 NCBI chr 4:51,439,218...51,469,502
Ensembl chr 4:51,443,763...51,470,951 		JBrowse link
G Inhba inhibin subunit beta A increases expression
multiple interactions 		ISO entinostat results in increased expression of INHBA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508 		JBrowse link
G Inhbe inhibin subunit beta E increases expression
multiple interactions 		ISO entinostat results in increased expression of INHBE mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519 		JBrowse link
G Ino80d INO80 complex subunit D decreases expression ISO entinostat results in decreased expression of INO80D mRNA CTD PMID:27188386 NCBI chr 9:71,940,941...72,007,879
Ensembl chr 9:71,951,031...72,040,232 		JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA
entinostat results in increased expression of INPP5D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589 		JBrowse link
G Insig1 insulin induced gene 1 decreases expression ISO entinostat results in decreased expression of INSIG1 mRNA CTD PMID:27188386 NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778 		JBrowse link
G Ip6k3 inositol hexakisphosphate kinase 3 increases expression ISO entinostat results in increased expression of IP6K3 mRNA CTD PMID:27188386 NCBI chr20:5,225,706...5,247,293
Ensembl chr20:5,226,134...5,273,392 		JBrowse link
G Iqca1 IQ motif containing with AAA domain 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRC11 mRNA
entinostat results in increased expression of DRC11 mRNA 		CTD PMID:27188386 NCBI chr 9:98,074,389...98,190,233
Ensembl chr 9:98,073,887...98,190,066 		JBrowse link
G Iqch IQ motif containing H increases expression ISO entinostat results in increased expression of IQCH mRNA CTD PMID:27188386 NCBI chr 8:72,784,932...72,978,632
Ensembl chr 8:72,787,756...72,978,598 		JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA
entinostat results in increased expression of IQGAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043 		JBrowse link
G Iqgap2 IQ motif containing GTPase activating protein 2 increases expression ISO entinostat results in increased expression of IQGAP2 mRNA CTD PMID:27188386 NCBI chr 2:28,629,558...28,904,649
Ensembl chr 2:28,629,558...28,904,649 		JBrowse link
G Irak4 interleukin-1 receptor-associated kinase 4 increases expression ISO entinostat results in increased expression of IRAK4 mRNA CTD PMID:27188386 NCBI chr 7:127,561,777...127,588,762
Ensembl chr 7:127,561,717...127,597,109 		JBrowse link
G Irf2bpl interferon regulatory factor 2 binding protein-like increases expression
multiple interactions 		ISO entinostat results in increased expression of IRF2BPL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF2BPL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:112,258,149...112,262,264
Ensembl chr 6:112,258,188...112,263,280 		JBrowse link
G Irx1 iroquois homeobox 1 multiple interactions
decreases expression
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA
entinostat results in decreased expression of IRX1 mRNA
entinostat results in increased expression of IRX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:33,123,122...33,128,951
Ensembl chr 1:33,123,122...33,128,951 		JBrowse link
G Irx2 iroquois homeobox 2 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of IRX2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA
entinostat results in decreased expression of IRX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:32,489,512...32,494,930
Ensembl chr 1:32,489,512...32,494,930 		JBrowse link
G Irx3 iroquois homeobox 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of IRX3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:31,384,803...31,388,241
Ensembl chr19:31,384,833...31,388,238 		JBrowse link
G Irx5 iroquois homeobox 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of IRX5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:30,812,033...30,816,885
Ensembl chr19:30,797,202...30,815,029 		JBrowse link
G Isg15 ISG15 ubiquitin-like modifier increases expression ISO entinostat results in increased expression of ISG15 mRNA CTD PMID:27188386 NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:172,066,369...172,067,656 		JBrowse link
G Isg20 interferon stimulated exonuclease gene 20 increases expression ISO entinostat results in increased expression of ISG20 mRNA CTD PMID:27188386 NCBI chr 1:142,234,729...142,246,403
Ensembl chr 1:142,236,137...142,246,401 		JBrowse link
G Islr immunoglobulin superfamily containing leucine-rich repeat increases expression ISO entinostat results in increased expression of ISLR mRNA CTD PMID:27188386 NCBI chr 8:67,467,013...67,469,989
Ensembl chr 8:67,444,536...67,487,493 		JBrowse link
G Ism1 isthmin 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISM1 mRNA
entinostat results in increased expression of ISM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:147,476,983...147,555,900
Ensembl chr 3:147,475,533...147,555,908 		JBrowse link
G Isoc2b isochorismatase domain containing 2b multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISOC2 mRNA
entinostat results in increased expression of ISOC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:78,001,735...78,022,565
Ensembl chr 1:78,001,735...78,022,564 		JBrowse link
G Isyna1 inositol-3-phosphate synthase 1 increases expression ISO entinostat results in increased expression of ISYNA1 mRNA CTD PMID:27188386 NCBI chr16:18,873,119...18,876,116
Ensembl chr16:18,873,121...18,875,955 		JBrowse link
G Itga1 integrin subunit alpha 1 increases expression ISO entinostat results in increased expression of ITGA1 mRNA CTD PMID:26272509 NCBI chr 2:48,379,181...48,545,336
Ensembl chr 2:48,386,249...48,545,284 		JBrowse link
G Itga11 integrin subunit alpha 11 increases expression ISO entinostat results in increased expression of ITGA11 mRNA CTD PMID:27188386 NCBI chr 8:72,041,432...72,150,137
Ensembl chr 8:72,016,652...72,150,137 		JBrowse link
G Itga9 integrin subunit alpha 9 increases expression
multiple interactions 		ISO entinostat results in increased expression of ITGA9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:127,185,244...127,493,296
Ensembl chr 8:127,169,226...127,493,296 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGAM mRNA CTD PMID:27188386 NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943 		JBrowse link
G Itgav integrin subunit alpha V multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGAV mRNA
entinostat results in decreased expression of ITGAV mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:89,245,382...89,333,512
Ensembl chr 3:89,245,095...89,333,511 		JBrowse link
G Itgb5 integrin subunit beta 5 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA
entinostat results in decreased expression of ITGB5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:80,333,588...80,449,373
Ensembl chr11:80,333,590...80,449,373 		JBrowse link
G Itgb8 integrin subunit beta 8 decreases expression ISO entinostat results in decreased expression of ITGB8 mRNA CTD PMID:27188386 NCBI chr 6:146,267,982...146,351,245
Ensembl chr 6:146,165,484...146,351,245 		JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA
entinostat results in increased expression of ITIH5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:73,161,886...73,261,930
Ensembl chr17:73,161,611...73,262,496 		JBrowse link
G Itm2a integral membrane protein 2A increases expression
multiple interactions 		ISO entinostat results in increased expression of ITM2A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:76,559,183...76,565,144
Ensembl chr  X:76,559,181...76,565,437 		JBrowse link
G Itpr1 inositol 1,4,5-trisphosphate receptor, type 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR1 mRNA
entinostat results in increased expression of ITPR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504 		JBrowse link
G Itpr3 inositol 1,4,5-trisphosphate receptor, type 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR3 mRNA
entinostat results in increased expression of ITPR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:5,138,553...5,204,189
Ensembl chr20:5,118,834...5,204,184 		JBrowse link
G Itpripl1 ITPRIP like 1 increases expression ISO entinostat results in increased expression of ITPRIPL1 mRNA CTD PMID:27188386 NCBI chr 3:134,858,316...134,861,241
Ensembl chr 3:134,854,417...134,868,960 		JBrowse link
G Jade2 jade family PHD finger 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of JADE2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:36,576,187...36,625,129
Ensembl chr10:36,576,187...36,623,532 		JBrowse link
G Jak3 Janus kinase 3 increases expression ISO entinostat results in increased expression of JAK3 mRNA CTD PMID:27188386 NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222 		JBrowse link
G Jakmip2 janus kinase and microtubule interacting protein 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAKMIP2 mRNA
entinostat results in decreased expression of JAKMIP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:35,783,472...35,998,849
Ensembl chr18:35,783,472...35,998,682 		JBrowse link
G Jarid2 jumonji and AT-rich interaction domain containing 2 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JARID2 mRNA
entinostat results in increased expression of JARID2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,983,217...20,161,970 		JBrowse link
G Jazf1 JAZF zinc finger 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA
entinostat results in increased expression of JAZF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:83,210,054...83,513,790
Ensembl chr 4:83,210,058...83,513,644 		JBrowse link
G Jcad junctional cadherin 5 associated multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA
entinostat results in increased expression of JCAD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:57,784,634...57,826,213
Ensembl chr17:57,784,634...57,826,183 		JBrowse link
G Jdp2 Jun dimerization protein 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of JDP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:110,988,927...111,033,392
Ensembl chr 6:110,992,806...111,033,392 		JBrowse link
G Jph4 junctophilin 4 increases expression ISO entinostat results in increased expression of JPH4 mRNA CTD PMID:27188386 NCBI chr15:32,549,536...32,558,859
Ensembl chr15:32,549,555...32,558,859 		JBrowse link
G Jup junction plakoglobin increases expression ISO entinostat results in increased expression of JUP mRNA CTD PMID:27188386 NCBI chr10:85,800,812...85,827,881
Ensembl chr10:85,800,814...85,827,429 		JBrowse link
G Kank2 KN motif and ankyrin repeat domains 2 increases expression ISO entinostat results in increased expression of KANK2 mRNA CTD PMID:27188386 NCBI chr 8:28,587,770...28,617,212
Ensembl chr 8:28,587,770...28,616,993 		JBrowse link
G Kank3 KN motif and ankyrin repeat domains 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of KANK3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:15,296,538...15,309,838
Ensembl chr 7:15,296,585...15,311,408 		JBrowse link
G Kansl1l KAT8 regulatory NSL complex subunit 1-like decreases expression ISO entinostat results in decreased expression of KANSL1L mRNA CTD PMID:27188386 NCBI chr 9:75,660,865...75,766,730
Ensembl chr 9:75,661,233...75,766,745 		JBrowse link
G Kat2b lysine acetyltransferase 2B multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA
entinostat results in decreased expression of KAT2B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616 		JBrowse link
G Kat6b lysine acetyltransferase 6B decreases expression ISO entinostat results in decreased expression of KAT6B mRNA CTD PMID:27188386 NCBI chr15:2,688,535...2,861,443
Ensembl chr15:2,688,811...2,844,343 		JBrowse link
G Kat7 lysine acetyltransferase 7 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA
entinostat results in decreased expression of KAT7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:80,718,335...80,752,387
Ensembl chr10:80,718,335...80,752,387 		JBrowse link
G Katnal2 katanin catalytic subunit A1 like 2 increases expression ISO entinostat results in increased expression of KATNAL2 mRNA CTD PMID:27188386 NCBI chr18:72,806,967...72,883,091
Ensembl chr18:72,806,900...72,883,256 		JBrowse link
G Kbtbd8 kelch repeat and BTB domain containing 8 increases expression
multiple interactions 		ISO entinostat results in increased expression of KBTBD8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KBTBD8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:129,232,781...129,245,608
Ensembl chr 4:129,232,027...129,245,605 		JBrowse link
G Kcna1 potassium voltage-gated channel subfamily A member 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNA1 mRNA
entinostat results in decreased expression of KCNA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:161,150,378...161,160,051
Ensembl chr 4:161,147,418...161,160,044 		JBrowse link
G Kcnab1 potassium voltage-gated channel subfamily A regulatory beta subunit 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNAB1 mRNA
entinostat results in decreased expression of KCNAB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:151,446,975...151,913,636
Ensembl chr 2:151,446,947...151,913,636 		JBrowse link
G Kcnc4 potassium voltage-gated channel subfamily C member 4 increases expression ISO entinostat results in increased expression of KCNC4 mRNA CTD PMID:27188386 NCBI chr 2:197,747,095...197,788,467
Ensembl chr 2:197,759,010...197,788,433 		JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
entinostat results in decreased expression of KCND2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522 		JBrowse link
G Kcne3 potassium voltage-gated channel subfamily E regulatory subunit 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of KCNE3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNE3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:163,936,035...163,942,998
Ensembl chr 1:163,935,991...163,950,162 		JBrowse link
G Kcnj12 potassium inwardly-rectifying channel, subfamily J, member 12 increases expression
multiple interactions 		ISO entinostat results in increased expression of KCNJ12 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNJ12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:46,196,110...46,245,008
Ensembl chr10:46,195,428...46,260,169 		JBrowse link
G Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of KCNJ13 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:95,509,228...95,528,400
Ensembl chr 9:95,510,877...95,520,817 		JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA CTD PMID:27188386 NCBI chr 3:60,353,990...60,518,110
Ensembl chr 3:60,354,146...60,518,104 		JBrowse link
G Kcnj4 potassium inwardly-rectifying channel, subfamily J, member 4 increases expression ISO entinostat results in increased expression of KCNJ4 mRNA CTD PMID:27188386 NCBI chr 7:112,927,494...112,954,547
Ensembl chr 7:112,922,532...112,954,826 		JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA
entinostat results in increased expression of KCNK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:70,856,985...70,895,053
Ensembl chr19:70,856,985...70,895,051 		JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA
entinostat results in decreased expression of KCNK10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:123,419,778...123,555,820
Ensembl chr 6:123,423,950...123,555,614 		JBrowse link
G Kcnk6 potassium two pore domain channel subfamily K member 6 increases expression
multiple interactions 		ISO entinostat results in increased expression of KCNK6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:93,652,888...93,661,419 JBrowse link
G Kcnn2 potassium calcium-activated channel subfamily N member 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of KCNN2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:40,004,693...40,445,043
Ensembl chr18:40,155,939...40,445,045 		JBrowse link
G Kcnn4 potassium calcium-activated channel subfamily N member 4 increases expression ISO entinostat results in increased expression of KCNN4 mRNA CTD PMID:27188386 NCBI chr 1:89,084,306...89,102,279
Ensembl chr 1:89,086,814...89,102,275 		JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 increases expression ISO entinostat results in increased expression of KCNQ1 mRNA CTD PMID:27188386 NCBI chr 1:207,721,134...208,054,073
Ensembl chr 1:207,721,131...208,054,072 		JBrowse link
G Kcns3 potassium voltage-gated channel, modifier subfamily S, member 3 increases expression ISO entinostat results in increased expression of KCNS3 mRNA CTD PMID:27188386 NCBI chr 6:39,527,410...39,584,105
Ensembl chr 6:39,523,777...39,618,848 		JBrowse link
G Kcnt2 potassium sodium-activated channel subfamily T member 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of KCNT2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:54,214,831...54,609,889
Ensembl chr13:54,215,307...54,607,924 		JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 increases expression
multiple interactions 		ISO entinostat results in increased expression of KCTD12 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:86,214,786...86,220,725
Ensembl chr15:86,214,840...86,224,539 		JBrowse link
G Kctd14 potassium channel tetramerization domain containing 14 increases expression
multiple interactions 		ISO entinostat results in increased expression of KCTD14 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD14 mRNA 		CTD PMID:27188386 NCBI chr 1:161,172,906...161,177,914
Ensembl chr 1:161,171,451...161,178,413 		JBrowse link
G Kctd15 potassium channel tetramerization domain containing 15 decreases expression ISO entinostat results in decreased expression of KCTD15 mRNA CTD PMID:27188386 NCBI chr 1:96,395,794...96,411,502
Ensembl chr 1:96,395,794...96,410,631 		JBrowse link
G Kctd19 potassium channel tetramerization domain containing 19 increases expression ISO entinostat results in increased expression of KCTD19 mRNA CTD PMID:27188386 NCBI chr19:50,169,814...50,202,121
Ensembl chr19:50,169,891...50,202,103 		JBrowse link
G Kctd21 potassium channel tetramerization domain containing 21 increases expression ISO entinostat results in increased expression of KCTD21 mRNA CTD PMID:27188386 NCBI chr 1:161,061,318...161,081,002
Ensembl chr 1:161,054,045...161,088,271 		JBrowse link
G Kdm6b lysine demethylase 6B multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KDM6B mRNA
entinostat results in decreased expression of KDM6B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:54,619,520...54,641,014
Ensembl chr10:54,619,544...54,629,610 		JBrowse link
G Kdm7a lysine demethylase 7A decreases expression ISO entinostat results in decreased expression of KDM7A mRNA CTD PMID:27188386 NCBI chr 4:68,866,263...68,992,979
Ensembl chr 4:68,871,677...68,931,506 		JBrowse link
G Kdr kinase insert domain receptor increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of KDR mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA
entinostat results in decreased expression of KDR protein 		CTD PMID:21041383 PMID:26272509 PMID:27188386 NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192 		JBrowse link
G Kiaa0040 KIAA0040 ortholog increases expression
multiple interactions 		ISO entinostat results in increased expression of KIAA0040 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:74,807,959...74,845,530
Ensembl chr13:74,807,982...74,845,530 		JBrowse link
G Kiaa1755 KIAA1755 ortholog increases expression ISO entinostat results in increased expression of KIAA1755 mRNA CTD PMID:27188386 NCBI chr 3:167,270,476...167,305,337
Ensembl chr 3:167,192,612...167,304,240 		JBrowse link
G Kif13b kinesin family member 13B increases expression ISO entinostat results in increased expression of KIF13B mRNA CTD PMID:27188386 NCBI chr15:43,084,059...43,241,719
Ensembl chr15:43,080,910...43,241,719 		JBrowse link
G Kif15 kinesin family member 15 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF15 mRNA
entinostat results in decreased expression of KIF15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:131,479,337...131,550,202 		JBrowse link
G Kif16b kinesin family member 16B increases expression ISO entinostat results in increased expression of KIF16B mRNA CTD PMID:27188386 NCBI chr 3:150,428,233...150,707,755
Ensembl chr 3:150,366,838...150,707,770 		JBrowse link
G Kif1a kinesin family member 1A increases expression
multiple interactions 		ISO entinostat results in increased expression of KIF1A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:101,010,447...101,094,891
Ensembl chr 9:101,010,447...101,094,777 		JBrowse link
G Kif28 kinesin family member 28 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA CTD PMID:27188386 NCBI chr13:93,959,492...94,014,255
Ensembl chr13:93,959,492...94,014,255 		JBrowse link
G Kif6 kinesin family member 6 increases expression ISO entinostat results in increased expression of KIF6 mRNA CTD PMID:27188386 NCBI chr 9:18,573,925...18,870,789
Ensembl chr 9:18,573,789...18,870,729 		JBrowse link
G Kifc2 kinesin family member C2 increases expression ISO entinostat results in increased expression of KIFC2 mRNA CTD PMID:27188386 NCBI chr 7:110,261,257...110,269,007
Ensembl chr 7:110,261,009...110,269,005 		JBrowse link
G Kirrel1 kirre like nephrin family adhesion molecule 1 increases expression
multiple interactions
decreases expression 		ISO entinostat results in increased expression of KIRREL1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIRREL1 mRNA
entinostat results in decreased expression of KIRREL1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:174,819,564...174,912,998
Ensembl chr 2:174,819,572...174,912,960 		JBrowse link
G Kiss1r KISS1 receptor increases expression
multiple interactions 		ISO entinostat results in increased expression of KISS1R mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:10,435,766...10,439,424
Ensembl chr 7:10,435,766...10,439,424 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA
entinostat results in increased expression of KIT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812 		JBrowse link
G Kitlg KIT ligand increases expression
multiple interactions 		ISO entinostat results in increased expression of KITLG mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793 		JBrowse link
G Kiz kizuna centrosomal protein decreases expression
multiple interactions 		ISO entinostat results in decreased expression of KIZ mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:154,730,873...154,838,410
Ensembl chr 3:154,730,634...154,838,410 		JBrowse link
G Klf12 KLF transcription factor 12 decreases expression ISO entinostat results in decreased expression of KLF12 mRNA CTD PMID:27188386 NCBI chr15:83,037,548...83,469,998
Ensembl chr15:83,045,463...83,670,640 		JBrowse link
G Klf15 KLF transcription factor 15 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA
entinostat results in increased expression of KLF15 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:124,522,909...124,542,373 		JBrowse link
G Klf4 KLF transcription factor 4 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA
entinostat results in increased expression of KLF4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592 		JBrowse link
G Klf9 KLF transcription factor 9 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA
entinostat results in increased expression of KLF9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641 		JBrowse link
G Klhdc7a kelch domain containing 7A increases expression
multiple interactions 		ISO entinostat results in increased expression of KLHDC7A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHDC7A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:157,501,740...157,507,843
Ensembl chr 5:157,485,191...157,507,954 		JBrowse link
G Klhdc8a kelch domain containing 8A multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA
entinostat results in decreased expression of KLHDC8A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:46,287,011...46,296,429
Ensembl chr13:46,288,344...46,296,429 		JBrowse link
G Klhl1 kelch-like family member 1 decreases expression ISO entinostat results in decreased expression of KLHL1 mRNA CTD PMID:27188386 NCBI chr15:79,106,164...79,550,684
Ensembl chr15:79,106,164...79,550,684 		JBrowse link
G Klhl14 kelch-like family member 14 increases expression
multiple interactions 		ISO entinostat results in increased expression of KLHL14 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:13,079,159...13,192,728
Ensembl chr18:13,079,159...13,193,557 		JBrowse link
G Klhl18 kelch-like family member 18 increases expression
multiple interactions 		ISO entinostat results in increased expression of KLHL18 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:119,279,081...119,337,850
Ensembl chr 8:119,279,081...119,337,719 		JBrowse link
G Klhl24 kelch-like family member 24 decreases expression ISO entinostat results in decreased expression of KLHL24 mRNA CTD PMID:27188386 NCBI chr11:94,348,024...94,382,085
Ensembl chr11:94,351,157...94,382,050 		JBrowse link
G Klhl35 kelch-like family member 35 decreases expression ISO entinostat results in decreased expression of KLHL35 mRNA CTD PMID:27188386 NCBI chr 1:163,172,811...163,185,663
Ensembl chr 1:163,177,672...163,185,691 		JBrowse link
G Klhl42 kelch-like family, member 42 decreases expression ISO entinostat results in decreased expression of KLHL42 mRNA CTD PMID:27188386 NCBI chr 4:181,730,343...181,760,899
Ensembl chr 4:181,735,244...181,757,013 		JBrowse link
G Klhl5 kelch-like family member 5 increases expression ISO entinostat results in increased expression of KLHL5 mRNA CTD PMID:27188386 NCBI chr14:43,497,915...43,565,833
Ensembl chr14:43,497,918...43,537,894 		JBrowse link
G Klhl7 kelch-like family member 7 decreases expression ISO entinostat results in decreased expression of KLHL7 mRNA CTD PMID:27188386 NCBI chr 4:11,898,766...11,947,796
Ensembl chr 4:11,898,769...11,947,796 		JBrowse link
G Klk10 kallikrein related-peptidase 10 increases expression
multiple interactions 		ISO entinostat results in increased expression of KLK10 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:103,371,638...103,375,918
Ensembl chr 1:103,371,638...103,375,918 		JBrowse link
G Klk6 kallikrein related-peptidase 6 increases expression ISO entinostat results in increased expression of KLK6 mRNA CTD PMID:27188386 NCBI chr 1:103,415,411...103,422,682
Ensembl chr 1:103,416,886...103,422,690 		JBrowse link
G Klk8 kallikrein related-peptidase 8 increases expression
multiple interactions 		ISO entinostat results in increased expression of KLK8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:103,388,352...103,395,195
Ensembl chr 1:103,388,352...103,395,195 		JBrowse link
G Klkb1 kallikrein B1 increases expression
multiple interactions 		ISO entinostat results in increased expression of KLKB1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLKB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:53,690,180...53,714,570
Ensembl chr16:53,691,220...53,716,339 		JBrowse link
G Klrg2 killer cell lectin like receptor G2 increases expression
multiple interactions 		ISO entinostat results in increased expression of KLRG2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:68,314,347...68,341,759
Ensembl chr 4:68,330,660...68,341,043 		JBrowse link
G Kmt5b lysine methyltransferase 5B decreases expression ISO entinostat results in decreased expression of KMT5B mRNA CTD PMID:27188386 NCBI chr 1:210,429,672...210,479,042
Ensembl chr 1:210,430,127...210,479,035 		JBrowse link
G Kndc1 kinase non-catalytic C-lobe domain containing 1 increases expression ISO entinostat results in increased expression of KNDC1 mRNA CTD PMID:27188386 NCBI chr 1:204,119,597...204,167,967
Ensembl chr 1:204,119,659...204,167,965 		JBrowse link
G Kremen1 kringle containing transmembrane protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of KREMEN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:84,295,931...84,361,534
Ensembl chr14:84,297,700...84,361,614 		JBrowse link
G Krt17 keratin 17 increases expression ISO entinostat results in increased expression of KRT17 mRNA CTD PMID:27188386 NCBI chr10:85,679,068...85,683,792
Ensembl chr10:85,679,070...85,683,787 		JBrowse link
G Krt18 keratin 18 increases expression
multiple interactions 		ISO entinostat results in increased expression of KRT18 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848 		JBrowse link
G Krt23 keratin 23 increases expression ISO entinostat results in increased expression of KRT23 mRNA CTD PMID:27188386 NCBI chr10:84,930,603...84,946,929
Ensembl chr10:84,930,603...84,946,929 		JBrowse link
G Krt7 keratin 7 increases expression
multiple interactions 		ISO entinostat results in increased expression of KRT7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:134,407,626...134,423,787
Ensembl chr 7:134,407,584...134,423,786 		JBrowse link
G Krt8 keratin 8 increases expression
multiple interactions 		ISO entinostat results in increased expression of KRT8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403 		JBrowse link
G L1cam L1 cell adhesion molecule increases expression
multiple interactions 		ISO entinostat results in increased expression of L1CAM mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:156,748,597...156,775,116
Ensembl chr  X:156,748,597...156,775,077 		JBrowse link
G L1td1 LINE-1 type transposase domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of L1TD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1TD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:118,488,688...118,501,591
Ensembl chr 5:118,488,688...118,501,591 		JBrowse link
G L3mbtl1 L3MBTL histone methyl-lysine binding protein 1 increases expression ISO entinostat results in increased expression of L3MBTL1 mRNA CTD PMID:27188386 NCBI chr 3:172,014,774...172,053,181
Ensembl chr 3:172,021,416...172,053,181 		JBrowse link
G Lacc1 laccase domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of LACC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:58,799,477...58,816,840
Ensembl chr15:58,786,637...58,816,840 		JBrowse link
G Lactb lactamase, beta increases expression
multiple interactions 		ISO entinostat results in increased expression of LACTB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,452,679...76,469,986
Ensembl chr 8:76,452,349...76,468,716 		JBrowse link
G Lamc1 laminin subunit gamma 1 increases expression ISO entinostat results in increased expression of LAMC1 mRNA CTD PMID:27188386 NCBI chr13:67,924,872...68,051,986
Ensembl chr13:67,924,872...68,051,986 		JBrowse link
G Lamc3 laminin subunit gamma 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of LAMC3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:35,562,989...35,624,460
Ensembl chr 3:35,562,713...35,624,460 		JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of LAMP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:122,038,734...122,087,745
Ensembl chr  X:121,922,187...122,087,675 		JBrowse link
G Lamp3 lysosomal-associated membrane protein 3 increases expression ISO entinostat results in increased expression of LAMP3 mRNA CTD PMID:27188386 NCBI chr11:94,657,817...94,726,451
Ensembl chr11:94,661,399...94,726,195 		JBrowse link
G Lancl2 LanC like glutathione S-transferase 2 decreases expression ISO entinostat results in decreased expression of LANCL2 mRNA CTD PMID:27188386 NCBI chr 4:88,771,974...88,813,920
Ensembl chr 4:88,773,437...88,832,899 		JBrowse link
G Larp4 La ribonucleoprotein 4 increases expression
multiple interactions 		ISO entinostat results in increased expression of LARP4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LARP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:132,983,276...133,031,514
Ensembl chr 7:132,980,385...133,029,633 		JBrowse link
G Larp7 La ribonucleoprotein 7, transcriptional regulator increases expression
multiple interactions 		ISO entinostat results in increased expression of LARP7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LARP7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:218,672,145...218,687,332
Ensembl chr 2:218,672,208...218,687,308 		JBrowse link
G Layn layilin increases expression
multiple interactions 		ISO entinostat results in increased expression of LAYN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:60,261,325...60,280,797
Ensembl chr 8:60,263,456...60,281,418 		JBrowse link
G Lca5 lebercilin LCA5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LCA5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:93,187,735...93,255,060
Ensembl chr 8:93,197,702...93,254,991 		JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions 		ISO entinostat results in increased expression of LCK mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267 		JBrowse link
G Lcorl ligand dependent nuclear receptor corepressor-like decreases expression ISO entinostat results in decreased expression of LCORL mRNA CTD PMID:27188386 NCBI chr14:69,482,919...69,620,269
Ensembl chr14:69,518,837...69,587,177 		JBrowse link
G Lctl lactase-like decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:73,506,096...73,534,668
Ensembl chr 8:73,513,634...73,534,668 		JBrowse link
G Ldhd lactate dehydrogenase D increases expression
multiple interactions 		ISO entinostat results in increased expression of LDHD mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:56,492,827...56,497,695
Ensembl chr19:56,482,924...56,509,197 		JBrowse link
G Ldlrap1 low density lipoprotein receptor adaptor protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of LDLRAP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDLRAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:152,239,296...152,262,290
Ensembl chr 5:152,229,505...152,262,290 		JBrowse link
G Lef1 lymphoid enhancer binding factor 1 increases expression ISO entinostat results in increased expression of LEF1 mRNA CTD PMID:27188386 NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929 		JBrowse link
G Lemd1 LEM domain containing 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LEMD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:46,183,860...46,250,105
Ensembl chr13:46,218,085...46,250,562 		JBrowse link
G Lgals1 galectin 1 increases expression ISO entinostat results in increased expression of LGALS1 mRNA CTD PMID:27188386 NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800 		JBrowse link
G Lgals3 galectin 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of LGALS3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737 		JBrowse link
G Lgr5 leucine rich repeat containing G protein coupled receptor 5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LGR5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LGR5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:52,973,151...53,107,964
Ensembl chr 7:52,974,332...53,108,163 		JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions 		ISO entinostat results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:139,276,810...139,474,740
Ensembl chr 2:139,276,789...139,474,737 		JBrowse link
G Lhx2 LIM homeobox 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LHX2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645 		JBrowse link
G Lhx4 LIM homeobox 4 increases expression ISO entinostat results in increased expression of LHX4 mRNA CTD PMID:26272509 NCBI chr13:70,423,768...70,477,337
Ensembl chr13:70,427,399...70,467,505 		JBrowse link
G Lhx8 LIM homeobox 8 increases expression
multiple interactions 		ISO entinostat results in increased expression of LHX8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:245,904,712...245,929,376
Ensembl chr 2:245,904,712...245,929,376 		JBrowse link
G Lifr LIF receptor subunit alpha increases expression
multiple interactions 		ISO entinostat results in increased expression of LIFR mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:57,951,787...58,020,357
Ensembl chr 2:57,952,975...58,020,364 		JBrowse link
G Lig3 DNA ligase 3 decreases expression ISO entinostat results in decreased expression of LIG3 mRNA CTD PMID:27188386 NCBI chr10:68,215,371...68,238,705
Ensembl chr10:68,215,407...68,238,704 		JBrowse link
G Lim2 lens intrinsic membrane protein 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LIM2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:102,974,188...102,980,358
Ensembl chr 1:102,974,188...102,980,358 		JBrowse link
G Lima1 LIM domain and actin binding 1 increases expression ISO entinostat results in increased expression of LIMA1 mRNA CTD PMID:27188386 NCBI chr 7:132,780,556...132,880,343
Ensembl chr 7:132,780,556...132,880,386 		JBrowse link
G Litaf lipopolysaccharide-induced TNF factor increases expression
multiple interactions 		ISO entinostat results in increased expression of LITAF mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LITAF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930 		JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LIX1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:66,802,044...66,859,040
Ensembl chr 1:66,802,272...66,860,627 		JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:61,778,971...61,800,960
Ensembl chr18:61,772,917...61,800,820 		JBrowse link
G Lmf1 lipase maturation factor 1 increases expression ISO entinostat results in increased expression of LMF1 mRNA CTD PMID:27188386 NCBI chr10:15,094,432...15,188,665
Ensembl chr10:15,098,138...15,188,664 		JBrowse link
G Lmnb1 lamin B1 decreases expression ISO entinostat results in decreased expression of LMNB1 mRNA CTD PMID:27188386 NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283 		JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:172,965,944...173,028,980
Ensembl chr 4:172,965,951...173,025,156 		JBrowse link
G Lmo4 LIM domain only 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LMO4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:235,924,574...235,941,609
Ensembl chr 2:235,924,403...235,941,275 		JBrowse link
G Lmo7 LIM domain 7 increases expression
multiple interactions 		ISO entinostat results in increased expression of LMO7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551 		JBrowse link
G Lnpk lunapark, ER junction formation factor decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LNPK mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LNPK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:79,826,318...79,894,514
Ensembl chr 3:79,832,753...79,894,403 		JBrowse link
G Lnx1 ligand of numb-protein X 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of LNX1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:33,868,517...33,971,217
Ensembl chr14:33,868,571...33,971,217 		JBrowse link
G Lonrf3 LON peptidase N-terminal domain and ring finger 3 increases expression ISO entinostat results in increased expression of LONRF3 mRNA CTD PMID:27188386 NCBI chr  X:120,430,975...120,469,648
Ensembl chr  X:120,430,996...120,464,572 		JBrowse link
G Loxl1 lysyl oxidase-like 1 increases expression ISO entinostat results in increased expression of LOXL1 mRNA CTD PMID:27188386 NCBI chr 8:67,587,636...67,612,224
Ensembl chr 8:67,587,636...67,612,224 		JBrowse link
G Loxl4 lysyl oxidase-like 4 increases expression ISO entinostat results in increased expression of LOXL4 mRNA CTD PMID:27188386 NCBI chr 1:251,345,445...251,365,640
Ensembl chr 1:251,347,238...251,365,577 		JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of LPAR3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:237,785,371...237,854,199
Ensembl chr 2:237,787,766...237,854,197 		JBrowse link
G Lpcat2 lysophosphatidylcholine acyltransferase 2 increases expression ISO entinostat results in increased expression of LPCAT2 mRNA CTD PMID:27188386 NCBI chr19:30,261,369...30,325,715
Ensembl chr19:30,262,676...30,325,775 		JBrowse link
G Lpcat4 lysophosphatidylcholine acyltransferase 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LPCAT4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPCAT4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:119,499,128...119,507,275
Ensembl chr 3:119,499,128...119,507,362 		JBrowse link
G Lpgat1 lysophosphatidylglycerol acyltransferase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of LPGAT1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPGAT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:105,825,630...105,896,366
Ensembl chr13:105,820,468...105,896,364 		JBrowse link
G Lpin1 lipin 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LPIN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPIN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991 		JBrowse link
G Lpl lipoprotein lipase decreases expression ISO entinostat results in decreased expression of LPL mRNA CTD PMID:27188386 NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107 		JBrowse link
G Lrat lecithin retinol acyltransferase increases expression ISO entinostat results in increased expression of LRAT mRNA CTD PMID:27188386 NCBI chr 2:170,562,148...170,571,212
Ensembl chr 2:170,565,543...170,571,148 		JBrowse link
G Lratd1 LRAT domain containing 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LRATD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRATD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:42,646,515...42,650,988
Ensembl chr 6:42,640,190...42,651,204 		JBrowse link
G Lrch1 leucine rich repeats and calponin homology domain containing 1 decreases expression ISO entinostat results in decreased expression of LRCH1 mRNA CTD PMID:27188386 NCBI chr15:56,469,403...56,659,201
Ensembl chr15:56,481,395...56,659,100 		JBrowse link
G Lrfn1 leucine rich repeat and fibronectin type III domain containing 1 increases expression ISO entinostat results in increased expression of LRFN1 mRNA CTD PMID:27188386 NCBI chr 1:92,866,864...92,888,984
Ensembl chr 1:92,874,827...92,888,982 		JBrowse link
G Lrmda leucine rich melanocyte differentiation associated increases expression ISO entinostat results in increased expression of LRMDA mRNA CTD PMID:27188386 NCBI chr15:1,275,139...2,334,153
Ensembl chr15:1,274,199...2,334,089 		JBrowse link
G Lrp12 LDL receptor related protein 12 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA CTD PMID:27188386 NCBI chr 7:72,825,979...72,897,308
Ensembl chr 7:72,825,979...72,897,171 		JBrowse link
G Lrp2 LDL receptor related protein 2 decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of LRP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA
entinostat results in increased expression of LRP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535 		JBrowse link
G Lrrc17 leucine rich repeat containing 17 increases expression
multiple interactions 		ISO entinostat results in increased expression of LRRC17 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048 		JBrowse link
G Lrrc3b leucine rich repeat containing 3B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LRRC3B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:12,404,309...12,481,618
Ensembl chr15:12,336,369...12,481,866 		JBrowse link
G Lrrc4 leucine rich repeat containing 4 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC4 mRNA
entinostat results in decreased expression of LRRC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:58,398,942...58,402,538
Ensembl chr 4:58,397,302...58,402,808 		JBrowse link
G Lrrc55 leucine rich repeat containing 55 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA
entinostat results in decreased expression of LRRC55 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:90,676,547...90,687,392
Ensembl chr 3:90,680,160...90,685,280 		JBrowse link
G Lrrc8a leucine rich repeat containing 8 VRAC subunit A decreases expression ISO entinostat results in decreased expression of LRRC8A mRNA CTD PMID:27188386 NCBI chr 3:33,902,299...33,934,989
Ensembl chr 3:33,908,268...33,933,625 		JBrowse link
G Lrrc8b leucine rich repeat containing 8 VRAC subunit B multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA
entinostat results in decreased expression of LRRC8B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:4,655,273...4,721,648
Ensembl chr14:4,655,273...4,721,076 		JBrowse link
G Lrrc8c leucine rich repeat containing 8 VRAC subunit C decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of LRRC8C mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8C mRNA
entinostat results in increased expression of LRRC8C mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:4,528,721...4,621,259
Ensembl chr14:4,531,823...4,620,049 		JBrowse link
G Lrrc8e leucine rich repeat containing 8 VRAC subunit E increases expression
multiple interactions 		ISO entinostat results in increased expression of LRRC8E mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:7,376,103...7,387,250
Ensembl chr12:7,380,585...7,387,249 		JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of LRRFIP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:99,039,590...99,167,805
Ensembl chr 9:99,039,614...99,167,779 		JBrowse link
G Lrrk1 leucine-rich repeat kinase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of LRRK1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:129,254,815...129,390,217
Ensembl chr 1:129,254,515...129,389,941 		JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of LRRN3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:64,216,164...64,247,293
Ensembl chr 6:64,215,878...64,247,614 		JBrowse link
G Lsamp limbic system-associated membrane protein decreases expression
multiple interactions 		ISO entinostat results in decreased expression of LSAMP mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:72,053,285...74,223,019
Ensembl chr11:72,053,285...72,702,134 		JBrowse link
G Lsm8 LSM8 homolog, U6 small nuclear RNA associated multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSM8 mRNA
entinostat results in decreased expression of LSM8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:48,272,128...48,277,994
Ensembl chr 4:48,272,164...48,280,162 		JBrowse link
G Ltbp2 latent transforming growth factor beta binding protein 2 increases expression ISO entinostat results in increased expression of LTBP2 mRNA CTD PMID:27188386 NCBI chr 6:110,161,029...110,261,586
Ensembl chr 6:110,161,029...110,257,298 		JBrowse link
G Ly75 lymphocyte antigen 75 increases expression
multiple interactions 		ISO entinostat results in increased expression of LY75 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878 		JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions 		ISO entinostat results in increased expression of LYN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:21,437,127...21,553,097
Ensembl chr 5:21,437,084...21,554,461 		JBrowse link
G Lypd3 Ly6/Plaur domain containing 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of LYPD3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:89,354,354...89,358,806
Ensembl chr 1:89,354,335...89,358,810 		JBrowse link
G Lyzl6 lysozyme-like 6 increases expression
multiple interactions 		ISO entinostat results in increased expression of LYZL6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:89,044,375...89,049,210
Ensembl chr10:89,044,375...89,049,210 		JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of LZTS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:25,309,502...25,364,942
Ensembl chr16:25,309,507...25,364,940 		JBrowse link
G Mab21l2 mab-21 like 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA
entinostat results in decreased expression of MAB21L2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:174,244,538...174,247,620
Ensembl chr 2:174,238,828...174,252,064 		JBrowse link
G Macc1 MET transcriptional regulator MACC1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MACC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:146,495,544...146,574,254
Ensembl chr 6:146,495,861...146,574,260 		JBrowse link
G Macrod2 mono-ADP ribosylhydrolase 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MACROD2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:148,173,821...150,191,077
Ensembl chr 3:148,173,829...150,188,058 		JBrowse link
G Macroh2a1 macroH2A.1 histone decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MACROH2A1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:8,484,340...8,547,268
Ensembl chr17:8,484,246...8,547,257 		JBrowse link
G Macroh2a2 macroH2A.2 histone decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MACROH2A2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:30,220,975...30,270,652
Ensembl chr20:30,221,011...30,270,652 		JBrowse link
G Madcam1 mucosal vascular addressin cell adhesion molecule 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MADCAM1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of MADCAM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:10,686,920...10,690,322
Ensembl chr 7:10,686,250...10,690,322 		JBrowse link
G Maf MAF bZIP transcription factor decreases expression ISO entinostat results in decreased expression of MAF mRNA CTD PMID:26272509 NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378 		JBrowse link
G Mafb MAF bZIP transcription factor B decreases expression ISO entinostat results in decreased expression of MAFB mRNA CTD PMID:26272509 NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975 		JBrowse link
G Magea9 MAGE family member A9 multiple interactions ISO entinostat affects the reaction [decitabine affects the expression of MAGEA9 mRNA]; entinostat affects the reaction [decitabine affects the expression of MAGEA9 protein] CTD PMID:17290406 NCBI chr  X:147,655,721...147,661,093
Ensembl chr  X:147,655,721...147,661,093 		JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 increases expression ISO entinostat results in increased expression of MAGI2 mRNA CTD PMID:26272509 NCBI chr 4:15,278,518...16,762,427
Ensembl chr 4:15,278,518...16,762,199 		JBrowse link
G Magi3 membrane associated guanylate kinase, WW and PDZ domain containing 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MAGI3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAGI3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:194,206,587...194,405,468
Ensembl chr 2:194,206,934...194,405,157 		JBrowse link
G Mak male germ cell-associated kinase decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MAK mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:23,889,417...23,936,857
Ensembl chr17:23,889,516...23,936,855 		JBrowse link
G Mal2 mal, T-cell differentiation protein 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of MAL2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:87,790,239...87,823,219
Ensembl chr 7:87,790,239...87,850,403 		JBrowse link
G Mamdc2 MAM domain containing 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MAMDC2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAMDC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:230,290,482...230,443,014
Ensembl chr 1:230,290,499...230,442,711 		JBrowse link
G Maml2 mastermind-like transcriptional coactivator 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MAML2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAML2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:18,552,480...18,869,923
Ensembl chr 8:18,552,281...18,869,900 		JBrowse link
G Man2a2 mannosidase, alpha, class 2A, member 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MAN2A2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN2A2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:143,712,157...143,736,624
Ensembl chr 1:143,716,072...143,736,562 		JBrowse link
G Mansc1 MANSC domain containing 1 increases expression ISO entinostat results in increased expression of MANSC1 mRNA CTD PMID:27188386 NCBI chr 4:169,170,164...169,190,379
Ensembl chr 4:169,170,164...169,189,864 		JBrowse link
G Maoa monoamine oxidase A increases expression
multiple interactions 		ISO entinostat results in increased expression of MAOA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAOA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:8,615,239...8,681,372
Ensembl chr  X:8,615,239...8,682,631 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO entinostat results in increased expression of MAP1LC3B protein modified form CTD PMID:20962572 NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO entinostat results in decreased expression of MAP2K6 mRNA CTD PMID:26272509 NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721 		JBrowse link
G Map3k2 mitogen activated protein kinase kinase kinase 2 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA CTD PMID:27188386 NCBI chr18:24,081,444...24,153,940
Ensembl chr18:24,081,444...24,147,323 		JBrowse link
G Map3k20 mitogen-activated protein kinase kinase kinase 20 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MAP3K20 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K20 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:77,538,146...77,697,540
Ensembl chr 3:77,537,956...77,697,538 		JBrowse link
G Map3k21 mitogen-activated protein kinase kinase kinase 21 increases expression
multiple interactions 		ISO entinostat results in increased expression of MAP3K21 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K21 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:70,776,233...70,810,889
Ensembl chr19:70,777,472...70,810,882 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of MAP3K5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:16,505,596...16,723,898 		JBrowse link
G Map3k6 mitogen-activated protein kinase kinase kinase 6 increases expression ISO entinostat results in increased expression of MAP3K6 mRNA CTD PMID:27188386 NCBI chr 5:150,724,029...150,736,113
Ensembl chr 5:150,724,216...150,736,111 		JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 increases expression ISO entinostat results in increased expression of MAP3K8 mRNA CTD PMID:27188386 NCBI chr17:58,078,175...58,098,455
Ensembl chr17:58,078,320...58,098,452 		JBrowse link
G Map4k1 mitogen activated protein kinase kinase kinase kinase 1 increases expression ISO entinostat results in increased expression of MAP4K1 mRNA CTD PMID:27188386 NCBI chr 1:93,398,460...93,419,996
Ensembl chr 1:93,398,454...93,419,993 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100 		JBrowse link
G Mapk13 mitogen activated protein kinase 13 increases expression
multiple interactions 		ISO entinostat results in increased expression of MAPK13 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:6,836,979...6,847,197
Ensembl chr20:6,837,013...6,847,191 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
decreases expression 		ISO [3-(4-methylphenylsulfonyl)-2-propenenitrile co-treated with entinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein
entinostat results in decreased expression of MAPK8 mRNA 		CTD PMID:15964800 PMID:27188386 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427 		JBrowse link
G Mapre2 microtubule-associated protein, RP/EB family, member 2 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPRE2 mRNA CTD PMID:27188386 NCBI chr18:15,303,502...15,444,306
Ensembl chr18:15,303,533...15,442,796 		JBrowse link
G Marchf11 membrane associated ring-CH-type finger 11 decreases expression ISO entinostat results in decreased expression of MARCHF11 mRNA CTD PMID:27188386 NCBI chr 2:78,628,793...78,730,164
Ensembl chr 2:78,628,191...78,755,104 		JBrowse link
G Marchf2 membrane associated ring-CH-type finger 2 increases expression ISO entinostat results in increased expression of MARCHF2 mRNA CTD PMID:27188386 NCBI chr 7:15,183,931...15,209,988
Ensembl chr 7:15,183,925...15,202,002 		JBrowse link
G Marchf3 membrane associated ring-CH-type finger 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of MARCHF3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARCHF3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:52,435,292...52,587,321
Ensembl chr18:52,435,296...52,587,297 		JBrowse link
G Marchf9 membrane associated ring-CH-type finger 9 increases expression ISO entinostat results in increased expression of MARCHF9 mRNA CTD PMID:27188386 NCBI chr 7:64,764,346...64,767,824
Ensembl chr 7:64,764,347...64,767,824 		JBrowse link
G Marcks myristoylated alanine rich protein kinase C substrate decreases expression ISO entinostat results in decreased expression of MARCKS mRNA CTD PMID:27188386 NCBI chr20:42,240,185...42,245,882
Ensembl chr20:42,240,185...42,245,882 		JBrowse link
G Mark1 microtubule affinity regulating kinase 1 decreases expression ISO entinostat results in decreased expression of MARK1 mRNA CTD PMID:27188386 NCBI chr13:98,981,727...99,086,998
Ensembl chr13:98,983,020...99,086,701 		JBrowse link
G Marveld3 MARVEL domain containing 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of MARVELD3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:54,818,180...54,832,871
Ensembl chr19:54,818,180...54,832,871 		JBrowse link
G Matk megakaryocyte-associated tyrosine kinase increases expression ISO entinostat results in increased expression of MATK mRNA CTD PMID:27188386 NCBI chr 7:9,107,711...9,116,864
Ensembl chr 7:9,107,722...9,112,746 		JBrowse link
G Matn2 matrilin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of MATN2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MATN2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:67,380,140...67,529,767
Ensembl chr 7:67,380,168...67,530,153 		JBrowse link
G Matn3 matrilin 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of MATN3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MATN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:37,467,729...37,487,776
Ensembl chr 6:37,467,729...37,487,776 		JBrowse link
G Matr3 matrin 3 increases expression ISO entinostat results in increased expression of MATR3 mRNA CTD PMID:26272509 NCBI chr18:27,428,190...27,474,421
Ensembl chr18:27,432,179...27,470,421 		JBrowse link
G Mb myoglobin increases expression
multiple interactions 		ISO entinostat results in increased expression of MB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:110,640,511...110,647,742
Ensembl chr 7:110,640,512...110,647,958 		JBrowse link
G Mb21d2 Mab-21 domain containing 2 decreases expression ISO entinostat results in decreased expression of MB21D2 mRNA CTD PMID:27188386 NCBI chr11:85,330,526...85,429,543
Ensembl chr11:85,330,503...85,476,241 		JBrowse link
G Mbd2 methyl-CpG binding domain protein 2 increases expression ISO entinostat results in increased expression of MBD2 mRNA CTD PMID:27188386 NCBI chr18:66,449,196...66,516,112
Ensembl chr18:66,449,358...66,516,111 		JBrowse link
G Mbd5 methyl-CpG binding domain protein 5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MBD5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:53,742,458...54,147,970
Ensembl chr 3:54,075,084...54,139,389 		JBrowse link
G Mbnl2 muscleblind-like splicing regulator 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MBNL2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBNL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:103,792,134...103,949,827
Ensembl chr15:103,792,152...103,949,827 		JBrowse link
G Mbnl3 muscleblind-like splicing regulator 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of MBNL3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:135,526,256...135,621,499
Ensembl chr  X:135,532,494...135,621,976 		JBrowse link
G Mboat1 membrane bound O-acyltransferase domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MBOAT1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,540,041...34,653,698 		JBrowse link
G Mcam melanoma cell adhesion molecule increases expression ISO entinostat results in increased expression of MCAM mRNA CTD PMID:27188386 NCBI chr 8:53,376,225...53,384,407
Ensembl chr 8:53,376,197...53,384,406 		JBrowse link
G Mcc MCC regulator of WNT signaling pathway multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA
entinostat results in increased expression of MCC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:37,042,350...37,517,114
Ensembl chr18:37,049,253...37,517,076 		JBrowse link
G Mcf2l MCF.2 cell line derived transforming sequence-like decreases expression ISO entinostat results in decreased expression of MCF2L mRNA CTD PMID:27188386 NCBI chr16:83,209,277...83,355,683
Ensembl chr16:83,209,280...83,354,956 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO [fludarabine co-treated with entinostat] results in increased expression of MCL1 protein CTD PMID:15059916 NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782 		JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:237,596,544...237,705,770
Ensembl chr 2:237,626,302...237,705,769 		JBrowse link
G Mcrip2 MAPK regulated co-repressor interacting protein 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of MCRIP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCRIP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:15,388,325...15,393,302
Ensembl chr10:15,388,325...15,398,730 		JBrowse link
G Mcub mitochondrial calcium uniporter dominant negative subunit beta decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MCUB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:221,153,525...221,223,814
Ensembl chr 2:221,153,525...221,223,814 		JBrowse link
G Me1 malic enzyme 1 increases expression ISO entinostat results in increased expression of ME1 mRNA CTD PMID:27188386 NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275 		JBrowse link
G Me3 malic enzyme 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of ME3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:152,946,595...153,148,026
Ensembl chr 1:152,946,628...153,148,026 		JBrowse link
G Mecom MDS1 and EVI1 complex locus decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of MECOM mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA
entinostat results in increased expression of MECOM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:114,837,815...115,393,052
Ensembl chr 2:114,837,840...115,393,038 		JBrowse link
G Med14 mediator complex subunit 14 increases expression
multiple interactions 		ISO entinostat results in increased expression of MED14 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:12,709,406...12,800,642
Ensembl chr  X:12,709,472...12,800,640 		JBrowse link
G Medag mesenteric estrogen-dependent adipogenesis increases expression
multiple interactions 		ISO entinostat results in increased expression of MEDAG mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEDAG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:10,649,526...10,670,913
Ensembl chr12:10,649,526...10,692,756 		JBrowse link
G Megf10 multiple EGF-like domains 10 increases expression
multiple interactions 		ISO entinostat results in increased expression of MEGF10 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEGF10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:52,803,292...52,953,431
Ensembl chr18:52,847,781...52,950,675 		JBrowse link
G Meiob meiosis specific with OB-fold increases expression ISO entinostat results in increased expression of MEIOB mRNA CTD PMID:27188386 NCBI chr10:14,336,869...14,369,566
Ensembl chr10:14,338,288...14,369,565 		JBrowse link
G Meioc meiosis specific with coiled-coil domain increases expression ISO entinostat results in increased expression of MEIOC mRNA CTD PMID:27188386 NCBI chr10:88,128,939...88,147,833
Ensembl chr10:88,128,990...88,147,829 		JBrowse link
G Meis1 Meis homeobox 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MEIS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:97,356,949...97,499,646
Ensembl chr14:97,322,748...97,495,083 		JBrowse link
G Meltf melanotransferrin increases expression ISO entinostat results in increased expression of MELTF mRNA CTD PMID:27188386 NCBI chr11:82,389,420...82,411,270
Ensembl chr11:82,389,420...82,411,270 		JBrowse link
G Meox1 mesenchyme homeobox 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MEOX1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976 		JBrowse link
G Mest mesoderm specific transcript decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MEST mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEST mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:60,321,814...60,332,288
Ensembl chr 4:60,316,102...60,333,509 		JBrowse link
G Metrn meteorin, glial cell differentiation regulator multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METRN mRNA
entinostat results in decreased expression of METRN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:15,321,200...15,323,218
Ensembl chr10:15,321,200...15,323,642 		JBrowse link
G Mettl21a methyltransferase 21A, HSPA lysine multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA CTD PMID:27188386 NCBI chr 9:73,400,223...73,484,677
Ensembl chr 9:73,471,813...73,481,339 		JBrowse link
G Mettl8 methyltransferase 8, tRNA N3-cytidine increases expression
multiple interactions 		ISO entinostat results in increased expression of METTL8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:76,140,465...76,271,367
Ensembl chr 3:76,144,178...76,271,400 		JBrowse link
G Mex3a mex-3 RNA binding family member A decreases expression ISO entinostat results in decreased expression of MEX3A mRNA CTD PMID:27188386 NCBI chr 2:176,287,900...176,297,369
Ensembl chr 2:176,287,900...176,297,369 		JBrowse link
G Mex3b mex-3 RNA binding family member B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MEX3B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEX3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:146,264,319...146,268,554
Ensembl chr 1:146,264,318...146,268,543 		JBrowse link
G Mfap3l microfibril associated protein 3 like decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of MFAP3L mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA
entinostat results in increased expression of MFAP3L mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:34,422,490...34,465,544
Ensembl chr16:34,426,696...34,441,709 		JBrowse link
G Mfap5 microfibril associated protein 5 increases expression ISO entinostat results in increased expression of MFAP5 mRNA CTD PMID:27188386 NCBI chr 4:157,399,919...157,422,448
Ensembl chr 4:157,395,597...157,422,448 		JBrowse link
G Mfn2 mitofusin 2 decreases expression ISO entinostat results in decreased expression of MFN2 mRNA CTD PMID:27188386 NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495 		JBrowse link
G Mfsd9 major facilitator superfamily domain containing 9 decreases expression ISO entinostat results in decreased expression of SLC67A2 mRNA CTD PMID:26272509 NCBI chr 9:50,515,209...50,534,698
Ensembl chr 9:50,515,214...50,534,707 		JBrowse link
G Mgarp mitochondria-localized glutamic acid-rich protein increases expression
multiple interactions 		ISO entinostat results in increased expression of MGARP mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGARP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:137,582,152...137,590,294
Ensembl chr 2:137,582,152...137,590,481 		JBrowse link
G Mgp matrix Gla protein increases expression ISO entinostat results in increased expression of MGP mRNA CTD PMID:27188386 NCBI chr 4:171,497,472...171,500,888
Ensembl chr 4:171,497,471...171,500,859 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of MGST2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGST2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:137,821,787...137,866,664
Ensembl chr 2:137,836,140...137,866,661 		JBrowse link
G Mia MIA SH3 domain containing increases expression ISO entinostat results in increased expression of MIA mRNA CTD PMID:27188386 NCBI chr 1:91,601,326...91,603,019
Ensembl chr 1:91,601,327...91,603,019 		JBrowse link
G Miat myocardial infarction associated transcript decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MIAT mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:50,075,026...50,090,259 JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression
multiple interactions 		ISO entinostat results in increased expression of MICB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:87,623,826...87,640,872 		JBrowse link
G Mid1ip1 MID1 interacting protein 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MID1IP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:14,733,539...14,735,859
Ensembl chr  X:14,732,830...14,739,079 		JBrowse link
G Mill1 MHC I like leukocyte 1 increases expression ISO entinostat results in increased expression of MICA mRNA CTD PMID:27188386 NCBI chr 1:87,500,591...87,526,983
Ensembl chr 1:87,500,676...87,526,981 		JBrowse link
G Mis18a MIS18 kinetochore protein A decreases expression ISO entinostat results in decreased expression of MIS18A mRNA CTD PMID:27188386 NCBI chr11:43,454,129...43,467,157
Ensembl chr11:43,454,161...43,476,264 		JBrowse link
G Mitf melanocyte inducing transcription factor increases expression ISO entinostat results in increased expression of MITF mRNA CTD PMID:26272509 NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression ISO entinostat results in decreased expression of MKI67 protein CTD PMID:21041383 NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase increases expression
multiple interactions 		ISO entinostat results in increased expression of MLKL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLKL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:56,186,860...56,213,886
Ensembl chr19:56,186,860...56,213,858 		JBrowse link
G Mlxipl MLX interacting protein-like increases expression
multiple interactions 		ISO entinostat results in increased expression of MLXIPL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLXIPL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:27,178,158...27,213,675
Ensembl chr12:27,178,158...27,213,660 		JBrowse link
G Mmaa metabolism of cobalamin associated A decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MMAA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:45,523,352...45,553,602
Ensembl chr19:45,523,379...45,555,375 		JBrowse link
G Mme membrane metallo-endopeptidase increases expression
multiple interactions 		ISO entinostat results in increased expression of MME mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MME mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463 		JBrowse link
G Mmp16 matrix metallopeptidase 16 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MMP16 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMP16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:36,109,265...36,353,252 		JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases secretion
decreases expression 		ISO entinostat results in decreased secretion of MMP2 protein
entinostat results in decreased expression of MMP2 protein 		CTD PMID:20421217 PMID:21041383 NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856 		JBrowse link
G Mmp25 matrix metallopeptidase 25 increases expression
multiple interactions 		ISO entinostat results in increased expression of MMP25 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP25 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:13,164,974...13,180,503
Ensembl chr10:13,164,977...13,180,503 		JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases secretion
decreases expression
increases expression 		ISO entinostat results in decreased secretion of MMP9 protein
entinostat results in decreased expression of MMP9 protein
entinostat results in increased expression of MMP9 mRNA 		CTD PMID:20421217 PMID:21041383 PMID:27188386 NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442 		JBrowse link
G Mns1 meiosis-specific nuclear structural 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MNS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:82,029,587...82,050,276
Ensembl chr 8:82,029,587...82,050,274 		JBrowse link
G Mob3b MOB kinase activator 3B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MOB3B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOB3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:54,342,509...54,534,164
Ensembl chr 5:54,338,056...54,454,678 		JBrowse link
G Mocos molybdenum cofactor sulfurase increases expression
multiple interactions 		ISO entinostat results in increased expression of MOCOS mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MOCOS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:16,206,402...16,251,928
Ensembl chr18:16,206,402...16,251,928 		JBrowse link
G Morf4l2 mortality factor 4 like 2 increases expression ISO entinostat results in increased expression of MORF4L2 mRNA CTD PMID:27188386 NCBI chr  X:104,874,850...104,885,946
Ensembl chr  X:104,852,693...104,892,855 		JBrowse link
G Morn5 MORN repeat containing 5 increases expression ISO entinostat results in increased expression of MORN5 mRNA CTD PMID:27188386 NCBI chr 3:39,799,531...39,827,482
Ensembl chr 3:39,799,019...39,827,482 		JBrowse link
G Mpdu1 mannose-P-dolichol utilization defect 1 decreases expression ISO entinostat results in decreased expression of MPDU1 mRNA CTD PMID:27188386 NCBI chr10:54,873,467...54,880,536
Ensembl chr10:54,873,473...54,879,195 		JBrowse link
G Mpped2 metallophosphoesterase domain containing 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MPPED2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:113,635,614...113,810,307
Ensembl chr 3:113,635,407...113,811,783 		JBrowse link
G Mrgprf MAS related GPR family member F increases expression
multiple interactions 		ISO entinostat results in increased expression of MRGPRF mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRGPRF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:209,893,384...209,902,852
Ensembl chr 1:209,892,450...209,903,614 		JBrowse link
G Mrtfa myocardin related transcription factor A decreases expression ISO entinostat results in decreased expression of MRTFA mRNA CTD PMID:27188386 NCBI chr 7:114,424,481...114,594,594
Ensembl chr 7:114,424,481...114,594,594 		JBrowse link
G Msl3 MSL complex subunit 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MSL3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSL3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:29,210,388...29,228,060
Ensembl chr  X:29,210,427...29,228,054 		JBrowse link
G Msrb3 methionine sulfoxide reductase B3 decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of MSRB3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA
entinostat results in increased expression of MSRB3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:58,188,827...58,311,459
Ensembl chr 7:57,968,124...58,311,116 		JBrowse link
G Mst1 macrophage stimulating 1 increases expression ISO entinostat results in increased expression of MST1 mRNA CTD PMID:27188386 NCBI chr 8:117,646,485...117,652,016
Ensembl chr 8:117,647,438...117,652,015 		JBrowse link
G Msx1 msh homeobox 1 increases expression ISO entinostat results in increased expression of MSX1 mRNA CTD PMID:26272509 NCBI chr14:77,185,802...77,189,735
Ensembl chr14:77,185,802...77,189,735 		JBrowse link
G Msx2 msh homeobox 2 increases expression ISO entinostat results in increased expression of MSX2 mRNA CTD PMID:26272509 NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945 		JBrowse link
G Mt1-ps3 metallothionein 1, pseudogene 3 increases expression ISO entinostat results in increased expression of MT1E mRNA CTD PMID:27188386 PMID:32870474 NCBI chr17:79,695,812...79,696,200
Ensembl chr17:79,695,809...79,696,200 		JBrowse link
G Mt2 metallothionein 2 increases expression ISO entinostat results in increased expression of MT2A mRNA CTD PMID:27188386 PMID:32870474 NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709 		JBrowse link
G Mt2-ps1 metallothionein 2, pseudogene 1 increases expression ISO entinostat results in increased expression of MT1HL1 mRNA CTD PMID:27188386 NCBI chr20:3,163,749...3,164,121 JBrowse link
G Mt3 metallothionein 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of MT3 mRNA
Zinc promotes the reaction [entinostat results in increased expression of MT3 mRNA] 		CTD PMID:21170156 PMID:21303554 NCBI chr19:10,854,676...10,856,080
Ensembl chr19:10,854,677...10,856,080 		JBrowse link
G Mtarc1 mitochondrial amidoxime reducing component 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MTARC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:98,854,235...98,894,208
Ensembl chr13:98,871,289...98,894,252 		JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of MTARC2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:98,894,347...98,928,754
Ensembl chr13:98,897,108...98,928,781 		JBrowse link
G Mthfd1 methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of MTHFD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,713,510...100,781,013
Ensembl chr 6:100,713,681...100,781,957 		JBrowse link
G Mthfd1l methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like decreases expression ISO entinostat results in decreased expression of MTHFD1L mRNA CTD PMID:27188386 NCBI chr 1:42,849,424...43,038,313
Ensembl chr 1:42,849,374...43,038,309 		JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2 mRNA CTD PMID:27188386 NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350 		JBrowse link
G Mthfsd methenyltetrahydrofolate synthetase domain containing decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MTHFSD mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTHFSD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:66,072,952...66,086,917
Ensembl chr19:66,056,560...66,086,925 		JBrowse link
G Mtmr11 myotubularin related protein 11 increases expression ISO entinostat results in increased expression of MTMR11 mRNA CTD PMID:27188386 NCBI chr 2:186,410,851...186,421,024
Ensembl chr 2:186,412,291...186,421,026 		JBrowse link
G Mttp microsomal triglyceride transfer protein decreases expression ISO entinostat results in decreased expression of MTTP mRNA CTD PMID:27188386 NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650 		JBrowse link
G Mtus1 microtubule associated scaffold protein 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MTUS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTUS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:57,905,991...58,051,466
Ensembl chr16:57,906,128...58,051,474 		JBrowse link
G Mtus2 microtubule associated scaffold protein 2 decreases expression ISO entinostat results in decreased expression of MTUS2 mRNA CTD PMID:27188386 NCBI chr12:11,742,713...12,115,798
Ensembl chr12:11,742,713...11,787,314 		JBrowse link
G Muc20 mucin 20, cell surface associated decreases expression ISO entinostat results in decreased expression of MUC20 mRNA CTD PMID:27188386 NCBI chr11:81,492,844...81,506,571
Ensembl chr11:81,492,891...81,506,571 		JBrowse link
G Muc4 mucin 4, cell surface associated increases expression
multiple interactions 		ISO entinostat results in increased expression of MUC4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:81,513,321...81,575,200 JBrowse link
G Mustn1 musculoskeletal, embryonic nuclear protein 1 decreases expression ISO entinostat results in decreased expression of MUSTN1 mRNA CTD PMID:27188386 NCBI chr16:6,079,355...6,081,608
Ensembl chr16:6,079,277...6,081,586 		JBrowse link
G Mvb12a multivesicular body subunit 12A increases expression ISO entinostat results in increased expression of MVB12A mRNA CTD PMID:27188386 NCBI chr16:18,286,231...18,291,096
Ensembl chr16:18,286,231...18,292,583 		JBrowse link
G Mvb12b multivesicular body subunit 12B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MVB12B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:37,431,636...37,590,276
Ensembl chr 3:37,431,636...37,615,407 		JBrowse link
G Mxd1 max dimerization protein 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MXD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:120,654,731...120,678,972
Ensembl chr 4:120,654,731...120,675,129 		JBrowse link
G Mxra7 matrix remodeling associated 7 decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of MXRA7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA
entinostat results in increased expression of MXRA7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:102,501,848...102,530,231
Ensembl chr10:102,489,604...102,530,231 		JBrowse link
G Mxra8 matrix remodeling associated 8 increases expression ISO entinostat results in increased expression of MXRA8 mRNA CTD PMID:27188386 NCBI chr 5:171,731,153...171,735,879
Ensembl chr 5:171,731,353...171,735,879 		JBrowse link
G Myb MYB proto-oncogene, transcription factor decreases expression ISO entinostat results in decreased expression of MYB mRNA CTD PMID:27188386 NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547 		JBrowse link
G Mybpc2 myosin binding protein C2 increases expression
multiple interactions 		ISO entinostat results in increased expression of MYBPC2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYBPC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:104,130,642...104,154,101
Ensembl chr 1:104,131,323...104,154,101 		JBrowse link
G Mycn MYCN proto-oncogene, bHLH transcription factor increases expression
multiple interactions 		ISO entinostat results in increased expression of MYCN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508 		JBrowse link
G Myh9 myosin, heavy chain 9 increases expression ISO entinostat results in increased expression of MYH9 mRNA CTD PMID:27188386 NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963 		JBrowse link
G Myl10 myosin light chain 10 increases expression
multiple interactions 		ISO entinostat results in increased expression of MYL10 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYL10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:25,606,558...25,619,270
Ensembl chr12:25,606,570...25,669,814 		JBrowse link
G Myl9 myosin light chain 9 increases expression ISO entinostat results in increased expression of MYL9 mRNA CTD PMID:27188386 NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:165,742,046...165,748,410 		JBrowse link
G Mylip myosin regulatory light chain interacting protein increases expression
multiple interactions 		ISO entinostat results in increased expression of MYLIP mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471 		JBrowse link
G Mylk myosin light chain kinase decreases expression
multiple interactions 		ISO entinostat results in decreased expression of MYLK mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659 		JBrowse link
G Myo10 myosin X increases expression ISO entinostat results in increased expression of MYO10 mRNA CTD PMID:27188386 NCBI chr 2:77,831,532...78,036,137
Ensembl chr 2:77,831,532...78,036,137 		JBrowse link
G Myo1b myosin Ib decreases expression ISO entinostat results in decreased expression of MYO1B mRNA CTD PMID:27188386 NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:57,181,987...57,344,328 		JBrowse link
G Myo1c myosin 1C increases expression ISO entinostat results in increased expression of MYO1C mRNA CTD PMID:27188386 NCBI chr10:60,996,642...61,019,022
Ensembl chr10:60,996,638...61,019,022 		JBrowse link
G Myo1d myosin ID increases expression
multiple interactions 		ISO entinostat results in increased expression of MYO1D mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958 		JBrowse link
G Myo5b myosin Vb increases expression ISO entinostat results in increased expression of MYO5B mRNA CTD PMID:27188386 NCBI chr18:70,313,717...70,613,918
Ensembl chr18:70,311,990...70,613,918 		JBrowse link
G Myocd myocardin decreases expression ISO entinostat results in decreased expression of MYOCD mRNA CTD PMID:27188386 NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819 		JBrowse link
G Myof myoferlin increases expression
multiple interactions 		ISO entinostat results in increased expression of MYOF mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768 		JBrowse link
G Myoz3 myozenin 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of MYOZ3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOZ3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:56,296,565...56,316,582
Ensembl chr18:56,296,565...56,316,582 		JBrowse link
G Myt1l myelin transcription factor 1-like decreases expression ISO entinostat results in decreased expression of MYT1L mRNA CTD PMID:27188386 NCBI chr 6:51,892,858...52,291,830
Ensembl chr 6:52,155,754...52,291,828 		JBrowse link
G Myzap myocardial zonula adherens protein increases expression ISO entinostat results in increased expression of MYZAP mRNA CTD PMID:26272509 NCBI chr 8:81,036,599...81,123,933
Ensembl chr 8:81,036,601...81,123,810 		JBrowse link
G N4bp2l1 NEDD4 binding protein 2-like 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of N4BP2L1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:4,938,199...4,965,003
Ensembl chr12:4,927,142...4,963,045 		JBrowse link
G N4bp3 Nedd4 binding protein 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of N4BP3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:36,400,053...36,407,609
Ensembl chr10:36,400,057...36,407,637 		JBrowse link
G Naalad2 N-acetylated alpha-linked acidic dipeptidase 2 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAALAD2 mRNA
entinostat results in decreased expression of NAALAD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:23,682,499...23,756,066
Ensembl chr 8:23,683,395...23,756,060 		JBrowse link
G Nab1 Ngfi-A binding protein 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NAB1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:56,545,547...56,585,045
Ensembl chr 9:56,545,729...56,614,210 		JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression ISO entinostat results in increased expression of NABP1 mRNA CTD PMID:27188386 NCBI chr 9:57,570,326...57,625,926
Ensembl chr 9:57,618,505...57,626,052 		JBrowse link
G Nacc2 NACC family member 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NACC2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NACC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:29,278,077...29,345,098
Ensembl chr 3:29,281,190...29,344,840 		JBrowse link
G Nadk2 NAD kinase 2, mitochondrial decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NADK2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:59,844,854...59,886,989
Ensembl chr 2:59,844,854...59,886,988 		JBrowse link
G Naglu N-acetyl-alpha-glucosaminidase increases expression
multiple interactions 		ISO entinostat results in increased expression of NAGLU mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAGLU mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:86,501,864...86,509,333
Ensembl chr10:86,501,836...86,509,315 		JBrowse link
G Nags N-acetylglutamate synthase increases expression ISO entinostat results in increased expression of NAGS mRNA CTD PMID:27188386 NCBI chr10:87,598,516...87,602,650
Ensembl chr10:87,598,220...87,602,650 		JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAIP mRNA
entinostat results in decreased expression of NAIP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:33,241,520...33,293,184
Ensembl chr 2:33,241,521...33,276,859 		JBrowse link
G Nalf1 NALCN channel auxiliary factor 1 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA
entinostat results in decreased expression of NALF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:86,415,540...86,938,150
Ensembl chr16:86,415,488...86,938,150 		JBrowse link
G Nanog Nanog homeobox increases expression
multiple interactions 		ISO entinostat results in increased expression of NANOG mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061 		JBrowse link
G Nans N-acetylneuraminate synthase increases expression
multiple interactions 		ISO entinostat results in increased expression of NANS mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:65,575,970...65,593,164
Ensembl chr 5:65,576,015...65,610,547 		JBrowse link
G Nav1 neuron navigator 1 decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of NAV1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA
entinostat results in increased expression of NAV1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:49,418,755...49,671,117
Ensembl chr13:49,418,755...49,671,004 		JBrowse link
G Naxe NAD(P)HX epimerase increases expression ISO entinostat results in increased expression of NAXE mRNA CTD PMID:27188386 NCBI chr 2:175,816,824...175,818,903
Ensembl chr 2:175,816,824...175,818,889 		JBrowse link
G Nbl1 NBL1, DAN family BMP antagonist increases expression ISO entinostat results in increased expression of NBL1 mRNA CTD PMID:27188386 NCBI chr 5:156,601,986...156,613,182
Ensembl chr 5:156,601,986...156,613,186 		JBrowse link
G Nbn nibrin decreases expression ISO entinostat results in decreased expression of NBN mRNA CTD PMID:27188386 NCBI chr 5:34,256,678...34,291,163
Ensembl chr 5:34,256,627...34,291,162 		JBrowse link
G Ncald neurocalcin delta multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA
entinostat results in decreased expression of NCALD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,417,683...70,849,763
Ensembl chr 7:70,419,433...70,849,482 		JBrowse link
G Nceh1 neutral cholesterol ester hydrolase 1 increases expression ISO entinostat results in increased expression of NCEH1 mRNA CTD PMID:27188386 NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:112,003,502...112,064,272 		JBrowse link
G Ncln nicalin increases expression
multiple interactions 		ISO entinostat results in increased expression of NCLN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCLN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:8,862,324...8,872,699
Ensembl chr 7:8,862,751...8,872,698 		JBrowse link
G Ncoa2 nuclear receptor coactivator 2 decreases expression ISO entinostat results in decreased expression of NCOA2 mRNA CTD PMID:27188386 NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776 		JBrowse link
G Ncoa7 nuclear receptor coactivator 7 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NCOA7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:28,674,614...28,835,891
Ensembl chr 1:28,675,426...28,835,886 		JBrowse link
G Ncr3lg1 natural killer cell cytotoxicity receptor 3 ligand 1 increases expression ISO entinostat results in increased expression of NCR3LG1 mRNA CTD PMID:27188386 NCBI chr 1:105,701,953...105,718,251
Ensembl chr 1:105,710,883...105,716,732 		JBrowse link
G Ndp norrin cystine knot growth factor NDP decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NDP mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:8,379,569...8,404,019
Ensembl chr  X:8,379,569...8,406,802 		JBrowse link
G Ndst3 N-deacetylase and N-sulfotransferase 3 decreases expression ISO entinostat results in decreased expression of NDST3 mRNA CTD PMID:27188386 NCBI chr 2:214,386,804...214,552,739
Ensembl chr 2:214,389,447...214,539,164 		JBrowse link
G Ndufaf7 NADH:ubiquinone oxidoreductase complex assembly factor 7 increases expression
multiple interactions 		ISO entinostat results in increased expression of NDUFAF7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDUFAF7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:21,860,788...21,871,965
Ensembl chr 6:21,856,865...21,872,146 		JBrowse link
G Ndufb1 NADH:ubiquinone oxidoreductase subunit B1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NDUFB1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:126,880,537...126,888,935
Ensembl chr 6:126,880,537...126,888,864 		JBrowse link
G Nebl nebulette increases expression ISO entinostat results in increased expression of NEBL mRNA CTD PMID:27188386 NCBI chr17:85,022,953...85,374,848
Ensembl chr17:85,022,963...85,374,172 		JBrowse link
G Necab1 N-terminal EF-hand calcium binding protein 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECAB1 mRNA
entinostat results in increased expression of NECAB1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:33,155,078...33,375,707
Ensembl chr 5:33,153,975...33,375,707 		JBrowse link
G Nedd9 neural precursor cell expressed, developmentally down-regulated 9 decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of NEDD9 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEDD9 mRNA
entinostat results in increased expression of NEDD9 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668 		JBrowse link
G Nefh neurofilament heavy chain increases expression ISO entinostat results in increased expression of NEFH mRNA CTD PMID:27188386 NCBI chr14:84,044,428...84,054,413
Ensembl chr14:84,044,023...84,054,417 		JBrowse link
G Nefl neurofilament light chain increases expression
multiple interactions 		ISO entinostat results in increased expression of NEFL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515 		JBrowse link
G Nefm neurofilament medium chain decreases expression
increases expression 		ISO entinostat results in decreased expression of NEFM mRNA
entinostat results in increased expression of NEFM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163 		JBrowse link
G Negr1 neuronal growth regulator 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NEGR1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEGR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:248,283,164...249,015,538
Ensembl chr 2:248,283,353...249,018,410 		JBrowse link
G Nell2 neural EGFL like 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NELL2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917 		JBrowse link
G Neu1 neuraminidase 1 decreases expression ISO entinostat results in decreased expression of NEU1 mRNA CTD PMID:33770205 NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,902,120...3,906,383 		JBrowse link
G Neurl1b neuralized E3 ubiquitin protein ligase 1B increases expression ISO entinostat results in increased expression of NEURL1B mRNA CTD PMID:27188386 NCBI chr10:17,258,317...17,289,362
Ensembl chr10:17,258,328...17,289,362 		JBrowse link
G Neurod2 neuronal differentiation 2 decreases expression ISO entinostat results in decreased expression of NEUROD2 mRNA CTD PMID:27188386 NCBI chr10:83,820,092...83,824,277
Ensembl chr10:83,819,663...83,824,885 		JBrowse link
G Neurod6 neuronal differentiation 6 decreases expression ISO entinostat results in decreased expression of NEUROD6 mRNA CTD PMID:27188386 NCBI chr 4:86,176,909...86,180,155
Ensembl chr 4:86,175,992...86,181,235 		JBrowse link
G Nf1 neurofibromin 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NF1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:64,803,986...65,037,086
Ensembl chr10:64,804,266...65,034,946 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NFATC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFATC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990 		JBrowse link
G Nfatc2 nuclear factor of activated T-cells 2 increases expression ISO entinostat results in increased expression of NFATC2 mRNA CTD PMID:27188386 NCBI chr 3:177,615,189...177,747,493
Ensembl chr 3:177,618,314...177,747,380 		JBrowse link
G Nfatc4 nuclear factor of activated T-cells 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NFATC4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:33,256,912...33,284,522
Ensembl chr15:33,274,153...33,285,582 		JBrowse link
G Nfe2 nuclear factor, erythroid 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NFE2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:136,261,234...136,273,850
Ensembl chr 7:136,261,236...136,268,585 		JBrowse link
G Nfe2l1 NFE2 like bZIP transcription factor 1 decreases expression ISO entinostat results in decreased expression of NFE2L1 mRNA CTD PMID:39237058 NCBI chr10:82,296,824...82,309,472
Ensembl chr10:82,292,508...82,309,375 		JBrowse link
G Nfe2l3 NFE2 like bZIP transcription factor 3 increases expression ISO entinostat results in increased expression of NFE2L3 mRNA CTD PMID:27188386 NCBI chr 4:81,837,404...81,865,258
Ensembl chr 4:81,837,404...81,865,532 		JBrowse link
G Nfib nuclear factor I/B increases expression
multiple interactions 		ISO entinostat results in increased expression of NFIB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:101,805,168...102,020,618
Ensembl chr 5:101,805,168...102,019,945 		JBrowse link
G Nfic nuclear factor I/C increases expression ISO entinostat results in increased expression of NFIC mRNA CTD PMID:27188386 NCBI chr 7:8,928,423...8,963,455
Ensembl chr 7:8,904,117...8,963,409 		JBrowse link
G Nfrkb nuclear factor related to kappa B binding protein decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NFRKB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFRKB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:38,089,574...38,121,506
Ensembl chr 8:38,089,999...38,121,501 		JBrowse link
G Ngef neuronal guanine nucleotide exchange factor increases expression
multiple interactions 		ISO entinostat results in increased expression of NGEF mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:95,594,823...95,692,381
Ensembl chr 9:95,594,823...95,692,251 		JBrowse link
G Ngfr nerve growth factor receptor increases expression
multiple interactions 		ISO entinostat results in increased expression of TNFRSF10B protein
TNFSF10 protein promotes the reaction [entinostat results in increased expression of TNFRSF10B protein] 		CTD PMID:21041383 NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305 		JBrowse link
G Nhlh2 nescient helix loop helix 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NHLH2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:192,132,848...192,138,186
Ensembl chr 2:192,132,686...192,138,186 		JBrowse link
G Niban1 niban apoptosis regulator 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NIBAN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIBAN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724 		JBrowse link
G Nid1 nidogen 1 increases expression ISO entinostat results in increased expression of NID1 mRNA CTD PMID:27188386 NCBI chr17:93,069,013...93,142,416
Ensembl chr17:93,069,278...93,142,386 		JBrowse link
G Nin ninein decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NIN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:94,261,382...94,363,679
Ensembl chr 6:94,263,206...94,363,610 		JBrowse link
G Nipal3 NIPA-like domain containing 3 increases expression ISO entinostat results in increased expression of NIPAL3 mRNA CTD PMID:27188386 NCBI chr 5:152,970,934...153,010,006
Ensembl chr 5:152,968,910...153,008,845 		JBrowse link
G Nkain3 Sodium/potassium transporting ATPase interacting 3 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA
entinostat results in decreased expression of NKAIN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:38,410,576...39,106,910
Ensembl chr 5:38,386,841...39,106,385 		JBrowse link
G Nkd2 NKD inhibitor of WNT signaling pathway 2 increases expression ISO entinostat results in increased expression of NKD2 mRNA CTD PMID:27188386 NCBI chr 1:31,268,856...31,299,390
Ensembl chr 1:31,272,519...31,299,387 		JBrowse link
G Nkx2-3 NK2 homeobox 3 decreases expression ISO entinostat results in decreased expression of NKX2-3 mRNA CTD PMID:27188386 NCBI chr 1:252,427,356...252,430,309
Ensembl chr 1:252,427,162...252,430,742 		JBrowse link
G Nlgn1 neuroligin 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NLGN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:110,184,987...111,110,316
Ensembl chr 2:110,186,573...110,909,984 		JBrowse link
G Nlgn2 neuroligin 2 increases expression ISO entinostat results in increased expression of NLGN2 mRNA CTD PMID:27188386 NCBI chr10:55,042,175...55,056,578
Ensembl chr10:55,043,185...55,056,578 		JBrowse link
G Nln neurolysin increases expression
multiple interactions 		ISO entinostat results in increased expression of NLN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:36,867,436...36,966,749
Ensembl chr 2:36,853,551...36,966,680 		JBrowse link
G Nme8 NME/NM23 family member 8 increases expression ISO entinostat results in increased expression of NME8 mRNA CTD PMID:27188386 NCBI chr17:49,932,861...50,000,610
Ensembl chr17:49,932,860...50,000,608 		JBrowse link
G Nmi N-myc (and STAT) interactor increases expression
multiple interactions 		ISO entinostat results in increased expression of NMI mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:56,824,778...56,848,891
Ensembl chr 3:56,811,314...56,848,717 		JBrowse link
G Nmnat3 nicotinamide nucleotide adenylyltransferase 3 increases expression ISO entinostat results in increased expression of NMNAT3 mRNA CTD PMID:27188386 NCBI chr 8:107,771,124...107,888,528
Ensembl chr 8:107,771,509...107,900,016 		JBrowse link
G Nmrk1 nicotinamide riboside kinase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NMRK1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:225,475,975...225,503,414
Ensembl chr 1:225,475,830...225,503,602 		JBrowse link
G Nmrk2 nicotinamide riboside kinase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NMRK2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:9,165,567...9,168,638
Ensembl chr 7:9,165,146...9,168,637 		JBrowse link
G Nmu neuromedin U increases expression ISO entinostat results in increased expression of NMU mRNA CTD PMID:27188386 NCBI chr14:32,198,789...32,226,397
Ensembl chr14:32,198,943...32,226,632 		JBrowse link
G Nnmt nicotinamide N-methyltransferase increases expression ISO entinostat results in increased expression of NNMT mRNA CTD PMID:27188386 NCBI chr 8:57,820,156...57,851,301
Ensembl chr 8:57,825,464...57,843,174 		JBrowse link
G Noct nocturnin increases expression
multiple interactions 		ISO entinostat results in increased expression of NOCT mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:137,422,074...137,442,282
Ensembl chr 2:137,422,074...137,442,282 		JBrowse link
G Nod2 nucleotide-binding oligomerization domain containing 2 increases expression ISO entinostat results in increased expression of NOD2 mRNA CTD PMID:27188386 NCBI chr19:34,555,832...34,596,281
Ensembl chr19:34,555,832...34,722,846 		JBrowse link
G Nog noggin decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NOG mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of MADCAM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of SNRPN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCY10P1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AGO4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AHI1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AJUBA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKT3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD28 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD44 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANTXR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AP3M1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APOLD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP29 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARK2C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL4C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARSD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASXL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATOSB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP2B1-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP7A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GALNT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAALC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BACE1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAIAP2-DT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAZ2B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BBIP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCHE mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BMPR1B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C12ORF76 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C21ORF58 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF49 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C5ORF24 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C8ORF76 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CASTOR3P mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBFB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC121 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC50 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC80 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC92 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD99L2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC14A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDV3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CENPV mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP112 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP120 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP70 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLIP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COL11A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COL2A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COL9A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COX11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREB5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CREBRF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CROT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNNA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNNBIP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXXC4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CYFIP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DACH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DBP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDAH2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIDO1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIO3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMAC2L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DMRT3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DNAJC18 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNB2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGR4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMSY mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EOLA2-DT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERLEC1P1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERP27 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERP44 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EYA4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM226B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FARP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRY mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSTL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FXR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GASK1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLRB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLUD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GOLGA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPATCH2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR161 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSDME mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSK3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1B1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BW4P mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDAC9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEPH mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEY1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HHAT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTATIP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IKZF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ILDR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGAV mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAKMIP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KANSL1-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNAB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KDM6B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF15 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIRREL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCA5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LGR5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00515 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00648 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LNPK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPCAT4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPIN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRATD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSM8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAGI3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAMDC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAML2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN2A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K20 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPRE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBD5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MBNL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCUB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MECOM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEST mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METRN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEX3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMP16 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MOB3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTHFSD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTUS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MVB12B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MXRA7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAALAD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAIP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NALF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NBPF10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEDD9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFATC4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFRKB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOVA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPAS4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2C1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRCAM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OGFOD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OGG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPN3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTUD7B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PABPN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PALLD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARP8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARVA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDCD4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE4B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDLIM7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX13 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF20L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3CA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3R1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3R3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PKP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLCH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLPP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPM1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPOX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R3E mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R9A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2D mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP3CA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM16 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRICKLE1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRKD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRMT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTCH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGIS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN21 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPN5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRO mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PURG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB18 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB27A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAP1GDS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBM24 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBMS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of REC8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGS20 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RIN2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL31 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPL37 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPS15A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RUBCN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RYR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCAPER mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEC24B-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SENP7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEPSECS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERTAD4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SESTD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SH3RF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIPA1L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A37 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC2A12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC35E2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLITRK4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMIM11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMIM17 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMPD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNAPC3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNTB2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOCS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOSTDC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SP8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPON1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SREK1IP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSBP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GAL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST8SIA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STX17 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SULF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYTL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAGLN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAGLN3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCAF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCAIM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TFDP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of THAP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMED4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM106C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM161B-DT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM169 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM170B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM182 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM231 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM88 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM8B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMSB15A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPCN2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPM2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPT1-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIB2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIM52-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TXNIP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UACA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2J1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP47 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VASH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VCAM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDFY3-AS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WDR27 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of YPEL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB20 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB26 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H12C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZC3H6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZCCHC18 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZDHHC21 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFHX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFYVE16 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZHX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF148 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF197 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF226 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF280A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF286A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF37BP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF467 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503-AS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF519 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF664 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF704 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF763 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF84 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF862 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF93 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN16-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSWIM5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AAK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AARS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCC6P1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACADSB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACOX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACOXL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTL6B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADORA2B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AGPAT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AK4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1B1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKEF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKLE1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1S3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APBB2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APH1B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOBEC3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOE mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP42 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARL5B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASAP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP1B2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GALT5-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEST2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BICD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BLVRB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRI3BP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF87 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C14ORF132 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C16ORF89 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1ORF94 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1QTNF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C6ORF132 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARD19 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC13 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCM2L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCND1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD109 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD19 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD58 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCA7L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDCP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDYL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPZ mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGAS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHCHD10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNB4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNPY2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL13A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL8A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRLF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTBP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CUZD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB561 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP26A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP4X1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCXR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEF6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND2C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DGKK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHX58 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLGAP1-AS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMXL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNMT3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOC2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPEP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPP10-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRAM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DRC11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EARS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ECI2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ECRG4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EEF1A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EHD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF2AK4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EIF4EBP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELAVL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENTPD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L4B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPOR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERFE mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVMER61-1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESYT3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNPPL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETV4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EXOSC6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FA2H mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM114A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM181B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM20A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM20C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM24B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM78A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLN2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL16 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL21P mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FDXR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FIBCD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FKBP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FNDC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXJ1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXRED2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FRAT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FST mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FXYD5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FXYD7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABBR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARIN5A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCOM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDPD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFPT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GGT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLT8D2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GOLGA8H mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPHA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPM6B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR143 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR160 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRB14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIN2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRK6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSE1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCN4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HENMT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DMA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSD11B2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPB8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTR3A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICMT-DT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGF2BP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBPL1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL6R mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IPW mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF2BPL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISOC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGAM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAKMIP2-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JARID2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KBTBD8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNE3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNJ12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNN2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1217 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHDC7A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL18 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLKB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1TD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LARP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LARP7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDLRAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00173 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00992 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01503 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LITAF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPGAT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAOA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K21 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPK13 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARCHF3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MATN2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MATN3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCRIP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MED14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEDAG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEGF10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGARP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MGST2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MID1IP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR1915HG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLKL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLXIPL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MME mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP25 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MOCOS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRGPRF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTARC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MTHFD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYBPC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYL10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOZ3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NACC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAGLU mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NCLN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDUFAF7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECAB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEGR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFATC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIBAN1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOP16 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPTX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPTX2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR3C1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NTF4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ODAD3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OGDHL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OMA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ONECUT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P2RX5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P3H2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P4HA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PACSIN3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAGE4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAH mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAK6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PALM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAPPA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAQR5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PARP12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCBD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE8A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PELO mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PER1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGCKA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3CB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G12A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLPP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLPPR5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLTP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLXDC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMAIP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMEPA1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMM2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PNPLA3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POSTN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPAP2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1H mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1J mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R14A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R1B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3D mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP2R2C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKAG2-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCA mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PROCR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRODH mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PROSER2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR16 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRX1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTCHD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYCARD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYY mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB11FIP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB29 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAP1GAP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGEF1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASL11B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASL12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBP7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBPMS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RET mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHBDL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOF mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOQ mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHPN2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPOR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF43 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ROR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPL22L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPP25 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRML mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS24 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RRBP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTN4IP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S1PR5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAMHD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SC5D mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCARB1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1G mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEC24D mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEL1L3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA6A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINA5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINE1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH2B3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH2D3A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3KBP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHE mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHFL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SKAP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC10A4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC15A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC16A1-AS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC18B1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC24A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC44A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC47A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC4A11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC52A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN13 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMAD7 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMIM24 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMIM3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMIM43 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMKR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOAT1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPINK2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPMIP6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPTLC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SREBF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRPX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SSTR2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAR mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAT6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STRA6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SUSD3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SVOPL mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNGR1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNM mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TARS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCF24 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCF7L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TCIRG1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRD12 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TESC mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TEX15 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFCP2L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THEMIS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THSD4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THSD7A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TIMM44 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TIMP4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TJP3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TLE2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TLL2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMED5 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEFF2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM125 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM200B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM220 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM268 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM37 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS11E mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10C mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF12A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNMD mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNNC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIB3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM14 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM22 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM24 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM25 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM69 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIML2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPC6 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSPO mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC39A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC39B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTYH2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB2A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TUBB4A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TYMSOS mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UBASH3B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGP2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNC5B mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP25 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP32P2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP9X mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAT1L mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VHRT mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VRTN mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VSIG10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VWA8 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WIF1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT8A mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWOX mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XBP1 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZHX2 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF165 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF296 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF589 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF600 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF814 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZSCAN10 mRNA; [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZYG11A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103 		JBrowse link
G Nop16 NOP16 nucleolar protein increases expression
multiple interactions 		ISO entinostat results in increased expression of NOP16 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOP16 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:10,028,058...10,032,975
Ensembl chr17:10,028,034...10,033,038 		JBrowse link
G Nos1 nitric oxide synthase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NOS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO entinostat inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] CTD PMID:20421217 NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880 		JBrowse link
G Nostrin nitric oxide synthase trafficking increases expression ISO entinostat results in increased expression of NOSTRIN mRNA CTD PMID:27188386 NCBI chr 3:74,312,594...74,378,852
Ensembl chr 3:74,312,647...74,396,455 		JBrowse link
G Notch2 notch receptor 2 increases expression ISO entinostat results in increased expression of NOTCH2 mRNA CTD PMID:27188386 NCBI chr 2:188,299,336...188,432,823
Ensembl chr 2:188,299,336...188,432,823 		JBrowse link
G Nova1 NOVA alternative splicing regulator 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NOVA1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOVA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:69,506,983...69,632,437
Ensembl chr 6:69,506,983...69,632,437 		JBrowse link
G Npas4 neuronal PAS domain protein 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NPAS4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPAS4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:211,710,640...211,728,038
Ensembl chr 1:211,711,338...211,716,102 		JBrowse link
G Npffr2 neuropeptide FF receptor 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NPFFR2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:18,794,868...18,842,186
Ensembl chr14:18,797,234...18,842,186 		JBrowse link
G Npl N-acetylneuraminate pyruvate lyase increases expression ISO entinostat results in increased expression of NPL mRNA CTD PMID:27188386 NCBI chr13:68,205,602...68,247,940
Ensembl chr13:68,205,603...68,247,999 		JBrowse link
G Nptx1 neuronal pentraxin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NPTX1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPTX1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:105,309,578...105,318,829
Ensembl chr10:105,309,578...105,318,863 		JBrowse link
G Nptx2 neuronal pentraxin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NPTX2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPTX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:15,151,136...15,162,045
Ensembl chr12:15,151,136...15,162,045 		JBrowse link
G Nptxr neuronal pentraxin receptor increases expression ISO entinostat results in increased expression of NPTXR mRNA CTD PMID:27188386 NCBI chr 7:113,217,046...113,235,122
Ensembl chr 7:113,217,050...113,235,156 		JBrowse link
G Npy neuropeptide Y increases expression ISO entinostat results in increased expression of NPY mRNA CTD PMID:27188386 NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310 		JBrowse link
G Npy2r neuropeptide Y receptor Y2 decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of NPY2R mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA
entinostat results in increased expression of NPY2R mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:170,200,027...170,210,286
Ensembl chr 2:170,200,027...170,210,448 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NQO1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NQO2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:31,114,825...31,144,062
Ensembl chr17:31,114,529...31,143,662 		JBrowse link
G Nr2c1 nuclear receptor subfamily 2, group C, member 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NR2C1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2C1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:30,602,338...30,655,610
Ensembl chr 7:30,603,018...30,658,349 		JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NR2F1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924 		JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NR2F2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:133,420,227...133,431,975 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NR3C1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR3C1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843 		JBrowse link
G Nrcam neuronal cell adhesion molecule decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NRCAM mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRCAM mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:67,129,723...67,425,510
Ensembl chr 6:67,129,801...67,430,539 		JBrowse link
G Nrep neuronal regeneration related protein decreases expression ISO entinostat results in decreased expression of NREP mRNA CTD PMID:27188386 NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742 		JBrowse link
G Nrg1 neuregulin 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NRG1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849 		JBrowse link
G Nrgn neurogranin increases expression ISO entinostat results in increased expression of NRGN mRNA CTD PMID:27188386 NCBI chr 8:45,444,223...45,452,417
Ensembl chr 8:45,444,223...45,452,417 		JBrowse link
G Nrip3 nuclear receptor interacting protein 3 decreases expression
increases expression 		ISO entinostat results in decreased expression of NRIP3 mRNA
entinostat results in increased expression of NRIP3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:173,224,532...173,249,829
Ensembl chr 1:173,224,532...173,251,769 		JBrowse link
G Nrk Nik related kinase increases expression
multiple interactions 		ISO entinostat results in increased expression of NRK mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:107,159,154...107,256,417
Ensembl chr  X:107,159,233...107,256,417 		JBrowse link
G Nrn1 neuritin 1 decreases expression ISO entinostat results in decreased expression of NRN1 mRNA CTD PMID:27188386 NCBI chr17:28,335,426...28,344,354
Ensembl chr17:28,334,616...28,344,354 		JBrowse link
G Nrp1 neuropilin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of NRP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702 		JBrowse link
G Nrp2 neuropilin 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NRP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:71,616,602...71,731,869
Ensembl chr 9:71,616,657...71,731,871 		JBrowse link
G Nrtn neurturin increases expression ISO entinostat results in increased expression of NRTN mRNA CTD PMID:27188386 NCBI chr 9:1,669,099...1,674,957
Ensembl chr 9:1,641,618...1,675,133 		JBrowse link
G Nsd2 nuclear receptor binding SET domain protein 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NSD2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:81,057,727...81,135,866
Ensembl chr14:81,057,727...81,123,027 		JBrowse link
G Nsmaf neutral sphingomyelinase activation associated factor decreases expression ISO entinostat results in decreased expression of NSMAF mRNA CTD PMID:27188386 NCBI chr 5:24,315,319...24,378,346
Ensembl chr 5:24,315,319...24,375,355 		JBrowse link
G Nsun7 NOP2/Sun RNA methyltransferase family member 7 increases expression ISO entinostat results in increased expression of NSUN7 mRNA CTD PMID:27188386 NCBI chr14:42,233,062...42,289,013
Ensembl chr14:42,233,062...42,288,958 		JBrowse link
G Ntf4 neurotrophin 4 increases expression
multiple interactions 		ISO entinostat results in increased expression of NTF4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NTF4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:105,030,035...105,032,866
Ensembl chr 1:105,029,764...105,034,038 		JBrowse link
G Ntn4 netrin 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NTN4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:30,073,637...30,187,407
Ensembl chr 7:30,073,333...30,188,309 		JBrowse link
G Ntrk2 neurotrophic receptor tyrosine kinase 2 decreases expression ISO entinostat results in decreased expression of NTRK2 mRNA CTD PMID:27188386 NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628 		JBrowse link
G Nucb2 nucleobindin 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of NUCB2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:180,185,121...180,221,644
Ensembl chr 1:180,199,551...180,230,116 		JBrowse link
G Nwd2 NACHT and WD repeat domain containing 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of NWD2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:44,833,623...45,024,962
Ensembl chr14:44,834,856...45,024,047 		JBrowse link
G Nxpe3 neurexophilin and PC-esterase domain family, member 3 increases expression ISO entinostat results in increased expression of NXPE3 mRNA CTD PMID:27188386 NCBI chr11:58,195,951...58,246,739
Ensembl chr11:58,195,976...58,248,644 		JBrowse link
G Oat ornithine aminotransferase increases expression
multiple interactions 		ISO entinostat results in increased expression of OAT mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OAT mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:196,777,975...196,797,754 		JBrowse link
G Obsl1 obscurin like cytoskeletal adaptor 1 increases expression ISO entinostat results in increased expression of OBSL1 mRNA CTD PMID:27188386 NCBI chr 9:84,416,447...84,442,415
Ensembl chr 9:84,416,240...84,442,415 		JBrowse link
G Odad1 outer dynein arm docking complex subunit 1 increases expression ISO entinostat results in increased expression of ODAD1 mRNA CTD PMID:27188386 NCBI chr 1:105,530,196...105,557,358
Ensembl chr 1:105,531,085...105,558,023 		JBrowse link
G Odad2 outer dynein arm docking complex subunit 2 decreases expression ISO entinostat results in decreased expression of ODAD2 mRNA CTD PMID:27188386 NCBI chr17:59,910,665...60,104,929
Ensembl chr17:59,910,757...60,103,547 		JBrowse link
G Odad3 outer dynein arm docking complex subunit 3 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ODAD3 mRNA
entinostat results in increased expression of ODAD3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:28,796,909...28,810,587
Ensembl chr 8:28,796,701...28,810,511 		JBrowse link
G Ogdhl oxoglutarate dehydrogenase L increases expression
multiple interactions 		ISO entinostat results in increased expression of OGDHL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OGDHL mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:7,584,666...7,610,705
Ensembl chr16:7,584,657...7,610,698 		JBrowse link
G Ogfod1 2-oxoglutarate and iron-dependent oxygenase domain containing 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of OGFOD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OGFOD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:10,950,950...10,980,519
Ensembl chr19:10,950,060...10,980,519 		JBrowse link
G Ogg1 8-oxoguanine DNA glycosylase decreases expression
multiple interactions 		ISO entinostat results in decreased expression of OGG1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OGG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604 		JBrowse link
G Ogt O-linked N-acetylglucosamine (GlcNAc) transferase decreases expression ISO entinostat results in decreased expression of OGT mRNA CTD PMID:27188386 NCBI chr  X:70,811,317...70,856,123
Ensembl chr  X:70,811,319...70,856,123 		JBrowse link
G Oip5-as1 OIP5 antisense RNA 1 decreases expression ISO entinostat results in decreased expression of OIP5-AS1 mRNA CTD PMID:27188386 NCBI chr 3:127,032,122...127,045,658 JBrowse link
G Olfm1 olfactomedin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of OLFM1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:31,918,512...31,956,261
Ensembl chr 3:31,918,573...31,956,260 		JBrowse link
G Olfm3 olfactomedin 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of OLFM3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:205,417,962...205,640,479
Ensembl chr 2:205,598,959...205,640,479 		JBrowse link
G Olfml1 olfactomedin-like 1 increases expression ISO entinostat results in increased expression of OLFML1 mRNA CTD PMID:27188386 NCBI chr 1:170,889,912...170,914,300
Ensembl chr 1:170,889,980...170,915,762 		JBrowse link
G Olfml2a olfactomedin-like 2A increases expression
multiple interactions 		ISO entinostat results in increased expression of OLFML2A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:43,098,299...43,127,621
Ensembl chr 3:43,098,299...43,127,621 		JBrowse link
G Olfml3 olfactomedin-like 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of OLFML3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:193,932,665...193,935,494
Ensembl chr 2:193,932,665...193,935,494 		JBrowse link
G Olig3 oligodendrocyte transcription factor 3 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLIG3 mRNA CTD PMID:27188386 NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274 		JBrowse link
G Oma1 OMA1 zinc metallopeptidase increases expression
multiple interactions 		ISO entinostat results in increased expression of OMA1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OMA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:123,312,038...123,455,540
Ensembl chr 5:123,312,766...123,366,005 		JBrowse link
G Onecut2 one cut homeobox 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of ONECUT2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ONECUT2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:60,101,967...60,161,095
Ensembl chr18:60,102,126...60,107,668 		JBrowse link
G Opcml opioid binding protein/cell adhesion molecule-like decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of OPCML mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA
entinostat results in increased expression of OPCML mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:34,451,629...35,562,897
Ensembl chr 8:34,451,500...35,558,966 		JBrowse link
G Opn3 opsin 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of OPN3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:90,121,560...90,152,076
Ensembl chr13:90,121,560...90,152,076 		JBrowse link
G Oprk1 opioid receptor, kappa 1 decreases expression ISO entinostat results in decreased expression of OPRK1 mRNA CTD PMID:27188386 NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671 		JBrowse link
G Optn optineurin increases expression ISO entinostat results in increased expression of OPTN mRNA CTD PMID:27188386 NCBI chr17:78,118,847...78,169,543
Ensembl chr17:78,118,866...78,169,543 		JBrowse link
G Osbpl10 oxysterol binding protein-like 10 increases expression
multiple interactions 		ISO entinostat results in increased expression of OSBPL10 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:123,536,818...123,796,822
Ensembl chr 8:123,539,235...123,796,822 		JBrowse link
G Otud7b OTU deubiquitinase 7B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of OTUD7B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OTUD7B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:186,350,811...186,411,461
Ensembl chr 2:186,350,798...186,409,440 		JBrowse link
G P2rx5 purinergic receptor P2X 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of P2RX5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P2RX5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:58,276,329...58,291,108
Ensembl chr10:58,276,257...58,287,935 		JBrowse link
G P3h2 prolyl 3-hydroxylase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of P3H2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P3H2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:88,139,086...88,280,221
Ensembl chr11:88,139,078...88,281,203 		JBrowse link
G P4ha2 prolyl 4-hydroxylase subunit alpha 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of P4HA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of P4HA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:38,743,894...38,772,741
Ensembl chr10:38,743,894...38,772,993 		JBrowse link
G Pabpn1 poly(A) binding protein, nuclear 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PABPN1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PABPN1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:32,337,955...32,342,700
Ensembl chr15:32,338,089...32,342,691 		JBrowse link
G Pacsin1 protein kinase C and casein kinase substrate in neurons 1 increases expression ISO entinostat results in increased expression of PACSIN1 mRNA CTD PMID:27188386 NCBI chr20:5,719,929...5,769,492
Ensembl chr20:5,721,311...5,767,109 		JBrowse link
G Pacsin3 protein kinase C and casein kinase substrate in neurons 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of PACSIN3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PACSIN3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:97,683,054...97,691,619
Ensembl chr 3:97,679,244...97,691,628 		JBrowse link
G Pah phenylalanine hydroxylase increases expression
multiple interactions 		ISO entinostat results in increased expression of PAH mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAH mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:23,793,096...23,885,631
Ensembl chr 7:23,792,781...23,885,627 		JBrowse link
G Pak6 p21 (RAC1) activated kinase 6 increases expression
multiple interactions 		ISO entinostat results in increased expression of PAK6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAK6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:126,092,576...126,128,320
Ensembl chr 3:126,093,013...126,128,318 		JBrowse link
G Palld palladin, cytoskeletal associated protein decreases expression
multiple interactions
increases expression 		ISO entinostat results in decreased expression of PALLD mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PALLD mRNA
entinostat results in increased expression of PALLD mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:33,238,943...33,632,236
Ensembl chr16:33,238,956...33,632,232 		JBrowse link
G Palm3 paralemmin 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of PALM3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PALM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr19:41,026,757...41,035,217
Ensembl chr19:41,026,518...41,035,293 		JBrowse link
G Pamr1 peptidase domain containing associated with muscle regeneration 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PAMR1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:109,340,411...109,443,595
Ensembl chr 3:109,341,476...109,443,585 		JBrowse link
G Papln papilin, proteoglycan-like sulfated glycoprotein increases expression ISO entinostat results in increased expression of PAPLN mRNA CTD PMID:26272509 NCBI chr 6:109,129,268...109,163,300
Ensembl chr 6:109,129,261...109,161,483 		JBrowse link
G Pappa pappalysin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PAPPA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAPPA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:83,513,358...83,751,361 		JBrowse link
G Paqr5 progestin and adipoQ receptor family member 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of PAQR5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAQR5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:71,327,397...71,409,201
Ensembl chr 8:71,327,397...71,409,201 		JBrowse link
G Parp12 poly (ADP-ribose) polymerase family, member 12 increases expression
multiple interactions 		ISO entinostat results in increased expression of PARP12 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PARP12 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:68,793,411...68,851,214
Ensembl chr 4:68,806,100...68,850,541 		JBrowse link
G Parp8 poly (ADP-ribose) polymerase family, member 8 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PARP8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARP8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:50,408,404...50,581,513
Ensembl chr 2:50,408,404...50,581,233 		JBrowse link
G Parva parvin, alpha decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PARVA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARVA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:175,981,725...176,139,523
Ensembl chr 1:175,981,432...176,139,526 		JBrowse link
G Patj PATJ, crumbs cell polarity complex component increases expression ISO entinostat results in increased expression of PATJ mRNA CTD PMID:27188386 NCBI chr 5:118,177,557...118,480,301
Ensembl chr 5:118,177,565...118,480,301 		JBrowse link
G Patz1 POZ (BTB) and AT hook containing zinc finger 1 decreases expression ISO entinostat results in decreased expression of PATZ1 mRNA CTD PMID:27188386 NCBI chr14:82,378,226...82,396,679
Ensembl chr14:82,377,697...82,396,686 		JBrowse link
G Pax2 paired box 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of PAX2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:253,555,447...253,646,623
Ensembl chr 1:253,555,418...253,645,438 		JBrowse link
G Pax3 paired box 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of PAX3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141 		JBrowse link
G Pax5 paired box 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of PAX5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:63,554,784...63,741,380
Ensembl chr 5:63,560,722...63,739,987 		JBrowse link
G Pax6 paired box 6 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PAX6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763 		JBrowse link
G Pbx2 PBX homeobox 2 decreases expression ISO entinostat results in decreased expression of PBX2 mRNA CTD PMID:27188386 NCBI chr20:4,156,107...4,161,503
Ensembl chr20:4,156,107...4,161,827 		JBrowse link
G Pcbd2 pterin-4 alpha-carbinolamine dehydratase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of PCBD2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCBD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:8,850,349...8,902,420 JBrowse link
G Pcdh10 protocadherin 10 increases expression
multiple interactions 		ISO entinostat results in increased expression of PCDH10 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:130,553,432...130,619,591
Ensembl chr 2:130,553,425...130,613,407 		JBrowse link
G Pcdh17 protocadherin 17 decreases expression ISO entinostat results in decreased expression of PCDH17 mRNA CTD PMID:27188386 NCBI chr15:66,631,549...66,725,007
Ensembl chr15:66,633,142...66,722,105 		JBrowse link
G Pcdh18 protocadherin 18 decreases expression ISO entinostat results in decreased expression of PCDH18 mRNA CTD PMID:27188386 NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:135,983,144...135,996,826 		JBrowse link
G Pcdh20 protocadherin 20 increases expression
multiple interactions 		ISO entinostat results in increased expression of PCDH20 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:70,834,042...70,840,298
Ensembl chr15:70,834,042...70,840,298 		JBrowse link
G Pcdh8 protocadherin 8 increases expression
multiple interactions 		ISO entinostat results in increased expression of PCDH8 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH8 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr15:61,607,521...61,612,090
Ensembl chr15:61,607,521...61,612,097 		JBrowse link
G Pcdh9 protocadherin 9 decreases expression ISO entinostat results in decreased expression of PCDH9 mRNA CTD PMID:27188386 NCBI chr15:75,748,472...76,646,644
NCBI chr15:76,078,024...76,127,778
Ensembl chr15:75,749,278...76,645,302 		JBrowse link
G Pcdha2 protocadherin alpha 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PCDHA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHA2 mRNA 		CTD PMID:26272509 PMID:27188386
G Pcdhb13 protocadherin beta 13 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PCDHB6 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB6 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:29,420,029...29,423,883 JBrowse link
G Pcdhb15 protocadherin beta 15 multiple interactions
decreases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB7 mRNA
entinostat results in decreased expression of PCDHB7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:29,454,334...29,457,872 JBrowse link
G Pcdhb20 protocadherin beta 20 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PCDHB14 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDHB14 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr18:29,485,888...29,489,282
Ensembl chr18:29,454,999...29,489,427 		JBrowse link
G Pcdhb5 protocadherin beta 5 decreases expression ISO entinostat results in decreased expression of PCDHB4 mRNA CTD PMID:27188386 NCBI chr18:29,302,466...29,305,048 JBrowse link
G Pcm1 pericentriolar material 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PCM1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:57,711,833...57,808,842
Ensembl chr16:57,711,833...57,808,599 		JBrowse link
G Pcmtd1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PCMTD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCMTD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:17,071,629...17,143,803
Ensembl chr 5:17,071,629...17,142,010 		JBrowse link
G Pcna proliferating cell nuclear antigen decreases expression ISO entinostat results in decreased expression of PCNA protein CTD PMID:21041383 NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901 		JBrowse link
G Pcnx2 pecanex 2 increases expression ISO entinostat results in increased expression of PCNX2 mRNA CTD PMID:27188386 NCBI chr19:70,616,240...70,766,869
Ensembl chr19:70,616,240...70,766,869 		JBrowse link
G Pcolce procollagen C-endopeptidase enhancer multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCOLCE mRNA
entinostat results in increased expression of PCOLCE mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:24,720,972...24,727,287
Ensembl chr12:24,720,936...24,727,287 		JBrowse link
G Pcsk2 proprotein convertase subtilisin/kexin type 2 decreases expression ISO entinostat results in decreased expression of PCSK2 mRNA CTD PMID:27188386 NCBI chr 3:151,333,938...151,636,628
Ensembl chr 3:151,333,234...151,638,849 		JBrowse link
G Pcsk5 proprotein convertase subtilisin/kexin type 5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PCSK5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:224,263,823...224,694,350
Ensembl chr 1:224,264,678...224,694,347 		JBrowse link
G Pdcd4 programmed cell death 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PDCD4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDCD4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:262,926,656...262,950,189 		JBrowse link
G Pde10a phosphodiesterase 10A decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PDE10A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:54,313,343...54,765,668
Ensembl chr 1:54,317,732...54,764,051 		JBrowse link
G Pde1a phosphodiesterase 1A decreases expression ISO entinostat results in decreased expression of PDE1A mRNA CTD PMID:27188386 NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:85,154,184...85,519,212 		JBrowse link
G Pde3a phosphodiesterase 3A increases expression
multiple interactions 		ISO entinostat results in increased expression of PDE3A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:175,904,077...176,169,270 		JBrowse link
G Pde3b phosphodiesterase 3B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PDE3B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE3B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:178,041,207...178,204,503
Ensembl chr 1:178,041,207...178,204,503 		JBrowse link
G Pde4a phosphodiesterase 4A increases expression
multiple interactions 		ISO entinostat results in increased expression of PDE4A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:27,966,978...28,029,721
Ensembl chr 8:27,966,996...28,046,924 		JBrowse link
G Pde4b phosphodiesterase 4B decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PDE4B mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE4B mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:122,135,174...122,598,267 		JBrowse link
G Pde4dip phosphodiesterase 4D interacting protein increases expression ISO entinostat results in increased expression of PDE4DIP mRNA CTD PMID:27188386 NCBI chr 2:187,982,002...188,178,937
Ensembl chr 2:187,981,878...188,178,869 		JBrowse link
G Pde8a phosphodiesterase 8A increases expression
multiple interactions 		ISO entinostat results in increased expression of PDE8A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE8A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:144,575,203...144,698,216
Ensembl chr 1:144,575,428...144,698,215 		JBrowse link
G Pdgfa platelet derived growth factor subunit A increases expression
multiple interactions 		ISO entinostat results in increased expression of PDGFA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr12:20,759,366...20,780,337
Ensembl chr12:20,754,208...20,780,322 		JBrowse link
G Pdgfrb platelet derived growth factor receptor beta decreases expression ISO entinostat results in decreased expression of PDGFRB protein CTD PMID:29845424 NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233 		JBrowse link
G Pdgfrl platelet-derived growth factor receptor-like increases expression ISO entinostat results in increased expression of PDGFRL mRNA CTD PMID:27188386 NCBI chr16:58,051,421...58,111,327
Ensembl chr16:58,051,440...58,111,327 		JBrowse link
G Pdia5 protein disulfide isomerase family A, member 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of PDIA5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDIA5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr11:78,777,436...78,892,370
Ensembl chr11:78,777,419...78,864,329 		JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 increases expression ISO entinostat results in increased expression of PDK4 mRNA CTD PMID:32870474 NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381 		JBrowse link
G Pdlim1 PDZ and LIM domain 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PDLIM1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:248,991,818...249,040,409
Ensembl chr 1:248,991,818...249,047,379 		JBrowse link
G Pdlim3 PDZ and LIM domain 3 multiple interactions ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM3 mRNA CTD PMID:27188386 NCBI chr16:53,085,020...53,116,495
Ensembl chr16:53,085,020...53,116,217 		JBrowse link
G Pdlim4 PDZ and LIM domain 4 increases expression ISO entinostat results in increased expression of PDLIM4 mRNA CTD PMID:27188386 NCBI chr10:38,699,444...38,713,696
Ensembl chr10:38,699,444...38,713,659 		JBrowse link
G Pdlim7 PDZ and LIM domain 7 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PDLIM7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDLIM7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:9,129,603...9,144,956
Ensembl chr17:9,129,525...9,144,956 		JBrowse link
G Pdpn podoplanin increases expression
multiple interactions 		ISO entinostat results in increased expression of PDPN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:160,884,995...160,919,112
Ensembl chr 5:160,884,993...160,925,637 		JBrowse link
G Pdyn prodynorphin increases expression
multiple interactions 		ISO entinostat results in increased expression of PDYN mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDYN mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:137,354,161...137,366,503
Ensembl chr 3:137,354,161...137,366,503 		JBrowse link
G Pelo pelota mRNA surveillance and ribosome rescue factor increases expression
multiple interactions 		ISO entinostat results in increased expression of PELO mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PELO mRNA 		CTD PMID:27188386 NCBI chr 2:48,530,902...48,532,670
Ensembl chr 2:48,530,907...48,532,761 		JBrowse link
G Per1 period circadian regulator 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PER1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PER1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211 		JBrowse link
G Per2 period circadian regulator 2 decreases expression ISO entinostat results in decreased expression of PER2 mRNA CTD PMID:27188386 NCBI chr 9:99,454,828...99,497,069
Ensembl chr 9:99,454,830...99,496,993 		JBrowse link
G Pex13 peroxisomal biogenesis factor 13 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PEX13 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX13 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:101,804,673...101,822,367
Ensembl chr14:101,804,673...101,822,367 		JBrowse link
G Pex5l peroxisomal biogenesis factor 5-like decreases expression ISO entinostat results in decreased expression of PEX5L mRNA CTD PMID:27188386 NCBI chr 2:117,623,199...117,836,772
Ensembl chr 2:117,623,199...117,836,685 		JBrowse link
G Pf4 platelet factor 4 decreases expression ISO entinostat results in decreased expression of PF4 mRNA CTD PMID:27188386 NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392 		JBrowse link
G Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 decreases expression ISO entinostat results in decreased expression of PFKFB3 mRNA CTD PMID:27188386 NCBI chr17:71,893,320...71,974,526
Ensembl chr17:71,893,416...71,975,052 		JBrowse link
G Pfkp phosphofructokinase, platelet increases expression
multiple interactions 		ISO entinostat results in increased expression of PFKP mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr17:68,639,749...68,704,055
Ensembl chr17:68,639,481...68,705,752 		JBrowse link
G Pgap1 post-GPI attachment to proteins inositol deacylase 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PGAP1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGAP1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:63,470,023...63,538,772
Ensembl chr 9:63,470,024...63,538,772 		JBrowse link
G Pgcka1 PDCD10 and GCKIII kinases associated 1 multiple interactions
increases expression 		ISO [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGCKA1 mRNA
entinostat results in increased expression of PGCKA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:44,740,965...44,832,180
Ensembl chr14:44,740,972...44,831,613 		JBrowse link
G Pgf placental growth factor increases expression
multiple interactions 		ISO entinostat results in increased expression of PGF mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGF mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:110,547,153...110,557,747 		JBrowse link
G Pgm1 phosphoglucomutase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PGM1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PGM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:119,710,734...119,770,159
Ensembl chr 5:119,710,737...119,770,159 		JBrowse link
G Phc1 polyhomeotic homolog 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PHC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:157,182,348...157,205,504
Ensembl chr 4:157,182,348...157,204,709 		JBrowse link
G Phc2 polyhomeotic homolog 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PHC2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHC2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:146,285,000...146,383,664
Ensembl chr 5:146,285,008...146,383,663 		JBrowse link
G Phf20l1 PHD finger protein 20-like 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PHF20L1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF20L1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:100,219,598...100,285,580
Ensembl chr 7:100,219,639...100,285,580 		JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PHLDA1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542 		JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of PHLDA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920 		JBrowse link
G Phldb3 pleckstrin homology-like domain, family B, member 3 increases expression ISO entinostat results in increased expression of PHLDB3 mRNA CTD PMID:27188386 NCBI chr 1:89,328,991...89,347,446
Ensembl chr 1:89,328,819...89,347,436 		JBrowse link
G Phox2b paired-like homeobox 2b decreases expression ISO entinostat results in decreased expression of PHOX2B mRNA CTD PMID:27188386 NCBI chr14:41,420,011...41,424,527
Ensembl chr14:41,420,011...41,424,494 		JBrowse link
G Phtf2 putative homeodomain transcription factor 2 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PHTF2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHTF2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:15,107,341...15,222,683
Ensembl chr 4:15,107,373...15,222,692 		JBrowse link
G Pid1 phosphotyrosine interaction domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PID1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PID1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070 		JBrowse link
G Pigh phosphatidylinositol glycan anchor biosynthesis, class H increases expression ISO entinostat results in increased expression of PIGH mRNA CTD PMID:27188386 NCBI chr 6:103,601,369...103,630,214
Ensembl chr 6:103,601,520...103,630,159 		JBrowse link
G Pik3ap1 phosphoinositide-3-kinase adaptor protein 1 increases expression ISO entinostat results in increased expression of PIK3AP1 mRNA CTD PMID:27188386 NCBI chr 1:250,040,250...250,194,364
Ensembl chr 1:250,040,250...250,154,226 		JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PIK3CA mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3CA mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411 		JBrowse link
G Pik3cb phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta increases expression
multiple interactions 		ISO entinostat results in increased expression of PIK3CB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3CB mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:108,474,017...108,579,140
Ensembl chr 8:108,474,019...108,579,331 		JBrowse link
G Pik3cd phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta increases expression ISO entinostat results in increased expression of PIK3CD mRNA CTD PMID:27188386 NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PIK3R1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3R1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PIK3R3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3R3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:134,936,790...135,009,303
Ensembl chr 5:134,934,857...135,007,762 		JBrowse link
G Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 increases expression ISO entinostat results in increased expression of PIK3R5 mRNA CTD PMID:26272509 NCBI chr10:53,631,469...53,699,550
Ensembl chr10:53,631,476...53,699,539 		JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase increases expression
multiple interactions 		ISO entinostat results in increased expression of PIM1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764 		JBrowse link
G Pim2 Pim-2 proto-oncogene, serine/threonine kinase increases expression
multiple interactions 		ISO entinostat results in increased expression of PIM2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIM2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:17,289,509...17,294,778
Ensembl chr  X:17,289,509...17,294,778 		JBrowse link
G Pip4k2b phosphatidylinositol-5-phosphate 4-kinase type 2 beta decreases expression ISO entinostat results in decreased expression of PIP4K2B mRNA CTD PMID:27188386 NCBI chr10:83,202,379...83,231,292
Ensembl chr10:83,197,287...83,231,292 		JBrowse link
G Pipox pipecolic acid and sarcosine oxidase increases expression
multiple interactions 		ISO entinostat results in increased expression of PIPOX mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr10:63,267,946...63,281,556
Ensembl chr10:63,267,972...63,282,273 		JBrowse link
G Pir pirin increases expression ISO entinostat results in increased expression of PIR mRNA CTD PMID:27188386 NCBI chr  X:33,740,428...33,851,049
Ensembl chr  X:33,740,429...33,851,049 		JBrowse link
G Pkdcc protein kinase domain containing, cytoplasmic increases expression
multiple interactions 		ISO entinostat results in increased expression of PKDCC mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 6:17,208,171...17,217,488
Ensembl chr 6:17,208,171...17,218,042 		JBrowse link
G Pknox2 PBX/knotted 1 homeobox 2 increases expression ISO entinostat results in increased expression of PKNOX2 mRNA CTD PMID:27188386 NCBI chr 8:44,789,464...45,051,933
Ensembl chr 8:44,789,467...44,979,754 		JBrowse link
G Pkp4 plakophilin 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PKP4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PKP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:64,040,995...64,244,586
Ensembl chr 3:64,141,771...64,244,586 		JBrowse link
G Pla2g12a phospholipase A2, group XIIA increases expression
multiple interactions 		ISO entinostat results in increased expression of PLA2G12A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G12A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:221,110,722...221,126,966
Ensembl chr 2:221,110,685...221,126,964 		JBrowse link
G Pla2g2a phospholipase A2 group IIA increases expression
multiple interactions 		ISO entinostat results in increased expression of PLA2G2A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:156,359,725...156,362,297 		JBrowse link
G Pla2g3 phospholipase A2, group III increases expression
multiple interactions 		ISO entinostat results in increased expression of PLA2G3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr14:82,589,908...82,597,542
Ensembl chr14:82,591,862...82,597,542 		JBrowse link
G Pla2g4a phospholipase A2 group 4A increases expression
multiple interactions 		ISO entinostat results in increased expression of PLA2G4A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641 		JBrowse link
G Pla2g7 phospholipase A2 group VII increases expression
multiple interactions 		ISO entinostat results in increased expression of PLA2G7 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G7 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:24,859,502...24,901,747 		JBrowse link
G Plaat1 phospholipase A and acyltransferase 1 increases expression ISO entinostat results in increased expression of PLAAT1 mRNA CTD PMID:27188386 NCBI chr11:85,022,297...85,041,999
Ensembl chr11:85,022,297...85,031,826 		JBrowse link
G Plaat3 phospholipase A and acyltransferase 3 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLAAT3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:214,211,755...214,245,551
Ensembl chr 1:214,211,791...214,246,763 		JBrowse link
G Plaat5 phospholipase A and acyltransferase 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLAAT5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:214,276,553...214,307,600
Ensembl chr 1:214,277,044...214,307,598 		JBrowse link
G Plac1 placenta enriched 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLAC1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAC1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:137,740,896...137,874,688
Ensembl chr  X:137,740,890...137,905,210 		JBrowse link
G Plau plasminogen activator, urokinase increases expression ISO entinostat results in increased expression of PLAU mRNA CTD PMID:27188386 NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030 		JBrowse link
G Plaur plasminogen activator, urokinase receptor increases expression ISO entinostat results in increased expression of PLAUR mRNA CTD PMID:27188386 NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130 		JBrowse link
G Plbd1 phospholipase B domain containing 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLBD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLBD1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,204,198...171,260,488
Ensembl chr 4:171,204,198...171,260,488 		JBrowse link
G Plcg2 phospholipase C, gamma 2 increases expression ISO entinostat results in increased expression of PLCG2 mRNA CTD PMID:27188386 NCBI chr19:62,456,196...62,592,684
Ensembl chr19:62,453,259...62,592,684 		JBrowse link
G Plch1 phospholipase C, eta 1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PLCH1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLCH1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:150,298,547...150,514,120
Ensembl chr 2:150,299,075...150,464,019 		JBrowse link
G Pld1 phospholipase D1 increases expression ISO entinostat results in increased expression of PLD1 mRNA CTD PMID:27188386 NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245 		JBrowse link
G Pld5 phospholipase D family, member 5 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PLD5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr13:90,426,689...90,765,072
Ensembl chr13:90,428,490...90,783,066 		JBrowse link
G Plekha2 pleckstrin homology domain containing A2 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLEKHA2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr16:73,641,338...73,704,068
Ensembl chr16:73,641,344...73,703,087 		JBrowse link
G Plekha3 pleckstrin homology domain containing A3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PLEKHA3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 3:82,030,653...82,051,866
Ensembl chr 3:82,029,034...82,052,553 		JBrowse link
G Plekha4 pleckstrin homology domain containing A4 increases expression ISO entinostat results in increased expression of PLEKHA4 mRNA CTD PMID:27188386 NCBI chr 1:105,142,296...105,165,297
Ensembl chr 1:105,142,348...105,165,297 		JBrowse link
G Plekhb1 pleckstrin homology domain containing B1 increases expression ISO entinostat results in increased expression of PLEKHB1 mRNA CTD PMID:27188386 NCBI chr 1:164,410,901...164,425,216
Ensembl chr 1:164,410,903...164,428,568 		JBrowse link
G Plekhg1 pleckstrin homology and RhoGEF domain containing G1 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PLEKHG1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHG1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:42,612,023...42,841,727
Ensembl chr 1:42,612,122...42,841,719 		JBrowse link
G Plekhg3 pleckstrin homology and RhoGEF domain containing G3 increases expression ISO entinostat results in increased expression of PLEKHG3 mRNA CTD PMID:27188386 NCBI chr 6:100,998,965...101,042,120
Ensembl chr 6:100,994,417...101,042,118 		JBrowse link
G Plekhg4 pleckstrin homology and RhoGEF domain containing G4 increases expression ISO entinostat results in increased expression of PLEKHG4 mRNA CTD PMID:27188386 NCBI chr19:50,161,722...50,176,491
Ensembl chr19:50,159,754...50,182,133 		JBrowse link
G Plekhh2 pleckstrin homology, MyTH4 and FERM domain containing H2 increases expression ISO entinostat results in increased expression of PLEKHH2 mRNA CTD PMID:27188386 NCBI chr 6:15,783,179...15,893,479
Ensembl chr 6:15,784,645...15,893,537 		JBrowse link
G Plekhm3 pleckstrin homology domain containing M3 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PLEKHM3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHM3 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 9:73,659,998...73,819,079
Ensembl chr 9:73,664,817...73,799,503 		JBrowse link
G Plg plasminogen decreases expression ISO entinostat results in decreased expression of PLG mRNA CTD PMID:27188386 NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:50,872,926...50,917,320 		JBrowse link
G Pllp plasmolipin increases expression ISO entinostat results in increased expression of PLLP mRNA CTD PMID:27188386 NCBI chr19:10,321,080...10,341,869
Ensembl chr19:10,321,080...10,342,226 		JBrowse link
G Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLOD2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022 		JBrowse link
G Plp2 proteolipid protein 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr  X:17,506,153...17,509,552
Ensembl chr  X:17,506,059...17,509,550 		JBrowse link
G Plpp1 phospholipid phosphatase 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PPAP2A mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPAP2A mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:46,172,202...46,233,632
Ensembl chr 2:46,172,197...46,234,676 		JBrowse link
G Plpp2 phospholipid phosphatase 2 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLPP2 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLPP2 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 7:10,826,534...10,834,628
Ensembl chr 7:10,826,549...10,834,627 		JBrowse link
G Plpp3 phospholipid phosphatase 3 increases expression ISO entinostat results in increased expression of PLPP3 mRNA CTD PMID:27188386 NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667 		JBrowse link
G Plpp4 phospholipid phosphatase 4 decreases expression
multiple interactions 		ISO entinostat results in decreased expression of PLPP4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLPP4 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 1:193,260,181...193,389,659
Ensembl chr 1:193,260,434...193,389,675 		JBrowse link
G Plpp5 phospholipid phosphatase 5 decreases expression ISO entinostat results in decreased expression of PLPP5 mRNA CTD PMID:27188386 NCBI chr16:73,052,204...73,056,609
Ensembl chr16:73,052,204...73,056,643 		JBrowse link
G Plppr1 phospholipid phosphatase related 1 decreases expression ISO entinostat results in decreased expression of LPPR1 mRNA CTD PMID:27188386 NCBI chr 5:68,232,963...68,520,784
Ensembl chr 5:68,232,963...68,592,444 		JBrowse link
G Plppr5 phospholipid phosphatase related 5 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLPPR5 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLPPR5 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 2:208,143,058...208,422,836
Ensembl chr 2:208,142,871...208,439,051 		JBrowse link
G Pls1 plastin 1 increases expression
multiple interactions 		ISO entinostat results in increased expression of PLS1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLS1 mRNA 		CTD PMID:26272509 PMID:27188386 NCBI chr 8:105,196,312...105,306,252
Ensembl chr 8:105,197,455...105,292,447 		JBrowse link
G Pls3 plastin 3 increases expression
multiple interactions